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for  the  largest portion  (22.9%) of  the  total global years  lived with disability  (YLD)  in 2010. 
While  premature  mortality  associated  with  mental  and  substance  use  disorders  is  low, 
disability attributable  to  this disorder class  is higher  than  for any other medical condition. 
Within  the  group  of  psychiatric  disorders  depressive  disorders  account  for  42.5%  of  YLD 
followed  by  substance  use  disorders  (17.3%),  anxiety  disorders  (15.3%),  and  finally 
schizophrenia  (7.4%)  and  bipolar  disorder  (7.4%)  (Whiteford  et  al.,  2013).  Based  on  the 
National  Comorbidity  Survey  Replication  lifetime  prevalence  for  the  most  common 






markers and a  considerable overlap of  symptoms between different diagnostic  categories 
(Simmons and Quinn, 2014). The classification systems Diagnostic and Statistical Manual of 
Mental  Disorders  (DSM)  (American  Psychiatric  Association,  2013)  and  International 
Classification of Diseases (ICD) (World Health Organization, 1993) treat mental disorders as 
categorical  concepts  (present/absent)  for  which  a  defined  combination  and  numbers  of 
symptoms  (often  within  a  defined  timeframe)  have  to  be  present.  Moreover  the 
classification  systems  are  polythetic, meaning  that  they  list multiple  symptoms  for  each 
disorder, yet not all of them have to be present to consider a specific diagnosis. According to 
Krueger and Bezdjian (2009) these main characteristics of the DSM and the ICD raise three 
conceptual  problems:  comorbidity,  within‐diagnosis  heterogeneity,  and  subthreshold 
symptomatology.  Comorbidity  occurs  when  patients  meet  diagnostic  criteria  for  two  or 
more psychiatric disorder (Plomin et al., 2009). The National Comorbidity Survey Replication 
reports a  lifetime prevalence of 27.7%  for at  least two psychiatric disorders and 17.3%  for 











The  problems  of  comorbidity,  within‐diagnosis  heterogeneity,  and  subthreshold 
symptomatology  do  not  just  remain  problems  of  the  diagnostic  classification  systems. 
Indeed,  they  determine  how  we  see  and  study  mental  illness.  The  high  prevalence  of 
comorbidity  ‐  illustrating  the  blending  of mental  disorders  into  one  another  –  pose  the 
question of whether the disorders really are distinct and we can therefore expect to identify 
individual,  underlying,  etiological  factors  (Krueger  and  Bezdjian,  2009).  Further,  when 
studying  one  diagnostic  group  we  should  be  aware  of  the  huge  heterogeneity  and  ask 
ourselves  if  we  can  expect  to  detect  an  underlying  disease  mechanism  in  individuals 
displaying  very  different  phenotypes  (Krueger  and  Bezdjian,  2009).  Lastly  subthreshold 




Many  researchers  are  convinced  that  advances  in  therapeutic  and  prognostic  decision‐
making will only be possible based on the accurate diagnosis of mental illness (Craddock and 
Owen, 2010) and  for  this  the classification needs  to be more directly  linked  to underlying 
biological mechanisms (Adam, 2013; Craddock and Owen, 2010;  Insel et al., 2010; Krueger 
and Bezdjian, 2009). So far, clinical neuroscience and genetic studies have failed to confirm 





based  intermediate  phenotypes  across  diagnostic  borders  (Meyer‐Lindenberg  and 
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Regardless of  the diagnostic and  classification problems  for mental disorders, population, 
family,  and  twin  studies  have  provided  evidence  of  overall  high  heritability,  32‐37%  for 
major depressive disorder  (Sullivan et  al., 2000; Wray  and Gottesman, 2012),  62‐85%  for 
bipolar  disorder  (McGuffin  et  al.,  2003;  Wray  and  Gottesman,  2012),  67‐85%  for 
schizophrenia (Cardno and Gottesman, 2000; Wray and Gottesman, 2012), and 50‐80% for 
autism spectrum disorder  (Lichtenstein et al., 2010; Ronald and Hoekstra, 2011; Sandin et 
al., 2014). These high estimates encouraged  researchers  to start searching  for  the genetic 
roots of psychiatric disorder. But since  the early  linkage studies  failed to  identify so‐called 
mendelian  disease  genes  and  after  an  era  of  candidate  gene  studies  with  mostly 
inconsistent,  non‐reproducible  results,  the  conclusion  had  to  be  drawn  that  mental 
disorders are highly polygenic (Craddock and Sklar, 2013; Flint and Kendler, 2014; Gratten et 









et al., 2013), autism spectrum disorder  (Gaugler et al., 2014), bipolar disorder    (Lee et al., 
2013), and major depressive disorder (Flint and Kendler, 2014; Lee et al., 2013; Lubke et al., 
2012).  So‐called  genome‐wide  association  studies  (GWAS)  provide  an  unbiased  approach 
whereby  large numbers of unrelated  cases  and  controls  are  compared  for  the  frequency 
distribution  of  these  common  SNP.  The  most  recent  and  largest  GWAS  identified  108 
independent genetic loci for schizophrenia (Schizophrenia Working Group of the PGC, 2014), 




(OR)~1.06‐1.3  (Schizophrenia Working  Group  of  the  PGC,  2014).  The  current  absence  of 
comparable  numbers  of  genome‐wide  association  findings  for  other  major  psychiatric 
disorders  is mainly due to the  lack of big enough samples (Gratten et al., 2014; Sullivan et 




Nevertheless,  in  2013  two  papers  were  published  by  the  Cross‐Disorder  Group  of  the 
Psychiatric Genomics Consortium (Cross‐Disorder Group of the PGC, 2013; Lee et al., 2013) 
which  tried  to  assess  the  shared  genetic  risk  for  five major  psychiatric  disorders  (autism 
spectrum  disorder,  attention  deficit‐hyperactivity  disorder,  bipolar  disorder,  major 
depressive disorder and schizophrenia) using large samples, genome‐wide SNP data and two 
slightly  different  methodological  approaches.  Overall  both  papers  provide  evidence  for 
shared genetic risk between psychiatric disorders, particularly pronounced between adult‐




have  been  implicated  in  psychiatric  disorders, with OR  between  ~2  and  20  for  individual 
variants. These structural changes involve deletions or duplications of >100 kilobases of DNA 
and they often occur de novo – meaning that they are present in affected individuals but not 
their  parents  (Gratten  et  al.,  2014).  CNV  seem  to  be  particularly  relevant  for  autism 
spectrum  disorder  (Sanders  et  al.,  2011;  Sebat  et  al.,  2007)  and  schizophrenia  (The 
International  Schizophrenia  Consortium,  2008;  Walsh  et  al.,  2008;  Xu  et  al.,  2008).  The 
largest meta‐analysis of CNV  in schizophrenia confirmed previous findings of deletions and 
duplications  as well  as  specific exon‐disrupting deletions  in  the  gene NRXN1  (all OR≥7.5). 
However,  all  of  these  CNV  are  not  disease  specific  and  have  at  the  same  time  been 
associated with mental retardation, autism spectrum disorder, and epilepsy (Levinson et al., 







disorders, many  questions  remain.  (I) What  is  the  functional  importance  of  the  variants 
identified by genetic studies, considering that >80% of the SNP fall  in  intronic or  intergenic 
regions (Hindorff et al., 2009)? (II) How do different disease‐associated variants combine to 
cause pathology (Gratten et al., 2014)? (III) Where is the missing heritability to be found,  if 






65%  for  schizophrenia  (Cardno  and  Gottesman,  2000)  and,  40‐70%  for  bipolar  disorder 
(Craddock and Sklar, 2013). This indicates that genes are not entirely responsible for disease 




The  involvement  of  non‐genetic  factors  in  the  development  of  medical  conditions  [e.g. 
tobacco  smoking and  lung cancer  (Gandini et al., 2008)] has  long been  recognized.  In  the 
case of mental disorders it took longer for research to appreciate and consider the impact of 
the environment. There is now a large body of literature available on environmental factors 
repeatedly  associated with  increased  risk  for  schizophrenia  (Brown,  2011;  van  Os  et  al., 
2010). However, exposures  to early biological hazards  (e.g. malnutrition and  stress during 
pregnancy, preterm birth), psychosocial  factors and cannabis use have all been associated 
with  an  increased  risk  for  major  depressive  disorder,  bipolar  disorder,  as  well  as 
schizophrenia  (Uher,  2014).  As  a  psychosocial  factor,  childhood  adversities  (e.g.  sexual 
abuse,  physical  abuse,  neglect)  have  been  linked  to  mental  disease  outcome  across 
countries (Kessler et al., 2010) and have recently been confirmed by large meta‐analyses as 







to  establish  causative  relationships  based  on  epidemiological  data.  But  the  information 
coming from observational studies can help to generate new hypothesis about the etiology 
of different psychiatric disorders, which  can  then be  tested experimentally. Based on  the 
observation  that early psychosocial  stress  is  associated with  an  increased  risk  for  various 
mental diseases,  research using  animal models was  able  to  show  that  across mammalian 
species early or chronic stress during development can lead to long lasting alterations of the 
hypothalamic‐pituitary‐adrenal  (HPA)  axis  (Sanchez  et  al.,  2001)  –  dysfunctions, which  in 




to  develop  a  psychiatric  disorder,  a  new  field  has  emerged,  studying  gene‐environment 
interactions.  Staying with  the  previous  examples  of  stress  affecting HPA  axis  functioning, 
Wichers and colleagues (2009) were able to show that genetic predisposition to depression 
potentiates  the effect of developmental stress exposure  (Wichers et al., 2009),  illustrating 
an  interplay  of  genes  and  environment.  Overall  gene‐environment  interaction  research 
using  human  subjects  as well  as  animal models  (Caspi  and Moffitt,  2006;  Hunter,  2005; 










During  the  introduction  I  mentioned  the  purely  descriptive,  categorical  classification  of 
mental disorders, the huge within‐diagnosis heterogeneity, and the frequent occurrence of 
psychiatric  comorbidities.  I  also  pointed  out  that  we  are  confronted  with  an  incredible 
genetic heterogeneity upon which environmental factors take their effect.  In our approach 
to a better understanding of the etiology of mental disorders we break up the phenotypic 
heterogeneity of  individuals diagnosed with  schizophrenia. Our  strategy  is  to define more 
homogeneous subgroups based on quantitative and qualitative traits. We also try to identify 
common genetic variants or other biological phenomena associated with the phenotype of 
the specific subgroup  [phenotype‐based genetic association study  (PGAS)]  (Ehrenreich and 
Nave,  2014).  The  idea  is  that  a  shared  phenotype  will  be  linked  to  shared  biological 
mechanisms within the subgroup.  
 




for  Schizophrenia  (GRAS)  dataset  (Begemann  et  al.,  2010;  Ribbe  et  al.,  2010). GRAS  is  a 
sample of over 1100 schizophrenic and schizoaffective patients [according to the Diagnostic 
and  Statistical  Manual  of  Mental  disorders  Fourth  Edition  Text  Revision  (DSM‐IV‐TR])] 
(American  Psychiatric Association,  2000),  recruited  over  the  last  10  years  in  participating 
psychiatric  hospitals  and  other  mental  health  centers  throughout  Germany.  The  GRAS 
cohort comprises a comprehensive assessment of over 3000 phenotypic measures, as well 
as  genetic  and  serological  information  for  each  individual.  My  work  focused  on  the 
identification  and  quantification  of  symptom‐based  patient  subgroups  as  well  as  the 
operationalization of environmental exposure. My work was complemented by  the use of 




3.  GENETIC  MARKERS  OF  A  MUNC13  PROTEIN  FAMILY  MEMBER,  BAIAP3,  ARE  GENDER 





The  brain‐specific  angiogenesis  inhibitor  1‐associated  protein  3  (Baiap3)  is  predominantly 






vesicle  priming  (Brose  et  al.,  1995;  Koch  et  al.,  2000;  Varoqueaux  et  al.,  2002),  a  key 
mechanism  for  neurotransmitter  release.  Furthermore  synaptotagmin  is  also  crucial  for 
neurotransmitter  exocytosis  (Chapman,  2002).  Based  on  the  Allen  Brain  Atlas 
(http://mouse.brain‐map.org/) Baiap3  is  expressed  in  the  central, medial  and  basomedial 




function,  we  wanted  to  explore  the  role  of  this  protein.  We  combined  the  behavioural 
analysis of Baiap3  knockout  (KO) mice with  the  study of  SNP‐associated phenotypes  in  a 




To assess whether  the  loss of Baiap3 would  lead  to any detectable behavioral alterations, 
we subjected Baiap3 KO mice and their wildtype (WT)  littermates to a battery of standard 
behavioral  tests. We observed anxiety‐related behavioral alterations  in  the open  field  test 
for  KO  animals  of  both  sexes.  In  all  other  tests  we  saw  no  difference  in  performance 










(of  which  two  were  finally  used  for  analysis  –  rs2235632,  rs1132358)  with  minor  allele 
frequencies  >30%  and  determined  their  association  with  a  human  anxiety  measure.  To 
operationalize anxiety  in our cohort we constructed an anxiety composite score comprised 
of  the  trait  and  state  anxiety  subscales  of  the  State‐Trait  Anxiety  Inventory  (STAI),  the 
anxiousness  subscale of  the Brief Symptom  Inventory  (BSI) and  the anxiety  item  from  the 
Positive and Negative Syndrome Scale (PANSS). We found the anxiety composite score to be 
significantly associated with both SNP in female schizophrenic patients. Due to the fact that 
anxiety  disorders  and  substance  use  disorders  are  highly  comorbid  (Conway  et  al.,  2006; 
Grant et al., 2004; Marmorstein, 2012), we decided to check for associations of the chosen 
SNP  genotypes with  substances  use  disorders. We  found  the  same  genotypes  previously 
associated with  anxiety  in  females,  to be  associated with benzodiazepine use disorder  in 
males.  
 
Based  on  the  human  results  we  set  up  a  mouse  experiment  to  compare  tolerance 
development to diazepam (5mg/kg daily  intraperitoneal  injections for 10 consecutive days) 
in  Baiap3  KO  mice  and  their  WT  littermates.  In  this  experiment  we  observed  a  faster 
tolerance development  in male Baiap3 KO mice. When  comparing KO  and WT mice with 
regards  to  self‐administration  of midazolam  in  a  chronically  addicted  state, we  found  no 
genotype differences. We further injected KO and WT mice with pentylenetetrazole (PTZ), a 
noncompetitive  GABA  antagonist  with  epileptic  properties,  and  saw  a  higher  seizure 
propensity in Baiap3 KO mice of both sexes. To study possible differences in the response to 
benzodiazepines  and  benzodiazepine  withdrawal  in  vitro,  we  used  organotypic 
hypothalamus slices of Baiap3 KO and WT mice. Here we found higher basal network activity 
and no homeostatic adaption  to diazepam  treatment and withdrawal  in Baiap3 KO  slices. 
Immunostaining analysis did not yield a significant localization of Baiap3 to glutamatergic or 




In  summary,  we  associated  genetic  variation  in  BAIAP3  with  anxiety  in  females  and 
benzodiazepine  use  disorder  in  males.  In  mice  Baiap3  deficiency  was  associated  with 
increased  novelty‐induced  anxiety  in  both  sexes  (more  pronounced  in  females),  and  an 
altered  response  to  benzodiazepines  mainly  in  males.  In  vitro  we  saw  no  homeostatic 
adaption  to  diazepam  in  Baiap3  KO  hypothalamus  slices.  Overall  this  project  implies  an 
etiological  connection  between  anxiety  and  benzodiazepine  abuse  in mice  and  humans. 
Further research and a better understanding of the underlying biological mechanisms could 
have  the  potential  to  improve  the  treatment  of many  affected  individuals  since  anxiety 
disorders  and  substance  use  disorders  often  co‐occur  (Conway  et  al.,  2006; Grant  et  al., 
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as well  as  the  development  of  an  anxiety  composite  score  for  the  schizophrenic  sample 
(Supplementary Figure S2). I conducted all the statistical analyses for the human part (Table 
1, Supplementary Table S1, Supplementary Figure S5), contributed to the  interpretation of 
the  data,  designed  the  (above mentioned)  figures  and  tables,  and wrote  the  respective 
figure  legends  for the publication. Additionally,  I wrote the materials and methods section 
for  the  human  sample  of  the manuscript.  Together with my  first  author  colleagues  and 






reviewers  and  editors  concerning  the  human data  and  did  the  final proof  reading  of  the 
manuscript together with the other first authors before publication. 
INTRODUCTION
Anxiety disorders have high lifetime
prevalence rates (1) and exhibit a re-
markable comorbidity with substance
use disorders (2–4). This association
worsens treatment outcomes for both
conditions (5) and represents a signifi-
cant burden on individuals and society.
Both anxiety disorders and substance
use disorders are complex disorders that
arise from a combination of genetic in-
fluence and environmental factors. To
improve upon established treatment op-
tions, which include pharmacological as
well as cognitive-behavioral therapies
(6,7), a more detailed picture of the etiol-
ogy of these disorders is instrumental.
Estimates of heritability from twin and
family studies are in the range of
20–40% across the different anxiety dis-
orders (8,9) and in the range of 40–70%
for the major substance use disorders
(10). Recent studies point to the involve-
ment of a large number of genes with
relatively small effect sizes for both anxi-
ety disorder (11,12) and substance use
disorder (13–15). Although the interac-
tion between anxiety disorders and sub-
stance use disorders is likely bidirec-
M O L  M E D  1 9 : 1 3 5 - 1 4 8 ,  2 0 1 3  |  W O J C I K E T  A L .  |  1 3 5
Genetic Markers of a Munc13 Protein Family Member,
BAIAP3, Are Gender Specifically Associated with Anxiety and
Benzodiazepine Abuse in Mice and Humans
Sonja M Wojcik,1* Martesa Tantra,2,3* Beata Stepniak,2* Kwun-nok M Man,1,3 Katja Müller-Ribbe,2
Martin Begemann,2 Anes Ju,2 Sergi Papiol,2,3 Anja Ronnenberg,2 Artem Gurvich,2 Yong Shin,1,4
Iris Augustin,1,5 Nils Brose,1,3 and Hannelore Ehrenreich2,3
1Max Planck Institute of Experimental Medicine, Department of Molecular Neurobiology, Göttingen, Germany; 2Max Planck Institute
of Experimental Medicine, Clinical Neuroscience, Göttingen, Germany; 3DFG Center for Nanoscale Microscopy and Molecular
Physiology of the Brain, Göttingen, Germany; 4present address: BioElectronics, Institute of Microelectronics, Agency for Science,
Technology and Research (A*STAR), Singapore, Singapore; and 5present address: German Cancer Research Center, Department
Signaling and Functional Genomics, Heidelberg, Germany
Anxiety disorders and substance abuse, including benzodiazepine use disorder, frequently occur together. Unfortunately, treat-
ment of anxiety disorders still includes benzodiazepines, and patients with an existing comorbid benzodiazepine use disorder or a
genetic susceptibility for benzodiazepine use disorder may be at risk of adverse treatment outcomes. The identification of genetic
predictors for anxiety disorders, and especially for benzodiazepine use disorder, could aid the selection of the best treatment op-
tion and improve clinical outcomes. The brain-specific angiogenesis inhibitor I–associated protein 3 (Baiap3) is a member of the
mammalian uncoordinated 13 (Munc13) protein family of synaptic regulators of neurotransmitter exocytosis, with a striking expres-
sion pattern in amygdalae, hypothalamus and periaqueductal gray. Deletion of Baiap3 in mice leads to enhanced seizure propen-
sity and increased anxiety, with the latter being more pronounced in female than in male animals. We hypothesized that genetic
variation in human BAIAP3 may also be associated with anxiety. By using a phenotype-based genetic association study, we iden-
tified two human BAIAP3 single-nucleotide polymorphism risk genotypes (AA for rs2235632, TT for rs1132358) that show a significant
association with anxiety in women and, surprisingly, with benzodiazepine abuse in men. Returning to mice, we found that male, but
not female, Baiap3 knockout (KO) mice develop tolerance to diazepam more quickly than control animals. Analysis of cultured
Baiap3 KO hypothalamus slices revealed an increase in basal network activity and an altered response to diazepam withdrawal.
Thus, Baiap3/BAIAP3 is gender specifically associated with anxiety and benzodiazepine use disorder, and the analysis of
Baiap3/BAIAP3-related functions may help elucidate mechanisms underlying the development of both disorders.
Online address: http://www.molmed.org
doi: 10.2119/molmed.2013.00033
*SMW, MT, and BS contributed equally to this study.
Address correspondence to Sonja M Wojcik, Max Planck Institute of Experimental Medi-
cine, Department of Molecular Neurobiology, Hermann-Rein-Str. 3, D-37075 Göttingen,
Germany. Phone: +49-551-3899-722; Fax: +49-551-3899-715; E-mail: wojcik@em.mpg.de.
Submitted April 12, 2013; Accepted for publication May 14, 2013; Epub
(www.molmed.org) ahead of print May 14, 2013.
PROJECT I
20
tional and varies by the type of anxiety
(16), genetically determined anxiousness
personality traits may make the devel-
opment of an addiction more likely
(2,17–19). The recommended first-line
pharmacological treatments of anxiety
disorders are selective serotonin or sero-
tonin/norepinephrine reuptake in-
hibitors and the calcium channel modu-
lator pregabaline (6). However, primary
care physicians often still prescribe ben-
zodiazepines, which rank among the
most frequently abused prescription
medications (National Institute on Drug
Abuse [http://www.nida.nih.gov]), to
patients suffering from anxiety disorders
(20). Identifying genetic risk markers
would advance our understanding of
the biology of anxiety and benzodi-
azepine abuse and would be a valuable
step in improving treatment options for
these complex diseases.
In addition to human family, twin and
genome-wide association studies, animal
models are used to study the genetic
basis and neural circuitries of anxiety
and addiction. For both animals and hu-
mans, anxiety is an adaptive defensive
response to threatening stimuli necessary
for the survival of the species, whereas
anxiety disorders are an extreme and
maladaptive manifestation of normal
anxiety (21). Somatic anxiety symptoms
are mediated by the release of specific
neurotransmitters and neuropeptides.
The selection of candidate genes that are
being investigated in animal studies is
still largely driven by hypotheses of the
neural circuitries and neurotransmitter
systems thought to be involved in medi-
ating fear and anxiety (22). By using a
candidate gene approach, we investigate
the involvement of the brain-specific an-
giogenesis inhibitor I–associated protein
3 (Baiap3), which is highly expressed in
brain regions involved in processing fear,
such as the amygdalae, hypothalamus
and periaqueductal gray, in behavioral
phenotypes relevant for human psychiat-
ric disorders.
Baiap3 is a member of the mammalian
uncoordinated 13 (Munc13) family of
synaptic regulators of neurotransmitter
exocytosis (23–25). Baiap3 has a unique
and striking expression pattern (Allen
Brain Atlas [http://mouse.brain-
map.org]) in brain regions such as the
central, medial and basomedial amyg-
daloid nuclei; the hypothalamus; and the
periaqueductal gray. These areas are in-
volved in regulating autonomic functions
and are also critical in processing fearful
stimuli and mediating anxiety-related be-
haviors (26,27). The cellular function of
Baiap3 is currently unknown; however,
all other Munc13 members are regulators
of vesicle exocytosis in various cell types
(28). In the brain, Munc13-1 and
Munc13-2 are essential for membrane fu-
sion of synaptic vesicles containing clas-
sical neurotransmitters, such as gluta-
mate or γ-aminobutyric acid (GABA)
(25). Munc13-4, a non-neuronal Munc13
isoform most closely related to Baiap3 at
the sequence level, is involved in exocy-
tosis in cells of the hematopoietic system
(29,30).
To explore the function of Baiap3, we
combined the behavioral analysis of
Baiap3 knockout (KO) mice with a phe-
notype-based genetic association study
(PGAS) of the human BAIAP3 gene by
using the Göttingen Research Associa-
tion for Schizophrenia (GRAS) database
(31,32). Using this two-pronged ap-
proach, we identify Baiap3/BAIAP3 as the
first genetic risk marker for anxiety and




Animal maintenance. All experiments
were approved by the local Animal Care
and Use Committee of Lower Saxony,
Oldenburg, Germany. The first three cod-
ing exons of the murine Baiap3 gene were
preplaced with a neomycin resistance
cassette through homologous recombina-
tion in embryonic stem cells (129/Ola)
(Supplementary Figure S1A). Baiap3 mu-
tant mice of mixed 129/Ola;C57BL/6N
background were backcrossed for seven
more generations to C57BL/6N; all ex-
periments were done with WT and KO
littermates of the resulting generation 8.
After weaning, mice were group-housed
in standard plastic cages (n = 5 per cage)
and maintained in a temperature-
 controlled environment (21 ± 2°C) on a
12-h light–dark cycle with food and
water ad libitum, unless stated otherwise.
Drugs used in animal experiments.
Two classical benzodiazepines, positive
allosteric modulators of GABA type A re-
ceptors (GABAAR) were used: (i) the
long-acting benzodiazepine diazepam
(ratiopharm GmbH, Ulm, Germany) was
suspended in saline containing polysor-
bate 80 for intraperitoneal (IP) injection,
and (ii) the short-acting benzodiazepine
midazolam (ratiopharm) was added to
2% sucrose solution for oral administra-
tion. Antagonists used were as follows:
(i) flumazenil (Sigma-Aldrich Chemie,
Munich, Germany), routinely applied in
the clinic to counteract benzodiazepine
overdoses, was dissolved in saline con-
taining polysorbate 80 and HCl; and (ii)
pentylenetetrazole (PTZ) (Sigma-Aldrich
Chemie), a noncompetitive GABA antag-
onist with epileptogenic properties, was
dissolved in saline for IP injection.
Phenotypical characterization of
Baiap3 KO mice. Behavioral characteri-
zation of naive Baiap3 KO mice and their
WT littermates of both sexes began at the
age of 8 wks and was performed in the
following order: elevated plus-maze,
open field, light–dark box, hole board,
rotarod and exposure to a fear-condition-
ing chamber to assess novelty-induced
freezing behavior. Mouse numbers of all
individual experiments are given in the
figure legends.
Elevated plus-maze. The mouse was
placed in the central platform, facing an
open arm of the plus-maze. Behavior
was recorded over 5 min by an overhead
video camera. A personal computer
equipped with Viewer software 
(Biobserve, Bonn, Germany) was used to
calculate the time each animal spent in
open versus closed arms. The proportion
of time spent in open arms (natural aver-
sion) was used as a fear equivalent.
Open field. Spontaneous activity in
open field was tested in a gray Perspex
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arena (120 cm in diameter, 25 cm high),
virtually divided into three zones: cen-
tral, intermediate and peripheral. The
mouse was placed in the center, and the
test was started when the mouse reached
the wall. Over 7 min, the mouse was al-
lowed to freely explore the open field.
Behavior was recorded by a personal
computer–linked overhead video camera
and calculated using Viewer software.
Readouts were as follows: velocity, dis-
tance traveled, time spent in each zone
and initial latency to reach the wall.
Hole board. The hole board apparatus
(TSE Systems GmbH, Bad Homburg,
Germany) for measuring exploratory 
activity consisted of a 50 cm × 50 cm ×
35 cm transparent Perspex chamber with
a nontransparent floor raised above the
bottom of the chamber. The floor had 16
equally spaced holes, 2.4 cm in diameter,
fitted with a light barrier sensor (8 mm
below floor). Mice were allowed to ex-
plore the chamber for 5 min, and the
number of explored holes (head dips)
was recorded.
Rotarod. This test for motor function,
balance and coordination consists of a ro-
tating drum (Ugo Basile, Comerio,
Varese, Italy), accelerated from 4 to 40
revolutions per minute over 5 min. Each
mouse was placed individually on a
drum and the latency of falling from the
drum was recorded using a stopwatch.
To assess motor learning, the test was re-
peated 24 h later.
Novelty-induced fear response. To as-
sess novelty-induced fear response (indi-
cated by freezing behavior), a chamber
designed for training and testing of con-
text fear conditioning was used. Mice
were placed inside the chamber and al-
lowed to explore the chamber freely for
2 min, during which time no additional
stimulus was presented (equivalent to
the assessment of baseline freezing of the
fear-conditioning paradigm). Duration of
freezing behavior, defined as the ab-
solute lack of movement (excluding res-
piratory movements), was recorded by a
video camera and a personal computer
equipped with Video Freeze software
(MED Associates, St. Albans, VT, USA).
Pentylenetetrazole-induced seizures.
Seizure activity was induced in wakeful
mice by using a single IP injection of PTZ
(50 mg/kg body weight) (33). After injec-
tion of the compound, the mouse was
placed in a small, clear home cage and
closely observed for 30 min. Latencies to
focal (partial clonic), generalized (gener-
alized clonic) and maximal (tonic-clonic)
behavioral seizures were recorded. Fur-
thermore, four phases in the continuum
of behavioral response to IP PTZ injec-
tion were defined as follows: (i) hypoac-
tivity (progressive decrease in motor ac-
tivity until the animal came to rest in a
crouched or prone position with the ab-
domen in full contact with the cage bot-
tom); (ii) partial clonus (clonus seizure
activity affecting face, head and/or fore-
limb or forelimbs); (iii) generalized
clonus (sudden loss of upright posture,
whole body clonus involving all four
limbs and tail, rearing and autonomic
signs); and (iv) tonic-clonic (maximal)
seizure (generalized seizure character-
ized by tonic hindlimb extension—also
associated with death). Finally, latencies
to partial clonus (PC), generalized clonus
(GC) and tonic-clonic (TC) seizures were
summed to assign a seizure score to each
mouse, used as a quantitative trait mea-
sure for mapping according to the fol-
lowing equation: seizure score = [(0.2) ×
(1/PC latency) + (0.3) × (1/GC latency) +
(0.5) × (1/TC latency)] × 1,000. The
weighting factors (0.2, 0.3 and 0.5) in the
equation were included as a means of in-
corporating a measure of the progressive
nature of the PTZ-induced seizure phe-
notype into the severity rating because
generalized clonus is regarded as a more
significant event than partial clonus and
tonic hind limb extension as the most se-
vere component of the phenotype. There-
fore, the seizure score reflects the degree
of progression of the seizure phenotype
in each mouse (33).
Diazepam dependence, tolerance and
withdrawal. The mice received injections
of diazepam (5 mg/kg body weight IP)
for 10 consecutive days. Rotarod test was
performed 30 min after each diazepam
injection for 7 d, with baseline rotarod
training performed for 2 d before starting
injections. On d 11, diazepam with-
drawal was induced by flumazenil 
(15 mg/kg body weight IP), followed by
injection of PTZ (50 mg/kg body weight
IP) to induce withdrawal-related
seizures. Seizure induction by PTZ 
(50 mg/kg body weight IP) was also per-
formed on drug-naive mice.
Midazolam oral self-administration
and behavior testing in the addicted
state. To induce benzodiazepine depen-
dence as a prerequisite for oral self-
 administration (document of addiction),
group-housed mice received midazolam 
(ratiopharm) in 2% sucrose (to reduce the
bitter taste), instead of drinking water.
Midazolam concentration was increased
weekly, starting from 0.005 mg/mL 
until the maximum concentration of 
0.05 mg/mL was reached after 10 wks. A
respective control group received 2% 
sucrose only. One set of midazolam 
mice was then exposed to a midazolam
preference test. For this purpose, mice
were first switched to single housing
with a continued supply of midazolam
(0.05 mg/mL) for 2 wks. For the prefer-
ence test, every mouse had a choice of
two bottles containing either midazolam
(0.05 mg/mL) in 2% sucrose or 2% su-
crose alone for another 2 wks. The rela-
tive consumption of midazolam solution
was calculated. The other set of mice
(midazolam and control mice) stayed
group-housed and underwent automated
home cage observation using the
 LABORAS™ system (Metris, Hoofddorp,
Netherlands). LABORAS is a fully auto-
mated system for continuous behavior
recognition and tracking in small rodents.
For habituation before testing, mice were
temporarily put in single cages similar to
the LABORAS cage in the testing room
for 2 consecutive nights (1700 to 0900).
On the day of testing, Makrolon type 3
cages (840 cm2), filled with a 2-cm layer
of bedding used during the habituation
phase, were placed on each triangular
sensor platform (95 cm × 75 cm × 75 cm).
Food and sucrose solution with midazo-
lam (addicted group) or 2% sucrose (con-
trol group) were provided ad libitum. 
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Before each session, LABORAS was cali-
brated by using the calibration procedure
and reference weights supplied by
Metris. Movements during nighttime
(1800 to 0900) were recorded and distin-
guished as separate behavioral patterns
by the LABORAS software. Locomotion
duration and scratching frequency dur-
ing the dark phase (2000 to 0800) was 
analyzed.
Statistical analysis. Behavioral data
were analyzed separately for males and
females by the Mann-Whitney U test and
two-way analysis of variance (ANOVA),
including post hoc Bonferroni testing,
where applicable, using Prism4 (Graph-
Pad Software, San Diego, CA, USA). Sig-
nificance level was set to p < 0.05. All
data are presented as mean ± standard
error of the mean (SEM).
Human Sample
Schizophrenic patient sample. The
schizophrenic patient sample (n = 1,086)
was recruited across 23 sites throughout
Germany in the cross-sectional GRAS
study and most comprehensively pheno-
typed (31,32). The study was approved
by the Ethics Committee of the Georg-
August-University (Göttingen, Germany)
and the review boards of participating
centers and complies with the Declara-
tion of Helsinki. Patients fulfilling Diag-
nostic and Statistical Manual of Mental Dis-
orders: DSM-IV-TR, 4th edition, text
revision (34) criteria for schizophrenia or
schizoaffective disorder were included in
the analyses regardless of their disease
stage (acute, chronic, residual or remit-
ted). Almost all patients were of Euro-
pean Caucasian descent (Caucasian
94.7%; other ethnicities 1.9%; unknown
3.4%).
Healthy control sample. Voluntary
blood donors (n = 1,142) recruited fol-
lowing the national guidelines for blood
donation were included for case control
analysis (31,32). Also the majority of con-
trol subjects are of European Caucasian
ethnicity (Caucasian 97.8%; other ethnici-
ties 2%; unknown 0.2%).
Sociodemographic and clinical vari-
ables. Sociodemographic data (age, years
of education, level of unemployment),
information on substance use disorder
(summarizing abuse and dependence
based on the DSM-IV-TR criteria for alco-
hol and cannabis) and clinical variables
describing disease severity were used to
characterize the sample. Clinical vari-
ables included Positive and Negative
Syndrome Scale (PANSS) positive scale
as a measure of positive symptom sever-
ity (35) as well as chlorpromazine equiv-
alents to estimate the relative dose of an-
tipsychotic medication. The Global
Assessment of Functioning (GAF) scale
(DSM-IV-TR) was used as a measure of
impairment of psychological, social and
occupational functioning.
Target variables. The dichotomous
DSM-IV-TR benzodiazepine use disorder
diagnosis (summarizing abuse and de-
pendence) and the quantitative anxiety
composite score were our target vari-
ables. The anxiety composite score is
based on the aggregation of four anxiety-
related variables: (i) Brief Symptom In-
ventory (BSI) subscale anxiousness; (ii)
State-Trait Anxiety Inventory (STAI) sub-
scale trait anxiety; (iii) STAI subscale
state anxiety; and (iv) anxiety item of the
PANSS general psychopathology sub-
scale (Supplementary Figure S2).
DNA extraction and normalization.
Genomic DNA was purified from whole
blood by using JETQUICK Blood and
Cell Culture DNA Spin Kit (Genomed,
Loehne, Germany) according to the man-
ufacturer’s protocol. DNA aliquots were
stored at –80°C. For further analyses,
DNA was normalized to 50 ng/μL with
an automated robotic platform (Microlab
Star, Hamilton, Bonaduz, Switzerland).
Each sample was analyzed with a 0.8%
agarose gel for quality control.
Genotyping. The three selected SNPs
(rs11648169, rs2235632, rs1132358) of
BAIAP3 were analyzed by using Simple
Probes (TIB Molbiol, Berlin, Germany)
and genotyped using the LightCycler®
480 Genotyping Software implemented
in the LightCycler 480 system (Roche,
Mannheim, Germany). The reaction mix-
ture (10 μL) was prepared with 20 ng
DNA in 384-well plates following the
standard protocol (Roche). In each run,
eight positive controls (hgDNA, Bioline,
Luckenwalde, Germany) and negative
water blanks were included for quality
and internal control purposes. Of the
GRAS patients, a total of n = 1,082
(99.63%) were successfully genotyped for
BAIAP3 SNP1 (C/G) rs11648169, n =
1,086 (100%) for BAIAP3 SNP2 (G/A)
rs2235632 and n = 1,069 (98.43%) for
BAIAP3 SNP3 (C/T) rs1132358 and in-
cluded in the analyses. Of the healthy
control subjects, all n = 1,142 were suc-
cessfully genotyped for SNP1, SNP2 and
SNP3 of the BAIAP3 gene.
Statistical analyses. For all analyses,
statistical significance was set to 0.05.
Statistical analyses of human data were
performed by using SPSS for Windows,
version 17.0. Group differences in cate-
gorical and continuous variables were
assessed using χ2 or Mann-Whitney U
tests; in cases of normal distribution of
the continuous variable, t tests were per-
formed. Anxiety score composition was
done using z-standardized mean sub-
scale scores (BSI anxiousness, STAI trait
anxiety, STAI state anxiety) or, in the case
of PANSS anxiety, a z-standardized
single item, organized such that higher
values represent higher symptom sever-
ity. Intercorrelations and internal consis-
tency of the anxiety composite score was
calculated by using Pearson correlation
coefficient and Cronbach α (36). In the
GRAS sample, the following items or
scales were incomplete: BSI anxiousness
7.5% missing, STAI trait anxiety 20.2%,
STAI state anxiety 21.6% and PANSS
anxiety 3.2%. If all four anxiety variables
were available, the mean was calculated
for each respective subject as an individ-
ual anxiety composite score. In the case
of missing data, a linear regression-based
multiple imputation model (10 iterations)
of missing data was applied, if at least
three out of the four variables per subject
were available. For the 190 individuals
with imputed values, the final anxiety
composite score represents the mean of
10 imputed values for the missing item,
increasing the availability of the anxiety
score from n = 771 to n = 961 schizo-
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phrenic subjects (37). Analysis of covari-
ance (adjusted for age, PANSS positive
subscale score and chlorpromazine
equivalents) was used to analyze the ef-
fect of SNP genotypes on the standard-
ized anxiety composite score. For the
phenotype-genotype association analyses
(including peripheral blood mononuclear
cells [PBMCs]; see below) of the BAIAP3
SNP rs2235632, G carriers (GG and AG)
were aggregated and contrasted with in-
dividuals homozygous for the A allele,
and in the case of SNP rs1132358, C carri-
ers (CC and TC) were aggregated and
contrasted with TT individuals. SNP
rs11648169 was excluded from further




were perfusion-fixed, and organotypic
hypothalamus slices were immersion
fixed in 4% paraformaldehyde in phos-
phate buffer (pH 7.4). Brains were post-
fixed for 1 h, cryoprotected with 30%
 sucrose and frozen. For immunofluores-
cence analysis, free-floating brain sec-
tions of 40 μm thickness or organotypic
sections of 300 μm thickness were incu-
bated in primary antibodies for 72 h fol-
lowed by incubation with IgG- coupled
Alexa Fluor 488, Alexa Fluor 555 and
Alexa Flour 633 dyes (Invitrogen [Life
Technologies, Darmstadt, Germany]) for
24 h. Rabbit and guinea pig antibodies to
Baiap3 were raised to a purified frag-
ment (amino acids 617–973) containing
the munc homology domain (MHD)-1
and MHD-2 of mouse Baiap3. Commer-
cial primary antibodies used were rabbit
and guinea pig anti-vesicular glutamate
transporter 1 (VGLUT1), rabbit and
guinea pig anti-VGLUT2, rabbit and
guinea pig anti-vesicular inhibitory
amino acid transporter (Viaat), mouse
anti-Gephyrin (mAB7a) (all from Synap-
tic Systems, Göttingen, Germany), and
mouse anti-postsynaptic density protein
95 (PSD-95) (clone K28/48,  NeuroMab).
False color images of brain sections and
organotypic slices were obtained with a
fluorescence stereomicroscope (Leica
 FluoCombi III™) and an ApoTome™ flu-
orescence microscope (Axio Imager Z1;
Zeiss), respectively.
Hypothalamus slice culture. Organ-
otypic hypothalamus slices of 300-μm
thickness from postnatal d 5 (P5) and P6
mice were prepared in Hanks balanced
salt solution (24020-091; Invitrogen [Life
Technologies]) with 20% glucose and 
1 mmol/L kynurenic acid (Sigma-
Aldrich, Germany) (pH 7.4), by using a
McIlwain Tissue Chopper. Slices were
cultured in six-well plates on confetti cut
from 0.45-μm filters (FHLC04700; EMD
Millipore [Millipore Ireland B.V., Tulla-
green, Carrigtwohill County Cork, Ire-
land]) that were placed in 0.4-μm Milli-
cell cell culture inserts (PICM03050;
Millipore) for 5 d using a mixture of 41%
Earle basal medium Eagle (BME) (F 0225;
Biochrom, Berlin, Germany), with 25%
Earle balanced salt solution (1.8 mmol/L
CaCl2, 1 mmol/L NaH2PO4, 0.8 mmol/L
MgSO4, 116 mmol/L NaCl, 26.2 mmol/L
NaHCO3, 5.4 mmol/L KCl, 5 mmol/L glu-
cose), 20% heat-inactivated horse serum,
10% H2O, 25 mmol/L 4-(2- hydroxyethyl)-
1-piperazineethanesulfonic acid (HEPES)
(Biochrom), 28 mmol/L glucose, 1 mmol/L
GlutaMAX™ (35050; Invitrogen [Life Tech-
nologies]), 1 μg/mL insulin, 88 μg/mL
ascorbic acid, 0.25% MEM Vitamine Solu-
tion (K0373; Biochrom) and 0.5% MEM
Amino Acids (K0363; Biochrom). On d 5
in vitro, the cultures were switched to a
medium with identical components but
containing 5% horse serum, 55% BME
and 2 mmol/L GlutaMAX. At the same
time, diazepam was added to the me-
dium from a 60 mmol/L stock solution in
dimethylsulfoxide (DMSO) for a final
concentration of 10 μmol/L. For control
cultures, DMSO was added as a vehicle
control at the same dilution of 1:6,000.
The CO2 concentration was 5%, and me-
dium changes were done on the day after
culture and every 48 h after that.
Electrophysiological analyses. Organ-
otypic slices containing the ventromedial
hypothalamus were transferred to the
recording chamber between DIV10 and
DIV17. Recordings were started after a 
30-min recovery time, the extracellular
recording solution contained 120 mmol/L
NaCl, 26 mmol/L NaHCO3, 1 mmol/L
KH2PO4, 2 mmol/L KCl, 20 mmol/L glu-
cose, 2 mmol/L MgCl2, 2 mmol/L CaCl2
and 250 nmol/L flumazenil. Cells were
whole-cell voltage clamped at –70 or
–20 mV or recorded in current clamp mode
with an EPC 10 USB Double (HEKA,
 Lambrecht/Pfalz, Germany) under control
of the Patchmaster 2.52 program (HEKA).
All analyses were performed by using the
Mini Analysis Program (Synaptosoft, De-
catur, GA, USA). Recordings of miniature
inhibitory postsynaptic currents (mIPSCs)
were performed in the presence of
1 μmol/L tetrodotoxin (Tocris [R&D Sys-
tems, Wiesbaden- Nordenstadt, Germany])
and 10 μmol/L 2,3-dioxo-6-nitro-1,2,3,4-
 tetrahydrobenzo[ f ]quinoxaline-7-
sulfonamide (NBQX) (Tocris [R&D Sys-
tems]), with an intracellular solution
containing 100 mmol/L KCl, 50 mmol/L
K-gluconate, 10 mmol/L HEPES, 
0.1 mmol/L EGTA, 0.3 mmol/L GTP, 
4 mmol/L ATP and 0.2% biocytin. Action
potentials and spontaneous inhibitory post-
synaptic currents (IPSCs) were recorded
with an intracellular solution containing
20 mmol/L KCl, 130 mmol/L K-gluconate,
10 mmol/L HEPES, 0.1 mmol/L EGTA,
0.3 mmol/L GTP, 4 mmol/L ATP and
0.2% biocytin. Action potentials analyzed
were from the first minute of a 2-min
recording; membrane potentials were
measured after setting the current injec-
tion to 0 pA at the end of the recording.
IPSCs were recorded for 5 min after
switching the cell to a holding potential of
–20 mV and waiting for 1 min. Statistical
analyses were performed using GraphPad
Prism5.
Analysis of BAIAP3 mRNA levels in
PBMCs. PBMCs from 121 patients were
isolated by using the standard Ficoll-
Paque Plus isolation procedure (GE
Healthcare, Munich, Germany). For RNA
isolation, the miRNeasy Mini Kit (Qiagen,
Hilden, Germany) was used. A total of
1 μg RNA, a mixture of oligo dT, hexamer
primers, dNTPS (10 mmol/L each) and
SuperScriptIII (200 U; Invitrogen [Life
Technologies]) were used for transcription
into cDNA (20-μL reaction). The mixture
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was incubated for 10 min at 25°C and 45
min at 50°C, followed by 45 min at 55°C.
For the quantitative reverse transcriptase
polymerase chain reaction (qRT-PCR), a
1:10 dilution of the cDNA was used and
three replicate experiments per sample
were performed: 5 μL Power SYBR mix
(Applied Biosystems) and 1 pmol of 
each primer were added. BAIAP3 qRT-





The following cycling profile was run on
the LightCycler480 system (Roche): pre-
heating at 95°C for 10 min; 45 cycles of
95°C for 15 s, 60°C for 1 min. Cycle thresh-
old values of BAIAP3 were standardized
to cycle threshold values of GAPDH.
All supplementary materials are available
online at www.molmed.org.
RESULTS
Generation of Baiap3 KO Mice
Baiap3 shares the basic domain struc-
ture of other Munc13 isoforms, with two
munc-homology domains flanked by
two C2 domains but lacks the N-termini
contained in Munc13-1, -2 and -3 (23).
The murine Baiap3 gene contains 33 cod-
ing exons that span 8.7 kb. We generated
Baiap3 KO mice by homologous recombi-
nation in embryonic stem cells, replacing
the first three coding exons with a
neomycin selection cassette (Supplemen-
tary Figure S1A). Baiap3 KO mice are vi-
able, fertile and indistinguishable from
their wild-type (WT) littermates in the
home cage. In WT brain, the expression
pattern of Baiap3 protein analyzed by
immunofluorescence staining largely
matches the distribution of Baiap3
mRNA published in the Allen Brain
Atlas. Baiap3 protein is prominently ex-
pressed throughout the hypothalamus
and in the central, medial and basome-
dial amygdaloid nuclei, as well as in the
paraventricular nucleus of the thalamus
(Figure 1). Strong expression is further
detected in the septum, bed nucleus of
the stria terminalis, midbrain including
the periaqueductal gray and inferior col-
liculus, and brain stem including the
parabrachial nucleus and nucleus tractus
solitarius (Figure 1). Baiap3 immunoreac-
tivity appears punctate, but does not
seem to localize to either glutamatergic
or GABAergic pre- or postsynapses to a
significant degree (Supplementary Fig-
ures S1C–G). Adult Baiap3 KO mice lack
any detectable expression of Baiap3 pro-
tein by immunofluorescence and Western
blot analysis (Figure 1B, Supplementary
Figure S1B). Western blot analysis of
brains taken from newborn Baiap3 KO
animals revealed the presence of a weak
band that most likely corresponds to
Baiap3 protein expressed from a start
codon present in coding exon 4; how-
ever, this putative truncated Baiap3
product is barely detectable by the age of
3 wks and not present in adult animals
(Supplementary Figure S1B).
Novelty-Induced Anxiety in Baiap3
KO Mice
The striking expression pattern of
Baiap3 in the amygdala and other brain
regions involved in processing fear
piqued our interest, and we chose to as-
sess whether the genetic deletion of
Baiap3 led to any detectable behavioral
alterations. We subjected Baiap3 KO mice
and WT littermates of both sexes to a
battery of standard behavioral tests (Fig-
ures 2A–L; Supplementary Figures
S3A–J). In the open field, both male and
female Baiap3 KO mice showed an in-
creased latency to reach the wall upon
release in the center zone (Figures 2A, B).
Female but not male KO mice also made
fewer visits to the center (Figures 2C, D)
and spent significantly more time in the
periphery (Figures 2E, F). When placed
in a novel chamber (fear-conditioning
box), both male and female KO mice
showed an increased novelty-induced
freezing response (Figures 2K, L). Taken
together, these findings are indicative of
a heightened novelty-induced anxiety
level in Baiap3 KO animals, with a more
pronounced effect noted in females. In
contrast, classical tests, measuring anxi-
ety in the context of an inherent conflict
between a protected and a more anxio-
genic area, that is, elevated plus-maze
and light–dark box, did not reveal any
genotype differences (Figures 2G–J). Fur-
thermore, the distance traveled (motor
activity) in open field and elevated plus-
maze (Supplementary Figures S3A–D),
exploratory behavior (hole board; Sup-
plementary Figures S3E, F), motor learn-
ing and coordination (rotarod; Supple-
mentary Figures S3G, H) and body
weight (Supplementary Figures S3I, J)
were not affected by genotype.
BAIAP3 Is a Risk Marker for Anxiety in
Women
To explore the possibility of an associa-
tion of genetic variability in the human
BAIAP3 gene with specific biological
readouts, we made use of the GRAS data-
base of schizophrenic patients (31,32). Our
hypotheses regarding Baiap3/BAIAP3
function were based on the anxiety phe-
notype observed in Baiap3 KO mice and
on the prominent expression of Baiap3 in
brain regions involved in processing fear-
ful stimuli as well as in substance use dis-
orders. We selected three single-nucleotide
polymorphisms (SNPs) in the BAIAP3
gene: rs11648169 (C/G, intronic),
rs2235632 (G/A, intronic) and rs1132358
(C/T, coding sequence, synonymous
Asp1040Asp) (Supplementary Figure S4A)
from public databases [http://www.ncbi.
nlm. nih. gov/projects/SNP/; http://
browser. 1000genomes.org; http://
hapmap. ncbi. nlm.nih.gov/]. The selection
of SNPs was based on (i) a high minor al-
lele frequency (MAF ≥ 0.36) distribution
within the European Caucasian popula-
tion (http://www.ncbi.nlm.nih. gov/
SNP/), to increase the power to detect ge-
netic effects, and (ii) the potential for
functional consequences. The last criterion
could only partially be fulfilled; the ex-
onic SNP rs1132358 (C/T, Asp1040Asp,
synonymous) might potentially affect
mRNA structure or stability. All SNPs ful-
filled Hardy-Weinberg equilibrium crite-
ria, both in cases and in controls (p >
0.05). A construction of haplotype blocks
of the three SNPs revealed a similarly
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high degree of linkage disequilibrium be-
tween them in the GRAS sample (Supple-
mentary Figure S4B) and in healthy con-
trols (Supplementary Figure S4C). Case
control analysis of genotype frequencies
of the three SNPs did not reveal any sig-
nificant differences, indicating that the 
selected genetic variation in BAIAP3 is
not associated with schizophrenia risk
(Supplementary Figure S4D). We subse-
quently used the PGAS approach (32) to
analyze the three SNPs for association
with specific phenotypic readouts rele-
vant for anxiety disorders and substance
use disorders. For this step, an anxiety
composite score was constructed using
four anxiety-relevant variables (Supple-
mentary Figure S2), which showed a sig-
nificant association with only two of the
three selected SNPs (as expected because
of the high linkage disequilibrium be-
tween both markers and their similar
MAFs) for women but not for men 
(Table 1). SNP rs11648169 was excluded
from further analyses, since it yielded no
statistically significant effects.
BAIAP3 Is a Risk Gene for
Benzodiazepine Abuse in Men
Because anxiety disorders and sub-
stance use disorders often occur together,
and BAIAP3 is expressed in brain regions
relevant for emotionality and drug de-
pendence, we also screened for a possible
association between genetic variation in
BAIAP3 and substance use disorder. The
same risk genotypes (AA for rs2235632,
TT for rs1132358) that were associated
with anxiety in women showed a statisti-
cally significant association with benzodi-
azepine use disorder in men (Table 1).
Even though there was a similar ten-
dency for women (benzodiazepine use
disorder associated with 7.0%/7.7% in
AA/TT genotypes versus 4.7%/4.6% in
G/C carrier status), it did not reach sta-
tistical significance, perhaps because of
the lower numbers of women than men
in the GRAS sample. The genotype fre-
quencies of rs2235632 and rs1132358 did
not differ between men and women in




women 29.8%/46.9%/23.3%), and neither
of these two SNPs was associated with
disease-related or sociodemographic con-
trol variables (Table 1).
For the purpose of an association anal-
ysis of the relevant BAIAP3 genotypes
(GG/AG/AA in rs2235632 and
CC/TC/TT in rs1132358) with benzodi-
azepine use disorder, the GRAS sample
delivers an ideal, nearly experimental set-
ting. The distribution of these genotypes
among benzodiazepine users versus
nonusers is highly comparable, allowing
the identification of risk genotypes lead-
ing to benzodiazepine use disorder (Sup-
plementary Table S1). Most importantly,
the benzodiazepine dose was equal
across all genotypes (Supplementary
Table S1). Hence, the BAIAP3 risk geno-
types (AA for rs2235632, TT for
rs1132358) appear to confer a specific ge-
netic risk of developing benzodiazepine
use disorder given equal dose and likeli-
hood of exposure. Interestingly, neither
alcohol nor cannabis abuse were found to
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Figure 1. Immunofluorescence analysis of Baiap3 expression in mouse brain. (A) Sagittal
brain section of adult Baiap3 WT mouse stained with rabbit anti-Baiap3 antibody. (B)
Sagittal brain section of adult Baiap3 KO littermate showing the absence of Baiap3 im-
munoreactivity. Please note that the signal observed in the hippocampus of both WT and
KO brain is a nonspecific background staining. (C) Coronal brain section of adult WT
mouse stained for Baiap3 with a corresponding coronal diagram, adapted from the
mouse Paxinos brain atlas (Bregma –1.46). PB, parabrachial nucleus; NTS, nucleus tractus
solitarius; Hi, hippocampus; SC, superior colliculus; IC, inferior colliculus; PAG, periaqueduc-
tal gray; LS, lateral septum; Th, thalamus; Hy, hypothalamus; BST, bed nucleus of the stria
terminalis; PV, paraventricular thalamic nucleus; DM, dorsomedial hypothalamic nucleus;
VMH, ventromedial hypothalamic nucleus; Arc, arcuate nucleus; Ce, central amygdaloid
nucleus; BLA, basolateral amygdaloid nucleus, anterior part; BMA, basomedial amyg-
daloid nucleus, anterior part; ME, medial amygdaloid nucleus; ACo, anterior cortical
amygdaloid nucleus. Scale bars equal 1 mm.
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be associated with the two SNPs, point-
ing to a specific benzodiazepine link with
the selected BAIAP3 genotypes (Table 1).
To determine whether the identified
risk genotypes are associated with al-
tered expression of BAIAP3, we analyzed
the mRNA levels of BAIAP3 in PBMCs
obtained from 121 subjects by qRT-PCR.
We found a statistically significant asso-
ciation of the BAIAP3 risk genotypes
(AA for rs2235632, TT for rs1132358)
with lower BAIAP3 mRNA levels in
PBMCs of male individuals, which is at
least partially comparable to a gene dose
reduction or KO situation. This result is
not found in women, possibly because of
the lower numbers available for analysis
(Supplementary Figure S5). However,
these findings could also support the in-
terpretation that the effects of BAIAP3
risk alleles are gender specific.
Male Baiap3 KO Mice Show Faster
Development of Tolerance to
Benzodiazepines
On the basis of the identification of
human BAIAP3 risk genotypes for ben-
zodiazepine abuse in male patients, we
tested Baiap3 KO and WT littermates of
both sexes in experimental paradigms of
chronic benzodiazepine administration
to assess the development of tolerance,
dependence and withdrawal (Figure 3A).
The baseline performance of each mouse
in the rotarod test was established on
two consecutive days of rotarod training.
No significant genotype-dependent dif-
ferences were detected in baseline per-
formance (Supplementary Figures S3G,
H). Benzodiazepine dependence in
Baiap3 KO and WT mice of both sexes
was then induced with daily diazepam
injections (5 mg/kg IP) for 10 consecu-
tive days. To monitor the development of
tolerance to diazepam, motor perform-
ance on rotarod at 30 min after each in-
jection was evaluated over the first 7 d of
diazepam treatment. Rapid development
of tolerance to daily diazepam injections
was apparent in both sexes and genotypes
by an increase of the latency of falling
from rotarod over the course of 7 d (Fig-
ures 3B, C). Here, male Baiap3 KO mice
performed significantly better than their
WT littermates (Figure 3B), whereas no
such difference was detected for females
(Figure 3C). Thus, male Baiap3 KO mice
show faster development of tolerance to
diazepam.
Baiap3 KO Mice Have an Increased
Seizure Propensity
To evaluate whether Baiap3 genotype
would affect the propensity for di-
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Figure 2. Anxiety phenotype in Baiap3 KO mice. (A–F) Open field parameters. (A, B) The latency to reach the wall of the open field was
significantly increased in Baiap3 KO mice of both sexes, whereas visits to the center (C, D) and stay in the periphery (E, F) revealed anxi-
ety-like behavior only in females. Elevated plus-maze (G, H) and light–dark box (I, J) revealed no genotype-dependent differences in ei-
ther sex. (K, L) As readout of unspecific novelty-related anxiety, a higher freezing response was found in male as well as female Baiap3 KO
mice. Numbers tested: males, WT = 16–25, KO = 16–25; females, WT = 18–23, KO = 10–28. Mann-Whitney U test (A–D, I–L) and two-way
ANOVA (E–H), including Bonferroni testing, were applied. Means ± SEM are presented.
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azepam withdrawal-related seizures, the
susceptibility to PTZ-induced seizures
was first evaluated in diazepam-naive
mice. The seizure response of Baiap3 KO
mice of both sexes to PTZ (50 mg/kg IP)
was higher than that in WT animals,
with the difference just failing to reach
significance in males (Figures 3D, E). To
assess the effect of genotype on benzodi-
azepine withdrawal, the diazepam an-
tagonist flumazenil (15 mg/kg IP) was
injected on d 11, after 10 d of daily di-
azepam treatment, immediately followed
by PTZ injection (50 mg/kg IP) to trigger
withdrawal seizures (Figure 3A). Upon
flumazenil-induced diazepam with-
drawal, the response to PTZ in male
Baiap3 KO and WT mice did not differ
appreciably from the one found in di-
azepam-naive mice of both genotypes
(Figure 3F). In contrast, the genotype-
 dependent differences in diazepam-naive
females regarding seizure scores disap-
peared under conditions of diazepam
withdrawal (Figure 3G), which could be
explained by a ceiling effect. Thus, fe-
male and male Baiap3 KO mice are more
seizure-prone than their WT littermates,
and this propensity is not further in-
creased by benzodiazepine withdrawal.
Drug Self-administration and Basic
Behaviors Do Not Differ between
Baiap3 Genotypes upon Chronic
Addiction
To assess whether Baiap3 KO mice,
once addicted, would also be more
likely to orally self-administer benzodi-
azepines, we performed an experiment
on chronic midazolam addiction, where
self-application was assessed after
forced long-term exposure to escalating
doses of midazolam (Supplementary
Figure S6). We detected no genotype or
gender differences in the clear prefer-
ence for midazolam. Moreover, no geno-
type effects on body weight or basic be-
havior in the chronically addicted state
were noted (Supplementary Figure S6).
These data indicate that the Baiap3
genotype gender specifically affects the
development of tolerance, that is, drug
abuse at an early stage. In chronic ad-
diction, genotype effects are no longer
detectable.
Lack of Homeostatic Adaptation to
Diazepam in Baiap3 KO
Hypothalamus Slices
One hypothesis regarding predisposi-
tion to the development of addiction at
the cellular level is an altered response
to the addiction-inducing substance and
its withdrawal. Because Baiap3 KO mice
showed an increased seizure propensity
and an altered development of tolerance
to diazepam, we investigated whether
lack of Baiap3 leads to a measurably al-
tered response to diazepam treatment
and withdrawal in neurons in vitro. Be-
cause Baiap3 expression is highest in the
hypothalamus, we cultured organotypic
hypothalamus slices prepared from
male P5/P6 Baiap3 KO and WT animals
in the presence of either 10 μmol/L di-
azepam or vehicle (DMSO) and re-
corded from neurons in the ventrome-
dial hypothalamus in the presence of
the diazepam antagonist flumazenil to
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Figure 3. Diazepam tolerance and withdrawal in Baiap3 KO and WT mice. (A) Experimen-
tal design scheme. (B) Male diazepam-treated Baiap3 KO mice showed significantly
faster improvement of performance on the rotarod, consistent with a more rapid devel-
opment of tolerance to diazepam. (C) Rotarod performance of female mice was com-
parable between WT and KO. (D, E) Diazepam-naive Baiap3 KO mice display a higher
PTZ-induced seizure propensity compared with WT (significant in females, strong tendency
in males). (F, G) Flumazenil-induced diazepam withdrawal does not further increase PTZ-
 induced seizure propensity in Baiap3 KO mice. Seizure propensity of female mice became
comparable between genotypes, pointing to a ceiling effect. Numbers tested: males, 
WT = 25, KO = 25; females, WT = 21, KO = 23, except for (D) and (E), where males, WT = 7,
KO = 7; females, WT = 8; KO = 10. Mann-Whitney U test (D–G) and two-way repeated-
measures ANOVA (B, C), including Bonferroni, testing applied. Means ± SEM are presented.
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mimic diazepam withdrawal conditions
in vitro. We hypothesized that diazepam
treatment would lead to a homeostatic
adaptation in the GABAAR-mediated
mIPSCs (Figure 4A) that would become
apparent under diazepam withdrawal
conditions. Although we observed no
diazepam treatment–dependent differ-
ences that reached statistical signifi-
cance, there was a significant genotype-
dependent effect under diazepam
withdrawal conditions. Here, WT
mIPSC amplitudes were 27% smaller
(Figure 4B) and rise times 13% longer
than in KO neurons (Figure 4C), which
is suggestive of a homeostatic adapta-
tion to diazepam treatment in WT but
not in KO slices. No significant differ-
ences in mIPSC decay times and fre-
quencies were observed (Supplementary
Table S2). Because the sudden with-
drawal of diazepam should lead to an
increase in overall network activity, we
recorded action potential (AP) frequen-
cies in ventromedial hypothalamus
slices in the presence of flumazenil. Sur-
prisingly, KO slices already showed sig-
nificantly higher AP frequencies than
WT slices under control conditions, with
no further increase under diazepam
withdrawal conditions. By contrast, in
WT slices, we observed a significant in-
crease in AP frequency under diazepam
withdrawal conditions compared with
vehicle-treated WT slices (Figure 4D).
There was no significant difference in
the resting membrane potentials (Fig-
ure 4E), AP rise times, decay times and
half-widths (Supplementary Table S2).
IPSCs were recorded in the same cells 
at a holding potential of –20 mV to be
able to isolate spontaneous GABAAR-
mediated currents without drug appli-
cation. In WT slices, we observed a sig-
nificant effect of diazepam withdrawal,
with an increase in IPSC amplitude and
frequency compared with vehicle-
treated WT slices (Figures 4F, G), which
is in keeping with the overall higher fir-
ing rate and which was not apparent in
KO slices. In summary, these data show
that neurons in Baiap3 KO hypothala-
mus slices have higher AP firing rates,
likely consistent with the higher seizure
propensity found in vivo, and that
Baiap3 KO slices show no obvious
homeostatic adaptation to diazepam
treatment and withdrawal.
DISCUSSION
In this study, we identify two human
BAIAP3 risk genotypes that are associ-
ated with anxiety in women and benzo-
diazepine use disorder in men. We fur-
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Figure 4. Increased basal network activity and lack of homeostatic adaptation to di-
azepam treatment in Baiap3 KO hypothalamus slices. (A) Sample traces of mIPSC record-
ings from WT and KO hypothalamus slices that were cultured in the presence of di-
azepam or under vehicle control conditions with DMSO. Under diazepam withdrawal
conditions, Baiap3 WT mIPSC amplitudes were significantly smaller than in KO slices (B),
and WT mIPSC rise times were longer than in KO slices (C). (D) Baiap3 WT slices showed an
increase in AP frequency in response to diazepam withdrawal when compared with
DMSO-treated WT slices, whereas no such increase was apparent for Baiap3 KO slices,
which already showed an increased AP frequency under DMSO control conditions when
compared with WT slices. (E) The resting membrane potential was not affected by experi-
mental condition or Baiap3 genotype. IPSC amplitudes (F) and IPSC frequencies (G) were
increased in Baiap3 WT slices under diazepam withdrawal compared with DMSO-treated
WT slices. Mann-Whitney U test was used for AP and IPSC frequencies; Student t test was
used for all other parameters. Means ± SEM are presented.
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ther show that Baiap3 deficiency in mice
leads to (i) elevated seizure propensity;
(ii) increased anxiety in both genders,
with a more pronounced effect in fe-
males; and (iii) a faster development of
tolerance to benzodiazepines in male
mice. In vitro analysis of hypothalamic
slices revealed an increase in neuronal
baseline activity in the absence of Baiap3.
Withdrawal from chronic benzodi-
azepine application in vitro results in a
genotype-specific response pattern.
To the best of our knowledge, no other
genetic risk marker that is associated
with anxiety and benzodiazepine abuse
has been reported to date. We are aware
that, pending replication in nonschizo-
phrenic individuals, we cannot be sure
that our findings can be applied to the
general population. In spite of this limi-
tation, our findings suggest a role for
BAIAP3 and potential interaction part-
ners in the development of anxiety and
drug dependence.
Unfortunately, similar data from sam-
ples of equally well-phenotyped healthy
individuals or even other disease
groups are not available. This is particu-
larly true with regard to benzodiazepine
abuse, since short-term exposure is a
primary goal of controlled and med-
ically surveyed indications. Even look-
ing at other rare situations of long-term
exposure (for example, intractable
epilepsies), a homogeneous sample
comparable to the GRAS collection
would be difficult to imagine. In the
GRAS sample, there are no differences
between BAIAP3 genotypes regarding
benzodiazepine exposure or daily dose
(in case of exposure). This constellation
allowed us to analyze the specific ge-
netic risk of developing benzodiazepine
use disorder in a setting close to an ex-
perimental condition.
Importantly, the present study was
purely hypothesis-driven. Our hypothe-
ses for performing a human phenotype-
based genetic association study of
BAIAP3 were based on the anxiety phe-
notype we observed during basic behav-
ioral characterization of Baiap3 KO mice
as well as on the distinctive Baiap3 ex-
pression pattern in brain, which includes
regions relevant for addictive behaviors.
We find that in humans, female carriers
of the homozygous BAIAP3 risk geno-
types (AA for SNP rs2235632; TT for SNP
rs1132358) are more likely to meet crite-
ria for an anxiety disorder, whereas male
carriers of the same risk genotypes are
more likely to fulfill criteria for benzodi-
azepine use disorder. Neither SNP was
associated with schizophrenia in our
case control analysis. Furthermore, no as-
sociations with substance use disorder
other than benzodiazepine use disorder
were observed. In general, both genetic
linkage and candidate gene studies suf-
fer from lack of replicability (12). How-
ever, in our study, the parallel identifica-
tion of a gender-specific association of
BAIAP3/Baiap3 with anxiety and an al-
tered response to benzodiazepines in
both mice and men, lends strong support
to a causal link between BAIAP3 and the
observed phenotypes.
As for other genetic variations associ-
ated with anxiety disorders (11,12) or
substance use disorders (13–15), the im-
pact of BAIAP3 genotypes on anxiety
disorders or benzodiazepine use disorder
is likely to be small. However, the ob-
served effects and their gender speci-
ficity (across two species) are intriguing.
While we currently have no mechanistic
insight into this gender specificity, part
of the explanation may lie in the fact that
Baiap3 is expressed in sexually dimor-
phic brain regions such as the hypothala-
mus, amygdala and the bed nucleus of
the stria terminalis (38,39).
Given the higher prevalence of both
anxiety disorders and benzodiazepine use
disorder in women (9,40) the present find-
ings were surprising at first glance, but
the similarity of gender differences in
mice and humans underlines their signifi-
cance, encouraging follow-up work on
this gender effect. Admittedly, the gender
effects in humans may ultimately turn out
to be less prominent, since the total num-
ber of individuals with benzodiazepine
abuse in the GRAS sample is low, result-
ing in moderate significance levels only
for men. It cannot be excluded that, in a
larger sample, an association of benzodi-
azepine use disorder with the genotypes
investigated here might reach significance
for women as well. Furthermore, research
focusing on gender differences and social
desirability in self-reported anxiety sug-
gests an underreporting of fear and dis-
tress in men (41–43). Therefore, our use of
three self-reported measures in the calcu-
lation of the anxiety composite score
might partly explain the lack of associa-
tion of the BAIAP3 risk genotypes with
anxiety in men. Nevertheless, gender dif-
ferences in BAIAP3/Baiap3 genotype-phe-
notype associations most likely exist and
are worth pursuing.
Benzodiazepines are positive allosteric
modulators of GABAAR and thus en-
hancers of inhibitory GABAergic neuro-
transmission. Their sedative, anti-convul-
sive and amnesic effects are largely
mediated by the GABAARα1 subunit, the
anxiolytic effect by the α2 subunit and
muscle relaxation by α2, α3 and α5 sub-
units (44). To date, no specific risk associ-
ation of these obvious candidate genes
has been identified. At present we have
no evidence that would suggest that
Baiap3 interacts with GABAAR subunits.
However, the increased seizure propen-
sity observed in Baiap3 KO mice of both
sexes, which is already apparent without
prior diazepam treatment and with-
drawal, is indicative of an altered bal-
ance of excitatory and inhibitory sys-
tems. Our comparison of neuronal firing
rates in hypothalamus slices under base-
line and diazepam withdrawal condi-
tions uncovered an increase in basal net-
work activity in the absence of Baiap3.
This finding was unexpected, and al-
though presently limited to the hypothal-
amus, is consistent with the increased
seizure propensity observed in vivo. Even
though we do not know whether the
seizures observed in our PTZ-induction
model originate in the subcortical re-
gions that express Baiap3, subcortical
epileptogenesis with origins in the hypo-
thalamus is a feature seen in hypothala-
mic hamartomas (45), and the amygdala,
which also expresses Baiap3, is known to
play a key role in epileptogenesis (46).
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Interestingly, the human BAIAP3 gene is
located on chromosome 16p13.3, which
has been linked to electroencephalo-
graphic traits of idiopathic epilepsy syn-
dromes (47,48). We would thus argue
that further investigation of BAIAP3 as a
candidate gene for epilepsy-related phe-
notypes is warranted. Because we found
that Baiap3 did not colocalize with mark-
ers of GABAergic or glutamatergic pre-
and postsynapses to a significant degree
(Supplementary Figures S1C–G), the in-
creased seizure propensity in Baiap3 KO
mice of both sexes and the altered re-
sponse to benzodiazepines in males is
unlikely to be due to a direct effect of
Baiap3 at GABAergic or glutamatergic
synapses.
The neuronal circuitry underlying the
addictive properties of benzodiazepines
is less well understood than their molec-
ular mechanism of action. Unlike many
other addictive substances, benzodi-
azepines do not appear to increase
dopamine levels in the nucleus accum-
bens (49–51), although electrophysiologi-
cal studies suggest that benzodiazepines
increase firing of dopaminergic neurons
in the VTA through disinhibition of these
neurons via inhibition of nearby in-
hibitory interneurons (52,53). Additional
mechanisms, such as neuroendocrine re-
sponses to benzodiazepine treatment,
may play a critical role in the develop-
ment of benzodiazepine use disorder
(54). Furthermore, because expression of
Baiap3 in both the VTA and in the nu-
cleus accumbens is low (Allen Brain
Atlas), a direct effect of Baiap3 on the
mesolimbic dopamine pathway does not
appear be the most likely explanation for
the observed interaction between Baiap3
genotypes and the response to benzodi-
azepines. Instead, our findings support
the interpretation that the altered re-
sponse to benzodiazepines could be a
consequence of a local or global change
in neuronal excitability. Because all other
members of the Munc13 protein family
have been shown to be regulators of
SNARE-mediated exocytosis (25,29),
Baiap3 may regulate the release of one or
more modulatory neurotransmitters or
neuropeptides that influence the balance
between GABAergic and glutamatergic
neurotransmission. Baiap3 immuoreac-
tivity appears punctate (Supplementary
Figures S1C–G) and may localize to pep-
tidergic release sites, some of which may
also contain VGLUT2 or Viaat. Although
we presently cannot exclude the possibil-
ity that Baiap3 might have a postsynaptic
function, given what is know about the
function of all other members of the
Munc13 protein family, we think that a
pre-synaptic function is more likely. We
can furthermore not exclude the possibil-
ity that alterations in the hypothalamic-
pituitary-adrenal axis may play a role in
the anxiety phenotype or the altered re-
sponse to benzodiazepines seen in Baiap3
KO mice. We are currently investigating
whether Baiap3 is involved in regulating
exocytosis of dense core vesicles and/or
intracellular trafficking events that could
influence neuropeptide release or ex-
trasynaptic GABAARs.
CONCLUSION
To conclude, BAIAP3 had not previ-
ously been considered a candidate gene
for either psychiatric disorders or
epilepsy. Our study links BAIAP3/Baiap3
genotypes to anxiety and an altered re-
sponse to benzodiazepines in both mice
and men and thus strongly argues for
an involvement of BAIAP3 in these neu-
ropsychiatrically relevant phenotypes.
The identification of human genetic var-
iations that influence the risk for the de-
velopment of pathological phenotypes
as well as the response to pharmacologi-
cal treatments may pave the way for
more efficient treatments with fewer
side effects. Rodent models are usually
only imperfect representations of
human psychiatric conditions; however,
the simultaneous identification of Baiap3
as a biomarker for anxiety and the re-
sponse to benzodiazepines in mouse
and humans suggests that Baiap3 KO
mice will be a valuable tool in further
elucidating the genetic, physiological
and neuroanatomical underpinnings of
anxiety disorders and benzodiazepine
use disorder.
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Supplementary Table S1. Benzodiazepine use (%) and dose (lorazepam equivalents) in GRAS patients sorted by BAIAP3 genotypes.
BAIAP3 rs2235632 BAIAP3 rs1132358
p value p value
Males (GRAS sample) GC AG AA (χ2 value) a CC TC TT (χ2 value) a
N=181 N=351 N=187 N=184 N=347 N=175
Receiving benzodiazepines, No. (%) b 22 (12.2) 57 (16.2) 30 (16.0) .427 (χ2 =1.70) 20 (10.9) 57 (16.4) 30 (17.1) .165 (χ2 =3.60)
N=21d N=52d N=30 N=19d N=52d N=30
Benzodiazepine dose, mg, Mean±SD b, c 3.14±4.14 2.64±3.11 3.04±3.31 .833 (χ2 =0.37) 2.95±4.31 2.67±3.11 3.00±3.32 .979 (χ2 =0.04)
p value p value
Females (GRAS sample) GC AG AA (χ2 value) a CC TC TT (χ2 value) a
N=101 N=167 N=92 N=105 N=167 N=83
Receiving benzodiazepines, No. (%) b 28 (27.7) 34 (20.4) 23 (25.0) .363 (χ2 =2.02) 30 (28.6) 34 (20.4) 20 (24.1) .298 (χ2 =2.42)
N=27d N=33d N=21d N=29d N=33d N=18d
Benzodiazepine dose, mg, Mean±SD b, c 2.51±1.51 2.13±2.35 2.33±2.28 .227 (χ2 =2.97) 2.44±1.49 2.08±2.37 2.52±2.40 .234 (χ2 =2.90)
a For statistical methods Chi2 or Kruskal-Wallis test was used. 
b Refers to benzodiazepines as daily medical treatment. 
c Calculation of lorazepam equivalents according to Bezchlibnyk-Butler, K. Z. & Jeffries, J. J. (Eds) (2003) Clinical Handbook of Psychotropic
Drugs (13th ed). Cambridge (MA): Hogrefe & Huber. 
D Discrepancies in N due to missing information on benzodiazepine compound or daily dose. 
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Supplemental Data
Supplementary Table S2. The mIPSC frequencies and decay times and the AP rise times,
decay times and half-width were not affected by experimental condition or Baiap3
genotype.
WT DMSO KO DMSO WT Diazepam KO Diazepam
mIPSC Decay Time 20.27±4.35 ms 21.01±4.94 ms 21.40±4.22 ms 20.36±4.21 ms
mIPSC Frequency 3.99±3.26 Hz 5.59±5.78 Hz 4.43±3.74 Hz 3.61±2.80 Hz
AP Rise Time 0.97±0.36 ms 1.02±0.45 ms 1.05±0.37 ms 1.12±0.34 ms
AP Decay Time 1.17±0.17 ms 1.14±0.24 ms 1.14±0.24 ms 1.21±0.36 ms
AP Half-Width 1.22±0.19 ms 1.22±0.29 ms 1.20±0.26 ms 1.27±0.39 ms
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Supplementary Figure S1. Targeting strategy and expression of mouse Baiap3. (A) Targeting strategy for the mouse Baiap3 gene. The first
3 coding exons were replaced with a neomycin selection cassette (Neo). The targeting vector further contained 2 thymidine kinase cas-
settes (TK) for negative selection. (B) Western blot analysis of the expression of Baiap3, in P0, P7, P14, P21 and adult Baiap3 WT and KO ani-
mals. In Baiap3 KO pups, we detected a truncated Baiap3-immunoreactive product that decreased after P7 and was not detectable in
adult mice. An antibody to the valosin-containing-protein (VCP) ATPase was used as a loading control. (C-E) Immunostaining analyses in
the hypothalamic medial preoptic area show that Baiap3 largely does not co-localize with markers of glutamatergic and GABAergic
synapses. (C) Baiap3 (red) shows no co-localization with the vesicular glutamate tranporter (VGLUT)1 (green). (D) Baiap3 (red) shows
only limited co-localization with VGLUT2 (green) (E) Baiap3 (red) shows only limited co-localization with the vesicular inhibitory amino
acid transporter (Viaat) (green). (F) In organotypic hypothalamus slices Baiap3 (red) does not show significant co-localization with pre-
synaptic (Viaat, blue) or post-synaptic (Gephyrin, green) markers of GABAergic synapses or (G) with pre-synaptic (VGLUT2, blue) or post-
synaptic (postsynaptic-density-protein 95, green) markers of glutamatergic synapses. Scale bars equal 10μm. 
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Supplementary Figure S2. Anxiety composite score. Shown are variables composing the
anxiety composite score, their intercorrelations and internal consistency. Pearson's correla-
tion coefficients and Cronbach’s α given. 
Supplementary Figure S3. Baiap3 genotype does not affect activity level, exploratory behavior, motor function or body weight. (A,B) The
distance traveled during a 7-min session in the open field and (C,D) 5-min session in the elevated plus-maze was comparable among
genotypes and genders. (E,F) Exploratory behavior measured in the hole board, (G,H) motor coordination and learning, evaluated by ro-
tarod, as well as (I,J) body weight were comparable for both genders between Baiap3 KO and WT littermates. Numbers tested: males,
WT=16-25, KO=16-25; females, WT=18-23, KO=10-28. Mann-Whitney U test (A-F, I,J) and 2-way repeated measures ANOVA (G,H), including
Bonferroni testing, were applied. Mean±s.e.m. presented.
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Supplementary Figure S4. BAIAP3 genotyping strategy and case-control analyses. (A) Location of the selected single nucleotide poly-
morphisms (SNPs) in the BAIAP3 gene. Kb, kilobases. (B) Linkage disequilibrium map for N=1086 schizophrenic and schizoaffective patients
and (C) Linkage disequilibrium map for N=1142 healthy blood donors indicating a high degree of linkage between the 3 selected SNPs
in both groups. (D) Case-control comparisons reveal a similar distribution of the BAIAP3 SNP genotypes for patients and healthy individu-
als, thus excluding the selected BAIAP3 markers as risk factors for schizophrenia. 
Supplementary Figure S5. BAIAP3 mRNA expression in PBMCs. (A) SNP rs2235632: The risk genotype AA is associated with lower BAIAP3
mRNA levels in male but not in female patients. (B) SNP rs1132358: The risk genotype TT is associated with lower BAIAP3 mRNA levels in
male but not in female patients. Mann-Whitney U test applied, due to non-normal data distribution (A,B). 
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Supplementary Figure S6. High oral self-administration of midazolam (as readout of addiction), body weight, and basic behaviors in the
chronic addicted state are not affected by Baiap3 genotype. (A) Experimental design scheme. (B,C) Baiap3 KO and WT mice of both
genders displayed significant and comparable preference for midazolam over sucrose. (D,E) Chronic midazolam intake did not affect
body weight of male, but increased that of female mice independently of genotype. (F,G) Locomotion duration in LABORASTM remained
unaffected across genotypes and genders. (H,I) Scratching frequency in LABORASTM tended to be increased upon chronic high-dose mi-
dazolam across genotypes and genders. Numbers tested: males, WT= 6-8, KO=10-16; females, WT=6-10, KO=10-13, except for (B) and (C),
males, WT=8, KO=4; females, WT=5; KO=4; 2-way repeated measures ANOVA (B,C) as well as 2-way ANOVA (D-I), including Bonferroni test-
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Articles
Accumulated environmental risk determining age at 
schizophrenia onset: a deep phenotyping-based study
Beata Stepniak, Sergi Papiol, Christian Hammer, Anna Ramin, Sarah Everts, Lena Hennig, Martin Begemann, Hannelore Ehrenreich
Summary
Background Schizophrenia is caused by a combination of genetic and environmental factors, as fi rst evidenced by 
twin studies. Extensive eff orts have been made t o identify the genetic roots of schizophrenia, including large genome-
wide association studies, but these yielded very small eff ect sizes for i ndividual markers. In this study, we aimed to 
assess the relative contribution of genome-wide association study-derived genetic versus environmental risk factors 
to crucial determinants of schizophrenia severity: disease onset, disease severity, and socioeconomic measures.
Methods In this parallel analysis, we studied 750 male patients from the Göttingen Research Association for 
Schizophrenia (GRAS) dataset (Germany) with schizophrenia for whom both genome-wide coverage of single-
nucleotide polymorphisms and deep clinical phenotyping data were available. Specifi cally, we investigated the 
potential eff ect of schizophrenia risk alleles as identifi ed in the most recent large genome-wide association study 
versus the eff ects of environmental hazards (ie, perinatal brain insults, cannabis use, neurotrauma, psychotrauma, 
urbanicity, and migration), alone and upon accumulation, on age at disease onset, age at prodrome, symptom 
expression, and socioeconomic parameters.
Findings In this study, we could show that frequent environmental factors become a major risk for early schizophrenia 
onset when accumulated (prodrome begins up to 9 years earlier; p=2·9×10–¹⁰). In particular, cannabis use—an avoidable 
environmental risk factor—is highly signifi cantly associated with earlier age at prodrome (p=3·8×10–²⁰). By contrast, 
polygenic genome-wide association study risk scores did not have any detectable eff ects on schizophrenia phenotypes.
Interpretation These fi ndings should be translated to preventive measures to reduce environmental risk factors, since 
age at onset of schizophrenia is a crucial determinant of an aff ected individual’s fate and the total socioeconomic cost 
of the illness.
Funding German Research Foundation (Research Center for Nanoscale Microscopy and Molecular Physiology of the 
Brain), Max Planck Society, Max Planck Förderstiftung, EXTRABRAIN EU-FP7, ERA-NET NEURON.
Introd uction
Substantial eff orts have been made to identify the genetic 
roots of schizophrenia, in view of heritability estimates of 
up to 80%.1 However, awareness is increasing that so-
called disease genes of general signifi cance do not exist 
for the biologically highly heterogeneous, purely clinical 
construct of schizophrenia. This absence of shared disease 
genes is supported by the consistently very low odds ratios 
(ORs) for individual markers derived from genome-wide 
association studies that are based on ever-increasing 
numbers of individuals.1,2
The most recently published large Psychiatric 
Genomics Consortium (PGC) genome-wide association 
study, comprising 36 989 patients with schizophrenia 
and 113 075 healthy controls, identifi ed 108 genetic loci 
with genome-wide associations.2 In addition to these 
loci, a substantial proportion of schizophrenia risk has 
been suggested to lie in markers that do not achieve 
genome-wide signifi cance. Therefore, quantitative 
polygenic schizophrenia risk scores were calculated on 
the basis of nominal allele eff ects. These risk scores now 
explain up to 7% of variance in the diagnosis of 
schizophrenia in independent samples.2 Based on 
previous genome-wide association studies, the eff ects of 
polygenic schizophrenia risk scores on various disease-
relevant phenotypes have been explored with variable 
degrees of success.3,4
Importantly, genes alone cannot explain the develop-
ment of schizophrenia, as indicated by a roughly 50% 
concordance rate in monozygotic twins.5 Therefore, 
intensifi ed research into environmental risk factors 
is pivotal, also with respect to its inherent preventive 
potential. Perinatal brain insults, cannabis use, 
neurotrauma, psychotrauma, urbanicity, and migration 
are among the most prominently discussed environ-
mental hazards associated with the risk of schizophrenia 
development.6–9
By contrast with most previous work that assessed the 
eff ect of diff erent environmental factors on the risk of 
schizophrenia development, the aim of this study was to 
assess in patients with schizophrenia the eff ects of these 
factors alone and upon accumulation on disease onset, 
symptom expression, and socioeconomic parameters. 
Specifi cally, we retrospectively assessed environmental 
risk exposure before disease onset. Moreover, we aimed 
to do back-to-back comparisons of the eff ects of 
environmental risk factors and genome-wide association 
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schizophrenia risk scores) on the same outcome 
measures within the same population. Owing to the 
known diff erences between male and female patients 
with schizophrenia in terms of age at onset, 
psychopathological symptom clusters, vulnerability, and 
exposure to environmental stressors, we focused on male 
patients only.10,11 Similar analyses with female patients 
remain to be done.
Methods
Study design and participants
The study population for environmental risk assessment 
consisted of a total of 750 male patients with schizophrenia 
and schizoaff ective disorder (according to Diagnostic and 
Statistical Manual of Mental Disorders, Fourth Edition Text 
Revision [DSM-IV-TR]) from the Göttingen Research 
Association for Schizophrenia (GRAS) dataset.12,13 To 
make a polygenic schizophrenia risk score-based case–
control status prediction including both men and women, 
1067 patients with schizophrenia (according to DSM-IV-TR) 
from the GRAS sample (including the 750 male patients 
in whom we assessed environmental risk) and 1169 
healthy controls (anonymous blood donors) were 
analysed.12 The ethics committees of the Georg-August-
University (Göttingen, Germany) and of the 23 centres 
participating in GRAS throughout Germany approved the 
study, which complies with the Declaration of Helsinki. 
All participants (and/or authorised legal representatives) 
provided written informed consent.
Phenotyping procedures
A meticulous description of the GRAS data collection 
standard operating procedures is provided elsewhere.13 In 
brief, comprehensive information regarding the prodrome 
(which precedes schizophrenia onset and is characterised 
by cognitive decline, social withdrawal, and depression), 
disease onset (onset of fi rst psychotic episode), symptom 
expression, and socioeconomic functioning was acquired 
from a very detailed examination. These assessments 
included positive and negative syndrome scale (PANSS) 
rating, assessment based on the Structured Clinical 
Interview for DSM-IV Axis I Disorders (SCID-I) and other 
semi-structured interviews (assessing suicidality, 
education history, present employment status, and history 
of admissions to hospital), telephone consultations, 
questionnaires, and an essentially complete collection of 
hospital discharge letters. For example, for all outcome 
measures of socioeconomic functioning assessed here, 
patients’ self-reports were always double-checked against 
hospital letters. Education was measured as total years 
spent in school, further education, and professional 
training based on the highest qualifi cation achieved. 
Present employment status and livelihood were assessed 
and patients were classifi ed as either unemployed or not 
unemployed (in full-time or part-time employment, 
retired, or in education). For number of admissions to 
hospital, all admissions due to psychiatric diagnoses were 
counted. To assess cognitive symptoms, a composite score 
was calculated from diff erent neuropsychological tests, 
comprising reasoning (Leistungsprüfsystem subtest 3 
[LPS3]), executive function (Trail-Making Test, part B 
[TMT-B]), and verbal learning and memory (Verbal 
Learning and Memory Test [VLMT]).12 To estimate family 
mental illness burden, history of any severe mental illness 
(schizophrenia, psychosis, depression, or mania) in fi rst-
degree relatives was recorded.
Environmental risk exposure
To assess environmental risk exposure, specifi c 
information about perinatal complications, neurotrauma, 
psychotrauma, cannabis use, and migration was derived 
from the patient’s history and extensive semi-structured 
interviews with patients and relatives or caregivers (GRAS 
Manual13) and from SCID-I. Every patient was 
dichotomously (yes/no) classifi ed as having or not having 
been exposed (before disease onset and up to 18 years of 
age) to perinatal complications, neurotrauma, cannabis, 
psychotrauma, and migration. To measure urbanicity 
from birth until 18 years of age, information about place 
of residence and relocation was collected from hospital 
discharge letters and social history. If information was 
missing, patients were contacted by telephone or post 
with an urbanicity questionnaire. In cases of contradictory 
information or if the missing data could not be obtained, 
patients were excluded from the respective analysis. For 
paternal age at birth and season of birth, information was 
obtained from fi les.
Perinatal complications were defi ned as any deviations 
from normality during pregnancy (eg, alcohol or 
substance use, infections, pre-eclampsia, or diabetes), 
delivery (eg, premature or protracted birth, or hypoxia), 
and in early postnatal life (eg, pronounced jaundice). 
Neurotrauma was classifi ed as documented head trauma 
of any grade of severity, from mild trauma to concussion 
and contusion. For cannabis use, in addition to the 
dichotomous classifi cation of all patients into cannabis 
users and non-users, all people who had used cannabis 
before 18 years of age and before disease onset were 
grouped regarding frequency of use into: infrequent 
users (from fi ve times in life up to six times per year); 
regular users (from once per month up to every other 
day); and daily use. In this classifi cation, regular use and 
daily use referred to the 6-month period in life when use 
was heaviest. Cases of psychotrauma included loss of a 
fi rst-degree relative or close attachment fi gure of high 
importance (severity of loss ≥5 on a rating scale of 0–10), 
sexual abuse, severe physical abuse (comprising 
unpredictability of violence, injury caused by physical 
reprimand, or use of objects for corporal punishment), or 
any combination thereof. To measure urbanicity, each city 
the patients lived in was allocated to one of four categories 
according to its total population (category 1: ≤10 000, 
category 2: 10 001–50 000, category 3: 50 001–100 000, or 




www.thelancet.com/psychiatry   Published online October 22, 2014   http://dx.doi.org/10.1016/S2215-0366(14)70379-7 3
multiplied by the number of years that the person had 
spent living there. In cases of relocation, the same 
procedure was repeated for each new place of residence 
and values were added up to obtain one urbanicity score 
per individual. For further calculations, the urbanicity 
score was dichotomously grouped into rural (score 18–45) 
and urban (score 46–72) places of residence. To obtain 
clean data for the risk of 18 years of urban exposure, 
patients with a schizophrenia onset before 18 years of age 
were excluded (n=77). For the risk factor of migration, 
information from sociodemographic interviews was used 
to classify any patient who immigrated to Germany up to 
age 18 years as a migrant.
Statistical analysis of environmental risk
To assess group diff erences in continuous variables, we 
used the Mann-Whitney U test or, in cases of normal 
distribution of dependent continuous variables, the t test. 
We used logistic regression analysis to study the eff ects of 
more than one variable on dichotomous outcome 
categories. To compare means of more than two groups, 
we used the Kruskal-Wallis H test if the data followed a 
non-parametric distribution; otherwise, we used ANOVA 
if data followed a normal distribution. To assess frequency 
diff erences between groups we used the χ² test. To assess 
whether medians of more than two groups ascend or 
descend, we applied the Jonckheere-Terpstra trend test. 
Trends in frequency distributions were calculated with the 
Cochran-Armitage test. Covariate correction was done 
through calculation of linear regression-based 
standardised residuals when duration of disease or age, 
chlorpromazine equivalents of current antipsychotic 
medication, and PANSS negative subscale score were 
used as independent variables. We used a linear regression 
(forced entry) model to calculate the variance explained for 
age at prodrome and age at onset by either cannabis use 
alone or all other risk factors (perinatal complications, 
neurotrauma, psychotrauma, urbanicity, and migration). 
We generated Kaplan–Meier survival curves for diff erent 
cannabis use frequencies, with age at prodromal onset as 
the endpoint. We used the log-rank test to make pairwise 
comparisons of diff erent curves. For all analyses, statistical 
signifi cance was set to the 0·05 level. We applied 
Bonferroni correction as a very conservative method to 
account for multiple testing. P values that withstand this 
correction are underlined in the respective tables. 
Statistical analyses were done using SPSS for Windows 
version 17.0, except for the Cochran-Armitage test for 
trend, for which R version 2.15.1 was used.
Genotyping, quality control, population structure, and 
relatedness
Genotyping of the GRAS patients and control sample was 
done with a semi-custom Axiom myDesign genotyping 
array (Aff ymetrix, Santa Clara, CA, USA), based on 
a CEU (Caucasian residents of European ancestry 
from Utah, USA) marker backbone including 51 8 722 
single-nucleotide polymorphisms (SNPs), and a custom 
marker set including 102 537 SNPs. The array was 
designed using the Axiom Design center, applying diverse 
selection criteria.14 Genotyping was done by Aff ymetrix on 
a GeneTitan platform. Several quality control steps were 
used (SNP call rate >97%, Fisher’s linear discriminant 
>3·6, heterozygous cluster strength off set >–0·1, and 
homozygote ratio off set >–0·9). These steps were 
completed with use of either genotyping console software 
(Aff ymetrix) or R. In a subsequent step, markers in X, Y, 
and mitochondrial chromosomes and those with Hardy–
Weinberg equilibrium p<1 × 10–⁶ (healthy controls) or 
p<1 × 10–¹⁰ (GRAS patients) were removed, leaving 589 921 
SNPs available for analyses. We used this dataset to do a 
principal components analysis of the whole sample in 
EIGENSTRAT (SmartPCA module) to identify and 
exclude ancestral outliers in our participant collection, for 
which we used a sigma threshold of 5·0.15 This SNP 
dataset was pruned further, with minor allele frequency 
(minor allele frequency ≥0·05) and linkage disequilibrium 
between markers (r² ≤0·05) as inclusion criteria, leaving 
33 311 markers ready for relatedness ascertainment. 
Relatedness was ascertained with PLINK version 1.07 
through calculation of a genome-wide pairwise identity-
by-descent estimation.16 In those participant pairs with a 
PI-HAT relatedness coeffi  cient score greater than 0·2, one 
of the members of the pair was randomly excluded from 
analyses, resulting in exclusion of a total of 12 participants 
(in whom PI-HAT ranged from 0·2706 to 0·9996). This 
pairwise identity-by-descent estimation was also used to 
calculate multidimensional scaling components to control 
for population stratifi cation in polygenic analyses. 
Similarly, the inbreeding coeffi  cient was calculated from 
the previously mentioned 33 311 SNPs dataset. PLINK was 
also used to calculate multidimensional scaling com-
ponents and inbreeding coeffi  cients.16
Imputation
Genotype imputation was done with the prephasing or 
imputation approach implemented in IMPUTE2 and 
SHAPEIT (chunk size 3 Mb).17,18 A version of the phase 1 
integrated variant set release (v3) from the full 
1000 Genomes Project dataset (March, 2012)19 that is 
limited to variants with more than one minor allele copy 
(“macGT1”; Aug 26, 2012) was used as imputation 
reference dataset (INFO value >0·1 and minor allele 
frequency >0·005).
Derivation of polygenic schizophrenia risk scores
Polygenic schizophrenia risk scores were calculated as 
described in the most recent international collaborative 
genome-wide association study of schizophrenia.2 Briefl y, 
insertions/deletions, low-frequency genetic variants 
(minor allele frequency <10%), low imputation quality 
variants (INFO value <0·9), and extended major 
histocompatibility complex region genetic variants were 
excluded for these calculations. Variants in r² of 0·1 or 
For more on the Axiom Design 
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greater and within 500 kb of another marker with stronger 
eff ects were discarded, eventually leaving a set of 102 375 
SNPs ready for profi le scoring. Polygenic schizophrenia 
risk scores were calculated by application of the –score 
function in PLINK16 using subsets of SNPs below diff erent 
p value cutoff s (5 × 10–⁸, 1 × 10–⁶, 0·0001, 0·001, 0·01, 0·05, 
0·1, 0·2, 0·5, 1·0). For each SNP included under these 
subsets (amounting to a total of 60, 239, 1229, 3359, 10479, 
24 460, 35 486, 51 691, 81 137, 102 375, respectively), the 
imputation probability for the risk allele was weighted by 
its respective logarithm of the OR. The individual 
SNP values were added for each individual participant, 
leading to the calculation of ten polygenic schizophrenia 
scores for each person in the target sample.
Figure: Environmental risk contribution to disease onset in schizophrenia versus absence of genetic eff ects
(A) Proportion of variance explained (change in adjusted R² or Nagelkerke pseudo-R²) by polygenic genome-wide association study-derived schizophrenia risk scores 
at increasing p value thresholds. Note that the schizophrenia risk data displayed on the left of the graph are based on 1067 patients (of both sexes) with schizophrenia 
from the Göttingen Research Association for Schizophrenia sample and 1169 healthy controls (of both sexes), whereas the association with disease phenotypes has 
been calculated in the male subset of patients with schizophrenia assessed for environmental eff ects (also see appendix p 3). (B) Overlap of environmental risk 
exposure in 502 male patients with schizophrenia for whom complete information about all factors was available. (C) Eff ects of accumulated environmental risk on 
age at disease onset for the same 502 male patients. The overall p value is shown (in the box) and individual pairwise comparisons of the group with four or more risk 
factors versus all other groups are presented. The Kruskal-Wallis H test and Mann-Whitney U test were used for analysis; data are mean (SE) (Bonferroni-corrected 
signifi cance level: p<0·01). (D) Kaplan–Meier dose–response curves for patients with diff erent frequencies of cannabis use before disease onset and at up to 18 years of 
age compared with those who have never used cannabis. Regular use ranges from once per month up to every other day, whereas infrequent use includes frequencies 
from fi ve times in life up to six times per year. The log-rank test was used for group and pairwise intergroup comparisons (Bonferroni-corrected signifi cance level: 
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Statistical analysis of polygenic schizophrenia risk scores
As dependent variables in a linear regression model, 
quantitative traits (eg, age at onset and cognitive 
composite) were used to analyse the eff ects of polygenic 
schizophrenia scores. These trait values were corrected 
when applicable as indicated in the table footnotes. Ten 
multidimensional scaling components and the 
inbreeding coeffi  cient were selected as covariates of 
potential relevance. Adjusted R² values derived from a 
model including all of these covariates were subtracted 
from adjusted R² values from a model including 
covariates plus the respective polygenic schizophrenia 
scores. The diff erence between the adjusted R² represents 
the increase in the variance explained attributable to the 
score. For dichotomous variables (case–control study and 
suicidality), in an analogous fashion, Nagelkerke’s 
pseudo-R² from a logistic regression containing only 
covariates (10 multidimensional scaling components and 
inbreeding coeffi  cient) was compared against the one 
obtained in a model containing covariates and polygenic 
schizophrenia scores to estimate the proportion of 
variance of case–control status explained by the polygenic 
schizophrenia risk score. The potential eff ect of an 
interaction between the risk score and environmental 
load on phenotypes of interest was also assessed. For this 
purpose, adjusted R² of a model containing only 
environmental load as predictor was set as the baseline R² 
for comparisons with two models: a model containing 
environment plus covariates (multidimensional scaling 
components plus inbreeding coeffi  cient) plus polygenic 
schizophrenia risk score; and a model containing 
environment  plus covariates (multidimensional scaling 
components plus   inbreeding coeffi  cient) plus polygenic 
schizophrenia risk score plus the  interaction be tween 
environment and polygenic schizophrenia risk score 
(G × E). All calculations were done with SPSS version 17.0.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had fi nal responsibility for 
the decision to submit for publication.
Results
We studied comprehensively genotyped and phenotyped 
male patients from our GRAS dataset of patients with 
schizophrenia.12–14 We calculated polygenic schizophrenia 








fi rst psychotic 




fi rst psychotic 
episode 





fi rst psychotic 
episode 
and age ≤18 years
(n=197–217)†
Yes— before 
fi rst psychotic 
episode 





Age at disease onset (years) 25·53 (8·01) 23·68 (6·65) p=0·003
(Z=–2·97)
26·05 (8·25) 24·32 (7·32) p=0·001
(Z=–3·21)
25·29 (7·50) 23·20 (5·81) p=0·002
(Z=–3·15)
Age at prodrome (years) 22·71 (7·94) 20·52 (6·57) p=0·0003
(Z=–3·62)
23·37 (8·20) 21·32 (7·26) p=0·001
(Z=–3·30)
22·40 (7·19) 20·21 (6·07) p=0·003
(Z=–2·97)
Positive score on PANSS‡ 13·36 (5·94) 13·86 (6·24) p=0·436
(Z=–0·78)
13·11 (5·89) 13·90 (6·22) p=0·154
(Z=–1·43)
13·70 (6·56) 13·12 (5·37) p=0·741
(Z=–0·33)
Negative score on PANSS‡ 18·42 (7·70) 17·78 (7·27) p=0·242
(Z=–1·17)
18·07 (7·75) 18·33 (7·64) p=0·536
(Z=–0·62)
18·90 (7·88) 17·49 (7·11) p=0·091
(Z=–1·69)
Cognitive composite§ 0·03 (0·81) 0·11 (0·86) p=0·363
(t=–0·91)
–0·06 (0·87) 0·09 (0·80) p=0·061
(t=–1·88)
0·06 (0·84) 0·19 (0·74) p=0·575
(t=–0·56)
Suicidality¶ 142 (34·4%) 109 (39·2%) p=0·196
(χ²=1·67)
129 (39·7%) 130 (34·7%) p=0·170
(χ²=1·89)
74 (35·1%) 88 (41·3%) p=0·186
(χ²=1·75)
Socioeconomic variables
Education (years)|| 11·97 (2·93) 11·68 (2·92) p=0·095
(Z=–1·67)
12·11 (3·03) 11·86 (2·97) p=0·357
(Z=–0·92)
12·75 (3·24) 11·18 (2·44) p<0·00001
(Z=–5·12)
Unemployment** 173 (41·6%) 128 (45·6%) p=0·300
( χ²=1·08)
123 (37·4%) 171 (45·6%) p=0·027
(χ²=4·86)
79 (37·3%) 104 (48·6%) p=0·018
(χ²=5·58)
Number of hospital admissions‡ 7·41 (9·45) 8·68 (9·33) p=0·003
(Z=–2·96)
8·34 (10·93) 8·11 (8·49) p=0·256
(Z=–1·14)
6·57 (7·98) 10·17 (11·52) p<0·00001
(Z=–4·69)
Data are uncorrected means (SD) or n (%). For statistical analysis, the Mann-Whitney U test or χ2 test was used, and for normally distributed variables the t test was used. Signifi cance values are displayed 
uncorrected, and p values withstanding Bonferroni correction are underlined. PANSS=positive and negative syndrome scale.*Groups matched for age.†Because of missing data, sample sizes vary. ‡Corrected for 
duration of disease (standardised residuals after linear regression). §Corrected for age, PANSS negative, and chlorpromazine equivalent (standardised residuals after linear regression). ¶Suicidality=individuals 
who have attempted suicide in the past. ||Education refers to the total number of years spent to achieve the highest individual qualifi cation; people presently in education excluded. **Signifi cant results for 
unemployment were re-examined adding duration of disease as a covariate in a logistic regression model. Neurotrauma (no/yes) did remain a signifi cant predictor of unemployment (no/yes) in the model (Wald 
test=4·90, p=0·027, odds ratio 1·43). Cannabis use (no/yes) remained a signifi cant predictor of unemployment (no/yes) in the model (Wald test=6·08, p=0·014, odds ratio 1·65). 
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risk scores for each participant on the basis of p values 
and ORs available from the latest genome-wide 
association study of the PGC.2 Every patient’s exposure 
to selected environmental risk factors up to the age of 
18 years and before the onset of psychosis was established 
on the basis of SCID-I, semi-structured interviews, 
telephone consultations, questionnaires, and a 
comprehensive collection of hospitalisation letters.
As fi gure A and appendix p 3 show, polygenic 
schizophrenia risk scores based on diff erent levels of 
signifi cance highly signifi cantly (up to p=1·15 × 10–⁵⁰) 
reproduced the association with schizophrenia diagnosis 
in the GRAS sample, which supports the validity of the 
study population. By contrast, the same approach did not 
show any eff ect on schizophrenia-relevant phenotypes, 
thus questioning an appreciable role of polygenic 
schizophrenia risk score-grouped genome-wide 
association study-derived genotypes for co-determining 
lead illness features.
With a focus on the environment, we questioned 
whether the experience of single risk factors during a 
vulnerable time of brain development, ie, up to the age 
of 18 years and before the fi rst psychotic episode, has an 
eff ect on the time of illness or prodrome onset. Prodrome 
is a period of several years, typically preceding 
schizophrenia onset, which is clinically characterised by 
cognitive decline, social withdrawal, and depression.20 A 
comparison of individuals who had suff ered a particular 
environmental insult of interest, to the remaining 
patients without this insult (table 1), showed signifi cant 
results for perinatal complications (defi ned as any kind 
of deviation from normality that occurred during 
pregnancy or around birth), neurotrauma (comprising 
all levels of severity), and cannabis (ranging from any 
consumption up to regular use). All these risk factors 
were associated with younger age at disease onset (fi rst 
psychotic episode) and at prodrome start (all p values 
≤0·003, withstanding Bonferroni correction) (table 1). 
We note that age at onset co-determines overall 
prognosis.20 The earlier individuals develop schizo-
phrenia, the less progressed are their levels of education 
and socialisation. These factors in turn aff ect individual 
social functioning and social role performance and, 
consequently, societal costs.20 We did not record any 
eff ects on age at disease onset or age at prodrome for 
psychotrauma, urbanicity, and migration (table 2).
Next, we studied whether risk factor exposure had an 
eff ect on schizophrenia severity and socioeconomic 
Psychotrauma Urbanicity Migration*
No—before 
fi rst psychotic 
episode 
and age ≤18 years
(n=383–436)†
Yes—before 
fi rst psychotic 
episode 





(0–18 years of age) 




(0–18 years of age) 






fi rst psychotic 




fi rst psychotic 






Age at disease onset (years) 25·10 (7·60) 25·02 (8·09) p=0·567
(Z=–0·57)
26·48 (8·24) 25·90 (6·59) p=0·640
(Z=–0·47)
23·53 (6·21) 22·56 (4·37) p=0·595
(Z=–0·53)
Age at prodrome (years) 22·38 (7·44) 21·85 (8·32) p=0·146
(Z=–1·45)
23·71 (8·50) 22·69 (7·08) p=0·470
(Z=–0·72)
20·70 (6·20) 19·85 (4·09) p=0·902
(Z=–0·12)
Positive score on PANSS‡ 13·92 (6·44) 13·17 (5·59) p=0·272
(Z=–1·10)
12·95 (5·72) 13·96 (6·51) p=0·108
(Z=–1·61)
13·33 (5·85) 12·22 (5·97) p=0·041
(Z=–2·04)
Negative score on PANSS‡ 18·78 (7·64) 17·45 (7·50) p=0·017
(Z=–2·38)
18·09 (7·55) 18·02 (7·76) p=0·666
(Z=–0·43)
17·81 (7·32) 17·18 (6·75) p=0·718
(Z=–0·36)
Cognitive composite§ 0·02 (0·86) 0·04 (0·81) p=0·941
(t=–0·07)
0·03 (0·82) 0·10 (0·82) p=0·295
(t=–1·05)
0·23 (0·76) 0·01 (0·69) p=0·0004
(t=3·58)
Suicidality¶|| 145 (33·9%) 103 (40·6%) p=0·080
(χ²=3·07)
102 (31·3%) 95 (39·6%) p=0·041
(χ²=4·19)
174 (36·1%) 26 (37·1%) p=0·865
(χ²=0·03)
Socioeconomic variables
Education (years)** 12·23 (3·08) 11·57 (2·79) p=0·006
(Z=–2·75)
12·31 (2·91) 12·23 (3·27) p=0·547
(Z=–0·60)
11·91 (2·80) 10·18 (2·10) p<0·00001
(Z=–5·01)
Unemployment|| 185 (42·0%) 104 (40·5%) p=0·683
(χ²=0·17)
114 (35·1%) 115 (47·3%) p=0·003
(χ²=8·67)
243 (50·0%) 35 (50·7%) p=0·910
(χ²=0·01)
Number of hospital 
admissions‡
8·1 1 (10·28) 7·85 (7·85) p=0·927
(Z=–0·09)
7·92 (9·25) 8·42 (10·34) p=0·877
(Z=–0·15)
7·54 (8·51) 7·17 (12·91) p=0·147
(Z=–1·45)
Data are uncorrected means (SD) or n (%). For statistical analysis, the Mann-Whitney U test or χ² test was used, and for normally distributed variables the t test was used. Signifi cance values are displayed 
uncorrected, and p values withstanding Bonferroni correction are underlined. PANSS=positive and negative syndrome scale. *Groups matched for age. †Because of missing data, sample sizes vary. ‡Corrected for 
duration of disease (standardised residuals after linear regression). §Corrected for age, PANSS negative, and chlorpromazine equivalent (standardised residuals after linear regression). ¶Suicidality=individuals 
who have attempted suicide in the past. ||Signifi cant results for suicidality and unemployment were re-examined adding duration of disease as a covariate in a logistic regression model. Urbanicity (rural/urban) 
remained a signifi cant predictor of suicidality (no/yes) (Wald test=3·95, p=0·047, odds ratio 1·43) and unemployment (no/yes) (Wald test=9·77, p=0·002, odds ratio 1·77). **Education refers to the total number 
of years spent to achieve the highest individual qualifi cation; people presently in education excluded.  
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readouts. Indeed, patients with a history of perinatal 
complications and those who had started to use cannabis 
before illness onset had more admissions to hospital (all 
p values ≤0·003, withstanding Bonferroni correction). 
Neurotrauma, urbanicity, and cannabis use tended to be 
associated with higher unemployment rates (tables 1, 2). 
Psychotrauma, including loss of a close attachment 
fi gure and physical and sexual abuse, was associated with 
fewer years of education (p=0·006; table 2), as were 
cannabis use and migration (both with p values <0·00001, 
withstanding Bonferroni correction) (tables 1, 2). Season 
of birth21,22 and paternal age at birth,23 also previously 
discussed as schizophrenia risk factors, did not show 
associations with any outcome parameters (appendix 
pp 4–5); except for paternal age, which was signifi cantly 
associated with years spent in education (p=0·002, 
withstanding Bonferroni correction; appendix p 5).
The logical question of whether or not an accumulation 
of up to four or more risk factors would lead to a more 
severe disease expression has, to our knowledge, never 
previously been addressed. Figure B exemplifi es the 
complexity of environmental risk exposure in the male 
sample group, which is categorised for this illustration 
into three major domains: direct brain injury (perinatal 
complications and neurotrauma), psychological or 
indirect brain damage (psychotrauma, urbanicity, or 
migration), and cannabis use. To systematically study 
cumulative eff ects, we compared patients without risk 
factor exposure and those with one to four or more 
environmental risks. We recorded highly signifi cant 
group diff erences (all withstanding Bonferroni 
correction) for age at disease onset and prodromal onset 
(p values around 1 × 10–¹⁰), years of education 
(p=2·3 × 10–⁸), unemployment (p=0·0002), and number 
of admissions to psychiatric hospital (p=0·001) (table 3). 
Remarkably, every additional risk factor worsens the 
outcome further, as emphasised by highly signifi cant 
trend tests (table 3, fi gure C). Patients with none or one 
risk factor experience prodromal onset about 8 years 
later than do those with four or more environmental 
insults (p=3·7 × 10–¹⁰;  Cohen’s d=0·99; OR for prodrome 
before age 23 years versus after: OR 10 [95% CI 
4·27–21·70, χ²=36·63]). The strength of these 
associations could off set potential concerns regarding 
false-positive results.
Importantly, the eff ect of cannabis as a preventable 
environmental risk factor on age at onset (p=3·8 × 10–²⁰) is 
enormous (fi gure D). Cannabis use alone can explain 
10·2% of variance in age at disease onset, compared with 
4·7% explained by all other environmental risks together 
(linear regression model). This result calls for public 
education that targets prevention.
As an internal control (accounting for the unavailability 
worldwide of an adequate replicate sample), we split the 
male GRAS population into two equally sized samples 
according to recruitment date. This split-sample approach 
provided similar results for both halves of the population 
(appendix p 6).
No appreciable associations between any environmental 
factor tested here—alone or upon accumulation—with 
positive or negative symptom load or cognitive per-
formance were detectable. Within some environmental 
risk constellations, secondary factors predisposing to 
mental illness might be hidden, such as social status, 
societal integration, peer group pressure, access to drugs 
including cannabis, or family history of psychiatric 
disorders. For family load of mental disease, no diff erences 
were noted between risk factor groups (p>0·05; data not 
shown). Gene–environment interaction analyses based on 
genome-wide association study-derived polygenic schizo-
phrenia risk scores and individual environmental burden 
















Age at disease onset (years) 30·66 (7·68) 28·72 (9·34) 26·20 (7·42) 24·84 (5·64) 22·59 (5·21) p=9·3×10–11  (H=52·82) p=5·2×10–12 (J=36068·0)
Age at prodrome (years) 28·34 (7·97) 26·07 (9·32) 23·28 (7·82) 21·58 (6·15) 19·40 (5·26) p=2·9×10–10 (H=50·46) p=5·6×10–12 (J=28005·5)
Positive score on PANSS§ 13·05 (6·32) 13·50 (6·50) 13·16 (5·61) 13·84 (6·24) 12·63 (5·94) p=0·650 (H=2·47) NA
Negative score on PANSS§ 18·31 (7·37) 17·71 (7·87) 18·88 (7·58) 17·48 (6·66) 16·37 (7·29) p=0·189 (H=6·13) NA
Cognitive composite¶ –0·10 (0·85) –0·02 (0·88) –0·02 (0·85) 0·19 (0·77) 0·26 (0·74) p=0·916 (F=0·24) NA
Suicidality|| 8 (20·0%) 36 (33·6%) 50 (35·2%) 48 (37·5%) 32 (41·0%) p=0·229 (χ²=5·63) p=0·039 (χ²=4·27)
Sociodemographic variables
Education (years)** 13·71 (3·03) 13·48 (3·38) 12·24 (3·11) 11·93 (2·67) 10·93 (2·56) p=2·3×10–8 (H=41·34) p=7·7×10–10 (J=34112·5)
Unemployment 7 (17·5%) 33 (30·8%) 60 (42·3%) 55 (43·0%) 45 (57·0%) p=0·0002 (χ²=22·34) p=6·8×10–6 (χ²=20·24)
Number of hospital admissions§ 6·95 (9·80) 7·32 (7·77) 7·39 (7·38) 8·75 (12·05) 8·15 (7·94) p=0·001 (H=19·08) p=2·1×10–5 (J=56421·0)
Data are uncorrected means (SD) or n (%). NA=not applicable (no trend in data). *Because of missing data, sample sizes vary. †For statistical analysis, the Kruskal-Wallis H test or χ² test was used, and for normally 
distributed data ANOVA was used. Signifi cance values are displayed uncorrected, and p values withstanding Bonferroni correction are underlined. ‡To test for statistical trends, the Cochran–Armitage test 
(qualitative traits) or the Jonckheere-Terpstra test (quantitative traits) was used. Signifi cance values are displayed uncorrected, and p values withstanding Bonferroni correction are underlined. §Corrected for 
duration of disease (standardised residuals after linear regression). ¶Corrected for age, PANSS negative, and chlorpromazine equivalent (standardised residuals after linear regression). ||Suicidality=individuals 
who have attempted suicide in the past. **Education refers to the total number of years spent to achieve the highest individual qualifi cation; people presently in education excluded. 
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corrections (appendix pp 7–8). However, this fi nding does 
not exclude the possibility that interactions might exist 
between particular environmental risk factors and specifi c 
genetic loci that cannot be detected in aggregate.
Discussion
We used a large sample of thoroughly phenotyped male 
patients with schizophrenia to investigate for the fi rst 
time back-to-back in the same population the eff ects of 
genome-wide association study-derived genetic markers 
and of environmental risk factors on disease phenotypes 
(panel). In this population, we show: a qualitatively and 
quantitatively diff erent eff ect of defi ned single 
environmental hazards on disease onset and socio-
economic burden; a substantial eff ect of accumulated 
environmental risk factors on age at prodrome and 
schizophrenia onset; and an absence of detectable 
eff ects of genome-wide association study-derived 
polygenic schizophrenia risk scores on disease-relevant 
phenotypes. We also show that the relative signifi cance 
of cannabis as avoidable environmental risk on age at 
prodrome is substantial.
The absence of detectable eff ects of case-control 
genome-wide association study-derived polygenic 
schizophrenia risk scores on disease-relevant phenotypes 
might be less surprising when we consider the 
tremendous heterogeneity of people who fall into the 
diagnostic category of schizophrenia.24 Furthermore, 
detection of any risk score eff ects on disease variables, if 
at all relevant, might need huge sample sizes. On the 
other hand, SNP variants associated with disease risk as 
aggregated into genome-wide association study-derived 
polygenic schizophrenia risk scores might not always 
overlap with risk variants associated with specifi c 
syndrome domains (eg, see reference 25). Moreover, 
schizophrenia risk score-based analyses might not be 
optimised for study of association with disease-relevant 
phenotypes.
Environmental hazards diff er greatly in time and 
pattern of occurrence. Whereas perinatal complications 
happen early during development, neurotrauma and 
psychotrauma can occur at any point during childhood 
or adolescence, even repeatedly, and with variable 
intensity and individual perception. Urbanicity aff ects 
people continuously from birth until adulthood. 
Moreover, environmental hazards diff er in their initial 
mechanisms of action on the brain, even though they 
might share fi nal common deleterious pathways 
downstream. As shown in this study, environmental 
insults that directly—ie, physically or through specifi c 
drug eff ects—aff ect brain development, maturation, and 
integrity of cerebral structures have major eff ects on 
crucial outcome elements such as age at disease onset. 
Psychotrauma and migration act indirectly, probably by 
inducing high amounts of negative psychosocial stress.26 
Urbanicity is often referred to as a proxy for chronic 
inevitable, and therefore negative, everyday stress.27
A substantial amount of published work exists about 
early cannabis use and the raised risk of developing 
schizophrenia (eg, see references 28, 29), whereas work 
analysing the eff ect of cannabis on age at onset of 
schizophrenia is less abundant (eg, see a recent meta-
analysis30). Age at fi rst cannabis use has been falling31 and 
the harmful eff ects, especially of consumption during 
the teenage years on cognition, development of social 
competence, and education, have long been known. This 
specifi c window of vulnerability could indicate the crucial 
developmental role of the endogenous cannabinoid 
system.32,33 Interference with this system through 
exogenous cannabinoids has detrimental consequences 
on consolidation of maturing brain networks as shown 
in experimental studies.7,34 We noted that even minor 
consumption of cannabis has signifi cant eff ects on age at 
onset, indicating that the timepoint of exogenous 
cannabinoid infl uence is critical, rather than the dose.
Perinatal complications have previously been described 
to be associated with earlier age at onset of schizophrenia.35 
Panel: Research in context
Systematic review
Between Jan 1, 2005, and Dec 31, 2012, we did a cross-sectional study—the Göttingen 
Research Association for Schizophrenia (GRAS) data collection—of patients with 
schizophrenia, recruited from throughout Germany.12,13 We aimed to collect a disease 
population with a level of phenotyping accuracy unprecedented until now, 
complemented by comprehensive genotype and serological analyses.14 The deep 
phenotyping provided the basis for all outcome measures and items used in the present 
study. Systematic literature searches (on Medline and Google Scholar) in preparation for 
this work showed an accumulation of four or more environmental risk factors in the same 
population has never previously been studied, and in reports about more than one risk 
factor, assessed in the same group of individuals, no comparable numbers of 
comprehensively phenotyped and genotyped patients were evaluated. However, 
published studies about single environmental risk factors point to them having an 
important role not only in disease outbreak (schizophrenia risk),6–9, 21–23 but also in disease 
severity or modulation.30,35,36 So far, no study has provided data about accumulated 
environmental risk factors back-to-back with genetic data. However, these facts are less 
surprising when we consider that although funding for, and public awareness of, genetic 
trials have been substantial during the past decade, appreciable support for research into 
environmental risk factors has developed only very recently.
Interpretation
Our study is the fi rst to show that the eff ect of accumulated environmental risk factors on 
age at schizophrenia onset is huge, as indicated by the fact that the disease develops 
nearly a decade earlier in individuals with four or more environmental risk factors than in 
those with no environmental risk. The environmental eff ect will exert its share of damage 
in any individual genetically predisposed to schizophrenia. Not all risk factors are 
avoidable but some, such as cannabis use, certainly are. Here, awareness among clinicians 
and in the general public needs to grow. Other risk factors, such as migration and 
urbanicity, could be alleviated by psychosocial and sociopolitical actions. However, some 
factors (perinatal complications, neurotrauma, and psychotrauma) might not be easily 
avoidable. Yet even for these, prophylactic measures might apply (eg, better management 
of at-risk pregnancies, wearing a helmet when cycling, and early post-trauma 
intervention). Support for controlled studies of the effi  ciency of these potential 
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Regarding psychotrauma, sexual but also physical abuse 
has been linked to intensifi ed hallucinations.36 However, 
this fi nding was not replicable in our purely male 
population.
To obtain a clean and comparable dataset, environmental 
risk factors were assessed only when they occurred up to 
the age of 18 years. This timeframe was used to consider 
the most relevant time of brain development37 and 
thus most important susceptibility to environmental 
eff ects.32,33,38 Of course, the eff ect of environmental factors 
(eg, adult life events as disease trigger39), and certainly 
disease onset, can also take place much later.
So far, no assessment of environmental risk 
accumulation regarding schizophrenia onset or severity 
that was based on more than two risk factors in an 
appreciable number of patients has been done. Although 
psychotrauma, urbanicity, or migration per se did not 
aff ect age at onset in our study, our accumulation 
approach suggests that they still contribute to its 
reduction. This fi nding would support potential 
interaction eff ects, adding to our overall results. Similarly, 
although the genetic approach in our study using 
polygenic schizophrenia risk scores did not show any 
association with age at onset, some published studies 
indicate that it is determined by a combination of genetic 
and—to a greater extent—environmental factors.40
Patients with up to one environmental risk factor 
experienced prodromal onset roughly 8 years later than 
did those with four or more environmental insults. This 
time diff erence is highly relevant regarding chances of 
outcome, since early adulthood is the most crucial time 
in life during which the groundwork is laid for 
occupational integration and success, and social 
inclusion and stability. These processes will all be 
negatively aff ected by early onset of prodrome or 
psychosis.20
To summarise, we obtained in the same cohort of 
male individuals with schizophrenia robust eff ects of 
accumulated environmental risk on age-at-onset of 
schizophrenia or its prodrome, critical determinants of 
individual prognosis and socioeconomic burden, in 
contrast to non-detectable eff ect of accumulated 
genome-wide association study-derived risk variants (as 
assessed by the application of polygenic schizophrenia 
risk scores) on lead phenotypes of schizophrenia. 
Several important points can be emphasised here: fi rst, 
increased public awareness about the risks of early 
schizophrenia onset is needed, especially regarding the 
eff ects of cannabis. Second, after the tremendous 
interest in genome-wide association studies, the present 
study will hopefully lead to increased support of 
intensifi ed research into environmental risk factors and 
their mechanisms of action. Third, the genetic eff ect is 
probably highly specifi c, and defi nition of biological 
disease subgroups or syndromes rather than building 
on the heterogeneous clinical construct “schizophrenia” 
will be indispensable for successful genome-wide 
association studies in the future. By contrast, the eff ect 
of environmental factors is enormous but rather non-
specifi c, and will exert its share of damage in any 
genetically predisposed individual.
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Table S5  Association  of  polygenic  schizophrenia  scores  (PSS)  or  their 







































    PSS≤5x10‐8  PSS≤1x10‐6  PSS≤0.0001 PSS≤0.001  PSS≤0.01  PSS≤0.05  PSS≤0.1  PSS≤0.2  PSS≤0.5  PSS≤1.0 
Case‐control study a                       
Schizophrenia risk b  p‐value  3.31E‐13  1.67E‐17  1.14E‐27  1.88E‐39  2.56E‐50  2.17E‐50  1.15E‐50  1.66E‐47  1.32E‐48  2.66E‐48 
(N= 1067 SCZ  & 1169 HC)  R² change  0.031  0.043  0.072  0.108  0.144  0.143  0.144  0.134  0.138  0.137 
                       
Disease variables                       
Age at disease onset c  p‐value  0.517  0.835  0.396  0.224  0.303  0.733  0.557  0.454  0.448  0.441 
(N=700 SCZ males)  R² change  ‐0.001  ‐0.001  0.000  0.001  0.000  ‐0.001  ‐0.001  ‐0.001  ‐0.001  ‐0.001 
Age at prodrome c  p‐value  0.168  0.741  0.916  0.827  0.521  0.483  0.340  0.253  0.242  0.228 
(N=621 SCZ males)  R² change  0.001  ‐0.001  ‐0.002  ‐0.002  ‐0.001  ‐0.001  0.000  0.001  0.001  0.001 
PANSS positive c  p‐value  0.015  0.070  0.183  0.563  0.490  0.329  0.417  0.583  0.396  0.351 
(N=683 SCZ males)  R² change  0.007  0.003  0.001  ‐0.001  ‐0.001  0.000  ‐0.001  ‐0.001  0.000  0.000 
PANSS negative c  p‐value  0.478  0.323  0.576  0.823  0.317  0.430  0.306  0.515  0.426  0.443 
(N=678 SCZ males)  R² change  ‐0.001  0.000  ‐0.001  ‐0.001  0.000  ‐0.001  0.000  ‐0.001  ‐0.001  ‐0.001 
Cognitive composite c  p‐value  0.687  0.763  0.886  0.937  0.659  0.608  0.403  0.393  0.311  0.280 
(N=663 SCZ males)  R² change  ‐0.001  ‐0.001  ‐0.001  ‐0.002  ‐0.001  ‐0.001  0.000  0.000  0.000  0.000 
Suicidality b  p‐value  0.944  0.664  0.989  0.722  0.581  0.546  0.431  0.264  0.268  0.282 
























  n=104‐117b n=113‐126b n=439‐503b  
 
Disease variables   
Age at disease onset, mean±SD  25.89±7.73  25.61±8.42  24.75±7.61  p=0.179 (H=3.44) 
 
Age at prodrome, mean±SD  22.80±7.98  22.74±8.25  21.91±7.63  p=0.301 (H=2.40) 
   
PANSS positive, mean±SD c  14.22±5.78  13.01±6.08  13.64±6.18  p=0.194 (H=3.28) 
 
PANSS negative, mean±SD c  19.04±8.13  18.14±7.83  18.13±7.50  p=0.557 (H=1.17) 
 
Cognitive composite, mean±SD d  0.03±0.76  ‐0.04±0.82  0.05±0.86  p=0.370 (F=1.00) 
 





Education, years, mean±SD f  12.30±3.31  11.91±3.09  11.84±2.89  p=0.593 (H=1.04) 
 
Unemployment, n (%)  44 (38.6)  51 (41.1)  213 (42.8)  p=0.706 (2=0.70) 
 





distributed  data  ANOVA  was  used.  Bolded  values,  p<0.05.  Significance  values  are  displayed  uncorrected  with  p‐values 
withstanding Bonferroni correction underlined.  b Due  to missing data,  sample  sizes vary.  c Corrected  for duration of disease 
(standardized residuals after linear regression). d Corrected for age, PANSS negative, chlorpromazine equivalents (standardized 



































  n=122‐137b n=340‐381b n=106‐118b  
 
Disease variables   
Age at disease onset, mean±SD  25.53±8.96  25.08±7.58  25.19±7.74  p=0.896 (H=0.22) 
 
Age at prodrome, mean±SD  22.25±9.21  22.33±7.40  22.46±8.28  p=0.387 (H=1.90) 
   
PANSS positive, mean±SD c  13.09±5.77  13.36±6.12  14.36±6.31  p=0.357 (H=2.06) 
 
PANSS negative, mean±SD c  18.70±7.36  17.53±7.71  18.49±7.32  p=0.132 (H=4.05) 
 
Cognitive composite, mean±SD d  0.05±0.84  0.11±0.81  0.00±0.79  p=0.802 (F=0.22) 
 





Education, years, mean±SD f  11.56±2.62  12.53±3.12  11.70±3.00  p=0.002 (H=12.69) 
 
Unemployment, n (%)  57 (42.2)  148 (39.2)  50 (42.4)  p=0.733 (2=0.62) 
 




distributed  data  ANOVA  was  used.  Bolded  values,  p<0.05.  Significance  values  are  displayed  uncorrected  with  p‐values 
withstanding Bonferroni correction underlined.  b Due  to missing data,  sample  sizes vary.  c Corrected  for duration of disease 
(standardized residuals after linear regression). d Corrected for age, PANSS negative, chlorpromazine equivalents (standardized 









GROUP 1  No risk factor  One risk factor  Two risk factors  Three risk factors   Four or more risk factors  p a(H) a 
p b 
(J) b 
  n=18‐20c n=47‐54c n=62‐72c n=51‐64c  n=32‐39c  
 
Disease variables     















GROUP 2  No risk factor  One risk factor  Two risk factors  Three risk factors   Four or more risk factors  p a(H) a 
p b 
( J) b 
  n=19‐20c n=46‐55c n=70‐73c n=64‐65c  n=38‐40c  
 
Disease variables     























Disease variables        PSS according to different p‐value thresholds     PSS≤5x10‐8  PSS≤1x10‐6  PSS≤0.0001 PSS≤0.001  PSS≤0.01  PSS≤0.05  PSS≤0.1  PSS≤0.2  PSS≤0.5  PSS≤1.0 
Age at disease onset a 
PSS  p‐value  0.524  0.459  0.308  0.189  0.243  0.415  0.497  0.346  0.288  0.289 
R² change  0.008  0.008  0.009  0.010  0.009  0.008  0.008  0.008  0.009  0.009 
GxE  p‐value  0.080  0.039  0.860  0.950  0.834  0.683  0.897  0.844  0.768  0.768 
R² change  0.012  0.014  0.007  0.008  0.008  0.006  0.006  0.007  0.007  0.007 
Age at prodrome a 
PSS  p‐value  0.145  0.943  0.802  0.731  0.427  0.444  0.451  0.286  0.262  0.257 
R² change  0.010  0.005  0.006  0.006  0.007  0.007  0.007  0.008  0.008  0.008 
GxE  p‐value  0.126  0.014  0.178  0.399  0.531  0.454  0.683  0.736  0.638  0.669 
R² change  0.013  0.017  0.007  0.005  0.006  0.006  0.005  0.006  0.007  0.007 
PANSS positive a 
PSS  p‐value  0.104  0.388  0.192  0.472  0.921  0.891  0.997  0.844  0.979  0.997 
R² change  0.001  ‐0.003  ‐0.001  ‐0.004  ‐0.005  ‐0.005  ‐0.005  ‐0.005  ‐0.005  ‐0.005 
GxE  p‐value  0.427  0.643  0.989  0.865  0.637  0.777  0.925  0.839  0.927  0.995 
R² change  0.000  ‐0.005  ‐0.004  ‐0.006  ‐0.007  ‐0.007  ‐0.007  ‐0.007  ‐0.007  ‐0.007 
PANSS negative a 
PSS  p‐value  0.687  0.715  0.582  0.521  0.991  0.997  0.874  0.863  0.896  0.916 
R² change  0.001  0.001  0.002  0.002  0.001  0.001  0.001  0.001  0.001  0.001 
GxE  p‐value  0.147  0.904  0.261  0.654  0.983  0.810  0.930  0.856  0.906  0.855 
R² change  0.004  ‐0.001  0.002  0.000  ‐0.001  ‐0.001  ‐0.001  ‐0.001  ‐0.001  ‐0.001 
Cognitive composite a 
PSS  p‐value  0.853  0.595  0.613  0.336  0.694  0.928  0.891  0.885  0.890  0.888 
R² change  0.004  0.005  0.005  0.006  0.005  0.004  0.004  0.004  0.004  0.004 
GxE  p‐value  0.015  0.096  0.145  0.310  0.332  0.380  0.805  0.616  0.736  0.745 
R² change  0.016  0.009  0.007  0.006  0.004  0.004  0.002  0.002  0.002  0.002 
Suicidality b 
PSS  p‐value  0.191  0.308  0.900  0.460  0.588  0.794  0.745  0.629  0.618  0.691 
R² change  0.042  0.041  0.038  0.039  0.038  0.038  0.038  0.038  0.038  0.038 
GxE  p‐value  0.457  0.910  0.424  0.260  0.256  0.875  0.837  0.980  0.936  0.829 












The  amount  of  variance  (adjusted  R²)  explained  by  different  models  regarding  age  at  disease  onset  is  shown.  Purple  model  contains  only 
environmental  load as predictor. Blue model contains environmental  load and polygenic schizophrenia score  (PSS) as predictors. Finally, orange 
model  contains environmental  load, PSS and  the  interaction between  them  (GxE) as predictors. Overall,  in  the  sample under analysis, genetic 
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5. AUTOANTIBODIES AGAINST BRAIN ANTIGENS AND PSYCHIATRIC DISORDERS 
  
5.1. Overview of project III 
 
In 2007/2008 the anti-NMDA-receptor encephalitis was described as a disorder associated 
with high levels of N-methyl-D-aspartate (NMDA) receptor IgG antibodies, directed against 
the NR1 subunit of the receptor, in patients’ cerebrospinal fluid and blood (Dalmau et al., 
2008; Dalmau et al., 2007; Sansing et al., 2007). Individuals that received the diagnosis 
showed, besides severe general and neurological symptoms, personality changes, irritability, 
anxiety, memory loss, agitation, bizarre behavior, delusions, paranoid thoughts, and 
hallucinations – psychiatric symptoms reminiscent of schizophrenia (Dalmau et al., 2011; 
Dalmau et al., 2008; Florance et al., 2009; Gable et al., 2009; Irani et al., 2010b). As the 
underlying mechanism Hughes and colleagues (2010) suggested a titer-dependent reduction 
of NMDA receptor surface and total cluster density due to receptor internalization.  
 
There are different lines of evidence that support an involvement of the NMDA receptors in 
schizophrenia pathophysiology. NMDA glutamate receptor antagonists (phencyclidine, 
ketamine) can induce schizophrenia-like symptoms in healthy human subjects (Cohen et al., 
1962; Davies and Beech, 1960; Luby et al., 1959; Rosenbaum et al., 1959), and postmortem 
as well as imaging studies report NMDA receptor abnormalities in schizophrenic patients 
(Kristiansen et al., 2007; Pilowsky et al., 2006). The most recent GWAS, found markers in 
genes involved in glutamatergic neurotransmission to be among the most significantly 
associated with schizophrenia (Schizophrenia Working Group of the PGC, 2014) and the 
largest exome sequencing study of de novo mutations in schizophrenia to date, describes a 
significant enrichment of these mutations in the postsynaptic NMDA receptor complex 
(Fromer et al., 2014). 
 
Based on all previous evidence and intrigued by the description of the anti-NMDA receptor 
encephalitis we wanted to elucidate the role of serum NMDA receptor antibodies in brain 
diseases. Therefore the present study had five aims: (I) Describe the overall prevalence of 
antibodies directed against the NR1 subunit of the NMDA receptor in patients with 





the frequency of different immunoglobulin class (IgM, IgA, IgG) antibodies and their titers in 
healthy and ill subjects, and compare the functionality of IgM, IgA, and IgG; (III) Evaluate if 
patients with schizophrenia, tested positive for NMDA receptor antibodies, differ from 
schizophrenic patients tested negative, in symptomatology or disease onset; (IV) Study the 
importance of the blood-brain barrier for the development of pathology in mice and 
humans; (V) Search for genetic and environmental factors that are associated with antibody 
formation.  
 
Across all groups (schizophrenia, affective disorders, Parkinson, healthy) about 10% of 
individuals were tested positive for anti-NR1 NMDA receptor antibodies in serum. 
Immunoglobulin classes as well as titer were also comparable between all tested groups. 
Primary cortical neurons from mouse embryos (E16) were incubated with either IgM, IgA or 
IgG antibodies or seronegative Ig extract. The samples were obtained from patients 
(schizophrenia, affective disorders) and healthy controls. Antibodies of all Ig classes led to 
increased endocytosis compared with seronegative extracts regardless of disease state. 
When comparing Ig-positive and Ig-negative patients with schizophrenia we found no 
significant differences in measures of disease onset, disease severity, as well as cognitive 
and neurological functioning. We further studied ApoE homozygous KO
  
mice (Piedrahita et 
al., 1992), which have an impaired blood-brain barrier (Fullerton et al., 2001). ApoE KO and 
WT mice received intravenous tail injections of purified human IgM, IgA, and IgG antibodies 
on three consecutive days, upon which spontaneous activity was measured. Only ApoE KO 
mice showed a further reduction of spontaneous activity after the antibody application. 
Similarly only KO mice that had received the antibody treatment responded to MK-801 (non-
competitive NMDA receptor antagonist) challenge with increased activity – a psychosis 
related response. In an attempt to translate these findings back to humans, we compared 
schizophrenic patients that had or had not suffered birth complications or a neurotrauma 
with and without NMDA receptor antibodies. We assumed that birth complications as well 
as a head trauma are factors that can lead to an – at least temporarily – impaired blood-
brain barrier. In fact, NMDA receptor antibody positive patients with schizophrenia, which 
had experienced birth complications or a neurotrauma and were tested positive for 
antibodies experienced more neurological symptoms than any of the other groups. Our final 
goal was the identification of factors that would trigger antibody formation. Whilst we did 
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not find human leukocyte antigen (HLA) alleles to be associated with anti-NR1 seropositivity, 
a genome-wide association approach led the discovery of one significantly associated SNP 
(intergenic region on chromosome 1). Additionally we detected an association of past 
influenza A and B infection (IgG antibodies) with an increased prevalence of NMDA receptor 
antibodies in men. In summary we were able to show that NMDA receptor antibodies, 
comparable in isotypes, titers, and functionality, are rather common and not specific to 
brain disease. Only when blood-brain barrier integrity is compromised, we saw antibody 
related effects on neurological functions. Our study uncovered one genetic (SNP rs524991) 
and one environmental (influenza AB status) risk factor for antibody formation.  
 
5.2. Original publication 
 
Hammer C., Stepniak B., Schneider A., Papiol S., Tantra M., Begemann M., Siren A.L., Pardo 
L.A., Sperling S., Mohd Jofrry S., Gurvich A., Jensen N., Ostmeier K., Luhder F., Probst C., 
Martens H., Gillis M., Saher G., Assogna F., Spalletta G., Stocker W., Schulz T.F., Nave K.A., 
Ehrenreich H. (2014) Neuropsychiatric disease relevance of circulating anti-NMDA receptor 
autoantibodies depends on blood-brain barrier integrity. Mol Psychiatry 19:1143-9. 
 
Personal contribution 
As part of the anti-NMDA receptor autoantibody project I was responsible for the extensive 
phenotypical analyses of the human patient as well as the control samples in the study 
(Table 2, Figure 1d). I prepared the table and figure and wrote the figure legend as well as 
the respective part of the materials and methods section (‘Participants’, ‘Phenotypical 
analyses’, ‘Statistical analysis – Human data’). I was involved in the literature search before 
the writing of the paper. Together with the first author and under the supervision of Prof 
Hannelore Ehrenreich I discussed the results and their interpretation for the discussion 
section of the manuscript. During the review process I responded to queries concerning the 
human data and did the final proof reading of the manuscript together with the first author 
before publication. 
ORIGINAL ARTICLE
Neuropsychiatric disease relevance of circulating anti-NMDA
receptor autoantibodies depends on blood–brain barrier integrity
C Hammer1, B Stepniak1, A Schneider2,3,4, S Papiol1,3, M Tantra1,3, M Begemann1, A-L Sire´n5, LA Pardo6, S Sperling1, S Mohd Jofrry1,
A Gurvich1, N Jensen1, K Ostmeier1, F Lu¨hder7, C Probst8, H Martens9, M Gillis10, G Saher11, F Assogna12, G Spalletta12, W Sto¨cker8,
TF Schulz10, K-A Nave3,11 and H Ehrenreich1,3
In 2007, a multifaceted syndrome, associated with anti-NMDA receptor autoantibodies (NMDAR-AB) of immunoglobulin-G isotype,
has been described, which variably consists of psychosis, epilepsy, cognitive decline and extrapyramidal symptoms. Prevalence and
significance of NMDAR-AB in complex neuropsychiatric disease versus health, however, have remained unclear. We tested sera of
2817 subjects (1325 healthy, 1081 schizophrenic, 263 Parkinson and 148 affective-disorder subjects) for presence of NMDAR-AB,
conducted a genome-wide genetic association study, comparing AB carriers versus non-carriers, and assessed their influenza AB
status. For mechanistic insight and documentation of AB functionality, in vivo experiments involving mice with deficient blood–
brain barrier (ApoE / ) and in vitro endocytosis assays in primary cortical neurons were performed. In 10.5% of subjects, NMDAR-
AB (NR1 subunit) of any immunoglobulin isotype were detected, with no difference in seroprevalence, titer or in vitro functionality
between patients and healthy controls. Administration of extracted human serum to mice influenced basal and MK-801-induced
activity in the open field only in ApoE / mice injected with NMDAR-AB-positive serum but not in respective controls. Seropositive
schizophrenic patients with a history of neurotrauma or birth complications, indicating an at least temporarily compromised blood–
brain barrier, had more neurological abnormalities than seronegative patients with comparable history. A common genetic variant
(rs524991, P¼ 6.15E 08) as well as past influenza A (P¼ 0.024) or B (P¼ 0.006) infection were identified as predisposing factors for
NMDAR-AB seropositivity. The410% overall seroprevalence of NMDAR-AB of both healthy individuals and patients is unexpectedly
high. Clinical significance, however, apparently depends on association with past or present perturbations of blood–brain barrier
function.
Molecular Psychiatry advance online publication, 3 September 2013; doi:10.1038/mp.2013.110
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INTRODUCTION
N-methyl-D-aspartate receptors (NMDAR) are glutamate-gated
ion channels, abundantly expressed in mammalian brain.1 They
form heteromers of NR1, NR2 and NR3 subunits, and are pivotal
in regulating synapse function.2 In schizophrenia, NMDAR
hypofunction has been hypothesized due to induction of
psychotic symptoms by antagonists.3 In 2007, Dalmau et al.4,5
described a paraneoplastic syndrome, based on 12 women with
ovarian teratoma, carrying IgG autoantibodies (AB) against the
NMDAR NR1/2 subunits. The syndrome, termed ’anti-NMDAR
encephalitis’, variably consisted of psychosis, memory deficits,
seizures, dyskinesia, decreased consciousness and autonomic
instability. Since its initial description, a flood of publications
appeared. The search for anti-NR1 IgG AB in small samples
(N¼ 46–80) of schizophrenic patients yielded discordant results.6–8
Recently, 4400 previously collected cases of anti-NMDAR
encephalitis have been reviewed, most without associated tumor.9
Similarly, immunomodulatory treatment outcomes of these and
around 100 more cases have been summarized.10 As a syndrome-
pertinent pathophysiological mechanism, an AB-induced decrease of
NMDAR-mediated currents, due to enhanced receptor internalization
and thus reduced surface expression, has been suggested.11
Few studies explored a role of other classes of immunoglobulins
(Ig) in an NMDAR-AB syndrome. In individuals with slow cognitive
impairment, anti-NR1 IgA AB were found, which affected synaptic
protein expression and decreased NMDAR-mediated currents.12
Anti-NR1 IgM AB were described in a patient with bipolar
disorder13 and in patients with herpes simplex encephalitis.14 In
the largest study so far, investigating IgG, IgA and IgM, Steiner
et al.15 reported a higher prevalence of AB of all isotypes in 121
schizophrenic patients, compared with healthy controls or
patients suffering from affective disorders. Apart from tumors,
no sound information is available yet on putative susceptibility
factors for the development of anti-NR1 AB.
The present study was designed to (1) systematically screen in
an unbiased fashion a large number (N¼ 2817) of healthy
1Clinical Neuroscience, Max Planck Institute of Experimental Medicine, Go¨ttingen, Germany; 2Department of Psychiatry & Psychotherapy, University Medicine Go¨ttingen,
Go¨ttingen, Germany; 3DFG Research Center Nanoscale Microscopy and Molecular Physiology of the Brain (CNMPB), Go¨ttingen, Germany; 4German Center for Neurodegenerative
Diseases (DZNE), Go¨ttingen, Germany; 5Department of Neurosurgery, University Clinic of Wu¨rzburg, Wu¨rzburg, Germany; 6Department of Molecular Biology of Neuronal Signals,
Max Planck Institute of Experimental Medicine, Go¨ttingen, Germany; 7Department of Neuroimmunology, Institute for Multiple Sclerosis Research and Hertie Foundation,
University Medicine Go¨ttingen, Go¨ttingen, Germany; 8Institute for Experimental Immunology, affiliated to Euroimmun, Lu¨beck, Germany; 9Synaptic Systems GmbH, Go¨ttingen,
Germany; 10Institute of Virology, Hannover Medical School, Hannover, Germany; 11Department of Neurogenetics, Max Planck Institute of Experimental Medicine, Go¨ttingen,
Germany and 12Department of Clinical and Behavioral Neurology, IRCCS Santa Lucia Foundation, Rome, Italy. Correspondence: Professor H Ehrenreich, Clinical Neuroscience, Max
Planck Institute of Experimental Medicine, Go¨ttingen 37075, Germany.
E-mail: ehrenreich@em.mpg.de
Received 22 May 2013; revised 19 July 2013; accepted 22 July 2013
Molecular Psychiatry (2013), 1–7




individuals and subjects suffering from schizophrenia or other
brain diseases for presence of NMDAR-AB of IgG, IgA or IgM
isotype; (2) specifically address the question of why healthy AB
carriers might remain healthy, by extending this work to
experiments in vivo and in vitro; (3) search for genetic and
environmental factors predisposing to NMDAR-AB formation.
MATERIALS AND METHODS
Participants
Subject data were collected in accordance with ethical guidelines and the
Declaration of Helsinki. Sample selection was unbiased, that is sera
collection was concluded before analysis of NMDAR-AB was planned.
Schizophrenic patients (N¼ 1081) were recruited from 2005–2011 at 23
German sites in the GRAS (Go¨ttingen Research Association for Schizo-
phrenia) study. Patients fulfilling DSM-IV criteria for schizophrenia (81.5%)
or schizoaffective disorder (18.5%) were included regardless of disease
stage.16,17 Healthy GRAS controls were anonymized blood donors
(N¼ 1272; Transfusion Medicine, Go¨ttingen). Health was ensured by pre-
donation screening (questionnaires, interviews, hemoglobin, blood
pressure, pulse, temperature). Patients with affective disorders (N¼ 148)
were also included (ongoing GRAS extension). Parkinson patients (N¼ 263)
and respective controls (N¼ 53) were recruited from 2010–2011 in Italy
(Rome area). Of the GRAS patients, three volunteers carrying high titers of
anti-NR1 IgG, IgA, or IgM, and three seronegative controls agreed to blood
donation for mouse experiments (Supplementary Table S1, Supplementary
Appendix).
Phenotypical analyses
On all schizophrenic (GRAS) patients, extensive phenotypical characteriza-
tion was performed as referenced previously.16,17 Frequency and duration
of prodrome, age at first psychotic episode, positive and negative
syndrome scale (PANSS) scores, chlorpromazine equivalents, neurological
symptoms (CNI; Cambridge Neurological Inventory) including fine motor
skills (MacQuarrie dotting/tapping), current cognitive functioning
(composite score comprising reasoning, executive function, verbal
learning and memory), premorbid intelligence and global assessment of
functioning (GAF) were employed as disease characteristics. As factors
affecting blood–brain barrier (BBB) integrity, past neurotrauma (all severity
levels) and birth complications (all pre- and perinatal complications) were
carefully and comprehensively assessed. The final judgment regarding
experience of birth complications or neurotrauma in the schizophrenic
(GRAS) patient cohort was derived from a number of different sources.
First, the information from semi-structured interviews about birth and
neurotrauma history of each patient was used. To verify the data or
increase the amount of detailed information, all discharge letters of each
single patient were screened. In the case of neurotrauma, other semi-
structured interviews on critical life events, suicidality and aggressive
behavior toward others were used to explore whether patients had
experienced serious accidents (including brain trauma) or committed
suicide attempts that included, for example, falls or jumps from great
heights or had been involved in serious fights leading to head injuries.
Finally, information from the physical exam of each patient was included to
check whether any scars on the head or neck were found indicative of an
injury to the head. After collecting all the data, each patient was
dichotomously (yes/no) classified as having or not having experienced a
neurotrauma or birth complication. In case of contradictory information,
the treating physician and even the obstetric hospital were contacted, and
in case of still missing information or a high level of uncertainty, patients
were excluded from the analysis.
Serological analyses
Commercially available recombinant immunofluorescence tests (Euroim-
mun, Lu¨beck, Germany), standard procedures for clinical diagnosis (100%
sensitivity and 100% specificity), were used to detect NMDAR-AB, based on
HEK293 cells transfected with NR1 or NR1/NR2b NMDAR-subunits.5,18
Seropositivity was assessed by two researchers independently. Titers were
double-determined in two laboratories (MPI, Euroimmun) by identifying
the maximum dilution at which specific fluorescence was still visible. Few
samples with discrepant results were re-analyzed, leading to full
concordance. The presence of IgG AB against influenza A and B virus
was determined by ELISA (Novagnost-InfluenzaA-IgG, Novagnost-
InfluenzaB-IgG, Siemens Healthcare Diagnostics GmbH, Eschborn,
Germany), automatically processed on BEPIII (Siemens Healthcare
Diagnostics GmbH), and interpreted (manufacturer’s instructions) as
positive, negative or borderline (the latter negative for statistics).
Immunoglobulin purification
Ammonium sulfate precipitation of a serum fraction containing immu-
noglobulins (Ig) and dialysis was carried out as described.19 IgG, IgA, or IgM
were quantified by immunodiffusion using NOR partigen immunoplates
(Siemens Medical Solutions, Marburg, Germany).
Mouse experiments
Experiments were approved by the local Animal Protection Committee.
Male C57Bl/6N ApoE / 20 and wild-type (WT) mice, aged 12–16 weeks,
were used (housed at 4–5 per cage, 12 h light/dark cycle, food/water ad
libitum). Groups (4–6 each) received either extracted Ig fractions from
NMDAR-AB seropositive (IgG, IgA, or IgM) or seronegative individuals
(information on titer/concentration in Supplementary Table S1 and
Supplementary Appendix). Daily intravenous (tail) injections (150 ml each)
were performed on 3 consecutive days. Examiners were not aware of
group assignment (’blinded’). Spontaneous activity in open field (8min)
was tested in all mice 3–4 days before the first injection (initial group
matching). One day after the last injection, spontaneous activity (8min)
was again measured, followed by intraperitoneal injection (0.3mg per 10 ml
per gram of body weight) of the non-competitive NMDAR antagonist MK-
801 (Dizocilpine; [5R,10S]-(þ )-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cy-
clohepten-5,10-imine; Sigma-Aldrich GmbH, Munich, Germany) and
extended (120min) open-field observation.21 MK-801 acts as use-
dependent ion-channel blocker.
Endocytosis assays and quantification
Primary cortical neurons prepared from mouse embryos (E16) were
cultured on poly-L-lysine-coated glass-coverslips in MEMþ B27 (Invitrogen,
Karlsruhe, Germany) for 14 days. Glass coverslips were washed with cold
Hank’s balanced salt solution (HBSS), and incubated (20min, 4 1C) with Ig
extracts containing either NMDAR-AB of IgG, IgA or IgM isoforms or
seronegative Ig extracts (1:100) in HBSS. The examiner was unaware of the
nature of the extract (‘blinded’). Unbound AB was removed (3 HBSS
washes) before placing cells in pre-warmed (37 1C) growth medium for
15min to allow internalization. After medium wash-off (cold HBSS),
remaining surface NMDAR were labeled with anti-mouse NR1-AB (Abcam,
Cambridge, UK) for 15min on ice. After cold HBSS wash, surface-bound
NR1-AB was labeled (4 1C, 15min) with Alexa-488-coupled 2nd AB (anti-
mouse IgG; Invitrogen, Karlsruhe, Germany). After wash-off (HBSS; 4 1C) of
unbound AB, cells were fixed in 4% paraformaldehyde. For quantification,
confocal images of cell surface staining were taken with identical
acquisition parameter on SP2 LSM (Leica, Wetzlar, Germany). Signal
intensity was quantified with ImageJ, and ratio of intensity per cell surface
area calculated.
Genetic analyses
A semi-custom Axiom myDesign genotyping array (Affymetrix, Santa Clara,
CA, USA) was used. For description of array-specifications, quality controls
and genome-wide genetic association study (GWAS), see Supplementary
Appendix.
Statistical analysis
P-valueso0.05 were considered significant. Data in figures are expressed
as mean±s.e.m., in tables as mean±s.d.
Mouse experiments. Data were compared by analysis of variance, followed
by post-hoc tests where appropriate using Prism5 (GraphPad-Software Inc.,
La Jolla, CA, USA) or SPSS (SPSS-Statistics 17.0, IBM-Deutschland GmbH,
Munich, Germany). Greenhouse–Geisser correction was applied on
violation of sphericity.
Human data. Group differences in categorical and continuous variables
were assessed using Chi-square or Mann–Whitney U tests. A generalized
linear model was employed upon covariate inclusion. In case of normal
distribution of continuous variables, T-tests were performed. To assess
main effects and interactions between neurotrauma/birth complications
and Ig-positivity regarding CNI scores, two-way independent ANOVA was
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conducted. Corrected values reflect linear regression-based residuals when
age, chlorpromazine and PANSS negative scores were independent
variables. PLINK (v1.07) was used to test association between single-
nucleotide polymorphisms (SNPs) and anti-NR1 serological status
(allelic test) and deviations from Hardy–Weinberg equilibrium.22
Principal components were generated using EIGENSTRAT (http://
genetics.med.harvard.edu/reich/Reich_Lab/Software.html). Human leuko-
cyte antigen (HLA) types were imputed for seven HLA genes using
HiBag0.9.1 at four-digit resolution, based on a pre-fit European ancestry
model (http://cran.r-project.org/web/packages/HIBAG/index.html). P-values
were multiple-testing corrected (Bonferroni) where indicated, but are
displayed uncorrected.
RESULTS
NMDAR-AB seroprevalence in 2817 individuals
AB of all here analyzed isotypes (IgG, IgA and IgM), directed
against the NMDAR-NR1 subunit, were identified in 10.5% of
subjects (Table 1). Importantly, seroprevalence did not differ
between schizophrenic (GRAS) patients (8.6%) and GRAS controls
(10.8%, P¼ 0.078). An apparently higher incidence in affective-
disorder patients (16.2%) is explained by a higher mean age. In
fact, seroprevalence increases with age (Supplementary Figure S1,
Supplementary Table S2, Supplementary Appendix) and is higher
in male than female subjects (Supplementary Table S3,
Supplementary Appendix, 11.53% versus 8.68%, P¼ 0.017).
Seropositivity between Parkinson patients (13.3%) and respective
controls did not differ (11.3%, P¼ 0.694).
Seroprevalence and titer distribution of NMDAR-AB Ig isotypes
Considering each Ig class separately, again no differences in
seroprevalence among groups arose (Table 1). Occurrence of IgG
anti-NR1 was infrequent (0.6% in total) compared with IgA (5.9%)
or IgM (5.7%). A combination of IgA/IgM AB was present in 1.6%,
combinations including IgG in only 0.1% each. AB exclusively
against the NR1/NR2b heterodimer, that is without reactivity
against NR1 alone, were not identified. Titer distributions in
patient and control groups as possible explanation of NMDAR-AB
pathology did not differ (Supplementary Table S4, Supplementary
Figure S2, Supplementary Appendix).
NMDAR-AB functionality in a neuronal endocytosis assay
We next wondered whether AB from controls and patients differ
in functionality. Extracts from seropositive subjects, independently
of isotype or disease state, resulted in increased endocytosis,
compared with seronegative extracts (Figure 1a, Supplementary
Table S1, Supplementary Appendix).
Relevance of BBB integrity for NMDAR-AB effects in mice
Having comparable serological (% seropositivity, Ig-isotype, titer
distribution) and functional results in controls and patients, we
asked why healthy AB carriers remain healthy. We hypothesized
that a compromised BBB might decide on the pathophysiological
significance of NMDAR-AB. To approach this hypothesis experi-
mentally, we employed ApoE / mice20 (with known BBB
leakage)23–25 versus WT. Intravenous injection of purified Ig
fractions from NMDAR-AB seropositive (IgM, IgG, IgA) subjects
led to alterations in spontaneous open-field activity and the
response to MK-801 exclusively in ApoE / mice. Trends were
comparable in groups receiving IgM, IgG or IgA extracts, resulting
in significant differences on pooling (Figures 1b and c,
Supplementary Figure S3, Supplementary Appendix).
Translating experimental BBB findings to schizophrenic (GRAS)
patients
Overall, schizophrenic anti-NR1 carriers and non-carriers do not
differ with respect to disease phenotypes, covering the symptom
clusters of anti-NMDAR encephalitis (Table 2). Also, occurrence
and duration of prodromal phase and age of disease onset are
similar between the two groups, arguing against a sudden/
atypical syndrome start in AB carriers (Table 2). Following our BBB
hypothesis, we compared individuals with birth complications or
past brain trauma—conditions known to provoke temporary or
persistent (albeit often minor) BBB abnormalities.26,27 Indeed, also
in humans, a clear impact, that is a more severe neurological
phenotype, arises from the combination of compromised BBB
function and circulating NMDAR-AB (Figure 1d).
Identification of first genetic susceptibility factors
GWAS have been successful in identifying associations between
genomic variants and autoimmune disorders, such as rheumatoid
arthritis or systemic lupus erythematosus.28 We performed
GWAS to spot SNPs potentially predisposing to formation of
NMDAR-AB (Supplementary Appendix). We identified a genome-
wide significant SNP, rs524991 (A/G, P¼ 6.15E–08; Bonferroni
threshold P¼ 8.62E–08), with an odds ratio (OR) of 2.22
(95% confidence interval (CI)¼ 1.654–2.991; Supplementary
Figure S6, Supplementary Appendix). This variant with a minor
allele frequency of 12.45% in seropositive versus 6.01% in
seronegative individuals is located in an intergenic region on
chromosome1 (Supplementary Figure S7, Supplementary
Appendix). Its closest neighboring gene is nuclear factor I/A
(NFIA, 218.59 kb downstream), a transcription factor reported
to mediate neuroprotective effects of NMDAR activation.29
Separate analysis of SNP rs524991 association with NMDAR-
AB seropositivity (Table 3) showed a similar tendency for all study
groups (except Parkinson) and no gender difference
(Supplementary Table S8, Supplementary Appendix). Search
for a predisposing role of HLA alleles for NMDAR-AB formation
did not deliver hits, apart from a nominally significant association
of HLA-A03 with seropositivity (P¼ 0.01; Supplementary Table S9,
Supplementary Appendix).
Table 1. Prevalence of anti-NR1 AB in patients and controls
Anti-NR1 seropositivity—N (%)
Study group Any IgG IgA IgM IgGþ IgA IgGþ IgM IgAþ IgM IgGþ IgAþ IgM
GRASa patients (N¼ 1081) 93 (8.6) 7 (0.7) 56 (5.2) 46 (4.3) 0 (0) 0 (0) 16 (1.5) 0 (0)
Affective-disorder patients (N¼ 148) 24 (16.2) 5 (3.4) 15 (10.1) 7 (4.7) 1 (0.7) 0 (0) 2 (1.4) 0 (0)
GRASa controls (N¼ 1272) 137 (10.8) 5 (0.4) 75 (5.9) 80 (6.3) 2 (0.2) 3 (0.2) 19 (1.5) 1 (0.1)
Parkinson patients (N¼ 263) 35 (13.3) 1 (0.4) 17 (6.5) 25 (9.5) 1 (0.4) 1 (0.4) 7 (2.7) 1 (0.4)
Parkinson controls (N¼ 53) 6 (11.3) 0 (0) 3 (5.7) 3 (5.7) 0 (0) 0 (0) 0 (0) 0 (0)
Total (N¼ 2817) 295 (10.5) 18 (0.6) 166 (5.9) 161 (5.7) 4 (0.1) 4 (0.1) 44 (1.6) 2 (0.1)
aGRAS patients are schizophrenic individuals of the GRAS data collection (Go¨ttingen Research Association for Schizophrenia). GRAS controls are the respective
healthy control collective (see also Materials and methods).
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Identification of environmental susceptibility factors
As first risk factor for NMDAR-AB formation, the presence of a
tumor, preferentially an ovarian teratoma was identified.4 Other
predisposing factors have remained speculative. Infections have
been suggested as triggers of AB formation in autoimmune
diseases,30 for example, Epstein-Barr virus in multiple sclerosis.31
We hypothesized that a similar role might be attributed to
influenza for NMDAR-AB. Anti-NMDAR encephalitis was reported
in a patient with influenza H1N1 infection and two subjects after
respective vaccination.9 NMDAR-AB were described in pediatric
cases of encephalitis lethargica, a condition—not unequivocally—
associated with influenza.32,33 Strikingly, we found an increased
anti-NR1 AB prevalence in individuals carrying anti-influenza A
(P¼ 0.024, OR¼ 1.366, CI 95%¼ 1.042–1.790) and B (P¼ 0.006,
OR¼ 1.453, CI 95%¼ 1.109–1.904) IgG (Table 3). This association
was present in males only (Supplementary Table S10,
Supplementary Appendix).
DISCUSSION
The present study provides (1) the first large-scale systematic
screen for presence of NMDAR-AB in serum of healthy and
neuropsychiatrically diseased subjects. In 42800 unbiasedly selec-
ted individuals,410% seroprevalence of anti-NR1 AB, independent
of group affiliation, was found. (2) From this unexpected observa-
tion, the fundamental question arose of why healthy AB carriers
have remained healthy, despite comparable distribution of AB
isotypes, titers and in vitro functionality. An experimental mouse
model supports our central hypothesis, that is, the essential role of
BBB integrity. Only in ApoE mutant mice, but not in respective
controls, we find that human NMDAR-AB cause psychosis-related
behavioral perturbation.21 The BBB role is further underlined
by a hypothesis-driven outcome analysis of schizophrenic (GRAS)
patients with history of birth complications or neurotrauma
indicating past/present BBB insufficiency. (3) Ultimately, with a
genome-wide significant marker, SNP rs524991, and an association
of seropositivity with influenza AB status, we provide genetic and
environmental risk factors of NMDAR-AB formation.
The most remarkable finding of the present work is the high
seroprevalence of NMDAR-AB in healthy individuals. Only one
other study included a considerable number of healthy subjects in
a screen of psychiatric patients but reported seropositivity for only
1 in 240 controls (0.4%) and 2 in 108 (o2%) affective-disorder



















































































































































a Neuronal receptor endocytosis assay
b Mice: Spontaneous activity in open field
Before AB application After AB application
c Mice: Open field activity on MK-801 challenge










Figure 1. NMDAR-AB functionality and relevance of the blood–brain barrier. (a) Reduced AB binding to primary cortical neurons indicates
increased endocytosis of NMDAR after incubation with Ig extracts containing either NMDAR-AB of IgG, IgA or IgM isoforms (all Po0.05), or
seronegative Ig extracts (one-tailed T-tests). Mean values upon AB extracts (each tested in 1–3 independent experiments, dependent on
serum availability) were normalized to the mean of the respective seronegative control extracts. (b) ApoE / (KO) and WT mice do not differ
in spontaneous activity in the open field before AB injection. However, 1 day after the last of three daily injections with seropositive (þAB) or
seronegative (AB) Ig extracts, a decrease in spontaneous activity was evident exclusively in seropositive ApoE / (KOþAB) mice: two-way
ANOVA revealed a significant interaction effect of genotype and serotype (F¼ 8.96, Po0.01), as well as a significant main effect of genotype
(F¼ 27.81, Po0.0001), but not of serotype. (c) Only ApoE / (KO) mice with their known compromised BBB respond to intravenous NMDAR-
AB extracts with a hypersensitive (psychosis-related) response in the open field to the NMDAR antagonist MK-801. Using a generalized linear
model for repeated measures to evaluate results after MK-801 treatment, we obtained significant main effects of time (F¼ 36.25, Po0.001),
genotype (F¼ 9.54, Po0.01) and serotype (F¼ 4.85, Po0.05) as well as a significant genotype  serotype interaction effect (F¼ 5.75, Po0.05).
(d) In the GRAS sample of schizophrenic patients, birth complications and history of neurotrauma as readouts for temporarily/persistently
compromised BBB were examined in NMDAR-AB-positive versus negative subjects with respect to their impact on neurological symptom
severity (CNI total score, z-standardized). Birth complications showed an interaction with serotype (F¼ 5.80, Po0.05) regarding CNI and a
main effect (F¼ 11.24, P¼ 0.001). Likewise, past neurotrauma showed an interaction with serotype (F¼ 4.02, Po0.05). Group sizes are given as
numbers in brackets. *Po0.05; WT, wild type; KO, ApoE / knockout; AB, NMDAR-AB seronegative; þAB, NMDAR-AB seropositive; BC,
birth complications; NT, neurotrauma.
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was comparable to our study. Reasons for this discrepancy are
unclear but perhaps related to the smaller number of controls and
their younger age.15 Importantly, analytical materials/methods of
both studies were identical, schizophrenia patients show
comparable seroprevalence, and the here randomly selected
positive specimens for in vitro analyses all confirmed AB
functionality.
For exerting pathological effects, NMDAR-AB have to reach
NMDAR in the brain. This brain presence may occur via (1) AB
transfer over a compromised BBB, which normally restricts large
molecules from directly entering the brain in appreciable amounts
(expected transfer over an intact BBB, for example, of IgG is only
1/500, of IgA 1/600, and of IgM 1/3000 of the serum concentra-
tion); (2) slow accumulation of these large molecules due to
reduced cerebrospinal fluid (CSF) flow,34 in which case, however, a
retrograde CSF circulation would have to deliver the AB back to
brain tissue, or (3) intrathecal synthesis by B lymphocytes.34,35 Our
seroprevalence data do not allow any conclusion on AB
production in brain. Therefore, healthy AB carriers may differ
at least in part from seropositive disease groups by lack of
intrathecal AB synthesis. Nevertheless, with in vivo experiments in
mice and a hypothesis-driven human database screening, we
underscore the likely critical role of an intact BBB as protective
mechanism against circulating AB-mediated pathology in mouse
and man.
Wild-type mice were not behaviorally affected after injection of
human serum extract containing IgG, IgA or IgM NMDAR-AB.
In contrast, ApoE / mice showed differences in behavior on
AB injection, that is reduced spontaneous activity in the open
field and hyperlocomotion following MK-801. These behavioral
phenomena may be explained by the reported receptor
internalization and hypofunction after hippocampal infusion of
NMDAR-AB,11 as exactly opposite effects were described after
NMDA application in rats.36 Stimulation of locomotion by the
NMDAR antagonist MK-801 may be caused by hyperexcitability of
limbic circuits through NMDAR blockade on inhibitory GABAergic
neurons.37,38 This consequence of NMDA receptor inhibition
would be amplified by NMDAR-AB. Similarly, increased motor
cortex excitability in mice was provoked by NMDAR-AB injection
into the prefrontal area.39
In the GRAS sample of schizophrenic individuals, well-docu-
mented history of birth complications and brain trauma were
evaluated as proxy variables of past or present BBB impair-
ment.26,27 Indeed, affected individuals show more severe
neurological abnormalities when carrying NMDAR-AB. These
findings strengthen the hypothesis of BBB involvement in
NMDAR-AB pathology, and—replication provided—may even
justify recommendations of anti-NR1 serum screening in case of
neurotrauma or other conditions with anticipated BBB
dysfunction.
Importantly, we did not find any clinically relevant differences
when comparing all schizophrenic NMDAR-AB carriers with all
non-carriers. Perhaps with information on CSF (which we do not
have in our large cohort), an expected 30% of individuals with
Table 2. Baseline characteristics, according to study group (means±s.d. (range) are displayed, unless indicated otherwise)
Patients and control groups Total sample Ig-positive individuals Ig-negative individuals P-value (w2, Z, T value)a
Schizophrenic (GRAS) patients N¼ 774–1081b N¼ 63–93b N¼ 711–988b
Age, years 39.37±12.59 (17–79) 41.15±11.98 (18–75) 39.20±12.63 (17–79) 0.115 (Z¼  1.58)
Gender, N male (%) 723 (66.9) 68 (73.1) 655 (66.3) 0.181 (w2¼ 1.79)
Prodrome, N cases (%) 754 (80.6) 64 (79.0) 690 (80.8) 0.698 (w2¼ 0.15)
Duration of prodrome, years 2.81±3.57 (0–28.2) 2.64±3.01 (0–13.0) 2.83±3.62 (0–28.2) 0.853 (Z¼  0.19)
Age at first episode, years 25.88±8.90 (5–68) 25.85±8.98 (12–51) 25.89±8.90 (5–68) 0.890 (Z¼  0.11)
PANSS positive score 13.74±6.25 (7–38) 13.28±5.71 (7–31) 13.78±6.31 (7–38) 0.597 (Z¼ 0.60)
PANSS negative score 18.25±7.90 (7–46) 17.00±7.42 (7–37) 18.37±7.93 (7–46) 0.122 (Z¼  1.55)
PANSS general score 33.74±11.76 (16–82) 32.48±10.80 (16–75) 33.86±11.85 (16–82) 0.373 (Z¼  0.89)
CPZ 686.53±697.43 (0–7375) 628.04±537.82 (0–2620) 691.97±710.43 (0–7375) 0.580 (Z¼  0.55)
CNIc,d 0.00±1.00 ( 2.71–3.07)  0.03±0.92 ( 2.07–2.11) 0.00±1.01 ( 2.71–3.07) 0.742 (T¼ 0.33)
MacQuarrie dottinge 0.00±1.00 ( 3.61–3.22) 0.14±1.14 ( 2.67–3.07)  0.01±0.98 ( 3.61–3.22) 0.172 (T¼  1.37)
MacQuarrie tappinge 0.00±1.00 ( 4.83–3.14) 0.11±0.99 ( 2.00–3.10)  0.01±1.00 ( 4.83–3.14) 0.261 (T¼  1.13)
Cognitive composite score  0.02±0.84 ( 2.57–2.98)  0.01±0.89 ( 2.12–2.03)  0.02±0.84 ( 2.57–2.98) 0.946 (T¼  0.07)
Premorbid IQ (MWT-Bf ) 25.67±6.36 (4–42) 26.64±6.28 (6–36) 25.57±6.36 (4–42) 0.093 (Z¼  1.68)
GAF 45.70±17.18 (5–90) 46.26±16.54 (10–80) 45.65±17.25 (5–90) 0.642 (Z¼  0.47)
Neurotrauma, N cases (%) 648 (62.4) 55 (62.6) 593 (59.8) 0.592 (w2¼ 0.29)
Birth complications, N cases (%) 307 (39.7) 27 (42.9) 280 (39.4) 0.589 (w2¼ 0.29)
Healthy (GRAS) controls N¼ 1272 N¼ 137 N¼ 1135
Age, years 37.43±13.24 (18–69) 40.90±12.17 (19–68) 37.01±13.31 (18–69) o0.001 (Z¼  3.56)
Gender, N male (%) 780 (61.3) 95 (69.3) 685 (60.4) 0.041 (w2¼ 4.17)
Affective-disorder patients N¼ 148 N¼ 24 N¼ 124
Age, years 49.70±15.49 (20–92) 47.38±11.87 (25–76) 50.15±16.09 (20–92) 0.314 (Z¼  1.01)
Gender, N male (%) 70 (47.3) 11 (45.8) 59 (47.6) 0.875 (w2¼ 0.03)
Parkinson patients N¼ 253–263b N¼ 33–35b N¼ 220–228b
Age, years 66.04±10.08 (36–86) 69.06±8.33 (45–81) 65.59±10.26 (36–86) 0.055 (Z¼  1.92)
Gender, N male (%) 175 (66.5) 28 (80.0) 147 (64.5) 0.070 (w2¼ 3.29)
Parkinson controls N¼ 51–53b N¼ 6b N¼ 45–47b
Age, years 63.31±11.68 (22–80) 67.50±12.58 (44–78) 62.76±11.59 (22–80) 0.188 (Z¼  1.33)
Gender, N male (%) 21 (39.6) 2 (33.3) 19 (40.4) 0.738 (w2¼ 0.11)
Abbreviations: CPZ, chlorpromazine equivalents; GAF, global assessment of functioning; GRAS, Go¨ttingen Research Association for Schizophrenia; PANSS,
positive and negative syndrome scale. Bolded values, Po0.05. aFor statistical methods, Mann–Whitney U or w2 tests and for normally distributed variables,
T-tests were used. bDue to missing data, sample sizes vary. cCambridge Neurological Inventory mean value if more than 95 items were available. dCorrected for
age and CPZ. eCorrected for age, PANSS negative and CPZ. fMehrfach-Wortschatz-Intelligenz test (multiple choice vocabulary test).
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permanent barrier dysfunction40 could have been extracted and
would have allowed us to uncover a clinically relevant difference
between AB carriers and non-carriers among them. Instead, we
found a clinical difference between AB carriers and non-carriers
with past birth complication or neurotrauma as a proxy for at least
temporary BBB disturbance.26 It is interesting to speculate that the
reported 30% of schizophrenic patients with compromised barrier
function40 and the post-trauma individuals recognized here might
represent an (partly) overlapping subpopulation of schizophrenic
subjects. Along these lines of thought, future studies may be
initiated, analyzing CSF samples of a large number of
schizophrenic patients for NMDAR-AB titers and determining the
CSF-serum albumin quotient34 as marker of blood–CSF barrier
(dys)function.
Our study is the first to investigate putative genetic suscept-
ibility factors for the formation of anti-NR1 AB. A GWAS approach
led to the identification of the genome-wide significant risk
SNP rs524991. Further experiments providing mechanistic
insight as well as replication analyses are warranted. By a
hypothesis-driven approach,9,32,33 we uncovered an association
of influenza A or B AB with anti-NR1 seropositivity, suggesting
molecular mimicry. This phenomenon induces generation of AB
reacting both against pathogenic elements and autoantigens,30
and has a role in autoimmune diseases.41,42 As the influenza A
M2 channel and NMDAR share a common ligand, the antiviral
compound amantadine,43 a putative structural homology
might act as inducer of NMDAR-AB. The observed association
was found in males only. Interestingly, males have a higher
incidence of influenza,44 and male mice exert a more vigorous
immune response on influenza infection.45 This gender disposi-
tion might also explain the higher anti-NR1 AB prevalence in
males.
In conclusion, our study draws an increasingly complex picture
of NMDAR-AB pathology, with anti-NMDAR encephalitis possibly
constituting the extreme end of a broad spectrum of mild to
severe phenotypes associated with NMDAR autoimmunity.
Beyond the NMDAR-AB studied here, loss of blood–brain barrier
integrity may generally constitute a major risk factor for
detrimental effects of peripheral AB against central nervous
system epitopes.
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Table S1. Characteristics of sera used for in vivo and in vitro experiments 
 
List of sera of patients and healthy controls used for determination of AB functionality in vitro (receptor endocytosis assay) and in vivo 
(mouse intravenous injection experiments). Total concentrations of the respective Ig subclass in the ammonium sulfate precipitated 
serum fractions are consistent with published serum levels of immunoglobulins in the general adult population (Gonzalez-Quintela A, 
et al. Serum levels of immunoglobulins (IgG, IgA, IgM) in a general adult population and their relationship with alcohol consumption, 
smoking and common metabolic abnormalities. Clin Exp Immunol 2008;151:42-50). 
Total concentration in fraction (g/l) Usage of purified serum 







in Ig extract IgG IgA IgM Endocytosis Injection 
IgG 706594 49 m healthy control 32 10 16.84 4.35 1.44 √  
 BPD00045 45 f bipolar affective disorder 100 32 4.25 NA NA √  
 SCZ00979 27 m schizoaffective disorder 320 100 11.50 NA NA √  
 SCZ01025 40 f schizoaffective disorder 100 100 14.37 NA NA √  
 UPD00066 32 f major depressive disorder 320 100 10.41 NA NA √  
 UPD00071 43 m major depressive disorder 1000 1000 20.13 1.92 1.26 √ √ 
IgA 706026 39 m healthy control 3200 3200 13.78 1.57 2.09 √  
 706472 37 m healthy control 1000 1000 18.13 3.42 2.44 √  
 SCZ00547 31 m schizophrenia 1000 1000 14.98 2.98 2.02 √  
 SCZ00857 43 f schizophrenia 1000 1000 20.81 4.86 1.15 √ √ 
 UPD00035 46 m major depressive disorder 320 320 13.78 4.86 1.50 √  
IgM 707334 47 m healthy control 3200 1000 14.98 3.09 1.44 √  
 708436 49 m healthy control 3200 320 21.51 2.88 1.32 √  
 SCZ00996 46 m schizoaffective disorder 1000 1000 32.20 4.86 1.56 √  
 SCZ00926 35 m schizoaffective disorder 1000 100 25.12 2.38 0.66 √ √ 
Negative 707340 37 f healthy control NA NA 9.89 0.81 1.26 √  
 708438 48 f healthy control NA NA 11.50 1.41 0.89 √  
  BPD00028 41 m bipolar affective disorder NA NA 16.21 5.52 1.21 √ √ (control for IgA) 
 SCZ00071 41 m schizophrenia NA NA 25.12 1.74 1.62 √ √ (control for IgG) 
 SCZ00097 46 f schizophrenia NA NA 13.20 1.17 1.69 √  
 SCZ00397 37 m schizophrenia NA NA 16.84 3.20 1.56 √  
 SCZ00437 43 m schizophrenia NA NA 17.48 1.10 1.38 √ √ (control for IgM) 
 





Table S2. Mean age of study cohorts by Ig isotype 
 
 




all IgG IgA IgM 
Seronegative 
GRAS patients 41.1 (12.0) 34.0 (11.7) 42.0   (9.9) 43.4 (13.7) 39.2 (12.6)* 
Affective disorder patients 47.4 (11.9)* 45.6   (9.8) 50.6   (9.8)* 41.9 (11.0) 50.2 (16.1)* 
GRAS controls 40.9 (12.2) 43.8 (12.6) 39.6 (13.0) 42.2 (13.9) 37.0 (13.3) 
Parkinson patients 69.1   (8.3) 52.00  (NA) 68.8   (8.4) 68.1   (8.4) 65.6 (10.3) 
Parkinson controls 67.5 (12.6) NA 70.3   (6.5) 64.7 (18.1) 62.8 (11.6) 
 
* denotes significant difference (p ≤ 0.05) of patient group versus respective controls. p values were calculated using 2-tailed 









Figure S1. Age dependence of seropositivity  
 
Dotted lines connect single data points (seroprevalence per year of age), solid lines represent linear trends. Only GRAS patients 
and GRAS controls were included due to the significantly smaller size of the other cohorts. Patients younger than 23 and older 
















Male (N=1769) Female (N=1048) 
p (Pearson Chi²) 
all 11.53% 8.68% 0.017 
IgG 0.51% 0.86% 0.260 
IgA 6.56% 4.77% 0.052 
IgM 6.33% 4.68% 0.067 
 




Table S4. Distribution of anti-NR1 AB titers 
 
    Anti-NR1 AB titer (% of seropositive subjects) 
Study cohort Isotype 1:10 1:32 1:100 1:320 1:1000 1:3200 1:10000 all 
GRAS patients IgG 2 (28.6) 2 (28.6) 1 (14.3) 2 (28.6) 0   (0.0) 0   (0.0) 0   (0.0) 7 (100.0) 
 IgA 13 (23.3) 21 (37.5) 10 (17.9) 5   (8.9) 6 (10.7) 1   (1.8) 0   (0.0) 56 (100.0) 
 IgM 9 (19.6) 10 (21.7) 16 (34.8) 5 (10.9) 5 (10.9) 0   (0.0) 1   (2.2) 46 (100.0) 
Affective disorder patients IgG 0   (0.0) 2 (40.0) 1 (20.0) 1 (20.0) 1 (20.0) 0   (0.0) 0   (0.0) 5 (100.0) 
 IgA 3 (20.0) 6 (40.0) 4 (26.7) 2 (13.3) 0   (0.0) 0   (0.0) 0   (0.0) 15 (100.0) 
 IgM 0   (0.0) 1 (14.3) 4 (57.1) 1 (14.3) 1 (14.3) 0   (0.0) 0   (0.0) 7 (100.0) 
GRAS controls IgG 0   (0.0) 1 (20.0) 2 (40.0) 2 (40.0) 0   (0.0) 0   (0.0) 0   (0.0) 5 (100.0) 
 IgA 16 (21.3) 21 (28.0) 29 (38.7) 6   (8.0) 1   (1.3) 2   (2.7) 0   (0.0) 75 (100.0) 
 IgM 9 (11.3) 16 (20.0) 40 (50.0) 7   (8.8) 6   (7.5) 2   (2.5) 0   (0.0) 80 (100.0) 
Parkinson  patients IgG 0   (0.0) 0   (0.0) 0   (0.0) 1 (100.0) 0   (0.0) 0   (0.0) 0   (0.0) 1 (100.0) 
 IgA 4 (23.5) 3 (17.6) 6 (35.3) 2 (11.8) 2 (11.8) 0   (0.0) 0   (0.0) 17 (100.0) 
 IgM 4 (16.0) 9 (36.0) 10 (40.0) 1   (4.0) 1   (4.0) 0   (0.0) 0   (0.0) 25 (100.0) 
Parkinson  controls IgG 0   (0.0) 0   (0.0) 0   (0.0) 0   (0.0) 0   (0.0) 0   (0.0) 0   (0.0) 0   (0.0) 
 IgA 0   (0.0) 2 (66.7) 1 (33.3) 0   (0.0) 0   (0.0) 0   (0.0) 0   (0.0) 3 (100.0) 
 IgM 0   (0.0) 2 (66.7) 1 (33.3) 0   (0.0) 0   (0.0) 0   (0.0) 0   (0.0) 3 (100.0) 






Figure S2. Anti-NR1 AB titers: 100% stacked chart 
 
 





Figure S3. Mouse AB injection experiments presented separately for isotypes 
(Note: The IgM set of experiments includes a non-injection group to exclude effects of injection on spontaneous open field activity) 
  
Left panels: Spontaneous activity in the open field - Total distance traveled before and after Ig injection. Right panels: Open field activity upon MK-801 challenge.  





SNP array specifications and genotyping quality control 
 
Genotyping was performed using a semi-custom Axiom® myDesignTM genotyping array 
(Affymetrix, Santa Clara, CA, USA), based on a CEU (Caucasian residents of European 
ancestry from Utah, USA) marker backbone including 518.722 SNPs, and a custom marker 
set including 102.537 SNPs. The array was designed using the Axiom® Design center 
(www.affymetrix.com), applying diverse selection criteria (Table S5). Genotyping was 
performed by Affymetrix on a GeneTitan® platform. 
 
Table S5. Marker selection criteria 
 
Marker group Threshold # of markers 
Axiom CEU backbone MAF > 0.025, direct selection 518,722 
Functional Variants (CDS, UTR, exonic) MAF > 0.2, direct selection 27,369 
Markers contained in RefSeq / UCSC genes (+/- 2kbp) MAF > 0.2, r² > 0.8 31,190 
Markers in the MHC genomic region best tag 15,395 
Markers in CpG islands MAF > 0.2, direct selection 5,511 
Markers in  known splice sites MAF > 0.1, direct selection 95 
Markers in microRNA regions MAF > 0.2, direct selection 56 
Manual selection of candidate SNPs MAF > 0.2, best tag 22,921 
Affymetrix SNPs for quality control  3,334 
TOTAL   624,593 
 
MAF, minor allele frequency; CDS, coding sequence; UTR, untranslated region; RefSeq, NCBI reference sequence; UCSC, 
University of California Santa Cruz Genome Browser; kbp, kilo base pairs; MHC, major histocompatibility complex. 
 
In total, 3128 individuals were subjected to genotyping (Table S6). 
 
Table S6. Patient and healthy control groups selected for genotyping 
 
Study group N (%) 
GRAS patients 1177 (37.6) 
Affective disorder patients 173   (5.5) 
GRAS controls 1274 (40.7) 
Parkinson patients 276   (8.8) 
Parkinson controls 182   (5.8) 
Autism patients 29   (0.9) 
Other conditions 17   (0.5) 
TOTAL 3128  (100) 
 
Quality control (QC) was performed on sample and SNP level, according to the 
manufacturer’s recommendations (Table S7). A total of 3.086 individuals and 612.121 SNPs 






Table S7. Axiom® array quality control 
 
  Filter criteria Threshold for inclusion N 
Sample level     Samples passing QC step (%) 
 Pre QC  3,128  (100) 
 Dish QC ≥ 0.82 3,124 (99.8) 
 Cluster call rate ≥ 0.97 3,086 (98.7) 
SNP level     SNPs passing QC step (%) 
 Pre QC  624,593  (100) 
 SNP call rate ≥ 0.97 
 Fisher's Linear Discriminant (FLD) ≥ 3.6 
 Heterozygous Cluster Strength Offset (HetSO) ≥ -0.1 
  Homozygote Ratio Offset (HomRO) ≥ 0.3 612,121 (98.0) 
 
 
Genome-wide association study (GWAS) 
 
GRAS and affective disorder patients, as well as the healthy GRAS controls, were collected 
in Germany, whereas the Parkinson samples and controls were collected in Italy. An analysis 
of principal components (PCA) was performed, showing a clear clustering of samples by 
descent (Figure S4). Therefore, to reduce population stratification bias, GWAS was 
performed including only GRAS and affective disorder patients, as well as GRAS controls. 
 










Graphical presentation including all individuals 
showing the first 3 principal components. 
Samples collected in Germany are depicted in 







For the GWAS, PLINK v1.07 was used to calculate association statistics, applying a basic 
allelic model, and using the following filter criteria for SNP and sample exclusion: 
 Markers located on sex chromosomes 
 Hardy-Weinberg p < 5x10-7 in controls 
 Minor allele frequency < 0.01 
 missingness per marker > 0.05 
 missingness per individual > 0.02 
Overall, a total of 580.297 SNPs remained for analysis. The final dataset consisted of 245 
cases (anti-NR1 positive) and 2152 controls (anti-NR1 negative). 
A Q-Q plot was generated to visualize possible confounders (Figure S5). The genomic 
inflation factor was λ=1.01 (Devlin B, Roeder K. Genomic control for association studies. 
Biometrics 1999;55:997-1004). This low genomic inflation value justifies not including 














Figure S6. Manhattan plot 
 
Manhattan plot of single SNP test statistics. The genomic position is shown on the X axis, and the -log10(p) 
on the Y axis. The horizontal line denotes the threshold for significance after Bonferroni correction for 
580.297 tests (p=8.62E-08). A marker on chromosome 1 (rs524991) showing genome-wide significance, 
as well as surrounding SNPs (+/- 50kbp) are depicted in green. 
 
Figure S7. SNP rs524991 regional association plot 
 
 
Regional association plot showing 2000kbp 5’ and 3‘ of rs524991 (p=8.62E-08). The positions of 
neighboring genes are shown on the X axis, and the -log10(p) on the Y axis. Color coding denotes LD 







Table S8. SNP rs524991 association statistics by study group 
 




N      Genotypes (frequencies) 
d.f.=1 allelic, d.f.=1 
Both genders    GG (%) GA (%) AA (%)     
+ 92 65 (70.7) 27 (29.3) 0 (0.0)
GRAS patients 
- 976 867 (88.8) 105 (10.8) 4 (0.4)
2.92E-06 3.23E-06  (2.80, [1.78 - 4.39]) 
+ 24 18 (75.0) 6 (25.0) 0 (0.0)Affective disorder 
patients - 119 104 (87.4) 15 (12.6) 0 (0.0)
0.118 0.133   (2.12, [0.78 - 5.79]) 
+ 135 111 (82.2) 19 (14.1) 5 (3.7)
GRAS controls 
- 1115 977 (87.6) 135 (12.1) 3 (0.3)
0.007 0.006   (1.78, [1.17 - 2.72] 
+ 35 31 (88.6) 4 (11.4) 0 (0.0)
Parkinson patients 
- 220 187 (85.0) 32 (14.5) 1 (4.6)
0.547 0.551   (0.72, [0.25 - 2.11]) 
+ 6 4 (66.7) 2 (33.3) 0 (0.0)
Parkinson controls 
- 45 41 (91.1) 4    (8.9) 0 (0.0)
0.081 0.091 (4.30, [0.70 - 26.52]) 
+ 292 229 (78.4) 58 (19.9) 5 (1.7)
TOTAL 
- 2475 2176 (87.9) 291 (11.8) 8 (0.3)
7.64E-07 7.48E-07   (1.99, [1.51 - 2.63]) 
Males only     GG (%) GA (%) AA (%)     
+ 67 51 (76.1) 16 (23.9) 0 (0.0)
GRAS patients 
- 649 579 (89.2) 67 (10.3) 3 (0.5)
0.004 0.004   (2.28, [1.28 - 4.04]) 
+ 11 9 (81.8) 2 (18.2) 0 (0.0)Affective disorder 
patients - 55 51 (92.7) 4    (7.2) 0 (0.0)
0.251 0.262 (2.65, [0.45 - 15.45]) 
+ 92 76 (82.6) 13 (14.1) 3 (3.3)
GRAS controls 
- 646 562 (87.0) 83 (12.8) 1 (0.2)
0.064 0.063    (1.64, [0.97 - 2.76]) 
+ 28 25 (89.3) 3 (10.7) 0 (0.0)
Parkinson patients 
- 140 118 (84.3) 21 (15.0) 1 (0.7)
0.465 0.465    (0.63, [0.18 - 2.18]) 
+ 2 1 (50.0) 1 (50.0) 0 (0.0)
Parkinson controls 
- 19 18 (94.7) 1    (5.3) 0 (0.0)
0.04 0.046 (12.3, [0.61 - 250.5]) 
+ 200 162 (81.0) 35 (17.5) 3 (1.5)
TOTAL 
- 1509 1328 (88.0) 176 (11.7) 5 (3.3)
0.002 2.04E-03  (1.74, [1.22 - 2.48]) 
Females only     GG (%) GA (%) AA (%)     
+ 25 14 (56.0) 11 (44.0) 0 (0.0)
GRAS patients 
- 327 288 (88.1) 38 (11.6) 1 (0.3)
2.11E-05 2.97E-05 (4.33, [2.06 - 9.09]) 
+ 13 9 (69.2) 4 (30.8) 0 (0.0)Affective disorder 
patients - 63 52 (82.5) 11 (17.5) 0 (0.0)
0.272 0.300 (1.90, [0.55 - 6.52]) 
+ 39 31 (79.5) 6 (15.4) 2 (5.1)
GRAS controls 
- 421 371 (88.1) 49 (11.6) 1 (0.2)
0.024 0.022 (2.28, [1.11 - 4.69]) 
+ 7 6 (85.7) 1 (14.3) 0 (0.0)
Parkinson patients 
- 80 69 (86.3) 11 (13.7) 0 (0.0)
0.969 0.970 (1.04, [0.12 - 8.82]) 
+ 4 3 (75.0) 1 (25.0) 0 (0.0)
Parkinson controls 
- 26 23 (88.5) 3 (11.5) 0 (0.0)
0.461 0.477 (2.33, [0.21 - 25.66]) 
+ 88 63 (71.6) 23 (26.1) 2 (2.3)
TOTAL 
- 917 803 (87.6) 112 (12.2) 2 (0.2)
7.42E-06 8.81E-06 (2.68, [1.71 - 4.21]) 
 






Table S9. HLA type association with seropositivity 
 
Anti-NR1 seropositivity (%) p CI 95% Imputation 
HLA allele 




low high quality (mean) 
HLA-A               
1 14.0% 12.6% 0.343 0.88 0.68 1.14 0.954 
2 29.7% 28.7% 0.615 0.95 0.79 1.15 0.937 
3 15.6% 19.7% 0.010 1.33 1.07 1.65 0.944 
11 5.7% 4.8% 0.370 0.83 0.56 1.24 0.943 
24 9.6% 10.0% 0.727 1.05 0.79 1.40 0.907 
HLA-B               
7 13.3% 13.1% 0.874 0.98 0.76 1.26 0.833 
8 9.8% 8.5% 0.305 0.85 0.63 1.16 0.940 
15 8.4% 8.5% 0.917 1.02 0.75 1.38 0.616 
18 5.5% 4.9% 0.554 0.89 0.60 1.32 0.570 
35 10.6% 12.4% 0.168 1.20 0.93 1.56 0.476 
40 6.4% 7.1% 0.467 1.13 0.81 1.58 0.554 
44 11.9% 9.9% 0.150 0.81 0.61 1.08 0.869 
51 6.2% 5.4% 0.490 0.88 0.60 1.27 0.752 
HLA-C               
2 5.2% 5.3% 0.937 1.02 0.69 1.49 0.973 
3 13.2% 13.1% 0.927 0.99 0.77 1.27 0.945 
4 12.8% 15.3% 0.095 1.23 0.96 1.56 0.967 
5 7.1% 7.0% 0.932 0.99 0.70 1.38 0.967 
6 10.2% 11.2% 0.463 1.11 0.84 1.45 0.963 
7 31.0% 30.4% 0.793 0.98 0.81 1.17 0.957 
12 7.1% 6.8% 0.798 0.96 0.68 1.34 0.947 
HLA-DPB1               
1 5.2% 4.8% 0.624 0.91 0.61 1.35 0.885 
2 13.9% 14.3% 0.785 1.03 0.81 1.32 0.826 
3 9.7% 9.2% 0.696 0.94 0.70 1.27 0.713 
4 56.5% 58.0% 0.497 1.06 0.89 1.26 0.859 
HLA-DQA1         
1 41.8% 43.9% 0.331 1.09 0.92 1.29 0.892 
2 12.5% 11.6% 0.531 0.92 0.70 1.20 0.941 
3 14.3% 14.6% 0.819 1.03 0.81 1.31 0.823 
5 28.3% 27.7% 0.771 0.97 0.80 1.18 0.926 
HLA-DQB1               
2 19.8% 17.9% 0.273 0.88 0.71 1.10 0.947 
3 35.5% 36.4% 0.669 1.04 0.87 1.24 0.927 
5 17.4% 17.3% 0.985 1.00 0.80 1.25 0.937 
6 24.4% 26.5% 0.254 1.12 0.92 1.36 0.882 
HLA-DRB1               
1 10.5% 11.4% 0.511 1.09 0.84 1.43 0.838 
3 11.0% 9.5% 0.266 0.85 0.64 1.13 0.886 
4 13.7% 13.6% 0.932 0.99 0.77 1.27 0.727 
7 12.4% 11.6% 0.540 0.92 0.70 1.20 0.889 
11 14.1% 14.1% 0.968 1.00 0.79 1.28 0.603 
13 12.0% 14.5% 0.092 1.23 0.97 1.58 0.822 
15 14.0% 13.9% 0.995 1.00 0.78 1.28 0.892 
 
HLA types were imputed at 4-digit resolution for all genotyped subjects. However, for statistical power issues, statistics were 
performed at 2-digit resolution. A minimal allele frequency of 5% in seronegative or seropositive subjects was set as inclusion 





Table S10. Influenza association with anti-NR1 seropositivity, gender-specific 
 
Study cohort GRAS patients 
Affective disorder 
patients 
GRAS controls Parkinson patients Parkinson controls TOTAL 
anti-NR1 seropositivity + - + - + - + - + - + - 
N seropositive (%) 55 (80.9) 427 (65.7) 8 (72.7) 45 (76.3) 68 (71.6) 454 (66.4) 19 (67.9) 85 (57.8) 2 (100.0) 11 (57.9) 152 (74.5) 1022 (65.6) 
p (Pearson's chi²) 0.011 0.461 0.312 0.322 0.243 0.011 Influenza A (males) 
OR [CI 95%] 2.210 [1.182 - 4.131] 0.830 [0.193 - 3.559] 1.276 [0.795 - 2.048] 1.540 [0.653 - 3.632] NA 1.536 [1.102 - 2.140] 
N seropositive (%) 26 (38.2) 135 (20.8) 3 (27.3) 19 (32.2) 28 (29.5) 146 (21.3) 11 (39.3) 54 (36.7) 0 (0) 4 (21.1) 68 (33.3) 358 (23.0) 
p (Pearson's chi²) 0.001 0.746 0.075 0.798 0.471 0.001 Influenza B (males) 
OR [CI 95%] 2.362 [1.398 - 3.990] 0.789 [0.188 - 3.315] 1.540 [0.955 - 2.482] 1.114 [0.486 - 2.554] NA 1.677 [1.225 - 2.296] 
N seropositive (%) 16 (66.7) 221 (67.2) 8 (61.5) 45 (71.4) 29 (69.0) 310 (68.9) 6 (85.7) 56 (69.1) 4 (100.0) 17 (60.7) 63 (70.0) 649 (68.2) 
p (Pearson's chi²) 0.959 0.48 0.983 0.356 0.122 0.732 Influenza A (females) 
OR [CI 95%] 0.977 [0.406 - 2.355] 0.640 [0.184 - 2.220] 1.007 [0.508 - 1.996] 2.679 [0.306 - 23.433] NA 1.086 [0.678 - 1.739] 
N seropositive (%) 4 (16.7) 67 (20.4) 2 (15.4) 13 (20.6) 9 (21.4) 75 (16.7) 1 (14.3) 25 (30.9) 0 (0) 4 (14.3) 16 (17.8) 184 (19.3) 
p (Pearson's chi²) 0.663 0.665 0.433 0.356 0.419 0.718 Influenza B (females) 
OR [CI 95%] 0.782 [0.259 - 2.365] 0.699 [0.138 - 3.553] 1.364 [0.627 - 2.968] 0.373 [0.043 - 3.266] NA 0.901 [0.513 - 1.584] 
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RESEARCH ARTICLE
Seroprevalence of Autoantibodies against
Brain Antigens in Health and Disease
Liane Dahm, PhD,1* Christoph Ott, MSc,1* Johann Steiner, MD,2,3*
Beata Stepniak, MSc,1 Bianca Teegen, PhD,4 Sandra Saschenbrecker, PhD,4
Christian Hammer, PhD,1 Kathrin Borowski,4 Martin Begemann, MD,1
Sandra Lemke,4 Kristin Rentzsch,4 Christian Probst, PhD,4 Henrik Martens, PhD,5
J€urgen Wienands, PhD,6 Gianfranco Spalletta, MD, PhD,7
Karin Weissenborn, MD,8 Winfried St€ocker, MD,4 and
Hannelore Ehrenreich, MD, DVM1,9
Objective: We previously reported an unexpectedly high seroprevalence (10%) of N-methyl-D-aspartate-receptor
subunit-NR1 (NMDAR1) autoantibodies (AB) in healthy and neuropsychiatrically ill subjects (N52,817). This finding
challenges an unambiguous causal relationship of serum AB with brain disease. To test whether similar results would
be obtained for other brain antigen-directed AB previously connected with pathological conditions, we systematically
screened serum samples of 4,236 individuals.
Methods: Serum samples of healthy (n5 1,703) versus neuropsychiatrically ill subjects (schizophrenia, affective disor-
ders, stroke, Parkinson disease, amyotrophic lateral sclerosis, personality disorder; total n52,533) were tested. For
analysis based on indirect immunofluorescence, we used biochip mosaics of frozen brain sections (rat, monkey) and
transfected HEK293 cells expressing respective recombinant target antigens.
Results: Seroprevalence of all screened AB was comparable in healthy and ill individuals. None of them, however,
reached the abundance of NMDAR1 AB (again 10%; immunoglobulin [Ig] G 1%). Appreciable frequency was
noted for AB against amphiphysin (2.0%), ARHGAP26 (1.3%), CASPR2 (0.9%), MOG (0.8%), GAD65 (0.5%), Ma2
(0.5%), Yo (0.4%), and Ma1 (0.4%), with titers and Ig class distribution similar among groups. All other AB were found
in 0.1% of individuals (anti–AMPAR-1/2, AQP4, CV2, Tr/DNER, DPPX-IF1, GABAR-B1/B2, GAD67, GLRA1b, GRM1,
GRM5, Hu, LGl1, recoverin, Ri, ZIC4). The predominant Ig class depended on antigen location, with intracellular epi-
topes predisposing to IgG (chi-square5 218.91, p52.8 3 10248).
Interpretation: To conclude, the brain antigen-directed AB tested here are comparably detectable in healthy sub-
jects and the disease groups studied here, thus questioning an upfront pathological role of these serum AB.
ANN NEUROL 2014;76:82–94
The occurrence in serum of autoantibodies (AB)directed against brain antigens has long been recog-
nized in classical autoimmune diseases and in paraneo-
plastic syndromes (for review, see eg Diamond et al,1
Sutton and Winer2). Recent work reports the presence of
AB directed against brain epitopes in serum of 90% of
individuals, independent of any illness.3 In this pivotal
work, however, no antigen specificity of the brain-
targeting AB has been assessed. Some authors even pro-
pose the term immunculus for a normal network of con-
stitutively expressed natural AB interacting with different
extracellular, membrane, cytoplasmic, and nuclear self-
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antigens.4,5 Serum diversity of these antibodies is strongly
influenced by age, individually remarkably stable over
time, and interestingly also conserved among mammals.6
Originally stimulated by literature describing an
association of N-methyl-D-aspartate-receptor subunit-NR1
(NMDAR1) AB with a multifaceted neuropsychiatric syn-
drome,7–9 we determined the seroprevalence of NMDAR1
AB in 1,325 healthy and 1,492 neuropsychiatrically ill
subjects, among them 1,081 schizophrenic, 263 Parkinson
disease, and 148 affective disorder patients. We wondered
whether, in some of the ill individuals, NMDAR1 AB
might have accounted for or worsened their symptoms.
Surprisingly, however, we found a comparable seropreva-
lence of 10% NMDAR1 AB in all investigated groups,
with similar distribution of titers and immunoglobulin
(Ig) isotypes (IgM and IgA being most frequent and IgG
amounting overall to only 1%) and indistinguishable
AB functionality in healthy and ill subjects.10 Another
study on mentally ill versus healthy individuals ultimately
came to equal conclusions.11,12
At first assuming a potential pathological role of
circulating NMDAR1 AB, the most obvious question
that arose for us from this unexpected discovery was to
ask why healthy individuals have remained healthy. In a
series of mouse experiments, we showed that the integrity
of the blood–brain barrier (BBB) determines whether
brain epitope–specific serum AB can exert any measura-
ble symptoms.10 This result is perfectly in line with the
hypothesis of Diamond and coworkers1 that under con-
ditions of BBB compromise, AB can alter brain function
in otherwise healthy individuals. Closing the circle to the
above-cited work of Levin and colleagues,3 these authors
propose that the normal immunocompetent B-cell reper-
toire is full of B-cells making AB that recognize brain
antigens.1 The relevance of these AB is not understood
yet but likely goes far beyond clear-cut pathology.
The present study has been designed to systemati-
cally screen for the first time serum samples of a large
number of healthy individuals (n5 1,703) versus subjects
with neuropsychiatric diseases (schizophrenia, affective
disorders, ischemic stroke, Parkinson disease, amyotro-
phic lateral sclerosis [ALS], borderline personality disor-
der; total n5 2,533) for the presence of a panel of 25
distinct AB directed against defined brain antigens.13–22
Most of these AB have been associated in the past with
some kind of inflammatory brain disease (for more
detailed description, see Table 1). Specifically, we aimed
(1) to replicate and extend our recent work on
NMDAR1 AB to >1,400 more individuals, and using
this extended data set as a comparator matrix, (2) to
evaluate frequency, disease group distribution, Ig classes,
and titers of 24 other distinct brain-specific AB.
Subjects and Methods
Participants
Subject data were collected in accordance with ethical guidelines
and the Helsinki Declaration. Sample selection was unbiased,
that is, sera collection in >90% of individuals was concluded
before analysis of AB was planned. Schizophrenic and schizoaf-
fective patients (fulfilling Diagnostic and Statistical Manual of
Mental Disorders, 4th edition criteria) were recruited during
2005–2011 at 23 German sites (n5 1,152) in the G€ottingen
Research Association for Schizophrenia (GRAS) study23,24 as
well as independently at the Department of Psychiatry, Univer-
sity of Magdeburg (n5 226). In a total of n5 74 patients ini-
tially suspected to have schizophrenia, the diagnosis had to be
revised to “mental disease not yet classified” (referred to as
“others”). Healthy GRAS controls were anonymized blood
donors (n5 1,265; Transfusion Medicine, G€ottingen).24 As
such, they widely fulfill health criteria, ensured by a broad pre-
donation screening process containing standardized question-
naires, interviews, hemoglobin and other blood parameters,
blood pressure, pulse, and body temperature determinations.
Similarly, Magdeburg controls (n5 357) included blood
donors, students, and hospital personnel, undergoing regular
health screening. Patients with affective disorders were recruited
as part of an ongoing GRAS extension to other disease groups
(n5 211) or at Magdeburg University (n5 99). Parkinson dis-
ease patients (n5 258) and respective controls (n5 81) were
recruited during 2010–2011 in Italy (Rome area).10 Patients
with ischemic stroke (n5 442) and patients with ALS (n5 29)
were enrolled in G€ottingen and Hannover. Patients with bor-
derline personality disorder (n5 42) were from Magdeburg
University.
Serological Analyses
Serum samples of all 4,236 participants were tested for the
presence of NMDAR1 AB (independent of whether they had
had previous determinations of NMDAR1 AB10) and a large
panel of further defined antineural AB (see Table 1 for descrip-
tion) as follows: Biochip mosaics (Euroimmun, L€ubeck, Ger-
many) contained nonfixed nitrogen-frozen tissue cryosections
(4 mm; rat hippocampus, monkey cerebellum) and recombinant
cell substrates (formalin- or acetone-fixed recombinant HEK293
cells), each expressing a different neural antigen (NMDAR1,
amphiphysin, ARHGAP26, CASPR2, MOG, GAD65, Ma2, Yo,
Ma1, AMPAR-1/2, AQP4, CV2, Tr/DNER, DPPX-IF1,
GABAR-B1/B2, GAD67, GLRA1b, GRM1, GRM5, Hu, LGl1,
recoverin, Ri, ZIC4). Expression of the individual recombinant
protein (autoantigen) was validated by immunological methods
employing human or commercially available monospecific animal
antibodies.
Biochip mosaics were incubated each with 70 ml of
phosphate-buffered saline (PBS)-diluted serum, starting at 1:10,
for 30 minutes at room temperature, washed with PBS-Tween,
and immersed in PBS-Tween for 5 minutes. Bound antibodies
were stained with fluorescein isothiocyanate–labeled goat anti-
human IgA, IgG, and IgM (Euroimmun) for 30 minutes at
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room temperature. Slides were washed again with a flush of
PBS-Tween and then immersed in PBS-Tween for 5 minutes.
Drops of PBS-buffered, 1,4-diazabicyclo[2.2.2]octane–contain-
ing glycerol (approximately 20 ml per field) were placed onto a
cover glass, and the biochip slides were embedded in this
mounting medium simultaneously and examined by fluores-
cence microscopy. Positive and negative controls were included
with every test procedure. Samples were classified as positive or
negative based on fluorescence intensity of the transfected cells
in direct comparison with nontransfected cells and control sam-
ples. Endpoint titers refer to the last dilution showing a meas-
urable degree of fluorescence, with 1:10 being the cutoff for
positivity. The biochip mosaics have been validated and estab-
lished in previous studies.22,25
Statistical Analysis
Group differences in categorical variables were assessed using
chi-square test. Logistic regression analysis was employed to
study predictive effects of age and disease status on seropositiv-
ity. For all analyses, statistical significance was set to the 0.05
level. Statistical analyses were performed using SPSS for Win-
dows (v17.0; IBM-Deutschland, Munich, Germany).
Results
In full agreement with our recent work,10–12 NMDAR1
AB showed an overall frequency of 10%, increasing
with age, with comparable distribution across essentially
all disease groups as well as healthy individuals (Table 2).
Only age (b5 0.02, Wald5 42.09, p5 8.7 3 10211),
but not disease versus health status (b5 0.06,
Wald5 0.29, p5 0.594) predicted seropositivity in a
logistic regression model (R2Nagelkerkes50:02, model chi-
square5 49.21, p5 2.1 3 10211). Again, distribution of
titer range (IgM: chi-square5 5.75, p5 0.218; IgA: chi-
square5 3.65, p5 0.302; IgG: chi-square5 2.31,
p5 0.511) and Ig class (IgM, IgA, and IgG: chi-
square5 0.55, p5 0.759) were similar in healthy and ill
subjects, with IgG once more constituting the rarest iso-
type. Remarkably, in the Parkinson disease sample ana-
lyzed here, despite an average age close to the stroke
group, NMDAR1 AB seropositivity amounted to only
8.1%. The reasons for this low percentage are presently
unclear and call for replication.
Only 8 of the 24 other AB showed appreciable
seropositivity (range5 0.4–2.0%), but each was well
below the NMDAR1 AB frequency (Table 2): amphiphy-
sin (2.0%), ARHGAP26 (1.3%), CASPR2 (0.9%),
MOG (0.8%), GAD65 (0.5%), Ma2 (0.5%), Yo (0.4%),
and Ma1 (0.4%). As seen with NMDAR1 AB, frequen-
cies of AB against the other 8 antigens were similar over
all subject groups (healthy and disease: chi-square5 1.25,
p5 0.535), and titer ranges were comparable. In contrast
to NMDAR1 AB, however, seroprevalence of these 8 AB
tended to slightly (but not significantly) ascend with age
(Fig 1A). A total of 96 individuals carried AB of >1 Ig
class against the same antigen (Table 2).
Interestingly, comparable to NMDAR1 AB, the 2
other AB directed against extracellular antigens with still
substantial seropositivity (Table 2), CASPR2 and MOG,
FIGURE 1: (A) Seropositivity for autoantibodies (AB) directed against 8 defined brain antigens (amphiphysin, ARHGAP26,
CASPR2, MOG, GAD65, Ma2, Yo, and Ma1) by age. Displayed is the relative frequency (%) of seropositive individuals in the
respective age group of healthy (gray) versus ill (black) individuals. N-methyl-D-aspartate-receptor subunit-NR1 (NMDAR1) AB
are not included; for information on these AB see Hammer et al.10 (B) Immunoglobulin (Ig) class depends on antigen location.
Note the inverted pattern of distribution of the predominant Ig isotype in individuals carrying AB against intracellular versus
extracellular epitopes. NMDAR1 AB are included. For clarity, individuals who tested positive for AB of >1 Ig class/antigen
(n596) or for >1 antigen (n529) were excluded.








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































were rarely of the IgG class. In contrast, the remaining
relatively frequent 6 AB (Table 2), recognizing intracellu-
lar antigens (amphiphysin, ARHGAP26, GAD65, Ma2,
Yo, Ma1), were predominantly IgG. These highly signifi-
cant differences in immunoglobulin class frequencies
(chi-square5 218.91, p5 2.8 3 10248) may indicate
that the antigen location codetermines Ig class selection
(Fig 1B).
All other AB screened were found in 0.1% of
individuals (AMPAR-1/2, AQP4, CV2, Tr/DNER,
DPPX-IF1, GABAR-B1/B2, GAD67, GLRA1b, GRM1,
GRM5, Hu, LGl1, recoverin, Ri, ZIC4), making solid
conclusions difficult (Table 3). Overall, distribution in
healthy and ill subjects was again similar (seropositives/
tested, ill subjects: 19/2,5035 0.8% vs healthy subjects:
9/1,6935 0.5%; chi-square5 0.79, p5 0.375).
Of the n5 4,196 individuals who could ultimately
be successfully screened for all 25 antigens, 83.2%
(n5 3,493) were seronegative, 16% (n5 670) were sero-
positive for 1 (of 25), 0.7% (n5 29) for 2, and 0.1%
(n5 4) for 3 specific antigens. No significant difference
in overall seroprevalence was found between healthy and
ill individuals.
Discussion
A large number of individuals (N5 4,236), healthy or
suffering from different neuropsychiatric diseases, were
for the first time systematically screened for seropreva-
lence of 25 AB directed against defined brain antigens.
For NMDAR1 AB, the previously reported high overall
seroprevalence of 10%10 could be confirmed in the
present sample, extended in total number (2,817 plus
1,419 new subjects) and disease groups (schizophrenia,
affective disorders, and Parkinson disease, plus addition-
ally ischemic stroke, ALS, and borderline personality
disorder).
In contrast to NMDAR1 AB, all other 24 newly
tested brain-targeting AB revealed a much lower seropre-
valence (2.0%). As seen before10 and now replicated
with NMDAR1 AB, these newly explored 24 AB also
showed comparable frequency, titer, and Ig class distribu-
tion across all investigated groups. As predisposing fac-
tors for NMDAR1 AB seropositivity, we previously
identified a common genetic variant (rs524991) as well
as anti-influenza A or B seropositivity.10 The low fre-
quency of the 24 newly screened AB would require
>20,000 deeply phenotyped and genotyped subjects for
an investigation of this kind, which clearly limits the pos-
sibilities even of the present large study. Also, potential
conclusions regarding symptom aggravation by these cir-
culating AB in disease states would have to be built on
much larger numbers of comprehensively characterized
subjects. An exploratory analysis of the 8 most prevalent
AB taken together showed that seropositivity was not
predicted by positive influenza A or B titers (data not
shown), thus rendering a major role of influenza as a
general, nonspecific autoimmunity trigger unlikely.
It is important to mention that the autoimmune
diseases that have been previously associated with the 25
autoantibodies under study (see Table 1) have not been
the subject of the present investigation. This investigation
focused solely on seroprevalence of these AB in healthy
and neuropsychiatrically ill subjects. Moreover, the
potential presence of a nascent, not yet detected tumor
in one or the other individual under study, healthy or ill,
cannot be entirely excluded.
The data of the present study support earlier
hypotheses of a physiological presence in serum of AB
directed against brain antigens.1,3 In contrast to previ-
ous work investigating only overall serum IgG immuno-
reactivity with brain tissue, the AB reported here are
not only well defined regarding the distinct brain anti-
gens but were also systematically tested for all 3 major
Ig classes, IgG, IgM, and IgA. IgG and IgA AB are
formed by class switch (from IgM), spontaneously or
for instance in conditions of inflammation.26 An inter-
esting observation in the present study is the rarity of
the IgG class in AB directed against extracellular epi-
topes, NMDAR1, MOG, and CASPR2, as compared
to the highly significant predominance of this Ig isotype
in the 6 other rather frequently detected AB that all
recognize intracellular antigens (amphiphysin, ARH-
GAP26, GAD65, Ma2, Yo, Ma1). Hence, antigen loca-
tion (extracellular vs intracellular) apparently plays a
major role in isotype determination in “physiological
autoimmunity.” We note in this context that
“pathological or harmful autoimmunity” such as that
associated with anti-NMDAR1 encephalitis has been
linked to AB of the IgG class directed against an
extracellular epitope, namely NMDAR1.27
The present work aimed exclusively at analyzing
serum AB. For obvious reasons, cerebrospinal fluid
(CSF) was not available for the same large set of indi-
viduals. The obtained data may serve as a reference for
clinicians advising caution with respect to any conclu-
sions on a causal association of serum AB with brain
disease. The presence of these AB in the circulation
obviously does not allow any firm assumption as to
whether they play a pathophysiological role in any
brain-related syndrome, and certainly does not on its
own justify immunosuppressive treatment, unless they
are also proven to exist in an appreciable amount in
the CSF. Importantly, a certain rate of basic transfer is
expected to take place also in healthy individuals with
ANNALS of Neurology
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intact BBB, for example, for IgG, 1/500 of the serum
concentration.28 Therefore, detection of substantial CSF
AB levels appears mandatory for allowing conclusions
on a causal or symptom-aggravating association with
any central nervous system disorder, such as any kind
of encephalitis, epilepsy, psychosis, extrapyramidal symp-
toms, or cognitive decline. Similar conclusions were
drawn in a recent study on cases of anti-NMDAR1
encephalitis where CSF and serum levels were retrospec-
tively evaluated.27
In the absence of a temporary or permanent dis-
turbance of the BBB, serum AB would not be expected
to enter the brain in noticeable amounts. However, in
case of AB passage through a “leaky” BBB, facilitated
by genetic predisposition (eg, APOE4 carrier status),
during fetal life or upon brain trauma or inflammation,
symptom aggravation may well evolve.1,10,29,30 On the
other hand, considering earlier attempts to treat stroke
or epilepsy with AB against NMDAR1, there may even
be situations where AB entering the brain are protec-
tive.31 Importantly, AB may also penetrate into the
brain in other (noninflammatory) situations, for exam-
ple, stress.1 Thus, the individual repertoire of physiolog-
ical AB may modulate brain function and/or
codetermine outcome from brain disease. Undeniably,
exploring the role of brain antigen-directed serum AB is
just in its infancy, and much more research is needed to
understand their pathophysiological significance.
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INTRODUCTION
Erythropoietin (EPO), originally de-
scribed as a hematopoietic growth factor,
has been found to improve cognition al-
most since its first clinical approval for
the treatment of renal anemia, but this ef-
fect has long been attributed solely to its
indirect action via increased hemoglobin
(1). Over the last 15 years, the importance
of EPO for nonhematopoietic tissues, par-
ticularly the nervous system, has been
recognized increasingly. In addition to di-
rect neuroprotective and neuroregenera-
tive functions of the EPO system, its ef-
fects on neuroplasticity and cognition
have become evident (2–4). EPO treat-
ment has been shown to improve learning
and memory functions, not only in dis-
ease models, but also in healthy rodents
(5–7). In clinical trials on patients suffer-
ing from schizophrenia or multiple sclero-
sis, high-dose rhEPO infusions over sev-
eral months resulted in better cognitive
performance (8,9). Functional magnetic
resonance imaging 1 wk after just a single
high dose of rhEPO revealed an enhance-
ment of the hippocampal response during
memory retrieval in healthy human sub-
jects (10). Importantly, cognitive improve-
ment in these studies was not linked to an
increase in hemoglobin. Still-remaining
concerns that EPO might exert these cog-
nitive effects via enhanced hemoglobin
were further alleviated by the functional
separation of hematopoietic and neuro-
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Erythropoietin (EPO) improves cognitive performance in clinical studies and rodent experiments. We hypothesized that an intrin-
sic role of EPO for cognition exists, with particular relevance in situations of cognitive decline, which is reflected by associations of
EPO and EPO receptor (EPOR) genotypes with cognitive functions. To prove this hypothesis, schizophrenic patients (N > 1000) were
genotyped for 5′ upstream–located gene variants, EPO SNP rs1617640 (T/G) and EPOR STR(GA)n. Associations of these variants were
obtained for cognitive processing speed, fine motor skills and short-term memory readouts, with one particular combination of
genotypes superior to all others (p < 0.0001). In an independent healthy control sample (N > 800), these associations were con-
firmed. A matching preclinical study with mice demonstrated cognitive processing speed and memory enhanced upon trans-
genic expression of constitutively active EPOR in pyramidal neurons of cortex and hippocampus. We thus predicted that the
human genotypes associated with better cognition would reflect gain-of-function effects. Indeed, reporter gene assays and quan-
titative transcriptional analysis of peripheral blood mononuclear cells showed genotype-dependent EPO/EPOR expression differ-
ences. Together, these findings reveal a role of endogenous EPO/EPOR for cognition, at least in schizophrenic patients.
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protective actions using EPO variants, de-
void of hematopoietic properties (11). In
addition, neuroregenerative effects of
EPO in insects, lacking hematopoiesis,
suggest an intrinsic and phylogenetically
ancient significance of EPO for neuroplas-
ticity and cognition (12).
Studies on the role of EPO or EPOR
genotypes have focused on searching for
associations of genetic markers in these
genes with readouts of the hematopoietic
system in healthy individuals and disease
states, such as myeloproliferative or
myelodysplastic syndromes. The results
were mainly negative for EPO genotypes
(13–18), but several associations for EPOR
polymorphisms or rare mutations with
various forms of familial polycythemia
were identified (19,20). Three publications
deal with EPO genotypes in diabetic reti-
nopathy. One turned out negative (21),
whereas the other two found associations,
but the results remain contradictory since
opposing risk genotypes were described
(22,23). Another study reported an associ-
ation of an EPO genotype with age of
onset of amyotrophic lateral sclerosis (24).
No data are available yet on associations
of EPO or EPOR genotypes with brain
functions, including cognition.
We hypothesized that an inherent rele-
vance of EPO for cognitive functioning
and neuroplasticity in humans should be
reflected by associations of EPO and
EPOR genotypes with selected readouts of
cognitive performance and might be un-
covered in a disease characterized by cog-
nitive decline. To test these hypotheses, we
exploited the GRAS (Göttingen Research
Association for Schizophrenia) data collec-
tion, which provides a unique ground for
phenotype-based genetic association stud-
ies (PGAS) with information on over 1,000
well-characterized schizophrenic patients
(25,26). We show here that in this popula-
tion, as well as in a healthy replicate sam-
ple, EPO/EPOR genotypes are associated
with several domains of higher cognition.
Moreover, on the basis of reporter gene as-
says and mouse studies, we propose that
better performance is linked to higher




Disease sample. The GRAS data col-
lection was approved by the ethics com-
mittee of the Georg-August-University
(master committee) and the local internal
review boards of the collaborating cen-
ters. The project complies with the
Helsinki Declaration (27). Patients fulfill-
ing DSM-IV criteria for schizophrenia or
schizoaffective disorder were included
regardless of the stage of the disease
(acute, chronic, residual or remitted). All
study participants and, if applicable,
their legal representatives gave written
informed consent (for detailed informa-
tion on the GRAS sample, see reference
26). A total of N = 1,050 GRAS patients
were successfully genotyped for the EPO
SNP (single nucleotide polymorphism
T/G) rs1617640, N = 1,054 for the EPO
SNP (T/G) rs564449, and N = 1,054 for
EPOR short tandem repeat, STR(GA)n,
and are included in the present genetic
analyses. Most GRAS patients are of Eu-
ropean Caucasian ethnicity (Caucasian
95.4%; other ethnicities 1.8%; unknown
2.8%). Peripheral blood mononuclear
cells (PBMCs) were taken from a sub-
sample of the GRAS cohort (N = 98) to
analyze mRNA expression dependent on
genotype.
Case control sample. Healthy volun-
tary blood donors were recruited by the
Department of Transfusion Medicine at
the Georg-August-University of Göttin-
gen according to national guidelines for
blood donation to serve as control sub-
jects. As such, they widely fulfill health
criteria, ensured by a broad predonation
screening process including standardized
health questionnaires, interviews and as-
sessment of hemoglobin concentration,
blood pressure, pulse and body tempera-
ture. Of the N = 1,141–1,142 successfully
genotyped control subjects, 58.9% were
male (N = 672–673) and 41.1% female (N =
469–470). The average age was 34.61 ±
12.30 y (range 18 to 69). The majority of
the control subjects were of European
Caucasian ethnicity (Caucasian 97.8%;
other ethnicities 2%; unknown 0.2%).
Independent healthy control sample
(replicate sample). Unrelated volunteers
of German descent (that is, both parents
German) were selected randomly from the
general population of Munich, Germany,
and contacted by mail (28). To exclude
subjects with central neurological diseases
and psychotic disorders or individuals
who had first-degree relatives with psy-
chotic disorders, several screenings were
conducted before volunteers were enrolled
in the study. Firstly, subjects who re-
sponded were screened initially by phone
for the absence of neuropsychiatric disor-
ders. Secondly, detailed medical and psy-
chiatric histories were obtained for both
the patients themselves as well as their
first-degree relatives by using a semistruc-
tured interview. Thirdly, if inclusion crite-
ria were fulfilled, the subjects were invited
for a comprehensive interview including
the German version of the structured clini-
cal interview for DSM-IV (SCID I and
SCID II) (29) to confirm the absence of any
lifetime psychotic disorder. Additionally,
the family history assessment module (30)
was conducted to exclude psychotic disor-
ders among first-degree relatives. Further-
more, a neurological examination was
conducted to exclude subjects with current
central nervous system impairment. In
case of volunteers being older than 60
years, the Mini-Mental State Examination
(MMSE; 31) was performed to exclude
subjects with possible cognitive impair-
ment. Written informed consent was ob-
tained from all individuals after providing
them with a detailed description of the
study, which was approved by the local
ethics committee and carried out in accor-
dance with the Helsinki Declaration (27).
Phenotype-Based Genetic
Association Study (PGAS)
Disease sample. On the basis of find-
ings of our previous EPO treatment trial
with schizophrenic patients (9), neu-
ropsychological measures of processing
speed (Digit  Symbol-Coding [Zahlen-
Symbol-Test], a subtest of German ver-
sion of Wechsler Adult Intelligence Scale
[WAIS; 32]) and perceptual organization
(subtests Dotting and Tapping from Mac-
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Quarrie Test for Mechanical Ability; 33)
were selected from the GRAS database
for phenotype–genotype association
analyses (target variables). The “Verbal
Learning and Memory Test” (Verbaler
Lern- und Merkfähigkeitstest [VLMT];
34) was included as another  target vari-
able to cover aspects of short-term mem-
ory. Additionally, to demonstrate the
specificity of genotype associations with
the selected cognitive readouts, sociode-
mographic (that is, age, gender, level of
education) and clinical variables (age at
first episode, duration of disease, med-
ication status, Positive and Negative
Syndrome Scale [PANSS; 35] subscales
and Global Assessment of Functioning
[GAF; 36]) were included in the analysis
(see Table 1 for target and Table 2 for so-
ciodemographic and clinical variables).
Healthy individuals (replicate sample).
To replicate the phenotype–genotype asso-
ciations found in GRAS patients in an in-
dependent group of healthy individuals,
we aimed at covering comparable domains
of processing speed and perceptual organ-
ization. Digit  Symbol-Coding test as mea-
sure of processing speed and Block Design
(Mosaik-Test) as test of perceptual organi-
zation capacities (both from German ver-
sion of WAIS; 32) were employed. Unfor-
tunately, neuropsychological tests
measuring verbal memory were not avail-
able in sufficient numbers for  replication.
Statistical Analyses
Statistical analyses of phenotype–
 genotype associations for healthy and
schizophrenic individuals were per-
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Table 1. Association of EPO and EPOR genotypes with cognitive target variables in schizophrenic patients (GRAS) and healthy individuals.
EPO rs1617640 EPOR STR (GA)n EPO and EPOR
GG and 
Effect Effect 21–35 All other Effect 
GG GT TT (p)a Low sum High sum (p) repeats combinations (p)
Disease sample (GRAS), mean ± SD (95% CI)b,c,d
N = 161–172 N = 408–465 N = 345–381 N = 466–509 N = 448–509 N = 60–63 N = 854–955
Perceptual organization
Dotting and Tapping 0.08 ± 1.98 0.02 ± 1.83 –0.11 ± 1.94 1.492 0.01 ± 1.85 –0.03 ± 1.94 4.402 0.65 ± 1.92 –0.06 ± 1.88 10.259
(–0.22–0.38) (–0.14–0.19) (–0.30–0.09) (0.222) (–0.16–0.16) (–0.20–0.14) (0.045) (0.18–1.13) (–0.18–0.06) (0.001)
Processing speed
Digit Symbol-Coding (WAIS)e 40.13 ± 14.19 37.62 ± 12.73 36.93 ± 13.42 8.868 37.80 ± 13.20 37.77 ± 13.38 1.893 43.57 ± 14.46 37.40 ± 13.12 16.166
(38.0–42.3) (36.5–38.8) (35.6–38.3) (0.003) (36.7–38.9) (36.6–38.9) (0.169) (40.0–47.1) (36.6–38.2) (<0.001)
Cognition compositef 0.08 ± 0.94 –0.01 ± 0.88 –0.07 ± 0.92 3.327 –0.00 ± 0.89 –0.02 ± 0.93 4.274 0.37 ± 0.90 –0.04 ± 0.90 13.891
(–0.07–0.22) (–0.09–0.08) (–0.16–0.03) (0.036) (–0.09–0.07) (–0.11–0.06) (0.039) (0.14–0.59) (–0.10–0.02) (<0.001)
Verbal learning and 42.74 ± 13.22 42.22 ± 12.84 40.62 ± 12.69 0.852 42.22 ± 13.00 41.18 ± 12.82 5.298 46.72 ± 12.49 41.36 ± 12.83 9.063
memory (VLMT)g (40.7–44.8) (41.0–43.5) (39.3–42.0) (0.356) (41.1–43.4) (40.0–42.4) (0.022) (43.6–49.9) (40.5–42.2) (0.003)
Healthy individuals, mean ± SD (95% CI)h
N = 332 N = 1095 N = 859 N = 447 N = 434 N = 50 N = 831
Perceptual organization
Block Design (WAIS)e 31.78 ± 9.24 30.32 ± 9.43 30.32 ± 9.58 7.263 32.83 ± 9.18 30.99 ± 8.76 9.815 33.46 ± 9.23 31.83 ± 9.00 1.068
(30.8–32.8) (29.8–30.9) (29.7–31.0) (0.007) (32.0–33.7) (30.2–31.8) (0.002) (30.9–36.0) (31.2–32.4) (0.302)
Processing speed
Digit Symbol-Coding (WAIS)e 53.19 ± 13.22 51.74 ± 12.96 51.34 ± 13.33 4.116 54.29 ± 12.08 54.13 ± 12.12 0.004 56.56 ± 10.68 54.07 ± 12.16 1.678
(51.8–54.6) (51.0–52.5) (50.5–52.2) (0.043) (53.2–55.4) (53.0–55.3) (0.953) (53.6–59.5) (53.2–54.9) (0.196)
Cognition compositef 0.12 ± 0.88 –0.01 ± 0.88 –0.03 ± 0.89 7.768 0.22 ± 0.84 0.11 ± 0.79 4.142 0.34 ± 0.81 0.16 ± 0.82 2.025
(0.02–0.21) (–0.07–0.04) (–0.09–0.03) (0.005) (0.14–0.29) (0.04–0.19) (0.043) (0.11–0.56) (0.10–0.21) (0.155)
aEffects for GG versus T carriers.
bAnalysis of covariance (ANCOVA) with age, negative symptoms (PANSS), medication status (chlorpromazine equivalents) and duration of
disease as covariates, and Blom-transformed single targets.
cOwing to missing data upon phenotyping and the exclusion of nonnative German speakers for language-dependent readouts (VLMT),
sample size varies between N = 914–1018 in the total GRAS sample.
dCI, confidence interval.
eTest from German version of WAIS (32).
fCognition composite represents mean of Dotting and Tapping subtests and Digit Symbol-Coding test (both tests Blom transformed).
gExclusion of nonnative German speakers (N = 92).
hAnalysis of covariance (ANCOVA) with age as covariate and Blom-transformed single targets.
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Table 2. Sociodemographic and disease-related variables in schizophrenic patients and healthy controls are not associated with
EPO/EPOR genotypes.
EPO rs1617640 EPOR STR (GA)n EPO and EPOR
GG and 
Effect Effect 21–35 All other Effect 
Basic variables GG GT TT (p)a Low sum High sum (p) repeats combinations (p)
Disease sample (GRAS) (95% CI)b,c,d
N = 165-171 N = 452-483 N = 366-388 N = 496-519 N = 484-520 N = 60-63 N = 920-976
Age, mean ± SD, y 40.32 ± 12.48 39.15 ± 12.43 39.69 ± 12.74 (0.316) 39.67 ± 12.39 39.42 ± 12.71 (0.540) 37.34 ± 12.50 39.69 ± 12.55 (0.166)
(38.4–42.2) (38.0–40.3) (38.4–41.0) (38.6–40.7) (38.3–40.5) (34.23–40.5) (38.9–40.5)
Gender, no. (%), male 110 (63.6%) 332 (67.9%) 260 (67%) 1.002 352 (67.2%) 350 (66.4%) 0.094 43 (68.3%) 659 (66.8%) 0.059
(54.6–72.6) (62.9–72.9) (61.3–72.7) (0.317) (62.4–72.2) (61.5–71.4) (0.759) (54.3–82.2) (63.2–70.4) (0.808)
Ethnicity, no. (%), Caucasiane 171 (98.8%) 461 (94.3%) 368 (94.8%) 1.916 499 (95.4%) 501 (95.1%) 1.691 63 (100.0%) 937 (94.9%) 1.276
(97.2–100.4) (92.2–96.4) (92.6–97.1) (0.384) (93.6–97.2) (93.2–97.0) (0.429) (–) (93.5–96.3) (0.528)
Years of education, mean ± SDf 12.40 ± 3.15 12.11 ± 2.93 11.95 ± 3.23 (0.208) 12.16 ± 3.06 12.05 ± 3.10 (0.528) 12.75 ± 3.25 12.06 ± 3.07 (0.143)
(11.9–12.9) (11.8–12.4) (11.6–12.3) (10.7–14.5) (12.0–15.7) (11.9–13.6) (11.9–12.3)
Current occupation, no. (%), 30 (17.3%) 77 (15.7%) 59 (15.2%) 0.275 75 (14.3%) 91 (17.3%) 1.805 14 (22.2%) 152 (15.4%) 1.915
unemployed (3.8–30.9) (7.6–23.9) (6.0–24.4) (0.600) (6.4–22.3) (9.5–25.0) (0.179) (0.4–44.0) (9.7–21.1) (0.166)
Age at first episode, mean ± SD, y 26.72 ± 9.30 25.73 ± 8.21 26.75 ± 8.94 (0.742) 26.35 ± 8.71 26.19 ± 8.66 (0.654) 25.12 ± 9.30 26.35 ± 8.64 (0.101)
(25.3–28.1) (25.0–26.5) (25.9–27.6) (25.6–27.1) (25.5–26.9) (22.8–27.4) (25.8–26.9)
Duration of disease (first episode), 13.25 ± 11.48 13.28 ± 10.71 12.83 ± 10.34 (0.811) 13.27 ± 10.44 12.94 ± 10.96 (0.365) 11.80 ± 11.27 13.19 ± 10.66 (0.161)
mean ± SD, y (11.5–15.0) (12.3–14.2) (11.8–13.9) (12.4–14.2) (12.0–13.9) (9.0–14.6) (12.5–13.9)
Smoker status, no (%), smoker 57 (33.7) 128 (27.2) 113 (30.5) 2.776 148 (29.1) 154 (30.5) 0.244 22 (35.5) 276 (29.1) 1.135
(20.6–40.8) (23.2–31.2) (25.8–35.2) (0.250) (25.2–33.0) (26.5–34.5) (0.621) (23.6–47.4) (26.2–32.0) (0.287)
Chlorpromazine equivalents, 637.1 ± 514.8 724.29 ± 792.18 671.7 ± 647.5 (0.957) 751.5 ± 727.3 680.6 ± 674.2 (0.486) 542.6 ± 427.9 713.1 ± 714.2 (0.174)
mean ± SD (559.5–714.7) (653.6–794.9) (607.0–736.4) (637.9–736.1) (622.5–738.7) (436.9–648.3) (655.3–754.0)
PANSS positive, mean ± SD 13.49 ± 6.17 14.30 ± 6.75 13.16 ± 5.75 (0.669) 13.95 ± 6.45 13.53 ± 6.16 (0.355) 13.98 ± 6.59 13.72 ± 6.30 (0.805)
(12.6–14.4) (13.7–14.9) (12.6–13.7) (13.4–14-5) (13.0–14.1) (12.3–15.6) (13.3–14.1)
PANSS negative, mean ± SD 17.69 ± 7.78 18.68 ± 8.11 18.09 ± 7.73 (0.286) 18.80 ± 8.30 17.78 ± 7.49 (0.106) 18.18 ± 7.98 18.30 ± 7.92 (0.863)
(16.5–18.9) (17.9–19.4) (17.3–18.9) (18.1–19.5) (17.1–18.4) (16.2–20.2) (17.8–18.8)
PANSS general, mean ± SD 33.37 ± 11.17 34.56 ± 12.51 32.88 ± 11.28 (0.809) 34.10 ± 12.43 33.36 ± 11.25 (0.610) 33.20 ± 12.29 33.77 ± 11.83 (0.570)
(31.7–35.1) (33.4–35.7) (31.7–34.0) (33.0–35.2) (32.4–34.4) (30.1–36.3) (33.0–34.5)
PANSS total, mean ± SD 64.34 ± 22.53 67.43 ± 24.72 64.03 ± 22.08 (0.484) 66.89 ± 24.96 64.38 ± 21.73 (0.284) 65.30 ± 24.95 65.67 ± 23.36 (0.733)
(60.9–67.8) (65.2–69.7) (61.8–63.3) (64.7–69.1) (62.4–66.3) (59.0-71.6) (64.2–67.2)
GAF, mean ± SD 45.88 ± 18.48 45.30 ± 17.26 46.40 ± 16.67 (0.934) 46.09 ± 17.78 45.51 ± 16.72 (0.836) 47.02 ± 18.60 45.72 ± 17.16 (0.749)
(43.1–48.7) (43.7–46.9) (44.7–48.1) (44.5–47.6) (44.1–47.0) (42.4–51.7) (44.6–46.8)
Healthy individuals (95% CI)b
N = 335 N = 1,111 N = 869 N = 449 N = 437 N = 50 N = 836
Age, mean ± SD, y 51.12 ± 16.37 51.91 ± 15.45 52.18 ± 15.42 (0.686) 47.97 ± 14.16 48.52 ± 14.42 (0.427) 46.88 ± 15.14 48.32 ± 14.24 (0.605)
(49.4–52.9) (51.0–52.8) (51.2–53.2) (46.7–49.3) (47.2–49.9) (42.7–51.1) (47.4–49.3)
Gender, no. (%), male 160 (47.8%) 547 (49.2%) 416 (47.9%) 0.088 221 (44.6%) 198 (40.2%) 1.359 23 (46.0%) 396 (47.4%) 0.035
(40.0–55.5) (45.1–53.4) (43.1–52.7) (0.767) (38.1–51.2) (33.3–47.0) (0.244) (25.6–66.4) (42.5–52.3) (0.851)
Education, no. (%),low levelg 60 (20.6%) 287 (25.8%) 224 (25.8%) 4.316 101 (20.4%) 90 (18.3%) 1.108 7 (14.0%) 184 (22.0%) 3.386
(11.0–30.1) (20.8–30.9) (20.1–31.5) (0.116) (12.5–28.3) (10.3–26.2) (0.575) (–11.7–39.7) (16.0–28.0) (0.184)
aEffects for GG versus T carriers.
bMethods used: Mann-Whitney U tests and χ2 tests.
cOwing to missing data upon phenotyping, sample size varies between N = 771–1,049 in the total GRAS sample.
dCI, confidence interval.
eExploratory exclusion of non-Caucasian subjects did not appreciably alter any of the main findings of the paper.
fRating according to graduation/certificate; patients currently in school or in educational training are excluded.
gLow level education: equal or less than nine years of academic formation.
formed using SPSS for Windows version
17.0 (SPSS Inc., Chicago, IL, USA;
http:// www.spss.com). GraphPad Prism,
version 5.01 (La Jolla, CA, USA) was used
to analyze expression and mouse data.
Case control study (disease sample
versus healthy blood donors or repli-
cate sample). For EPOR STR (GA)n, the
sum of repeat lengths of both alleles was
analyzed. To account for intraindividual
allelic heterogeneity (that is, the degree
of heterogeneity between the two alle-
les), the difference between allelic repeat
lengths was calculated. Distributions of
single allele lengths, allelic repeat sum,
allelic heterogeneity and of EPO SNP
genotypes (SNPs rs1617640 and
rs564449) between schizophrenic subjects
and healthy controls were assessed by
χ2 tests with (EPOR) and without (EPO)
Monte Carlo sampling (1,000 runs).
PGAS. For the phenotype–genotype 
association analysis using the EPO SNP
rs1617640 as independent variable, T car-
riers (GT and TT) were aggregated and
contrasted with individuals homozygous
for the G allele. Group comparisons for
the EPOR repeat were based on median
splits (21–36 versus 37–54; for the first
PGAS approach, Tables 1 and 2) or tercile
splits (21–35 versus 36–38 versus 39–54;
for more detailed subgroup comparisons,
see Figure 1F) of allelic repeat sums. Data
on cognitive target variables are presented
such that higher values always indicate
better performance. They were standard-
ized to mean zero and variance one by
Blom transformation (37). In language-
 dependent tests (VLMT), nonnative Ger-
man speakers (N = 92) were excluded for
analyses. A cognition composite score was
calculated for each individual represent-
ing the mean of the Blom-transformed
data for processing speed and perceptual
organization. Genotype differences were
assessed by analysis of covariance includ-
ing covariates age (both healthy individu-
als and disease controls), duration of dis-
ease, chlorpromazine equivalents and
severity of negative symptoms (PANSS;
the latter three covariates only for the dis-
ease sample) as they are known to influ-
ence performance on neuropsychological
tests. Genotype differences with respect to
sociodemographic and clinical readouts
were tested using χ2 (nominal variables)
or Mann-Whitney U tests (continuous
variables). The impact of EPO and EPOR
genotypes on mRNA levels and expres-
sion differences dependent on EPOR
genotype were tested nonparametrically
using Kruskal-Wallis and Mann- Whitney
U tests in the subsample of patients of
whom PBMCs were available (N = 98).
DNA Extraction and Normalization
Disease sample and healthy blood
donors. Genomic DNA was purified
from whole blood using JETQUICK
Blood & Cell Culture DNA Spin Kit
(Genomed GmbH, Löhne, Germany) ac-
cording to the manufacturer’s protocol.
Resulting DNA samples were aliquoted
and stored at –80°C. For further analysis,
DNA was normalized to 50ng/μL with
an automated robotic platform (Microlab
Star, Hamilton, Bonaduz, Switzerland).
For quality control, each sample was an-
alyzed with a 0.8% agarose gel.
Healthy individuals (replicate sam-
ple). DNA extraction was done with the
QIAamp Blood Maxi Kit (Qiagen,
Hilden, Germany). DNA concentration
was adjusted using the PicoGreen quan-
titation reagent (Invitrogen, Karlsruhe,
Germany).
Genotyping—Analysis of SNPs in the
hEPO Gene
Disease sample and healthy blood
donors. The selected SNPs (rs1617640
and rs564449) in the EPO gene were ana-
lyzed using Simple Probes (TIB Molbiol,
Berlin, Germany) and called using the
LightCycler 480 Genotyping Software im-
plemented in the LightCycler 480 system
(Roche, Mannheim, Germany). The reac-
tion mixture (10 μL) was prepared with
20 ng of DNA in 384 well plates accord-
ing to standard protocols (Roche). In each
run, eight positive controls (hgDNA, Bio-
line, Luckenwalde, Germany) and nega-
tive water blanks were included for qual-
ity and internal control purposes.
Overall, successfully genotyped markers
amounted to 99.7–99.9%.
Healthy individuals (replicate sam-
ple). The SNP rs1617640 was genotyped
using the iPLEX assay on the Mass -
ARRAY MALDI-TOF mass spectrometer
(Sequenom, Hamburg, Germany). Geno-
typing call rates were all >95%.
Genotyping—Analysis of GA Repeats
(Both Disease Sample and Healthy
Individuals)
The polymorphic GA repeat in the pro-
moter region of hEPOR was amplified
from genomic DNA by PCR. Primers
were chosen from de la Chapelle et al.,
1993 (38): hEPOR_(GA)n forward: 5′-FAM
GGTGA CAGAG CAACA CCCTG-3′;
hEPOR_(GA)n reverse: 5′-ATCAG CATCT
CTTCC CAGCC-3′ resulting in a PCR
fragment of ~186bp. Due to the presence
of GGAA repeats in the same region (20),
we likely obtained aggregates of all re-
peats, that is, GGAA as well as GA. Since
we assume that the aggregates as a whole
are important for modulating function,
we did not further analyze the exact com-
position of the aggregates. In fact, our
data validate this assumption. For each
sample, the reaction mixture (20 μL) was
prepared in 384 well plates, each contain-
ing 20 ng of human genomic DNA,
125 μmol/L dNTPs each, 200 nmol/L
FAM-labeled forward primer and the re-
verse primer and 1U Phire polymerase
(Finnzymes, Espoo, Finland). The ampli-
cons were separated using size elec-
trophoresis on the ABI 3730 XL DNA Ana-
lyzer (Applied Biosystems, Foster City,
CA, USA). For this, samples were diluted
1:50 with 0.3 mmol/L EDTA and 4 μL
were mixed with 6 μL LIZ-500 Size Stan-
dard (Applied Biosystems). Raw data
were processed using the Gene Mapper
 Software 4.0 (Applied Biosystems).
Analysis of Peripheral Blood
Mononuclear Cells (PBMCs)
Blood was collected in CPDA (citrate
phosphate dextrose adenine) tubes from
schizophrenic patients with different
genotypes at the selected markers.
PBMCs were isolated applying the stan-
dard Ficoll-Paque Plus isolation proce-
dure (GE Healthcare, München, Ger-
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many). RNA was prepared using Qiagen
miRNeasy Mini Kit (Qiagen). 1 μg of
RNA per sample was used to synthesize
cDNA (SuperScriptIII, Invitrogen). The
qRT-PCR was performed with the aid of
SYBR Green detection on the LightCycler
480 system (Roche). The starting amount
of cDNA was 20 ng; the number of PCR
cycles was 30–34 for EPO and 27–31 for
EPOR. Primers were added at 0.5 pMol.
CT (cycle threshold) values for EPO and
EPOR were standardized to CT values of
GAPDH. hEPO_qRT-PCR forward: 5′-
TCCCA GACAC CAAAG TTAAT
TTCTA-3′; hEPO_qRT-PCR reverse: 5′-
CCCTG CCAGA CTTCT ACGG-3′;
hEPOR_qRT-PCR forward: 5′-TTGGA
GGACT TGGTG TGTTT C-3′;
hEPOR_qRT-PCR reverse: 5′-AGCTT
CCATG GCTCA TCCT-3′; hGAPDH_qRT-
PCR forward: 5′-CTGAC TTCAA CAGCG
ACACC-3′; hGAPDH_qRT-PCR reverse:
5′-TGCTG TAGCC AAATT CGTTG T-3′.
Cloning and Transfection Studies
Constructs. The EPO promoter con-
structs were built according to Tong and
coworkers (23). Briefly, the promoter site
(1.5 kb) including either G or T at
rs1617640 was PCR amplified from respec-
tive human samples and cloned into the
pGL3 basic vector (Promega, Mann heim,
Germany). In addition, constructs includ-
ing the 3′ region of human EPO, as this is
known to be of major importance for the
regulation of EPO expression, were de-
signed. For this, the following primers in-
cluding XbaI sites were used: hEPO_3′ for-
ward: 5′-GCGTC TAGAC CAGGT GTGTC
CACCT-3′; hEPO_3′ reverse: 5′-GCGTC
TAGAA TGACA ATCTC AGCGC-3′.
All constructs were verified by restric-
tion enzyme digestion and complete
bidirectional DNA sequencing.
Luciferase Assays. Neuro2a (N2a) cells
(LGC Standards GmbH, Wesel, Germany)
were plated in 96-well cell culture plates
(NUNC, Langenselbold, Germany) at
15,000 cells per well in DMEM supple-
mented with 5% FCS without antibiotics.
At 16–18 h after plating, cells were trans-
fected with Lipofectamine 2000 (Invitro-
gen) using the manufacturer’s protocol. Of
the different EPO constructs, 30 ng (con-
taining G or T) and 1 ng of pRL-TK-
 control vector (Promega) were cotrans-
fected. For each treatment, six replicates
were performed. At 24 h after transfection,
cobalt chloride (CoCl2), a well known
mimetic of hypoxic EPO induction (39,40),
was added in different concentrations to
induce chemical hypoxia to the transfected
cells. Concentrations were selected such
that after the CoCl2 exposure, no signs of
toxicity or increased cell death were ob-
served (Trypan blue counts <1% in all con-
ditions, including normoxic controls). At
48 h after transfection, cells in each well
were lysed, using 30 μL passive lysis
buffer (Promega). The dual-luciferase re-
porter assay (Promega) was used accord-
ing to the manufacturer’s protocol. Prior
to measurement, lysates were transferred
into a black plastic microtiter plate. Meas-
urements were performed with the micro -
plate reader Mitras LB940 (Berthold Tech-
nologies, Regensdorf, Switzerland) and
associated software MicroWin 2000. Firefly
values were divided by the corresponding
Renilla readings producing values ex-
pressed as relative luciferase units (RLU).
Mouse Studies
The generation and characterization of
cEPOR transgenic mice have been re-
ported in detail elsewhere (7). Briefly,
EPORR129C (cEPOR) bears a single point
mutation at nucleotide 484, that is, in the
exoplasmic domain, causing a substitu-
tion of cysteine for arginine at codon 129
of the N terminus (R129C). The cDNA se-
quence of cEPOR, containing a hemagglu-
tinin (HA; YPYDVPDY) tag inserted five
residues downstream of the signal pepti-
dase cleavage site (41,42) was excised
with PacI and SalI from the pMX-HA-
cEPOR plasmid. The HA-cEPOR cDNA
was inserted into pNN265 plasmid, with
a modified multiple cloning site, that car-
ries a 5′ hybrid intron and a 3′ intron plus
poly-A signal from SV40 through PacI
and SalI sites. Finally, the entire DNA
fragment of HA-cEPOR, flanked by a hy-
brid intron at the 5′ end and a polyadeny-
lation signal from SV40 at the 3′ end was
cut out from pNN265 vector using NotI
and placed downstream of the 8.5kb α-
CaMKII promoter. The TG founders were
produced by pronuclear injection of the
linearized DNA into C57BL6/N (TG1) or
FvB/N (TG2) zygotes. The analysis of line
TG1 mice was performed after 4–7 back-
crosses with C57BL6/N wild type mice
(that is, all results reported in this study
were obtained from generations 4–7 of the
TG1 line). The TG1 line was used (be-
cause of its clean C57BL6/N background)
for the behavioral experiments presented
here. Analysis of line TG2 mice was per-
formed after 8–9 backcrossings to
C57BL6/N mice. The genotype of trans-
genic offspring was analyzed by PCR of
tail genomic DNA using primers specific
for the 3′ end of the α-CaMKII promoter
sequence (5′-GGGAG GTAGG AAGAG
CGATG-3′) and the 5′ end of the HA-
cEPOR cDNA sequence (5′-CACCC
TGAGT TTGTC CATCC-3′) yielding a 769
bp product. PCR amplification of the tail
DNA was carried out with the following
conditions: 2 min at 94°C (1 cycle); 30 s at
94°C, 30 s at 60°C and 1 min at 72°C (35
cycles), followed by final extension at
72°C for 10 min.
Behavioral Testing
All experiments were approved by the
local animal care and use committee in
accordance with the German Animal
Protection Law. For behavioral testing,
mice were housed in groups of 3–5 in
standard plastic cages, food and water ad
libitum (except for the 5-choice [water
deprivation] and T-maze [food depriva-
tion] training periods). The temperature
in the colony room was maintained at
20°–22°C, with a 12 h light:dark cycle
(light on at 7 AM). Behavioral experi-
ments were conducted during the light
phase of the day (between 8 AM and 
5 PM). Mouse data were analyzed using
repeated measures analysis of variance
(ANOVA) and Mann-Whitney U tests.
Five-choice serial reaction time task 
(5-CSRTT). The 5-CSRTT measures higher
brain functions, ranging from various dis-
crete learning/memory to attentional par-
adigms (43,44). A detailed description of
the procedure and training steps is given
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elsewhere (7). In the present study, we re-
port only the results obtained in interven-
tion phase 3 (variable, short stimulus du-
ration, indicative of speed of processing).
Novel object recognition task. Briefly,
mice are habituated for 20 min to a gray
plastic arena (45 × 45 cm, 35 cm high)
with no objects. Next, for the training
session, an object is placed in the arena,
and the time the mouse spends exploring
the object (that is, nose ≤15 mm to the
object) is recorded for 10 min (video
tracking software Viewer 2; Biobserve,
Bonn, Germany). Next, a new, second ob-
ject is added to the arena and exploration
recorded for 10 min (testing session). The
whole procedure is repeated several days
later with a different set of objects and a
30 min interval between training and
testing session. We use plastic objects of
similar size (around 3 cm in diameter)
but different shape, texture, and color
(pilot experiments had confirmed that
mice show no spontaneous preference
for any of the objects).
T-maze. The T-maze consists of three
arms (clear plexiglas, 7 cm wide, 12.5 cm
high with the start arm 43.5 cm long, and
the goal arms 32.5 cm each). The goal
arms contain distinct visual cues on the
outer side of the walls; the start arm is
plain. A plastic pellet cup (2.2 cm high, 
3.5 cm in diameter) is situated in the rear
of each goal arm. To have equal olfactory
reward cues in both arms, we use pellet
cups consisting of two parts separated by
a perforated floor: the lower part contains
12 food pellets, which are inaccessible for
mice; the accessible upper part holds one
food pellet as reward. Before starting the
habituation procedure, mice are food de-
prived (1 h/day access to food in the home
cage) for 3 d. Another 3 d of habituation to
apparatus and reward (5 min of exposure
to the maze each day, with reward placed
at both ends of the T-maze) are followed
by training for 12 d, six trials/day. On the
first (sample) run of each trial, both goal
arms are baited, but the mouse is forced to
choose one of the goal arms (the other
being closed by a removable wooden
block: 16 cm × 6.9 cm). After entering the
preselected goal arm, the mouse is al-
lowed to consume the reward for 20 s and
then placed back in the start box. On the
second (choice) run, which during the ac-
quisition phase of training follows 20 s
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Figure 1. EPO and EPOR genotype analyses in schizophrenic patients of the GRAS data collection and healthy controls (blood donors). (A)
Genetic overview of EPO/EPOR including analyzed genetic markers. (B,C) A case control study reveals comparable distribution of EPO
SNP genotypes in schizophrenic and healthy control subjects, thus excluding EPO genotypes as risk factors for schizophrenia. (D,E) Case
control analysis of EPOR STR (GA)n repeat lengths shows comparable results for both samples, again excluding a risk constellation of EPOR
genotypes. (F) Grouping of genotype combinations with respect to Digit Symbol-Coding test performance uncovers one genotype highly
superior to all others: GG&21–35 (lowest) repeat sum. Mean ± standard error of the mean (SEM) given; χ2 tests and analysis of covariance
(ANCOVA) applied.
after the sample run, both goal arms are
open, and the mouse is rewarded for
choosing the previously unvisited arm.
The location of the sample arm (left or
right) is varied pseudorandomly across
trials so that mice received equal numbers
of left and right presentations, but no
more than two consecutive trials with the
same sample location. The mice are run in
squads of 6–8 (including both transgenic
and littermate control animals) to mini-
mize variation in intertrial intervals (12
min for all mice throughout the 12 d of
training). No-delay trials: Mice are trained
for 14 d in sample and choice runs with
20-s interval (10 trials on d 1; 6 trials/day
from d 2–14). Delay trials: After finishing
the no-delay procedure, mice are tested in
the delay procedure using two different
time intervals between sample and choice
run: 2 min and 6 min (3 d per delay; six
trials/ day containing three delay and
again three no-delay trials each—in an al-
ternating manner—to rule out motiva-
tional decrement and to obtain an internal
control condition).
Note: All experiments in this manu-
script were conducted in a blinded fash-
ion that is, with the respective investiga-
tor/rater being unaware of sample
assignment.




EPO SNPs rs1617640 (T/G) and
rs564449 (T/G), as well as EPOR STR
(GA)n, are not associated with schizo-
phrenia. When conducting phenotype-
based genetic association studies (PGAS)
to evaluate the contribution of certain
genotypes to defined subphenotypes, a
potential role of these genotypes as genetic
risk factors for schizophrenia should first
be explored. Therefore, we performed a
case control study on SNP rs1617640
(T/G) and SNP rs564449 (T/G), located in
the 5′ upstream region and in the 3′ regu-
latory region of the EPO gene, respec-
tively, as well as the STR (GA)n in the
EPOR 5′ upstream area (Figure 1A). To as-
sess the EPOR genotype, the repeat
lengths sum of both alleles was employed.
No significant difference in the distribu-
tion of EPO genotypes (Figures 1B, C; χ2 =
1.897 and p = 0.397; χ2 = 0.058 and p =
0.972) or of EPOR repeat lengths sum (Fig-
ure 1D; χ2 = 23.85, p = 0.917, evaluated
with Monte Carlo sampling on 1,000 runs)
between cases (N = 1,050–1,054) and
healthy controls (blood donor sample; N =
1,141–1,142) was found (for details see Fig-
ure 1 and Supplementary Table S1). An as-
sociation analysis of single allele repeat
lengths instead of allelic repeat lengths
sum between cases and controls also failed
to yield significant distribution differences
(χ2 = 32.15, p = 0.114, evaluated with
Monte Carlo sampling on 1,000 runs). Fur-
thermore, the intraindividual difference of
repeat lengths as a measure of marker het-
erogeneity did not vary between cases and
controls (Figure 1E; χ2 = 8.54, p = 0.967,
1000 Monte Carlo simulations). Thus, we
could not find any evidence for a role of
EPO/EPOR genotypes regarding the risk
to develop schizophrenia. For the follow-
ing phenotype analyses, the EPO SNP
rs564449 (T/G) had to be excluded due to
its low minor allele frequency (MAF~11%).
Phenotype-Based Genetic
Association Study (PGAS)
EPO SNP rs1617640 (T/G) and EPOR
STR (GA)n are associated with higher
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Figure 2. Mice with transgenic expression of constitutively active EPOR (cEPOR) driven by
the α-calcium/calmodulin-dependent protein kinase II (α-CaMKII) promoter demonstrate
highly superior cognitive performance compared with their wild type littermates. (A) Con-
struct used for transgenic expression. (B) Significant reduction of reaction time in the at-
tentional testing part of the 5-Choice Serial Reaction Time Task (5-CSRTT) reflects superior
speed of cognitive processing in transgenic mice. (C–F) Transgenic mice perform better in
Novel Object Recognition (NOR) (depicted is the number of visits of the new object) and
T-maze tests with or without delay, illustrating their supremacy in memory tasks. Exact N
numbers of all experiments are given directly in the bars or the line graph; all male mice,
5–8 month old at the time point of testing; mean ± standard error of the mean (SEM) pre-
sented; two-way ANOVA for repeated measures and Mann-Whitney U tests applied.
cognition in schizophrenia. In a previous
treatment trial, we showed that high-dose
EPO, infused weekly over 12 wks, im-
proves cognitive functions and reduces
cortical gray matter loss in chronic schizo-
phrenic patients. The domains most
prominently influenced by EPO were
speed of cognitive processing and short-
term memory (Repeatable Battery for the
Assessment of Neuropsychological Status
(RBANS™): subtests coding, digit span
and figure recall) (9). Assuming that an in-
fluence of genetic variation within the
EPO system on cognitive function would
be detectable targeting these domains, we
selected of the tests available within the
GRAS database those closest to the above
(same test or similar test regarding do-
main or loading on the same factor, that is,
tests leading to similar results in an indi-
vidual due to joint variation in response to
the same unobserved latent variable):
Digit Symbol-Coding test, VLMT, and
 Dotting/ Tapping (45). Indeed, significant
associations were detected for both, EPO
SNP rs1617640 (T/G) and EPOR STR(GA)n
low versus high repeat sum (Table 1): car-
riers of G at EPO SNP rs1617640 and of
EPOR STR(GA)n low repeat sum showed
superior performance. In contrast, none of
the relevant  sociodemographic or basic
disease variables revealed any significant
associations (Table 2). To see whether cer-
tain combinations of genotypes of the EPO
and EPOR genes would lead to better per-
formance in the sense of a potential inter-
action effect, we grouped them accord-
ingly. For EPOR genotypes, we assigned
all individuals to three equally sized
groups of allelic repeat sum carriers from
low to high (Figure 1F). Surprisingly, we
found one particular genotype combina-
tion, GG&21–35 (lowest) repeat sum, to be
highly superior compared with all others
with respect to performance in Digit
 Symbol-Coding test (p < 0.0001; see Fig-
ure 1F) but also in the other tests, where
associations had been found for either EPO
or EPOR or both (all p ≤ 0.003; Table 1).
In contrast to the clear associations with
cognitive parameters found here, and in
agreement with previous work by others,
for example (14), we did not see any evi-
dence of a potential association of
EPO/EPOR genotypes with blood indices.
In fact, we screened a total of 94 patients
(Göttingen participants of the GRAS
study) where comprehensive information
on blood data was available. Repeated de-
terminations over the year in these pa-
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Figure 3. Genotype-dependent EPO/EPOR expression differences using reporter gene assays and PBMCs. (A) Reporter gene constructs:
5′ upstream region of the EPO gene with either G or T at rs1617640 (left) and in addition with the 3′ regulatory region of EPO (right).
(B) G at SNP rs1617640 leads to significantly higher basal gene expression than T (baseline control). Addition of the 3′ regulatory region to
the construct induces downregulation of gene expression. This suppression is stepwise alleviated by increasing doses of CoCl2 (100 μmol/L
and 400 μmol/L). (C) In all conditions shown in (B), the suppressability (regulability) of gene expression compared with the baseline con-
trol (that is, normoxic control condition of B) is highest for the G genotype. (D) EPOR mRNA levels in peripheral blood mononuclear cells
(PBMCs) of patients, determined by qRT-PCR and normalized to GAPDH as the housekeeper, show that the lowest EPOR STR (GA)n repeat
length sum is associated with the highest EPOR expression. Gender distribution among the three repeat groups is well balanced
(males/all: 24/37, 18/31, 20/30; χ2 test p = 0.628). (E) Even when considering the individual EPO mRNA levels (which by themselves do not
reveal differences; data not shown) in form of an EPO/EPOR expression ratio, the significant difference between different STR length carri-
ers remains. N = 28–37 per group; mean ± standard error of the mean (SEM) presented; Mann-Whitney U tests applied.
tients (between 2–48 times each) allowed
a first step to substantiate each individ-
ual’s normal values (considering also the
reason for hospitalization, for example,
exclusion of values obtained after blood
loss due to a suicide attempt). These in
turn delivered the basis of the mean val-
ues given in Supplementary Table S2. As
shown there, all parameters are highly
similar among genotypes. Interestingly, in
this small cohort of individuals (N = 94)
with information on blood indices, N = 6
subjects carried the GG&21–35 (low) re-
peat sum genotype and could be checked
against all other genotype combinations.
Group comparison by Mann-Whitney U
test did not reveal any difference between
groups for hemoglobin levels (p = 0.413),
whereas the cognitive composite score al-
ready yielded a nearly significant result 
(p = 0.093) (Supplementary Figure S2).
cEPOR Expression in Pyramidal
Neurons of Cortex and Hippocampus
Increases Speed of Cognitive
Processing and Memory Functions in
Mice
On the basis of the above findings, we
speculated that the best performing geno-
type combination should be characterized
by higher EPO/EPOR expression. This
hypothesis is further supported by (i) the
cognition- improving effect of high-dose
EPO in clinical trials (8,9) and in mouse
studies (5,6) and (ii) our previous data on
mice with transgenic expression of consti-
tutively active EPOR (cEPOR) driven by
the α-calcium/calmodulin-dependent
protein kinase II (α-CaMKII) promoter
(Figure 2A). These mice show better per-
formance in higher cognitive tasks (7). We
reexamined these mice and specifically
conducted/ analyzed tests measuring
speed of cognitive processing and short-
term memory, analogous to our neuropsy-
chological findings in humans. In fact, we
found a clearly reduced reaction time in
the phase addressing selective attention in
the 5-CSRTT (2-way ANOVA for repeated
measures, F(1,14) = 6.159; p = 0.026; Figure
2B) as well as superior performance in
short-term memory tasks, that is, novel
object recognition (no-delay trials p =
0.038; 30-min delay trials p = 0.026; Mann-
Whitney U test) and T-maze (2-way
ANOVA for repeated measures, no-delay
trials F(1,22) = 19.61, p = 0.0002; 2-min delay
trials F(1,22) = 4.668, p = 0.042; Figures
2C–F). These data further support the hy-
pothesis of higher expression/activity of
the EPO system being associated with
better cognitive functioning.
Mechanistic Insight: Genotype-
 Dependent EPO/EPOR Expression
Differences
To better understand a potential influ-
ence of the EPO SNP rs1617640 on gene
expression, we used reporter gene assays
based on the 5′ upstream region of the
EPO gene with G or T at the respective
position. Additionally, we designed con-
structs including the 3′ regulatory region
of human EPO, as this is known to be
highly homologous between species and
thus of major importance for the complex
regulation of EPO gene expression (39,46)
(Figure 3A). As illustrated in Figure 3B, 
G at SNP rs1617640 leads to significantly
higher basal gene (luciferase) expression
than T. Upon addition of the 3′ regulatory
region to the construct, a remarkable
downregulation of gene expression can be
observed that is likely due to the interac-
tion with the 5′ region which is essential
for hypoxia-related EPO regulation (39,40).
This suppression is stepwise alleviated by
increasing doses of CoCl2 as an inducer of
chemical hypoxia. In all conditions, the
suppressability (regulability) of gene ex-
pression as compared with baseline is
highest for the G genotype (Figure 3C).
To explore the role of the EPOR STR
(GA)n repeat length sum on gene expres-
sion, we determined EPOR and EPO
mRNA in peripheral blood mononuclear
cells. The results show that the lowest re-
peat sum is associated with the highest
EPOR expression as well as with the
highest EPO/EPOR ratio as readout of
the interplay between the two genes
(Figures 3D, E). EPO mRNA levels per se
did not differ significantly between
EPOR repeat sum groups (data not
shown). The exact mechanisms explain-
ing the observed effects on quantitative
gene expression are still unclear. Both,
EPO and EPOR gene variants investi-
gated here are located in the promoter
areas of the respective genes, where they
may, for instance, directly or indirectly
influence transcription factor binding. In-
deed, regulation of these genes is highly
complex and involves many different
transcription and cofactors, the roles of
which are still widely obscure (46,47).
Replication of the EPO and EPOR
Genotype Associations with Cognitive
Performance in a Healthy Control
Sample
Having obtained associations of geno-
types in the EPO system with cognition in
a disease population, that is, individuals
suffering from schizophrenia with known
disease-typical cognitive deterioration, we
wanted to know whether similar findings
would be obtained in healthy controls.
Fortunately, a phenotyped control popula-
tion from Munich was available for com-
parison. Again, a case control study on
EPO SNP rs1617640 (T/G) as well as
EPOR STR (GA)n did not reveal differ-
ences between these healthy controls and
the GRAS subjects (Supplementary Table
S1, Supplementary Figure S1). This
healthy control population, however, has
several confines with respect to the GRAS
sample: (1) Of the relevant cognitive do-
mains, only one has been evaluated with
the same test, the other one just with a
similar test loading on the same factor
(that is, producing similar results in an in-
dividual based on a common underlying
source of variance); (2) The population is
considerably older on average; (3) The
sample has a different gender distribution
(Table 2). Despite these limitations, the as-
sociations are essentially reproduced
(Table 1), pointing to very robust effects.
Interestingly, having the GG&21–35 re-
peat sum genotype does not yield an ad-
vantage for healthy individuals who gen-
erally perform much better on all
cognitive tests as compared with schizo-
phrenic individuals (Table 1). This obser-
vation suggests that only subjects with an
inferior cognitive performance may bene-
fit from this specific genotypic constella-
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tion. We wondered whether the superior-
ity of the GG&21–35 group would be re-
vealed when selecting the subgroup of
healthy individuals with an average per-
formance equal to the mean performance
of the schizophrenic sample on the Digit
Symbol-Coding test. Indeed, the low per-
former group of healthy individuals
(Digit Symbol-Coding test performance
threshold ≤50) displays a similar tendency
of genotype superiority (p = 0.089) which
is not detectable in the high performer
group (Digit Symbol-Coding test per-
formance threshold >50, p = 0.809). These
results suggest that the GG&21–35 geno-
type may disclose its benefits particularly
in situations of reduced cognitive capacity
or (relative) cognitive impairment (Sup-
plementary Figure S3).
DISCUSSION
In the present hypothesis-driven study,
we identified novel associations of EPO
and EPOR genotypes with cognition,
namely speed of processing, short-term
memory and tasks requiring distinct fine
motor components, both in schizo-
phrenic patients and in a healthy control
population (replicate sample). On a mo-
lecular/cellular level, we demonstrate
that the cognitively more beneficial geno-
types are associated with higher expres-
sion/stronger regulability of expression.
In supporting preclinical experiments,
we show that mice with transgenic ex-
pression of constitutively active EPOR in
pyramidal neurons of cortex and hip-
pocampus (7) perform better in cognitive
domains reminiscent of those influenced
by EPO/EPOR genotypes in humans.
Interestingly, in the schizophrenic pop-
ulation that is defined by overall reduced
cognitive performance, one discrete
genotype combination (GG&21–35 repeat
sum) achieves highly superior cognitive
outcome, whereas this same combination
in healthy individuals has only the ten-
dency of an advantage. This advantage is
restricted to subjects with lower cogni-
tive capacity. Thus, higher EPO/EPOR
activity appears to be most beneficial in
situations of compromised function. We
note that in disease states, such benefit is
likely achieved by the upregulation of
the endogenous EPO system in the brain,
as seen for example, in stroke, schizo-
phrenia or Alzheimer’s disease (48–50).
In fact, this EPO/EPOR upregulation is
further potentiated by rhEPO treatment,
resulting in lasting cognitive improve-
ment (8,9,51,52).
The selection of the cognitive domains
reported here to show associations with
EPO/EPOR genotypes strictly followed
hypotheses derived from the results of
earlier rhEPO treatment studies (9).
Therefore, multiple testing issues do not
apply here. On the other hand, also for a
purely hypothesis-driven, exploratory
study, it is reassuring to obtain replica-
tion of the results in an independent
sample, in the present paper, a healthy
control population.
Limitations of the present work are
particularly (1) the incomplete availabil-
ity of identical neuropsychological tests
in the two populations studied (forcing to
use tests loading on the same factor, that
is, resulting in highly correlated readouts
in a given individual due to shared vari-
ance produced by a common underlying
variable), and (2) the different age/gen-
der distribution. Despite all these short-
comings, a similar pattern of associations
arose, pointing to robust effects and con-
firming the significance of EPO/EPOR
genotypes for higher  cognition.
We are aware that the use of transfec-
tion studies/reporter gene assays and of
PBMCs cannot answer all questions re-
lated to genotype-dependent brain ex-
pression of the EPO system. Especially
PBMCs are a heterogeneous population of
cells. There may be variations in the com-
position of mononuclear cells such as cir-
culating erythroid progenitor or precursor
cells, megakaryocytes, mast cells and
macrophages, lymphocytes, and endothe-
lial progenitor cells from sample to sam-
ple. Many of these cell types potentially
may serve as source of EPO expression in
the peripheral blood. We cannot exclude,
however, that our data on EPO and EPOR
mRNA mainly derive from a small frac-
tion of erythroid progenitors that express
these genes. Nevertheless, the pragmatic
approach to analyze PBMCs was the only
choice presently available for us to study
quantitative gene expression in a reason-
able number of humans with defined
genotype. To obtain further support for
increased expression/activation of the
EPO system leading to better cognition,
we additionally performed mouse studies
in a model of targeted upregulation of
EPOR in neuronal populations that are
known to play a pivotal role in the func-
tions of interest (7). The superiority of
these mice included essentially the same
cognitive domains as those found to be
influenced by EPO/EPOR genotypes in
human populations.
CONCLUSION
To conclude, we identified an intrinsic
role of the EPO system for higher cogni-
tion, reflected by associations of
EPO/EPOR genotypes with cognitive per-
formance, which may be of particular sig-
nificance in disease states. These findings
further suggest the EPO system as target
for treating human brain diseases that are
characterized by cognitive  decline.
ACKNOWLEDGMENTS
This work was supported by the Max
Planck Society and the DFG-Research
Center for Molecular Physiology of the
Brain (CMBP).We thank Fritz Benseler
and Anja Ronnenberg for their excellent
technical work, and the staff of the animal
facility at the Max Planck Institute of Ex-
perimental Medicine for maintenance of
the mouse colony. We are indebted to all
healthy individuals and all patients for
their participation in the study, and all
collaborating GRAS centers for their sup-
port. We are grateful to all colleagues who
contributed to the GRAS data  collection.
DISCLOSURE 
H Ehrenreich has submitted/holds
user patents for EPO in stroke, schizo-
phrenia and MS. Apart from that, the au-
thors declare that they have no compet-
ing interests as defined by Molecular
Medicine, or other interests that might be
perceived to influence the results and
discussion reported in this paper.
R E S E A R C H  A R T I C L E
M O L  M E D  1 8 : 1 0 2 9 - 1 0 4 0 ,  2 0 1 2  |  K Ä S T N E R  E T  A L .  |  1 0 3 9
REFERENCES
1. Nissenson AR. (1989) Recombinant human ery-
thropoietin: Impact on brain and cognitive func-
tion, exercise tolerance, sexual potency, and qual-
ity of life. Semin. Nephrol. 9:25–31.
2. Brines M, Cerami A. (2005) Emerging biological
roles for erythropoietin in the nervous system.
Nat. Rev. Neurosci. 6:484–94.
3. Sargin D, Friedrichs H, El-Kordi A, Ehrenreich H.
(2010) Erythropoietin as neuroprotective and
neuroregenerative treatment strategy: compre-
hensive overview of 12 years of preclinical and
clinical research. Best Pract. Res. Clin. Anaesthesiol.
24:573–94.
4. Siren AL, Fasshauer T, Bartels C, Ehrenreich H.
(2009) Therapeutic potential of erythropoietin
and its structural or functional variants in the
nervous system. Neurotherapeutics. 6:108–27.
5. Adamcio B, et al. (2008) Erythropoietin enhances
hippocampal long-term potentiation and mem-
ory. BMC Biol. 6:37.
6. El-Kordi A, Radyushkin K, Ehrenreich H. (2009)
Erythropoietin improves operant conditioning
and stability of cognitive performance in mice.
BMC Biol. 7:37.
7. Sargin D, et al. (2011) Expression of constitutively
active erythropoietin receptor in pyramidal neu-
rons of cortex and hippocampus boosts higher
cognitive functions in mice. BMC Biol. 9:27.
8. Ehrenreich H, et al. (2007) Improvement of cogni-
tive functions in chronic schizophrenic patients
by recombinant human erythropoietin. Mol. Psy-
chiatry. 12:206–20.
9. Wüstenberg T, et al. (2011) Recombinant human
erythropoietin delays loss of gray matter in
chronic schizophrenia. Mol. Psychiatry. 16:26–36, 1.
10. Miskowiak K, O’Sullivan U, Harmer CJ. (2007)
Erythropoietin enhances hippocampal response
during memory retrieval in humans. J. Neurosci.
27:2788–92.
11. Leist M, et al. (2004) Derivatives of erythropoietin
that are tissue protective but not erythropoietic.
Science. 305:239–42.
12. Ostrowski D, Ehrenreich H, Heinrich R. (2011)
Erythropoietin promotes survival and regenera-
tion of insect neurons in vivo and in vitro. Neuro-
science. 188:95–108.
13. Iliadou A, et al. (2007) Genomewide scans of red
cell indices suggest linkage on chromosome 6q23.
J. Med. Genet. 44:24–30.
14. Lin JP, O’Donnell CJ, Levy D, Cupples LA. (2005)
Evidence for a gene influencing haematocrit on
chromosome 6q23–24: genomewide scan in the
Framingham Heart Study. J. Med. Genet. 42:75–9.
15. Mejia OM, Prchal JT, Leon-Velarde F, Hurtado A,
Stockton DW. (2005) Genetic association analysis
of chronic mountain sickness in an Andean high-
altitude population. Haematologica. 90:13–9.
16. Percy MJ, McMullin MF, Lappin TR. (1997) Se-
quence analysis of the 3′ hypoxia-responsive ele-
ment of the human erythropoietin gene in pa-
tients with erythrocytosis. Biochem. Mol. Med.
62:132–4.
17. Sripichai O. et al. (2005) Genetic analysis of can-
didate modifier polymorphisms in Hb E-beta 
0-thalassemia patients. Ann. N. Y. Acad. Sci.
1054:433–8.
18. Zeng SM, Yankowitz J, Widness JA, Strauss RG.
(2001) Etiology of differences in hematocrit be-
tween males and females: sequence-based poly-
morphisms in erythropoietin and its receptor.
J. Gend. Specif. Med. 4:35–40.
19. Sokol L, Prchal J, Prchal JT. (1993) Primary familial
and congenital polycythaemia. Lancet. 342:115–6.
20. Sokol L, Prchal JT. (1994) Two microsatellite re-
peat polymorphisms in the EPO gene. Hum. Mol.
Genet. 3:219.
21. Balasubbu S, et al. (2010) Association analysis of
nine candidate gene polymorphisms in Indian
patients with type 2 diabetic retinopathy. BMC
Med. Genet. 11:158.
22. Abhary S, et al. (2010) Association between ery-
thropoietin gene polymorphisms and diabetic
retinopathy. Arch. Ophthalmol. 128:102–6.
23. Tong Z, et al. (2008) Promoter polymorphism of
the erythropoietin gene in severe diabetic eye
and kidney complications. Proc. Natl. Acad. Sci.
U. S. A. 105:6998–7003.
24. Ghezzi S, et al. (2009) Is erythropoietin gene a
modifier factor in amyotrophic lateral sclerosis?
Neurobiol. Aging. 30:842–4.
25. Begemann M, et al. (2010) Modification of cognitive
performance in schizophrenia by complexin 2 gene
polymorphisms. Arch. Gen. Psychiatry. 67:879–88.
26. Ribbe K. et al. (2010) The cross-sectional GRAS sam-
ple: a comprehensive phenotypical data collection
of schizophrenic patients. BMC Psychiatry. 10:91.
27. World Medical Association [WMA]. (1964) WMA
declaration of Helsinki - ethical principles for
medical research involving humans. Last
amended 2008 Oct. [cited 2012 Aug 21]. Available
from: http://www.wma.net/en/30publications/
10policies/b3/index.html 
28. van den Oord, EJ, et al. (2008) Genomewide asso-
ciation analysis followed by a replication study
implicates a novel candidate gene for neuroti-
cism. Arch. Gen. Psychiatry. 65:1062–71.
29. Wittchen H-U, Zaudig M, Fydrich T. (1997)
SKID-I und SKID-II, Strukturiertes Klinisches Inter-
view für DSM-IV. Hogrefe, Göttingen.
30. Rice JP, et al. (1995) Comparison of direct inter-
view and family history diagnoses of alcohol de-
pendence. Alcohol Clin. Exp. Res. 19:1018–23.
31. Folstein MF, Folstein SE, McHugh PR. (1975)
Mini-Mental State (a practical method for grad-
ing the state of patients for the clinician). J. Psych.
Res. 12:189–98.
32. Tewes U. (1994) HAWIE-R. Hamburg-Wechsler-
Intelligenztest für Erwachsene, Revision 1991;
Handbuch und Testanweisung. Bern: Verlag
Hans Huber.
33. Chapman RL. (1948) The MacQuarrie test for
mechanical ability. Psychometrika. 13:175–9.
34. Helmstaedter C, Durwen HF. (1990) The Verbal
Learning and Retention Test. A useful and differ-
entiated tool in evaluating verbal memory per-
formance [in German]. Schweiz. Arch. Neurol. Psy-
chiatr. 141:21–30.
35. Kay SR, Fiszbein A, Opler LA. (1987) The posi-
tive and negative syndrome scale (PANSS) for
schizophrenia. Schizophr. Bull. 13:261–76.
36. American Psychiatric Association (APA). (1994)
Diagnostic and statistical manual of mental disor-
ders: DSM-IV. 4th edition. Washington (DC): APA.
37. Blom G. (1958) Statistical estimates and trans-
formed beta-variables. Wiley, New York.
38. de la Chapelle A, Sistonen P, Lehvaslaiho H,
Ikkala E, Juvonen E. (1993) Familial erythrocyto-
sis genetically linked to erythropoietin receptor
gene. Lancet. 341:82–4.
39. Fandrey J. (2004) Oxygen-dependent and tissue-
specific regulation of erythropoietin gene expres-
sion. Am. J. Physiol. Regul. Integr. Comp. Physiol.
286:R977–88.
40. Stockmann C, Fandrey J. (2006) Hypoxia-induced
erythropoietin production: a paradigm for 
oxygen-regulated gene expression. Clin. Exp.
Pharmacol. Physiol. 33:968–79.
41. Constantinescu SN, et al. (2001) Ligand-independent
oligomerization of cell-surface erythropoietin re-
ceptor is mediated by the transmembrane domain.
Proc. Natl. Acad. Sci. U. S. A. 98:4379–84.
42. Yoshimura A, Longmore G, Lodish HF. (1990) Point
mutation in the exoplasmic domain of the erythro-
poietin receptor resulting in hormone-independent
activation and tumorigenicity. Nature. 348:647–9.
43. Humby T, Wilkinson L, Dawson G. (2005) Assaying
aspects of attention and impulse control in mice
using the 5-choice serial reaction time task. Curr.
Protoc. Neurosci. May 2005:Chapter 8, Unit 8 5H.
44. Robbins TW. (2002) The 5-choice serial reaction
time task: behavioural pharmacology and func-
tional neurochemistry. Psychopharmacology (Berl.).
163:362–80.
45. Berger S. (1998) The WAIS-R factors: usefulness
and construct validity in neuropsychological as-
sessments. Appl. Neuropsychol. 5:37–42.
46. Jelkmann W. (2011) Regulation of erythropoietin
production. J. Physiol. 589:1251–8.
47. Wallach I, et al. (2009) Erythropoietin-receptor gene
regulation in neuronal cells. Pediatr. Res. 65:619–24.
48. Assaraf MI, et al. (2007) Brain erythropoietin re-
ceptor expression in Alzheimer disease and mild
cognitive impairment. J. Neuropathol. Exp. Neurol.
66:389–98.
49. Ehrenreich H, et al. (2004) Erythropoietin: a can-
didate compound for neuroprotection in schizo-
phrenia. Mol. Psychiatry. 9:42–54.
50. Sirén AL, et al. (2001) Erythropoietin and erythro-
poietin receptor in human ischemic/hypoxic
brain. Acta Neuropathol. 101, 271–6.
51. Ehrenreich H, et al. (2007) Exploring recombinant
human erythropoietin in chronic progressive
multiple sclerosis. Brain. 130:2577–88.
52. Neubauer AP, Voss W, Wachtendorf M, Jung-
mann T. (2010) Erythropoietin improves neu-
rodevelopmental outcome of extremely preterm
infants. Ann. Neurol. 67:657–66.
1 0 4 0 |  K Ä S T N E R  E T  A L .  |  M O L  M E D  1 8 : 1 0 2 9 - 1 0 4 0 ,  2 0 1 2
E P O / E P O R  G E N O T Y P E S  I N F L U E N C E  C O G N I T I O N
M O L  M E D  1 8 ,  2 0 1 2  |  K Ä S T N E R E T  A L .  |  S 1
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Supplementary Table S2. Blood indices of a total of 94 patients (Göttingen participants of the GRAS study) with comprehensive
information on blood data available.
EPO (mean ± SD) EPOR (mean ± SD)
GG GT TT Low sum High sum
N=13 N=47 N=34 N=50 N=44
Hemoglobin (g/dl) 14.751 ±1.317 14.703 ±0.923 14.657 ±1.329 14.748 ±1.112 14.631 ±1.157
Hematocrit (%) 43.765 ±3.877 43.484 ±2.611 43.288 ±3.892 43.661 ±3.187 43.166 ±3.384
Erythrocytes (x0^6/μl) 4.860 ±0.439 4.902 ±0.391 4.831 ±0.488 4.894 ±0.442 4.844 ±0.423
Thrombocytes (x0^3/μl) 271.166 ±54.047 254.554 ±44.449 271.043 ±71.662 261.442 ±59.959 264.376 ±54.015
Repeated determinations over the years in these patients (between 2-48 times each) allowed in a first step to substantiate each
individual’s ‘normal’ blood values (considering also the reason for hospitalization, e.g. exclusion of values obtained after blood loss due to
a suicide attempt). These in turn delivered the basis of the mean values given in the Table.
Supplementary Table S1. Case control study: genotype frequencies of EPO SNPs in
schizophrenic patients (GRAS sample) versus healthy blood donors and versus healthy
replicate sample.
(SCZ, GRAS subjects: N=1050 for rs1617640 and N=1054 for rs564449; CON1, healthy blood
donors: N=1142; CON2, healthy replicate sample: N=2315).
Genotypic frequencies
EPO SNPs GG GT TT χ2 (p)a HWE (p)
rs1617640 SCZ (N=1050) 16.5% 46.5% 37.0% (.368)
CON1b (N=1142) 15.6% 49.5% 34.9% 1.897 (.397) (.357)
CON2c (N=2315) 14.5% 48.0% 37.5% 2.297 (.317) (.508)
GG GT TT
rs564449 SCZ (N=1054) 79.6% 19.5% 0.9% (.628)
CON1b (N=1142) 79.5% 19.4% 1.1% .058 (.972) (.877)
aComparison of genotype distribution between the respective control group (CON1 or
CON2) and the GRAS sample of schizophrenic patients (SCZ); bCON1= blood donors,
cCON2= healthy replicate sample
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Supplementary Figure S1. Case control study: frequency distribution of EPOR STR (GA)n re-
peat lengths sum and repeat lengths difference in the GRAS sample of schizophrenic pa-
tients versus subjects of a healthy replicate sample. An association analysis of single allele
repeat lengths instead of allelic repeat lengths sum between cases and controls also
failed to yield significant distribution differences (χ2=14.71, p=.903, evaluated with Monte
Carlo sampling on 1000 runs).
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Supplementary Figure S2. Subgroup analysis: hemoglobin and cognition composite val-
ues in GG&21-35 (low) repeat sum genotype carriers versus all other genotype combina-
tions. Of the cohort of patients with blood values available (Supplementary Table 2), N=6
individuals carried the GG&21-35 (low) repeat sum genotype and could be tested
against all other genotype combinations. Group comparison by Mann-Whitney U test did
not reveal any difference between groups for hemoglobin levels (p=.413). In contrast, de-
spite the small number of high performers (GG&21-35 (low) repeat sum carriers), the cog-
nitive composite score (available for most but not all of the patients with blood informa-
tion - see N numbers) yielded already a nearly significant result (p=.093) (mean±SEM
presented).
Supplementary Figure S3. The superiority of the ‘GG&21-35 repeat sum’ genotype versus
all other combinations is most prominent in individuals with low performance. Comparison
of the Digit Symbol-Coding (DSC) performance of individuals carrying the genotype
combination ‘GG&21-35 (lowest) repeat sum’ versus subjects with all other combinations.
Given are good (raw score > 50) and bad DSC performer groups (raw score <= 50).
Mean±SEM of raw scores presented, p-values from ANOVA with Blom-transformed DSC
score and age (schizophrenic sample and healthy controls), severity of negative symp-
toms (PANSS), medication and duration of disease (schizophrenic sample) as covariates.
A single gene defect causing claustrophobia
A El-Kordi1,2,8, A Ka¨stner1,8, S Grube1,8, M Klugmann3,9, M Begemann1,2, S Sperling1, K Hammerschmidt4, C Hammer1,
B Stepniak1, J Patzig3, P de Monasterio-Schrader3, N Strenzke5, G Flu¨gge2,6, HB Werner3, R Pawlak7, K-A Nave2,3
and H Ehrenreich1,2
Claustrophobia, the well-known fear of being trapped in narrow/closed spaces, is often considered a conditioned response to
traumatic experience. Surprisingly, we found that mutations affecting a single gene, encoding a stress-regulated neuronal
protein, can cause claustrophobia. Gpm6a-deficient mice develop normally and lack obvious behavioral abnormalities. However,
when mildly stressed by single-housing, these mice develop a striking claustrophobia-like phenotype, which is not inducible in
wild-type controls, even by severe stress. The human GPM6A gene is located on chromosome 4q32-q34, a region linked to panic
disorder. Sequence analysis of 115 claustrophobic and non-claustrophobic subjects identified nine variants in the noncoding
region of the gene that are more frequent in affected individuals (P¼ 0.028). One variant in the 30untranslated region was linked
to claustrophobia in two small pedigrees. This mutant mRNA is functional but cannot be silenced by neuronal miR124 derived
itself from a stress-regulated transcript. We suggest that loosing dynamic regulation of neuronal GPM6A expression poses a
genetic risk for claustrophobia.
Translational Psychiatry (2013) 3, e254; doi:10.1038/tp.2013.28; published online 30 April 2013
Introduction
The neuronal tetraspan membrane glycoprotein Gpm6a
has been implicated in neurite outgrowth and dendritic
spine formation,1–3 but the lack of a mouse mutant has
prevented any in vivo analysis of Gpm6a function. Specifi-
cally, the observation that Gpm6a expression in rodent brain
is downregulated by cortisol or following physical restraint
stress4 has been puzzling. As stress is a key factor for
triggering mental disorders,5 we investigated the behavioral
consequences of resident-intruder stress in mice lacking the
Gpm6a gene. We report here the unexpected finding
that the neuronal gene Gpm6a constitutes a genetic cause
of a highly unusual ‘claustrophobia-like’ phenotype in null
mutant mice, which otherwise develop completely normally. In
fact, only Gpm6a mouse mutants that have experienced a
mild ‘social stress’ exhibit this ‘claustrophobia-like’ behavior.
Moreover, we translate this finding to human individuals,
where we find rare sequence variants in the GPM6A
gene associated with claustrophobia. Mechanistic insight is
provided by the demonstration of a human variant-specific
loss of GPM6A regulability. We conclude that regulability
of the GPM6A gene under stress is required to
avoid claustrophobia, which emerges as an unusual stress
response.
Materials and methods
Generation and characterization of Gpm6a null mutant
mice. All experiments were approved by the local Animal
Care and Use Committee in accordance with the German
Animal Protection Law. Mice with a targeted inactivation of
the Gpm6a gene were generated. First a gene-targeting
vector (Figure 1a) was constructed. From the cloned mouse
(129SV) Gpm6a gene, a 6.5-kb fragment of intron 2 became
the long homologous arm. A 1.5-kb fragment that included
the 30-part of intron 1 and 6 bp at the 50-end of exon 2 became
the short homologous arm. It was cloned with tailored PCR
primers introducing Hind3 (50) and BamH1 (30) restriction
sites. For negative selection, a neomycin-resistance gene
(neo) under control of the herpes simplex virus (HSV)
thymidine kinase (tk) promoter (kindly provided by R
Sprengel, MPI Heidelberg) was utilized. The neomycin
cassette was subcloned with tailored PCR primers introdu-
cing at both the 50- and the 30-end BamH1 restriction sites
and translation termination codons in all reading frames. For
positive selection, a Cla1 fragment of the HSV-tk under
control of the HSV-tk promoter was subcloned into the
vector. The construct was verified by molecular sequencing,
and the vector backbone (pKSþ bluescript, Stratagene
Heidelberg, Germany) was linearized with Not1. Using
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standard procedures,6 R1 mouse embryonic stem cells
(R1-ES, provided by A Nagy, Toronto, Canada), suspended
in phosphate-buffered saline (PBS) with 40 mg linearized
targeting vector, were electroporated using a Bio-Rad
GenePulser (240 V and 500mF, Bio-Rad, Munich, Germany).
Transfected embryonic stem cells (2 107) were cultured on
gelatinized 10-cm dishes (Falcon, Heidelberg, Germany) for
1 day and then selected with 300mg ml 1 G418 and 2 mM
Gancyclovir. On day 10 after electroporation, 386 resistant
clones were picked and one with homologous recombination
was identified by semi-nested PCR. Amplification was (1) with
forward primer (50-GGGCTGACTTTTGGATTTTGTGG-30)
and reverse primer (50-GCCTCTCCACCCAAGCGGCCG
GAGAACCTGCGTGC-30) and (2) on the first PCR product
with alternative reverse primer (50-GCAATCCATCTTGTT
CATGGC-30). Embryonic stem cells were microinjected into
C57Bl6/6J blastocysts that were transferred to pseudo-
pregnant foster mothers. Highly chimeric males (N¼ 4) were
obtained that were bred to C57Bl6/6J females. We interbred
heterozygous offspring to obtain homozygous mutant mice,
which were born at the expected Mendelian frequency.
Gpm6a null mutant mice are viable and fertile. For genotyp-
ing (Figure 1b), genomic DNA was isolated from tail biopsies
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Figure 1 Generation of Gpm6a null mutant mice and discovery of behavioral consequences following stress. (a) Strategy to inactivate the mouse Gpm6a gene.
A neomycin resistance cassette flanked by translation stop codons in all reading frames was fused into exon 2, which is the first exon present in all Gpm6a transcripts. (b) PCR
genotyping to identify wild-type (WT) and mutant Gpm6a alleles. (c) Immunoblot analysis of cortex homogenates using antibodies directed against Gpm6a or tubulin, with or
without prior deglycosylation using PNGaseF. Gpm6a was undetectable in Gpm6a null mutants. Note that the abundance of Gpm6a was considerably reduced in
heterozygous mice. (d) Immunohistochemistry of brain sections with antibodies directed against Gpm6a or the related proteolipid protein (PLP). Note that Gpm6a was not
detected in Gpm6a null mutant mice that showed unchanged PLP expression. (e) Elevated plus maze (EPM) behavior of psychosocially stressed (resident-intruder paradigm)
as well as of sham-stressed Gpm6a null mutants (KO) reveals a prominent claustrophobia-like phenotype (N¼ 17–19 per group). (f) Sample track recording of EPM
performance, illustrating a Gpm6a mutant spending much less time in closed arms compared with its WT littermate. (g) Single housing (a prerequisite of performing the
resident-intruder stress) is sufficient to induce a claustrophobia-like phenotype in Gpm6a mutants (N¼ 7–9 per group), which is absent upon group housing, and (f) to reveal a
clear genotype difference in the expression of a stress-regulated gene, Fkbp5, in mouse amygdala (N¼ 7–9 per group). Mean±s.e.m. presented. DAPI, 40-6-diamidino-2-
phenylindole; HSK-tk, herpes simplex virus-thymidine kinase.
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to manufacturer’s directions. In a PCR co-amplification
reaction, the presence of the Gpm6a wild-type (WT) allele
was shown using forward primer #1 (50-TTGCTCTTCTAC
AGGGTGCT-30) and reverse primer #2 (50-CCTCCA
TCCTCTGTCATTCC-30), which yielded a 560-bp fragment.
We identified the targeted allele with forward primer #1 and
reverse primer #3 (50-GCAATCCATCTTGTTCAATGGC-30),
yielding a 310-bp fragment. For protein analysis (Figure 1c),
we prepared total cortex lysates from WT, heterozygous and
homozygous mice and determined the protein concentration
according to Bradford, and boiled the samples (5 min) before
loading. For immunoblot, we separated 40mg lysate by 12%
SDS-polyacrylamide gel electrophoresis and transferred the
samples on poly(vinylidene fluoride) membranes (Hybond-P,
Amersham Biosciences, Glattbrugg, Switzerland). We
blocked the membrane in 5% milk powder in PBS with
0.1% Tween (30 min at 37 1C). Antibodies were directed
against the C-terminus of Gpm6a (#24983; 1:500) or tubulin
(Sigma, Heidelberg, Germany; 1:5000) and applied in
blocking buffer (over night, 4 1C). Following wash, membrane
was incubated with horseradish peroxidase-conjugated sec-
ondary antibody (Dianova, Hamburg, Germany, 1:5000 in
blocking buffer). Immunoreactive bands were visualized by
enhanced chemiluminescence (Pierce, Bonn, Germany). For
immunohistochemistry (Figure 1d), WT and Gpm6a null
mutant mice were anesthetized with Avertin (250 mg/kg body
weight; Sigma), perfused with Hank’s balanced salt solution,
followed by 4% formaldehyde in PBS and the isolated brains
were post-fixed for 1 h. Vibratome sections (thickness 12mm,
Leica VT 1000S, Leica Biosystems, Wetzlar, Germany) were
permeabilized with 0.4% Triton X-100 in PBS (30 min, room
temperature), blocked in 4% horse serum in PBS (30 min,
room temperature) and incubated with antibodies against
Gpm6a (M6, rat monoclonal, 1:25; kind gift by Carl Lagenaur,7
Pittsburgh, USA) or proteolipid protein (A431, rabbit
polyclonal, 1:500)8 at 4 1C for 24 h. After wash, sections were
incubated with appropriate fluochrome-coupled secondary
antibodies (Dianova, Hamburg, Germany; 2 h, room tempera-
ture) and washed three times. Sections were imaged with
Leica DMRXA and OpenLab 2.0 software (Improvision,
Tu¨bingen, Germany).
Behavioral testing. For behavioral testing, mice were
housed in groups of three to five in standard plastic cages,
food and water ad libitum. The temperature in the colony
room was maintained at 20–22 1C, with a 12-h light/dark
cycle (light on at 0700 hours). Behavioral experiments were
conducted by an investigator, blinded to the genotype, during
the light phase of the day (between 0800 hours and 1700
hours). For behavioral experiments, eight different cohorts of
mice were used. The order of testing in the first cohort was as
follows: elevated plus maze (EPM), open field, hole board,
rotarod, pre-pulse inhibition, fear-conditioning, visual cliff. In
further cohorts, EPM release in closed arms, EPM in the
dark, mouse light/dark box test, mouse wide/narrow box test,
EPM retesting (‘exposure treatment’) and hearing were
performed. For electroretinogram, olfaction testing and
corticosterone determination upon metabolic cage exposure,
separate cohorts were used. Age of mice at the beginning of
testing was 19 weeks. Inter-test interval varied depending on
the degree of ‘test invasiveness’ but was at least 1 day. During
all tests, the investigator was ‘blinded’, that is, unaware of
mouse genotypes. For comprehensive test description of
basic tests, that is, EPM, open field, hole board, rotarod, visual
cliff test (vision), buried food finding test (olfaction), sucrose
preference test (motivation), pre-pulse inhibition, cued and
contextual fear-conditioning, and ultrasound vocalization
analysis, please see El-Kordi et al.9 Described in the following
are additional, modified or specifically designed tests.
EPM with release in closed arms. In this modified version,
mice were placed in the closed arms in the same plus-maze
described above. This test was done to address potential
motor factors influencing the time spent in arms. The test
was otherwise conducted in the same manner as the
classical EPM.
EPM in darkness. This test was again performed like the
classical EPM, just in full darkness to address potential
visual/perceptual factors affecting behavior in open/closed
space. The behavior of mice was monitored via infrared
camera.
Hot plate test. The hot plate test is used as a measure of
pain sensitivity. Mice were placed on a metal plate (Ugo
Basile, Comerio, Italy), preheated up to 55 1C. The latency of
hind paw licking or jumping was recorded. Mice were
removed from the platform immediately after showing the
response. A 40-s cutoff time was supposed to prevent
wounds, although none of the tested mice reached it.
Assessment of hearing by the acoustic startle response.
Individual mice were placed in small metal cages (90
40 40 mm3) to restrict major movements and exploratory
behavior. The cages were equipped with a movable platform
floor attached to a sensor that records vertical movements of
the floor. The cages were placed in four sound-attenuating
isolation cabinets (TSE GmbH, Bad Homburg, Germany).
Startle reflexes were evoked by acoustic stimuli delivered
from a loudspeaker that was suspended above the cage and
connected to an acoustic generator. The startle reaction to
an acoustic stimulus (pulse), which evokes a movement of
the platform and a transient force resulting from this
movement of the platform, was recorded with a computer
during a recording window of 100 ms and stored for further
evaluation. The recording window was defined from the
onset of the acoustic stimulus. An experimental session
consisted of a 2-min habituation to 65 dB background white
noise (continuous throughout the session), followed by a
baseline recording for 1 min at background noise. After
baseline recording, stimuli of different intensity and fixed
40 ms duration were presented. Stimulus intensity was varied
between 65 and 120 dB, such that 19 intensities from this
range were used with 3 dB step. Stimuli of the each intensity
were presented 10 times in a pseudorandom order with an
interval ranging from 8 to 22 s. The amplitude of the startle
response (expressed in arbitrary units) was defined as the
difference between the maximum force detected during a
recording window and the force measured immediately
before the stimulus onset. Amplitudes of responses for each
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stimulus intensity were averaged for individual animals.
Mean values for each experimental group were plotted on
the graph to provide the stimulus–response curves.
Mouse light/dark box test. The apparatus (36 20.5 19
cm3) consisted of two equal acrylic compartments, one
roofed, dark and one white, with a 300 lx light intensity in the
white compartment and separated by a divider with an
opening (size: 5.7 5 cm2) connecting both compartments.
Each mouse was tested by placing it in the black/dark area,
facing the white one, and was allowed to explore the novel
environment for 5 min. The roof of the dark compartment was
closed after releasing the mouse. The number of transfers
from one compartment to the other and the time spent in the
illuminated side were measured. This test exploited the
natural conflict between the animal’s drive to explore a new
environment and its tendency to rather stay in a closed, dark
and protected environment and to avoid bright light.
Mouse wide/narrow box test. This inhouse-made box (test
arena: length 60 cm, width 60 cm and height 30 cm)
consisted of two equal (each 30 cm length) gray plastic
compartments. One compartment was wide and open, the
other one narrow (consisting of 30 5 30 cm3 corridor).
Mice were placed in the wide compartment, facing the narrow
corridor. Light intensity in the wide compartment was 300 lx,
in the corridor 150 l . Time to enter the corridor was
recorded by a stopwatch. The behavior was recorded
throughout the 10 min testing period by a PC-linked overhead
video camera. ‘Viewer 2’ software was used to calculate
velocity, distance travelled, number of visits of and time spent
in both compartments.
Electroretinogram. Before the experiments, animals were
dark adapted for at least 12 h and all preparations were
carried out under dim red light.10 Mice were anaesthetized by
intraperitoneal injection of ketamine (0.125 mg g 1) and
xylazine (2.5 mg g 1). Supplemental doses of 1/4 the initial
dose were administered when changes in the constantly
monitored electrocardiogram or movements indicated that
the animals were waking up. Mice were placed on a heated
mat (Hugo Sachs Elektronik–Harvard Apparatus, March,
Germany) that kept the body temperature constant at 37 1C
under the control of a rectal thermometer. The head of the
mouse was placed inside a custom-designed Ganzfeld bowl
illuminated by a ring of 20 white light-emitting diode. The
pupil of the left eye was dilated with 1% atropine sulfate and a
silver wire ring electrode was coupled to the corneal surface
using electrode gel. The eye and electrode were kept moist
by a drop of 0.9% saline applied every 30 min. Subcutaneous
needle electrodes were inserted between the eyes (refer-
ence) and near the tail (ground). Electrical potentials were
amplified 1000 times, filtered between 0.1 and 8 kHz and
notch-filtered at 50 Hz using custom-designed hardware. The
Tucker Davis System III hardware and BioSig software
(Tucker-Davis Technology, Alachua, FL, USA) were used for
Elevated Plus Maze Exposure 'Therapy'
EPM
























































































































































Figure 2 Male Gpm6a mutants show a strong claustrophobia-like phenotype on top of mild anxiety features. (a) Behavior of Gpm6a knockout (KO) and wild-type (WT)
littermates in classical elevated plus maze (EPM); (b) in EPM performed in the darkness; and (c) in EPM upon release in closed arms. (d) Weekly exposure to EPM (over 3
weeks) led to reduction of closed arm aversion in Gpm6a KO. This adjustment also explains the weaker closed-arm avoidance seen in mice of b and c, which had had one
previous exposure to EPM. (e) In a newly developed wide/narrow box test, WT mice spent more time in the narrow area (left graph), whereas Gpm6a KO did not show narrow
space preference. (f) In the light/dark box, Gpm6a KO mice entered the light area faster; (g) explored less holes (requiring nose pokes in narrow holes); (h) spent less time in
the center of the open field, and (i) exerted higher baseline freezing in the fear-conditioning chamber. (j) Exposed to narrow metabolic cages for 3 h, Gpm6a KO excreted
higher levels of corticosterone via urine. (a–c): N¼ 17–18; (d): N¼ 8; (e): N¼ 32–35; (g–h): N¼ 17–18; (i, j): N¼ 12. Mean±s.e.m. presented.
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stimulus control and recordings. Scotopic responses to 10
white light flashes were averaged for each stimulus condi-
tion. Interstimulus intervals were 5 s for light intensities below
1 cds m 2 and 17 s for light intensities above 1 cds m 2. The
amplitude growth functions and latencies of the A-waves,
B-waves and oscillatory potentials in response to 0.1, 1 and
5 ms long-light flashes ranging between 0.0003 and
10 cds m 2 was analyzed using custom-written matlab
(Mathworks, Natick, MA, USA) software.
Corticosterone excretion. Urine samples were collected
using inhouse-made metabolic cages. Mice were placed in
small, narrow metal cages (90 40 40 mm3) to restrict
major movements and exploratory behavior, thus resulting in
stress-induced corticosterone release. These cages had a
wire-mesh floor enabling urine collection via a funnel. The
funnel was fixated on top of a collecting flask. Mice (12 per
genotype) were placed in the metabolic cages at 2200 hours
for 3 h each. Urine was collected at 0100 hours. Concentra-
tions of corticosterone were measured using a commercially
available EIA kit (BIOTREND, Cologne, Germany) according
to the manufacturer’s protocol. Urine creatinine was
determined photometrically (Jaffe method). Sample analysis
of WT and knockout (KO) animals was performed blinded
and in random order. Values were expressed as nmol per
day per g body weight.11
Resident-intruder (psychosocial stress) test. The procedure
is described in detail elsewhere.12,13 Briefly, male mice of
both genotypes (28 days old) were randomly assigned to
either the ‘stress’ or ‘sham stress’ group. As intruders, they
were subjected for 21 days (1 h daily, from 0900–1000 hours)
to resident male mice (male FVB, 2–3 months old, habituated
to resident cages for X10 days). To prevent injuries, direct
interaction was immediately terminated at the first attack
(usually occurring after a few seconds) by putting a grid cage
(140 75 60 mm3) over the intruder. Afterwards, intruder
mice were placed back in their home cage. Mice were
confronted with a different resident every day. Sham stress
consisted of placing the intruder mouse in an empty novel
cage for 1 h.
Restraint stress paradigm. Mice were kept undisturbed for at
least 1 week until a single 6-h restraint stress was performed
in a separate room (with mice left in their home cages and put
in wire mesh restrainers, secured at the head and tail ends
with clips) during the light period of the circadian cycle as
described.14 Control animals were left undisturbed.
Amygdala dissection. Mice were anaesthetized (intraperito-
neal sodium pentobarbital 50 mg kg 1) and perfused trans-
cardially (ice-cold PBS). Amygdalae were dissected from a
coronal slice  0.58 to  2.3 mm relative to Bregma and
stored in RNA later (Qiagen) at 4 1C until processed.14
Quantitative reverse transcription-PCR from amygdala.
Amygdala tissue was homogenized in Quiazol (Qiagen,
Hilden, Germany). Total RNA was isolated by using the
miRNeasy Mini Kit (Qiagen). First strand cDNA was
generated from total RNA using N9 random and Oligo(dT)
18 primers. The relative concentrations of mRNAs of interest
in different cDNA samples were measured out of three repli-
cates using the threshold cycle method (deltaCt) for each
dilution and were normalized to the normalization factor of
Hprt1 and H2afz genes calculated by the geNorm analysis
software. Reactions were performed using SYBR green PCR
master mix (ABgene, Foster City, CA, USA) according to the
protocol of the manufacturer. Cycling was done for 2 min at
50 1C, followed by denaturation at 95 1C for 10 min. The
amplification was carried out by 45 cycles of 95 1C for 15 s
and 60 1C for 60 s. The specificity of each primer pair was
controlled with a melting curve analysis. For quantitative











miR124. First strand cDNA synthesis and reactions were
generated from total RNA using the TaqMan MicroRNA RT
Kit, TaqMan MicroRNA Assay for hsa-miR124, TaqMan
MicroRNA Assay for sno-RNA142 as a housekeeper and
TaqMan 2 Universal PCR Master Mix (ABgene) according
to the manufacturer’s protocol. Cycling was done with 10 min
denaturation at 95 1C and amplification for 40 cycles at 95 1C
for 15 s and 60 1C for 60 s.
Human sample
Claustrophobic subjects. The present study was approved
by the Ethics Committee of the Georg-August-University. A
total of 47 subjects with clinical diagnosis of claustrophobia
according to Diagnostic and Statistical Manual of Mental
Disorders IV (DSM-IV)15 were included (Table 1). Healthy
subjects (N¼ 13) were recruited by e-mail announcements in
the Max Planck Institutes of Experimental Medicine (MPIEM)
and Biophysical Chemistry (MPBPC). Patients suffering from
psychiatric conditions other than psychotic disorders (N¼ 16;
that is, N¼ 7 affective disorder, N¼ 5 anxiety disorder, N¼ 2
substance use disorder, N¼ 2 others) were recruited from
the psychiatric hospital of the Georg-August-University
Go¨ttingen. In addition, N¼ 18 schizophrenic individuals with
a claustrophobic phenotype were selected from the GRAS
data collection.16 Claustrophobic subjects were invited to the
outpatient unit of the MPIEM for examination. In the case of
GRAS patients, extensive telephone interviews were per-
formed instead. Subjects underwent detailed claustrophobia
relevant phenotyping, after validation of diagnoses using
DSM-IV criteria15 by a trained psychologist/psychiatrist. The
subsequent examination procedure comprised a short ques-
tionnaire regarding sociodemographic information, history of
physical and psychiatric diseases, specifically for this project
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developed abbreviated German version of the Claustropho-
bia Questionnaire (CLQ)17 (Short CLQ-G) and the screening
questions of the Structured Clinical Interview of Diseases18
for anxiety disorders.
Non-claustrophobic subjects. A total of 68 subjects, who did
not suffer from claustrophobia, were matched to the
claustrophobic subjects regarding age, gender and clinical
diagnosis where applicable (Table 1). Again, healthy subjects
(N¼ 14) were recruited by e-mail announcements in the
MPIEM and MPBPC. Patients suffering from psychiatric
conditions other than psychotic disorders (N¼ 29; that is,
N¼ 18 affective disorder, N¼ 4 general anxiety disorder,
N¼ 4 substance use disorder, N¼ 3 others) were recruited
Table 1. Comparison of sociodemographic, general clinical and anxiety/claustrophobia relevant parameters in claustrophobic and non-claustrophobic subjects









Mean±s.d. Mean± s.d. Mean± s.d.
Sociodemographics
Age in years 43.56±13.22 43.87±12.11 43.35±14.02 0.733
Education in years 14.43±3.55 14.31±3.85 14.52±3.35 0.830
N % N % N % Effect P b
Gender
Female 81 70.4 13 27.7 21 30.9 0.139 0.710
Male 34 29.6 34 72.3 47 69.1
Ethnicity
Caucasian 112 97.4 47 100.0 65 95.6 2.129 0.546
African 1 0.87 — — 1 1.47
Other 2 1.73 — — 2 9.94
Marital status
Single 57 49.6 24 51.1 33 48.5 3.545 0.471
Married 33 28.7 12 25.5 21 30.9
Divorced 19 16.5 11 23.4 11 16.2
Widowed 3 2.6 — — 3 4.4
Main diagnoses according to DSM-IV
No clinical diagnosis 27 23.5 13 27.7 14 20.6 1.135 0.567
Schizophrenia 43 37.4 18 38.3 25 36.8
Other clinical diagnoses 45 39.0 16 34.0 29 43
Prevalence of anxiety disorders
Comorbid anxiety disorderc 68 59.1 29 61.7 39 57.4 0.702
Panic disorder 29 25.2 15 31.9 14 20.6 0.194
Agoraphobiad 56 48.7 47 100.0 9 13.2 o0.0001
Ssocial phobia 18 15.7 9 19.1 9 13.2 0.440
Specific phobia 38 33.0 20 42.6 18 26.5 0.106
Generalized anxiety disorder 13 11.3 7 14.9 6 8.8 0.375
Obsessive compulsive disorder 18 15.7 9 19.1 9 13.2 0.440
Mean±s.d. Mean±s.d. Mean±s.d. P a
Claustrophobia Relevant Items (Short CLQ-G)
Subscale ‘restriction’
Dark room 2.18±1.66 3.25±1.22 1.44±1.51 o0.000001
Well-lit room 1.51±1.46 2.53±1.27 0.78±1.12 o0.000001
Sleeping bag 1.04±1.45 1.87±1.58 0.47±1.01 o0.000001
Trunk 2.18±1.67 3.53±1.04 1.25±1.36 o0.000001
MRI scanner 1.65±1.67 3.17±1.05 0.60± 1.11 o0.000001
Mean of subscale 1.71±1.36 2.87±0.87 0.91±1.00 o0.000001
Subscale ‘suffocation’
Elevator 1.07±1.39 2.13±1.36 0.34±0.84 o0.000001
Breathe 0.83±1.09 1.26±1.24 0.54±0.87 o0.001
Crowded room 1.82±1.57 3.04±1.12 0.97±1.25 o0.000001
Under a car 1.23±1.44 2.17±1.51 0.59±0.97 o0.000001
Sauna 1.00±1.44 2.04±1.56 0.28±0.75 o0.000001
Mean of subscale 1.19±1.08 2.13±0.83 0.54±0.70 o0.000001
Mean of questionnaire 1.45±1.17 2.50±0.74 0.73±0.82 o0.000001
Abbreviation: MRI, magnetic resonance imaging.
aMann–Whitney U-test.
bFisher’s exact test/w2-square test.
cAnxiety disorders other than agoraphobia.
dAgoraphobia includes claustrophobia.
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from the psychiatric clinic of the Georg-August-University
Go¨ttingen. Furthermore, 25 schizophrenic non-claustropho-
bic individuals were selected from the GRAS data collec-
tion.16 The examination procedure comprised the same
battery of questionnaires as for the claustrophobic subjects
(above).
Pedigrees. To explore whether particular variations in
GPM6A are transmitted in families together with claustro-
phobia, we tried to contact all available family members of
the three claustrophobic individuals carrying the genetic
variation at locus c.*1834T4C. Only for two of the subjects,
SIWO and THKA (Figure 3b), it was possible to contact a
sufficient number of relatives. Claustrophobia diagnosis
according to DSM-IV criteria was confirmed by a telephone
interview carried out by a trained psychologist. Swabs for
genetic analysis and a short sociodemographic question-
naire, also containing items regarding the history of physical
and psychiatric diseases, the Short CLQ-G and the screen-
ing questions of the Structured Clinical Interview of Diseases
for anxiety disorders,18 were communicated via mail.
Abbreviated German version of the CLQ (Short CLQ-G).
To quantitatively assess the severity of claustrophobic
anxiety, nine items of the CLQ17,19 were selected and
translated into German language (Supplementary Table 1).
One item measuring fear experienced during magnetic
resonance imaging was added to the restriction subscale
because this situation may induce claustrophobia.20,21 The
CLQ is the most commonly used questionnaire for the
psychological assessment of claustrophobia and has excel-
lent psychometric properties (Cronbach’s a: 0.95; test–retest
reliability: 0.89).17 It is composed of two subscales measur-
ing two distinct but related fears: fear of restriction and fear of
suffocation. Anxiety severity is measured on a 5-point Likert
scale. To cover both subscales, five items from the
suffocation and four items from the restriction subscale with
high ecological validity were selected for construction of the
Short CLQ-G. Given the substantial reduction in item number
(B60%), the Short CLQ-G still achieves high internal
consistency (total scale: 0.932, restriction: 0.909, suffocation:
0.835) and split-half reliability (0.952, splits matched for
mean item difficulty) for the whole subject sample (N¼ 115;
N¼ 47 claustrophobic subjects; N¼ 68 non-claustrophobic
subjects; Supplementary Table 1).
GPM6A sequencing. DNA from all subjects participating
in this study (N¼ 115) was isolated from blood with the
Figure 3 Genetic analysis of GPM6A. (a) Sequencing strategy and overview of the detected variants. Displayed are the coding exons (filled boxes) and the noncoding
region of GPM6A (empty box). Arrows indicate rare variants found. Frequencies of rare variants in cases (black) versus controls (gray) are given. (b) Pedigrees of two
claustrophobic individuals (SIWO and THKA), carrying the mutation at locus c.*1834 (position 2882 in human GPM6A transcript variant 1, mRNA; NM_005277.3), suggesting
an association between this mutation and the claustrophobic phenotype. (c) Highly phylogenetically conserved genomic structure surrounding c.*1834T4C within the seed
sequence of miR124 in the 30untranslated region of GPM6A. (d) Expression analysis after miR124 nucleofection. Shown are the results of GPM6A RNA expression in
peripheral blood mononuclear cells (PBMCs) after nucleofection with miR124 from two patients and six controls (that is, not carrying the variant; age, gender and disease
matched; three controls per patient). Results were standardized to the results after just a pulse. (e) Restraint stress induces upregulation of miR124 in the amygdala of male
mice, identifying this miR as a stress-regulated transcript (N¼ 22 per group).
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JET Quick Kit (Genomed, Loehe, Germany). For analysis of
pedigree members (swabs), DNA was isolated with the
Isohelix DNA Swab Kit (Biolab Products, Goedenstorf,
Germany). PCR reaction: All exons, the putative promoter
region of Ex2B and the 30 untranslated region (30UTR) of
GPM6A were PCR-amplified from respective samples.
Primers are listed below. Sequencing: The PCR amplicons
were purified from unincorporated primers and deoxyribonu-
cleotide triphosphates by digesting with 1 U Shrimp Alkaline
Phosphatase und 5 U Exonuclease I (Exo) according to the
manufacturer’s instructions (USB Europe GmbH, Staufen,
Germany). Sequencing was carried out using the dideoxy
chain termination method with the BigDye Terminator v3.1
Cycle Sequencing Kit on a 3730XL DNA Analyzer (Applied
Biosystems, Foster City, CA, USA). Raw data were
processed with Sequencing Analysis 5.2 (Applied Biosys-
tems) and with different modules of the software package
Lasergene 7.0 (DNASTAR, Madison, WI, USA).
Primers for GPM6A sequencing approach
Amplified region Primer sequence (50-30) Size
(bp)






Exon 2b fw GAGGAGAGAAAAGGAAAACACAG 755
rv GAAACATTCATTAGCCTTACTGG
Exon 3 fw GAAAGTCTGGGTTGGGAAGGA 788
rv GATTTGTACCTGGCACTATTCTA
Exon 4 fw GAACCAGGGAAGAGGAGAAG 694
rv CCATACATCAATCAACAGTG
Exon 5 fw GCCAAGATATGATTTTCCAGCAG 709
rv GGGAGGATAAAAGTAGAATGC
Exon 6_7 fw GGAACTTGCTTAGATTTGATTAG 955
rv GACTTACTTACCCATTGTTTTCC
Exon 8* fw CGAGATAGCAAGGTGTAATGAAG 904
rv CATAAACATGAGTAATCTGAGG
30UTR* fw GAAGATCAGTGGCCATATTAC 1543
rv ATTGTACTTGAAAAGAATTCACAC
*For sequencing exon 8 and the associated 30UTR additional




Computational micro RNA (miRNA) search. To explore
putative miRNA-binding sites in the GPM6A 30UTR, several
analyses were performed. TargetScan, version 6.2 (http://
www.targetscan.org/) was used to identify miRNA-binding
sites. Screening and DDG prediction analysis for both alleles
of GPM6A were carried out using established algorithms
(http://genie.weizmann.ac.il/pubs/mir07/mir07_prediction.html).
Expression analysis after nucleofection. Peripheral blood
mononuclear cells (PBMCs) of claustrophobic patients with
the mutation in the 30UTR (N¼ 2) and three matches per
subject were freshly isolated using the standard Ficoll-Paque
Plus isolation procedure (GE Healthcare, Munich, Germany).
Using the Amaxa Nucleofector II Device (T-020), 6 106
cells were transfected with neg miRNA #2 or hsa-miR124
(Applied Biosystems) and cultured in RPMI supplemented
with 10% fetal calf serum. After 24 h, cells were harvested
and RNA extracted with the miRNeasy Mini Kit (Qiagen).
cDNA was synthesized using 200 U SuperScriptIII (Invitro-
gen, Karlsruhe, Germany). For quantification with quantita-
tive reverse transcription-PCR, the cDNA was used 1:10
diluted and four replicates per sample were performed; to 4ml
diluted cDNA, 5 ml Power SYBR mix (Applied Biosystems)
and 1 pmol of each primer (see below) were added.
Cycle threshold (CT) values for GPM6A were standardized





Statistical analyses. Data were analyzed using SPSS for
Windows version 17.0 (SPSS Inc., Chicago, IL, USA; http://
www.spss.com) (human data analyses) and Prism 4 for
Windows version 4.03 (GraphPad Software, Inc., La Jolla,
CA, USA) (mouse data analyses). Unless otherwise stated,
the data given in figures and text are expressed as
mean±s.e.m., and were compared by two- or three-way
analysis of variance with post-hoc planned comparisons or
by analysis of variance for repeated measurements,
Mann–Whitney U-test and w2 test, where appropriate.
Results
Gpm6a null mutant mice appear essentially normal in
development and basic behavior. We have generated
Gpm6a null mutant mice (KO) to explore the role of Gpm6a in
the behavioral response to stress (Figures 1a–d). Homo-
zygous KO mice were born at the expected Mendelian
frequency and are long-lived. By western blot analysis,
heterozygous mice expressed about 50% of the protein
(Figure 1c), demonstrating that Gpm6a abundance can be
regulated at the transcriptional level in vivo (see below).
Gpm6a KO mice reproduce well and exhibit no obvious
developmental defects (data not shown). Also, in a basic
behavioral test battery, which included the analysis of motor
and sensory functions, motivation and sensorimotor gating,
we found no difference from WT littermate controls
(Supplementary Figure 1).
Mild stress induces a claustrophobia-like phenotype in
Gpm6a null mutant mice. Unexpectedly, when applying
the resident-intruder paradigm13 in order to assess the
response to experimental stress, we noticed that sham-
stressed Gpm6a null mutant mice exhibit a prominent
phenotype in the EPM, consisting of a specific avoidance
of closed arms. To our knowledge, such a behavioral
response, which we like to term ‘claustrophobia’ in mice,
has not been reported before. This phenotype is specifically
striking, because normal rodents rapidly seek closed and
narrow spaces to hide, which is a protective trait. Interest-
ingly, the claustrophobia-like phenotype was only marginally
amplified in those mutant mice that had experienced the
resident-intruder stress (Figures 1e,f). As a prerequisite for
applying this stress paradigm is prior single housing (of all
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mice), we asked whether the relatively mild stress of social
withdrawal might have been sufficient to trigger the claus-
trophobia-like phenotype in Gpm6a mutants. Indeed, single-
housed, but not group-housed, Gpm6a mutants showed
claustrophobia (Figure 1g). In these experiments, 10 days of
single housing were sufficient to cause downregulation of the
stress-responsive gene Fkbp522,23 in the amygdala of WT
mice. Importantly, this downregulation was absent in Gpm6a
mutant mice, demonstrating a perturbation of the normal
stress response even at the molecular level (Figure 1h). A
comparable result was obtained for Npy5r as another marker
of stress (data not shown).24
Extra behavioral tests underline the claustrophobia-like
phenotype in Gpm6a / mice. As claustrophobia-like
behavior in mice has to our knowledge never been reported
before, we performed a large number of extra behavioral
tests in eight independent cohorts of male mice in order to
substantiate this unusual phenotype. In fact, claustrophobia
upon single housing was found in all cohorts of Gpm6a
mutants and maintained when EPM was performed in
darkness, using infrared cameras or when mice were
released in closed arms (Figures 2a–c). This behavioral
response did not rely on whisker functions or vocalizations,
as confirmed by whisker cutting and ultrasound recording,
respectively (data not shown). Similar to an ‘exposure
therapy’ in humans, repeated EPM testings of mutants
reduced and ultimately eliminated the claustrophobia-like
behavior (Figure 2d; note also the weaker closed arm
avoidance of mutants in Figures 1g and 2b,c;
Supplementary Figure 2B, showing cohorts that already
had one previous EPM test session). Also, other tests
confirmed our diagnosis of ‘claustrophobia’, such as a
specifically designed wide/narrow box, a light/dark box and
the hole board test, in all of which mutant mice lacked
preference for narrow and dark spaces (Figures 2e–g), that
is, displayed a highly abnormal behavior, considering
that rodents naturally prefer these spaces to hide and
thereby protect themselves from predators.
Further tests demonstrated slightly increased general
anxiety, again reminiscent of the known human claustropho-
bic phenotype. Mutants spent less time in the center of
the open field and showed increased ‘baseline freezing’ in the
fear-conditioning box (Figures 2h,i). The collection of urine
from mutant mice that were kept for 3 h in narrow metabolic
cages, revealed a significantly higher corticosterone excretion
compared with their WT littermates (at similar urine creatinine
values: WT 0.35±0.08 versus KO 0.39±0.06 mg per g body
weight and day; N¼ 12/group; P40.1), indicative of an
increased stress level (Figure 2j). As phobias/panic disorders
in humans are more prevalent in females than in males,25 we
additionally examined female mutant mice and confirmed a
very similar behavioral pattern as in male mice, that is, an
unaltered basic behavior and the avoidance of closed arms in
EPM (Supplementary Figure 2).
First considerations on a functional compensation for
loss of Gpm6a in null mutant mice. Interpreting stress at
the level of gene expression changes is difficult, because the
encoded proteins can be ‘upstream’ or ‘downstream’ of
stress perception, and either contribute to or protect from
abnormal stress response. This complicates the prediction of
cause and effect in a pathological situation. Gpm6a
mRNA is downregulated by chronic social stress and also
following prolonged cortisol treatment.26 As stimulation of
the hypothalamus–pituitary–adrenal (stress) axis leads to
cortisol release, it is likely that downregulated Gpm6a
expression mediates adaptation of the brain to stress and
is therefore a healthy response that serves a feedback
function in neuronal circuits exposed to stressful signals. The
loss of Gpm6a in null mutant mice is clearly tolerated,
presumably by the functional compensation of structurally
related membrane proteins that are co-expressed in devel-
opment (but are likely not stress regulated). One candidate
for functional compensation is the neuronal Gpm6b gene,
which encodes a highly related protein27 with a similar (but
not identical) spatio-temporal expression in brain28,29 and
which is, unlike Gpm6a, not among the identified stress-
regulated genes.26,30 In fact, this gene is upregulated under
basal conditions in the amygdalae of Gpm6a mutant mice
(KO: 1.04±0.06; WT: 0.86±0.05, normed to Hprt1 and
H2afz; Po0.05). To further investigate compensatory func-
tions between the two genes, we cross-bred Gpm6a mutant
mice with a newly generated line of Gpm6b null mutant
mice.31 The resulting double-mutant mice develop normally
and reproduce well, but show 20% unexplained mortality at
age 1 month. Further evidence that Gpm6a and Gpm6b have
overlapping functions was found in cultured cortical neurons,
in which the loss of both proteins reduced the collapse
response of growth cones to soluble ephrin-B5, a repulsive
signal.31 This significant but clearly limited evidence of
compensation strongly suggests that several (but not all)
Gpm6a functions are redundantly served by Gpm6b and
presumably other neuronal proteins. If stress-induced down-
regulation of Gpm6a expression in vivo were part of a
neuroprotective stress response, it would be plausible that
Gpm6a null mutant mice can develop normally but are
selectively affected at the behavioral level, simply because
Gpm6a compensating genes (such as Gpm6b) lack the
necessary downregulation following stress exposure.
Selected genomic sequencing of GPM6A reveals
associations with claustrophobia. As polymorphisms of
human GPM6A, specifically in the noncoding region, could
likewise interfere with dynamic gene regulation, we explored
the association of this gene with a predisposition to human
claustrophobia. A sample of 115 adult subjects (N¼ 47 self-
reported claustrophobics and N¼ 68 non-claustrophobic
controls) were recruited and interviewed with special
emphasis on general anxiety and claustrophobia (Table 1).
The sociodemographic description of the human sample
revealed similar distributions between claustrophobic and
non-claustrophobic individuals with regard to age, educa-
tional background, gender, ethnicity and marital status.
Moreover, cases and controls were well matched for co-
morbid disease state. The prevalence of DSM-IV anxiety
disorders other than claustrophobia (Table 1, included under
agoraphobia) did not substantially diverge between claus-
trophobic cases and controls. More than half of the total
sample (59%) reported to suffer from at least one (additional)
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anxiety disorder. Expectedly, most individuals suffered from
any kind of specific phobia (33%), followed by panic disorder
(25%), social phobia and obsessive-compulsive disorder
(both 16%). Generalized anxiety disorder was least frequent
in our sample (11%). Claustrophobic subjects displayed higher
severity ratings on all 10 items of an abbreviated German
version of the CLQ17 (Short CLQ-G; essentially all Po000001).
Despite a 60% reduction in item number, the Short CLQ-G
showed still very good psychometric properties comparable
to the original instrument (Supplementary Table 1).
On all 115 subjects, we performed genomic sequencing of
GPM6A covering all exons and flanking noncoding regions.
This identified nine single-base substitutions in GPM6A, all of
which were rare (most of them previously unreported) variants
in the noncoding regions. Interestingly, in claustrophobic
individuals, the sequenced regions were significantly more
polymorphic than in non-claustrophobic controls (P¼ 0.028;
Figure 3a). To investigate whether particular variants of
GPM6A are also genetically linked to claustrophobia, we
examined two families that shared sequence abnormalities in
the 30UTR. This allowed us to include information on more
than one family member (N¼ 10) within two small pedigrees
(Supplementary Table 2). Indeed, the sequence variants in
the 30UTR/noncoding region exon8 were consistently found in
claustrophobic (but not in non-claustrophobic) individuals
(Figure 3b). Unfortunately, the pedigrees were too small to
assess significance. Interestingly, however, when comparing
all mutation carriers in our sample of 115 individuals with all
non-mutation carriers (independent of the claustrophobia
diagnosis) significantly higher scores for most claustrophobia-
relevant items were found associated with the mutation
status (Supplementary Table 3).
A single-base substitution in the 30UTR of GPM6A
delivers first mechanistic insight. To gain mechanistic
insight into the possible role of GPM6A sequence variants in
the noncoding region, we focused on the newly identified
substitution T to C at position c.*1834 in the 30UTR of
exon8, consistently associated with claustrophobia in the two
pedigrees. In vertebrates, the c.*1834-T allele is conserved
from human to zebrafish (Figure 3c). Mechanistically, this
position is of particular interest because it is located within
the seed sequence of miR124. This miRNA is expressed in
brain and highly conserved.32 Indeed, in silico analysis of the
T-to-C substitution predicts the complete loss of miR124
binding (DDG¼  8.11 kJ mol 1).
To assess the effect of miR124 on expression of the
endogenous human GPM6A gene, we obtained PBMCs, in
which the GPM6A transcript can be detected and quantified
by reverse transcription-PCR. When miR124 was over-
expressed by nucleofection of freshly isolated PBMCs,
steady-state levels of GPM6A mRNA were significantly
decreased in cells that were homozygous for the c.*1834-T
(WT) allele, but not in PBMCs from the heterozygous carriers
of the mutant c.*1834-C allele (Figure 3d). miR124 is
expressed in the adult brain, but has only been studied in
neuronal development32,33 and for its role in neuroplasti-
city.34,35 We asked whether miR124 is also found in the
amygdalae of mice and stress regulated. To this end, WT
mice were exposed to restraint stress for 6 h, followed
immediately by amygdala dissection. Indeed, we detected a
significant upregulation of miR124 (Figure 3e) under stress.
Discussion
The behavioral analysis of Gpm6a mutant mice has led to the
unexpected finding that a single neuronal gene can cause an
isolated behavioral defect, best described as claustrophobia.
Belonging to the category of agoraphobia/panic disorder,
claustrophobia is often assumed to be a conditioned
response, following a related traumatic experience.25,36 In
our model, claustrophobia-like behavior was observed in mice
with a strong genetic predisposition (that is, Gpm6a defi-
ciency) when combined with rather mild chronic stress.
Interestingly, there was no obvious relationship between the
quality of stress (that is, single-housing) and the very specific
avoidance behavior. This not only suggests that loss of
Gpm6a expression is a key genetic determinant of claus-
trophobia, but also sufficient to turn an unrelated stressor into
a trigger of a unique behavioral response. We note that
Gpm6a itself is widely expressed in the CNS, including
hippocampus and amygdala as known sites of fear condition-
ing. Thus, there are no reasons to believe that the encoded
membrane protein has evolved in the context of specific
behavioral functions. It is much more likely that membrane
protein Gpm6a, similar to other proteolipids,37,38 is a
cholesterol-associated tetraspan,39 that binds other neuronal
membrane proteins, which provide functional specificity. It is
thus intriguing that Gpm6a has been found to stimulate
endocytosis of m-opioid receptors from the surface of neuronal
cells.40,41 We note that opioids are well known to be involved
in regulation of fear/anxiety and their extinction in mouse
and man.24
Virtually nothing was known about the cause of claustro-
phobia. Typically, anectodal evidence suggested traumatic
experiences, such as in individuals that became trapped alive,
but these incidents cannot explain the high frequency
of claustrophobia in otherwise normal people. The cause or
trigger of some cases of claustrophobia may still be related
to exposure to narrow spaces,36 traumatic brain injury42 and
other traumatic experiences, such as surviving of mining
accidents, but these are mostly poorly documented.
Our report of a mutant mouse model for claustrophobia
suggests that also human claustrophobia can have a familial
predisposition. We could identify a genetic component of
claustrophobia, involving GPM6A expression and its post-
transcriptional regulation by the (stress-regulated) neuronal
miR124. These data suggest that GPM6A may contribute
to the normal stress response in mouse and human. Larger
studies in human samples would be required to assess
exactly to what extent variants of GPM6A act as a
claustrophobia-susceptibility gene.
At first glance, the two findings in mouse and human appear
contradictory, because the claustrophobic phenotype was
associated with the murine Gpm6a null mutation and the
human GPM6A c.*1834-C allele. The latter is predicted to
encode a more stable mRNA, due to the loss of its miR124-
binding site. However, both findings can be reconciled with the
compensation of Gpm6a (in the null mutant) by related
proteins, such as Gpm6b. These proteins substitute for
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Gpm6a in neurons and allow mutant animals to develop
and behave normally. However, when exposed to stress
the expression of these genes is not downregulated
(unlike Gpm6a), as evidenced by the gene expression
profiling that had identified and later confirmed Gpm6a as
the only stress-responsive proteolipid in the adult brain.1,30
Along these lines, we note that miR124, which acts as a
stress-regulated mediator of GPM6A downregulation, as
shown here, does not have comparable functional binding
sites in GPM6B. Thus, loss of dynamic proteolipid expression
in neurons (and the inability to downregulate these proteins)
may predispose to abnormal stress response, rather than the
loss of Gpm6a per se.
The detailed downstream mechanisms will have to be
explored in other conditional mouse mutants in the future.
Gpm6a drives the rate of endocytosis that downregulates the
steady-state level of m-opioid receptors at the surface of
neuronal cells.40,41 Thus, our data are compatible with a
hypothetical model, in which a stress-induced phobia/panic
disorder might be caused (in part) by a reduced feedback
regulation of endogenous opioid receptor signalling.
Obviously, interactions with other proteins that also influence
behavior may be functionally relevant, and we note that the
human serotonin transporter has been reported to interact in
cis with GPM6A and GPM6B43 (and Jana Haase, Dublin,
Ireland, personal communication), whereas another study has
implicated this serotonin transporter in human panic dis-
orders.44 In turn,GPM6Amay also be relevant as a modifier of
other diseases, and it is intriguing that an association has
been found betweenGPM6A and the severity of depression in
patients with schizophrenia.45 The ramification of GPM6A
downstream mechanisms are therefore likely complex and
beyond the scope of this study. However, by placing the
dynamic expression of GPM6A/Gpm6a both upstream and
downstream of stress perception in the brain, we suggest a
working model of GPM6A/Gpm6a as a neuronal ‘brake’ for
maintaining a healthy stress response.
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Supplementary Table 1 
 
Psychometric properties of the Short CLQ-G  
 
 
 TOTAL SAMPLE 
(N=115) 
CLAUSTROPHOBIC 




INTERNAL CONSISTENCY (CRONBACH´S ΑLPHA)   
CLQ total  0.932 0.764 0.909 
’RESTRICTION’ (SR) 0.909 0.739 0.870 
’SUFFOCATION’ (SS) 0.835 0.764 0.790 
SPLIT-HALF RELIABILITYA    
 0.952 0.803 0.947 
ITEM DISCRIMINATIONB    
SR    
to be locked in a small, dark room  0.821 0.688 0.787 
to be locked in a small, well-lit room  0.822 0.587 0.800 
to lie in a sleeping bag  0.651 0.413 0.628 
to lie in the trunk of a car 0.842 0.444 0.826 
to lie in an MRI scanner 0.773 0.371 0.578 
SS    
to be in an elevator 0.739 0.533 0.558 
having difficulties to breathe through nose 0.518 0.327 0.586 
to be in the middle of a crowded concert hall  0.789 0.409 0.715 
to work under a car 0.684 0.315 0.716 
to be in a sauna 0.655 0.296 0.592 
ITEM DIFFICULTY (MEAN ±SD)    
SR    
to be locked in a small, dark room  2.18 ± 1.66 3.25 ± 1.22 1.44 ± 1.51 
to be locked in a small, well-lit room  1.51 ± 1.46 2.53 ± 1.27 0.78 ± 1.12 
to lie in a sleeping bag  1.04 ± 1.45 1.87 ± 1.58 0.47 ± 1.01 
to lie in the trunk of a car 2.18 ± 1.67 3.53 ± 1.04 1.25 ± 1.36 
to lie in an MRI scanner 1.65 ± 1.67 3.17 ± 1.05 0.60± 1.11 
SS    
to be in an elevator 1.07 ± 1.39 2.13 ± 1.36 0.34 ± 0.84 
having difficulties to breathe through nose 0.83 ± 1.09 1.26 ± 1.24 0.54 ± 0.87 
to be in the middle of a crowded concert hall  1.82 ± 1.57 3.04 ± 1.12 0.97 ± 1.25 
to work under a car 1.23 ± 1.44 2.17 ± 1.51 0.59 ± 0.97 
to be in a sauna 1.00 ± 1.44 2.04 ± 1.56 0.28 ± 0.75 
ACorrelation between split a (elevator, breathe, sauna, dark room, trunk) and split b (crowded room, under a car, well-lit room, sleeping bag, MRI scanner).
Both splits matched for mean item difficulty; BCorrelation between each item and the mean of the respective subscale. Indicates how well a certain item 




Cronbach’s alpha coefficients are given as measures of the internal consistency of the items included 
in the claustrophobia questionnaire. To calculate the split-half reliability (Spearman-Brown correlation 
between 2 test halves) reflecting the questionnaires’ homogeneity, the 10 single items were divided 
into 2 clusters such that both splits did not differ in mean item difficulty (split a: elevator, breathe, 
sauna, dark room, trunk and split b: crowded room, under a car, well-lit room, sleeping bag, MRI 
scanner). Item discrimination represents the correlation of a single item and the mean of the total 
scale or the subscale the item belongs to. It indicates how much a single test item influences the 
overall result, i.e. how representative the item is for the entire measure. Item difficulties are given as 
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Supplementary Table 3  
Comparison of sociodemographic and anxiety/claustrophobia relevant parameters  





NON- MUTATION  
CARRIERS (N=93) STATISTICS 
SOCIODEMOGRAPHICS    
 Mean ± SD Mean  ± SD pa 
Age in years 46.26±13.64  42.92±13.64 0.221 
Education in years  15.11±3.50  14.27±3.56 0.367 
 N % N % Effect  pb 
Gender      
female 19 86.4 62 66.7 
male 3 13.6 31 33.3 
3.315 0.069 
Ethnicity     
caucasian 22 100.0 90 96.8 
african - - 1 1.1 
other - - 2 2.1 
0.729 0.866 
Marital status     
single 11 50.0 46 49.5 
married 4 18.2 29 31.2 
divorced 7 31.8 15 16.1 
widowed - - 3 3.2 
4.035 0.399 
MAIN DIAGNOSES ACCORDING TO DSM-IV  
 N % N % Effect  pb 
no clinical diagnosis  4 18.2 23 24.7 
schizophrenia 9 40.9 34 36.6 
other clinical diagnoses 9 40.9 36 38.7 
0.437 0.804 
PREVALENCE OF ANXIETY DISORDERS  
 N % N % pb 
comorbid anxiety disorderc 14 63.6 54 58.1 0.810 
panic disorder 9 40.9 20 21.5 0.098 
agoraphobia 14 63.6 42 45.2 0.156 
claustrophobia 14 63.6 33 35.5 0.028 
social phobia 3 13.6 15 16.1 1.00 
specific phobia 9 40.9 29 31.2 0.452 
generalized anxiety disorder 3 13.6 10 10.8 0.712 
obsessive-compulsive disorder 6 27.3 12 12.9 0.109 
CLAUSTROPHOBIA RELEVANT ITEMS (SHORT CLQ-G)   
 Mean ±  SD Mean  ±  SD pa 
Subscale ’restriction’    
dark room 3.00±1.45 1.99±1.65 0.005 
well-lit room 2.00±1.57 1.38±1.41 0.085 
sleeping bag 1.73±1.55 0.88±1.38 0.012 
trunk 2.77±1.57 2.04±1.67 0.057 
magnetic resonance imaging scanner 2.32±1.46 1.49±1.68 0.023 
mean of subscale  2.36±1.27 1.56±1.33 0.010 
Subscale ‘suffocation’      
elevator 1.73±1.55 0.91±1.32 0.018 
breathe 1.31±.132 0.72±1.00 0.035 
crowded room 2.50±1.54 1.66±1.54 0.030 
under a car 1.77±1.54 1.11±1.39 0.059 
sauna 1.45±1.60 0.89±1.39  0.089 
mean of subscale 1.75±1.07 1.08±1.05 0.006 
Mean of questionnaire  2.06±1.08 1.31±1.16 0.006 
aMann-Whitney U-Test; b Fisher’s exact test/ Chi-square test; cAnxiety disorders other than agoraphobia;  
 1
 
Supplementary Figure 1: Basic behavior of male Gpm6a KO mice as well as visual 
function determined by electroretinography is normal. (A) Body weight; (B) Vision (visual 
cliff test); (C) Electroretinography; this was performed to exclude potential developmental 
alterations in the retina1 of mutant mice affecting visual perception (N=6 per group); grand 
averages±SEM of electroretinograms evoked by 0.075cds/m2 light flashes recorded from M6A 
mutant mice and wildtype littermates (n=6 each); over a range of 7 light intensities between 
0.0003cds/m2 and 10cds/m2, amplitudes and latencies of A- and B-waves (reflecting 
synchronous activity of photoreceptors and bipolar/retinal ganglion cells, respectively), as well 
as the amplitude and frequency of oscillatory potentials overlying the ascending B-wave 
(reflecting electric activity of amacrine cells), were normal in M6A mutants. No significant 
differences were obtained for any of the intensities tested. (D) Open field pattern (except for 
time spent in the center); (E) Rotarod; (F) Olfaction (buried food finding); (G) Pain sensation 
(hot plate); (H) Acoustic startle response (hearing); (I) Motivation (sucrose preference test); (J) 
Sensorimotor gating, measured by prepulse inhibition (PPI), and startle response are all 
indistinguishable between KO and WT. N=13-28 per group except for (C). Mean±SEM 
presented. 
 
Supplementary Figure 2: Brief behavioral characterization of female Gpm6a KO mice also 
reveals a claustrophobia-like phenotype. (A) Comparable to male KO mice, female KO have 
an aversion towards closed arms in the classical EPM as well as (B) in EPM conducted in 




Supplementary Table 1: Psychometric properties of the 'short German version' of the CLQ 
 
Supplementary Table 2: Description of the pedigree sample with respect to sociodemographic 
and anxiety/claustrophobia relevant readouts 
 
Supplementary Table 3: Comparison of sociodemographic and anxiety/claustrophobia relevant 




1 Zhao J, Iida A, Ouchi Y, Satoh S, Watanabe S. M6a is expressed in the murine neural retina and 
regulates neurite extension. Mol Vis 2008; 14: 1623-1630. 
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Mild expression differences of MECP2 influencing
aggressive social behavior
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Abstract
The X-chromosomal MECP2/Mecp2 gene encodes methyl-CpG-
binding protein 2, a transcriptional activator and repressor regu-
lating many other genes. We discovered in male FVB/N mice that
mild (~50%) transgenic overexpression of Mecp2 enhances
aggression. Surprisingly, when the same transgene was expressed
in C57BL/6N mice, transgenics showed reduced aggression and
social interaction. This suggests that Mecp2 modulates aggressive
social behavior. To test this hypothesis in humans, we performed
a phenotype-based genetic association study (PGAS) in >1000
schizophrenic individuals. We found MECP2 SNPs rs2239464 (G/A)
and rs2734647 (C/T; 30UTR) associated with aggression, with the
G and C carriers, respectively, being more aggressive. This finding
was replicated in an independent schizophrenia cohort. Allele-
specific MECP2 mRNA expression differs in peripheral blood
mononuclear cells by ~50% (rs2734647: C > T). Notably, the
brain-expressed, species-conserved miR-511 binds to MECP2
30UTR only in T carriers, thereby suppressing gene expression. To
conclude, subtle MECP2/Mecp2 expression alterations impact
aggression. While the mouse data provides evidence of an inter-
action between genetic background and mild Mecp2 overexpres-
sion, the human data convey means by which genetic variation
affects MECP2 expression and behavior.
Keywords genetic background; human; microRNA; mouse; phenotype-based
genetic association study
Subject Categories Genetics, Gene Therapy & Genetic Disease; Neuroscience
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Introduction
The X-chromosomal MECP2/Mecp2 gene encodes for methyl-CpG-
binding protein 2, which can act both as a transcriptional activator
and repressor (Chao & Zoghbi, 2012). Indeed, hundreds of genes
have been estimated to be regulated, directly or indirectly, by this
protein (Chahrour et al, 2008; Cohen et al, 2008). Complete or par-
tial loss-of-function mutations of MECP2 lead to Rett syndrome, char-
acterized by a gender-dependent array of symptoms, ranging from
early loss of acquired speech and motor skills to severe mental retar-
dation and neonatal encephalopathy, among many others (Amir
et al, 1999; Bienvenu & Chelly, 2006). Interestingly, gene duplica-
tion can cause very similar symptoms (Ramocki et al, 2010), and
both down- and upregulation of MECP2 are associated with behav-
ioral core features of autism spectrum disorders (ASD) (Peters et al,
2013).
Diverse genetic mouse models, ranging from complete loss-of-
function to reduced or enhanced expression, have been generated to
study consequences of Mecp2 mutations (Chen et al, 2001; Guy
et al, 2001; Shahbazian et al, 2002; Collins et al, 2004; Moretti et al,
2005; Samaco et al, 2008; Bodda et al, 2013). In fact, there is a cor-
relation between Mecp2 “dosage” and phenotype severity, indicating
a narrow normal expression range, with deviance in both directions
being disadvantageous (Chao & Zoghbi, 2012). Along these lines,
we have previously shown that mild overexpression of Mecp2 of
~1.4–1.5 times the wildtype (WT) level induces increased seizure
propensity and aggression in male FVB/N mice, together with alter-
ations in neuronal branching sites and augmented spine density
(Bodda et al, 2013). Application of an epileptogenic compound,
pentylenetetrazole, to transgenic (TG) neurons in vitro leads to a
marked increase in amplitude and frequency of calcium spikes
(Bodda et al, 2013).
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While epileptic seizure susceptibility is a well-established result
of alterations in MECP2 expression (Shahbazian et al, 2002; Collins
et al, 2004; Chahrour & Zoghbi, 2007; Chao et al, 2010; Chao &
Zoghbi, 2012; Bodda et al, 2013), information on the behavioral
consequences of mild overexpression is still rather limited. Dou-
bling the Mecp2 expression level in mice resulted in impaired social
interaction (Samaco et al, 2012). Mecp2 deficiency, however, also
led to abnormal social behavior such as deficits in nest building,
altered social interaction and enhanced aggression (Shahbazian
et al, 2002; Moretti et al, 2005; Fyffe et al, 2008; Kerr et al, 2008;
Samaco et al, 2008, 2009; Chao et al, 2010; Pearson et al, 2012).
Taken together, tightly regulated Mecp2 expression is obviously
critical for normal function of genes involved in social behavior
(Moretti et al, 2005).
Importantly, the reported phenotypes arose from diverse genetic
backgrounds of mice carrying Mecp2 mutations, not considering
basic phenotypical differences among mouse strains (Wolfer & Lipp,
2000; Moy et al, 2009; Pietropaolo et al, 2011; O’Leary et al, 2013;
Samaco et al, 2013). For example, behavioral comparisons between
FVB/N and C57BL/6N strains revealed that FVB/N mice showed a
higher frequency of bouts during behavioral paradigms of aggres-
sion (Mineur & Crusio, 2002; Pugh et al, 2004). Thus, the genetic
background might well mask or modulate phenotypical changes
induced by alterations in Mecp2 expression.
In humans, data on aggression/impulsivity in Rett or MECP2
gene duplication syndrome are scarce. A family study characterizing
neuropsychiatric phenotypes of 9 males and 9 females with MECP2
duplications revealed a high prevalence of hostility (63%) in female
carriers. Moreover, an asymptomatic Rett mutation carrier with the
mutation located in the deletion hotspot of the MECP2 30 region has
been reported to experience episodes of uncontrolled aggression
(Huppke et al, 2006).
This study has been designed (1) to explore the role of gender
and genetic background (FVB/N versus C57BL/6N) for behavioral
phenotypes associated with mild Mecp2 overexpression in mice,
that is, altered aggression, spontaneous home cage behavior and
predisposition to epileptic seizures, and (2) in parallel to search in
humans for social behavioral consequences of common single-
nucleotide polymorphisms (SNPs) within MECP2 and (3) to strive
for mechanistic insight into SNP-related MECP2 expression differ-
ences in man.
Results
Mild Mecp2 overexpression in FVB/N and C57BL/6N mice of both
genders leaves most basic behaviors unaltered but modulates
spontaneous home cage activity
To estimate the expression of the TG protein Mecp2WT_EGFP
(~100 kDa) compared to endogenous Mecp2 (~70 kDa) in TG mice,
we performed Western blot analysis with total protein extracted
from hippocampus and cerebellum. As described previously
for FVB/N mice (Bodda et al, 2013), the relative expression of
Mecp2WT_EGFP in brain amounts to 40–50% of endogenous Mecp2 in
both strains, leading to a subtle overexpression of ~1.4- to 1.5-fold
compared to WT. Mecp2WT_EGFP TG mice of both genders and
strains (FVB/N and C57BL/6N) develop and reproduce normally,
and are devoid of any immediately obvious phenotype. Also, upon
comprehensive testing of several independent cohorts of both geno-
types and genders at different ages, all major domains of basic
behavior, that is, general activity, anxiety, motor functions, explor-
atory behavior, sensory and cognitive functions were unaltered
when compared to the respective WT littermate controls (Table 1a,
b), thus confirming and extending our earlier report on male FVB/N
TG mice (Bodda et al, 2013).
We wondered whether subtle behavioral differences upon mild
overexpression of Mecp2 are perhaps not captured by the usual
behavioral test battery. Therefore, spontaneous home cage behav-
ior was monitored continuously overnight using LABORASTM.
Indeed, we found significant differences between TG and WT
mice. There was an overall tendency of reduced locomotion,
including climbing, and increased immobility in TG as compared
to WT, noticeable across strains and genders, except for male
FVB/N mice that failed to show significant changes in locomotion
(Fig 1).
Male Mecp2 transgenic mice of both genetic backgrounds
exhibit altered territorial social behavior and aggression as
compared to their WT littermates
Based on the unexpected observation that mild overexpression of
Mecp2 leads to increased territorial aggressive behavior of male TG
versus WT FVB/N mice when exposed to FVB/N intruders (Bodda
et al, 2013), we started here a series of new experiments on the
resident-intruder paradigm: (1) We aimed at testing reproducibility
of this phenomenon in FVB/N mice exposed to younger intruder
males of C57BL/6N background, that is, per se less aggressive
intruders (Mineur & Crusio, 2002; Pugh et al, 2004). This experi-
ment yielded similar results (Fig 2A), that is, increased territorial
aggression in TG FVB/N. (2) We were interested to see whether
another genetic background, C57BL/6N, would modify the effect of
Mecp2 overexpression. However, using the same resident–intruder
protocol as in FVB/N males, no attack by C57BL/6N males was
observed (Table 1b). As male C57BL/6N mice are generally less
aggressive compared to male FVB/N (Mineur & Crusio, 2002; Pugh
et al, 2004), the resident–intruder protocol had to be slightly modi-
fied by extending the cut-off time to 10 min and increasing the
basal level of aggression using warming (Greenberg, 1972; Gaskill
et al, 2012). Even though the necessary increase in surrounding
temperature (<38°C) is far below the temperature used to test pain
sensitivity (hot plate test; temperature set to 55°C), we note here
that the pain threshold in TG and WT mice was identical
(Table 1b). Prior to testing, the home cage of the resident mouse
was placed under a heat-emitting red lamp for 20 min to obtain
mild prewarming. Further, during testing, the home cage of the resi-
dent was positioned on a warming pad (set to 38°C). Surprisingly
and opposite to FVB/N mice, the attack latency of TG C57BL/6N
was longer, pointing to reduced territorial aggression as compared
to WT littermates. In fact, within the 10 min observation, 30% of
WT and 55% of TG residents of the C57BL/6N background did not
attack the intruder at all (Fig 2A). In contrast to the clear alteration
of territorial aggression in TG versus WT male mice of both strains,
the sociability test (mouse preferred over empty cage) revealed
entirely normal behavior, indistinguishable between TG and WT
(Fig 2B).
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The unforeseen result of reduced aggression in male TG
C57BL/6N prompted us to investigate the pattern of their territorial
behavior during the resident–intruder test. We measured frequency
and duration of agonistic encounters of the resident mouse for the
first 3 min upon introducing the intruder. Whereas the latency to
initiate the first contact was comparable between male WT and
TG C57BL/6N mice (8.5  1.3 s versus 10.7  1.9 s; P = 0.35),
TG mice exhibited lower frequency and duration of follow/chase
behavior, as well as sniffing of facial and anogenital areas of the
intruder mice than their WT littermates (Fig 3).
Since this territorial behavioral pattern of male C57BL/6N TG
mice indicated somewhat reduced social interest, we hypothesized
that these mice might also display other signs of changed social
interest/competence. Indeed, nest building capacity/quality, social
dominance measured by the tube test, and ultrasound vocalization
in response to an anesthetized female intruder, revealed inferiority
or at least a strong tendency thereof in TG animals (Fig 3).
Together, these data indicate that also in Mecp2 overexpressing mice
of C57BL/6N background, territorial aggressive behavior is a central
target phenotype. In these intrinsically non-aggressive mice, how-
ever, the direction of change is exactly opposite to the FVB/N strain
and accompanied by reduced social interest and competence.
Seizure propensity is increased upon mild Mecp2 overexpression,
independent of genetic background and gender
A common characteristic neurological phenotype found in different
mouse models of mutant Mecp2, ranging from complete loss-of-
function to overexpression, is epileptic seizures (Guy et al, 2001;
Shahbazian et al, 2002; Collins et al, 2004; Chahrour & Zoghbi,
2007). We previously reported in male FVB/N TG mice a higher sus-
ceptibility to seizure induction by the GABAA receptor antagonist,
pentylenetetrazole (PTZ) (Bodda et al, 2013). This work could now
be expanded to female FVB/N TG as well as to male and female
C57BL/6N TG mice. Indeed, PTZ-induced seizure propensity is
increased across genetic backgrounds and genders (Fig 4), pointing







































































































Figure 1. Spontaneous home cage activity of FVB/N and C57BL/6N mice of both genders is modulated by mild Mecp2 overexpression.
Results for male and female mice of both strains are presented. With the exception of male FVB/N mice, locomotion, immobility and climbing reveal similar TG effects across
genders and genetic backgrounds. N = 10–28; mean  s.e.m. given.
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The startle response to acoustic stimulation is augmented upon
mild Mecp2 overexpression in female mice of both genetic
backgrounds
Deletion of Mecp2 in GABAergic neurons resulted in reduction in
the startle response to acoustic stimuli of 120db (Chao et al, 2010),
but nothing has been known regarding a potential influence of mild
Mecp2 overexpression on startling. Since Mecp2 TG mice of both
genetic backgrounds exerted an exaggerated seizure reaction to a
GABAA receptor antagonist, PTZ, we wondered whether mild over-
expression of Mecp2 might also alter the startle reflex and/or the
prepulse inhibition of the startle response (PPI). Indeed, we found
enhanced startling in female but not male Mecp2 TG mice of both
FVB/N and C57BL/6N background (Fig 4). No changes in the
percentage of PPI were observed in any strain or gender (Table 1a,b).
Similar findings that the startle response at 120db does not necessar-
ily affect overall PPI were reported in the context of a study on
mouse inbred strain differences (Paylor & Crawley, 1997).
MECP2 SNP distribution is comparable in healthy and
schizophrenic individuals
Since our mouse studies revealed aggressive social behavior as a
central phenotype modulated by subtle Mecp2 overexpression, we
started a hypothesis-driven analysis on subjects of the GRAS
(Go¨ttingen Research Association for Schizophrenia) data collection
(Ribbe et al, 2010). Genotyping for association analyses was
performed for 4 SNPs located in the X-chromosomal MECP2 gene
with reasonably high minor allele frequency (Fig 5A). At first, a
potential genetic risk condition of the selected SNPs for schizophre-
nia was assessed: A case–control study comparing allele frequencies
of the 4 genotyped SNPs rs2239464, rs3027933, rs2075596, and
rs2734647 in 1052 GRAS patients versus 1248 healthy controls was
performed separately for men and women. All markers fulfilled
Hardy–Weinberg criteria, and no significant associations with
diagnosis were detected (Fig 5B,C). Due to strong linkage disequilib-
rium (LD) between markers, only rs2239464 and rs2734647 were
considered for the phenotype-based genetic association study
(PGAS, inclusion criterion r² < 0.8) (Fig 5D).
Normal genetic variation of MECP2 influences aggression and
impulsivity in man
We next selected aggression-related variables from the GRAS pheno-
typical data collection and tested their association with the 2
selected MECP2 SNPs separately in men and women. Poor impulse
control and a further trait reflecting behavioral expression of impul-
sive aggression (excitement) were chosen. For both, SNP rs2734647
in the 30UTR (Table 2) and for SNP rs2239464 (Table 3), significant
associations with these traits were found in men, with C carriers
and G carriers (the major alleles), respectively, being more aggres-
sive. Sociodemographic and clinical measures potentially confound-
ing these results did not differ between genotype groups. The
nominally significant result for years of education in males (SNP
rs2734647) was accounted for by including it as a covariate in all
models with target measures as dependent variables. In contrast, for
women, no statistically significant results were obtained. The
phenotype–genotype relationships could be reproduced in a small
independent sample of schizophrenic men (Table 4). Taken
together, an association of MECP2 genotypes with readouts of
aggression was found in two independent cohorts of men.
SNP rs2734647 in the 30UTR affects miR-511 binding and
gene expression
To examine possible functional implications of SNP rs2734647 in
the 30UTR on microRNA (miR)-dependent regulation of gene expres-
sion, in silico analyses were performed using TargetScan (Release
6.2) (Lewis et al, 2005; Grimson et al, 2007) and PITA (Kertesz

































































Figure 2. Territorial aggressive behavior in male mice is influenced by Mecp2 overexpression and genetic background.
A Latency to attack in the resident-intruder test is significantly reduced in male FVB/N TG mice but increased in C57BL/6N. Note the different cut-off for the 2 strains.
B Sociability testing in the tripartite chamber reveals a highly significant preference of male mice, independent of the genetic background, for a stranger mouse as
compared to an object (empty cage).
Data information: N = 10–24; mean  s.e.m. given.
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sites comprising the SNP rs2734647 position (i.e., c.*3638A>G).
Allele-specific differences of the predicted DDG values, indicating
strength of miR binding, are summarized in Fig 6A. While miR-
4711-3p and miR-511 are predicted to show preferential binding
in case of the presence of the T-allele, miR-515-3p has a strong
negative DDG only in case of the C-allele, and miR-519e lacks a
strong allele preference. In vitro luciferase assays using HEK293
cells revealed significantly reduced luciferase activity in case of
co-transfection of the plasmid carrying the T-allele with both miR-
4711-3p and miR-511 (Fig 6B). Co-transfection with miR-515-3p or
miR-519e did not lead to luciferase activity reduction for either
rs2734647 T or C (Fig 6B). In luciferase assays using N2a cells, the
positive result was only replicated for miR-511 (Fig 6C). In sum-
mary, these data strongly suggest miR-511 as rs2734647 genotype-
dependent candidate for MECP2 regulation in humans. For the sake
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Figure 3. Male TG C57BL/6N mice show reduced territorial social interaction as well as inferior social competence.
Upper 2 rows: Frequency and duration of determinants of territorial social interaction, that is, follow/chase behavior, nose/snout sniff and anogenital sniff, are consistently
reduced in TG carriers. Lower row: TG mice are inferior in nest building, social dominance behavior and ultrasound vocalization. N = 10–23; mean  s.e.m. given.
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in the cell lines used for transfection. Whereas mmu-miR-511 levels
were under the detection limit in N2a cells, hsa-miR-511 was clearly
expressed in HEK293 cells (3.59 × 103). However, since we always
used negative, that is, non-miR-transfected controls, Luciferase
assay results are unlikely to have been affected.
miR-511 is expressed in aggression-relevant human
brain regions
Since miR-511 seems to be an important modulator of rs2734647
genotype-dependent MECP2 expression in humans, we asked
whether this miR would be detectable in brain regions relevant for
impulsivity and aggression (frontal and prefrontal cortex, temporal
cortex, occipital cortex, hippocampus, and amygdala). Placenta was
used as developmental control tissue. In all regions examined, miR-
511 expression was found (Fig 6D). Importantly, the same holds
true for MECP2 using primers amplifying either MECP2_e2 only or
both isoforms (Fig 6E). In contrast, miR-4711-3p expression was not
detected (data not shown), at least questioning a role of this miR for
MECP2 regulation in the adult human brain. In the adult C57BL/6N
versus FVB/N mouse brain, the expression of miR-511 was low and
comparable between strains in cortex (2.39 × 105 versus
3.71 × 105), hippocampus (6.45 × 105 versus 3.78 × 105), and
cerebellum (2.22 × 105 versus 2.36 × 105). Strong expression
was found in embryonic tissue (C57BL/6N embryo head E17:
1.83 × 103; embryo body: 2.26 × 103), and highest in cultured
microglia (13.02 × 103).
Peripheral blood mononuclear cells (PBMC) of male rs2734647
T-carriers show lower MECP2 expression
Since miR-511 was shown to be expressed in dendritic cells and
macrophages (Tserel et al, 2011), we investigated the hypothesized
allele-specific downregulation of MECP2 expression in PBMC of
male subjects. Indeed, a significantly lower expression in T carriers
versus C carriers (amounting to around 50%) was detected with
primers amplifying both MECP2 isoforms, whereas MECP2_e2 alone
showed no expression difference dependent on the rs2734647 geno-
type (Fig 6F). This result may indicate that in T carriers mainly the
MECP2_e1 isoform is affected, at least in PBMC, potentially related
to isoform-specific different lengths of the MECP2 30UTR (Coy et al,
1999).
Sequence variation of miR-511 in mouse and man underlines the
importance of an interaction with the MECP2 30UTR
A perfect seed match of human hsa-miR-511 with the MECP2 30UTR



















































































Figure 4. Pentylenetetrazole-induced seizure propensity is increased uponmildMecp2 overexpression independent of strain and gender, whereas the startle
response is augmented in females only.
Upper row: Higher seizure scores are found in TG carriers across gender and genetic backgrounds.N = 6–14; Lower row: Significant increase in the startle response is observed
only in female mice of both genetic backgrounds. N = 11–28; mean  s.e.m. given.
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in luciferase activity in contrast to the C-allele, which results in a
mismatch in the seed binding region. C is the conserved ancestral
allele found in multiple other mammalian species, including mouse.
Strikingly, the seed sequence of mouse mmu-miR-511 differs from
hsa-miR-511 exactly regarding the nucleotide complementary to the
SNP position (Fig 6G). Thus, mmu-miR-511 shows an ideal seed
match to the mouse 30UTR, whereas hsa-miR-511 perfectly fits to
the human 30UTR carrying the T-allele. This observation may
emphasize the importance of the miR-511 interaction with MECP2.
Notably, screening of available data from Jackson Laboratories
(http://www.jaxlab.org) revealed that the two mouse lines
employed here are not polymorphic for the Mecp2 30UTR allele or
the miR-511 sequence. It would, however, be interesting to investi-
gate whether non-inbred mice are polymorphic for the respective
alleles.
Discussion
The present study shows that mildly increased Mecp2/MECP2
expression leads to alterations in male social aggression. Using
C57BL/6N versus FVB/N mice (with their known inherent strain dif-
ferences in aggressive behavior) (Mineur & Crusio, 2002; Pugh et al,
2004) as models, we demonstrate that the direction of change upon
mild Mecp2 overexpression in this behavioral target domain is sub-
ject to modification by the genetic background. In other words, the
resulting lower or higher social aggression depends on the basic
genetic make-up of a particular subject. Hints of MECP2 influencing
aggressive behavior could also be shown in two independent
cohorts of schizophrenic men, with a polymorphism in the 30UTR of
the gene co-determining both the level of MECP2 expression as well




N (%) P (OR, [95% CI])
GRAS patients GRAS controls allelic, d.f.=1
Females
rs2239464
GG 205 (61.4) 307 (64.0)
0.45 (1.10, [0.86 - 1.40])GA 117 (35.0) 158 (32.9)
AA 12   (3.6) 15   (3.1)
rs3027933
CC 236 (70.7) 341 (71.0)
0.80 (1.04, [0.79 - 1.36])CG 90 (26.9) 130 (27.1)
GG 8   (2.4) 9   (1.9)
rs2075596
GG 239 (71.3) 344 (71.7)
0.75 (1.05, [0.79 - 1.37])GA 87 (26.0) 127 (26.5)
AA 9   (2.7) 9   (1.9)
rs2734647
CC 234 (69.9) 337 (70.2)
0.77 (1.04, [0.80 - 1.36])CT 91 (27.2) 132 (27.5)
TT 10   (3.0) 11   (2.3)
Males
rs2239464
G 582 (81.4) 617 (80.3)
0.60 (0.93, [0.72 - 1.21])
A 133 (18.6) 151 (19.7)
rs3027933
C 606 (84.8) 655 (85.3)
0.77 (1.04, [0.78 - 1.39])
G 109 (15.2) 113 (14.7)
rs2075596
G 613 (85.2) 660 (85.9)
0.81 (1.04, [0.78 - 1.39])
A 104 (14.5) 108 (14.1)
rs2734647
C 608 (84.8) 646 (84.1)
0.71 (0.95, [0.72 - 1.26])











SNP rs# Test for HWE deviation (females)
P (total) P (controls) P (cases)
rs2239464 0.19 0.39 0.41
rs3027933 0.51 0.49 1.00
rs2075596 0.89 0.59 0.68




3`UTR can vary in length
2 3 4
Figure 5. Basic genetics of MECP2: Gene structure, Hardy-Weinberg statistics, linkage disequilibrium, and case-control analysis in schizophrenic (GRAS)
patients and healthy individuals.
A Schematic overview of MECP2 isoforms e1 and e2, including SNP positions. Digits depict exon numbers, solid black lines exon usage for the respective isoform.
Dashed lines denote SNP positions. Black fillings in boxes denote coding sequence, isoform-specific in exons 1 and 2.
B Test for deviation from Hardy-Weinberg-Equilibrium (HWE) in females only due to X-chromosomal location of MECP2.
C Case–control association analysis - separate for both genders - reveals similar distribution of SNPs in patients and controls.
D Linkage disequilibrium for all included GRAS patients and controls.
EMBO Molecular Medicine Vol 6 | No 5 | 2014 ª 2014 The Authors
EMBO Molecular Medicine MECP2 expression differences in aggression Martesa Tantra et al
672
men found in PBMC (around 50%) is in the range of the transgenic
overexpression in both mouse strains, emphasizing the physiologi-
cal significance of these findings as well as of our mouse models for
studying behavioral consequences of a normal “Mecp2 dose range”.
Even though in both schizophrenia samples, higher expression of
MECP2 (30UTR SNP rs2734647 C carriers lack suppressibility by
miR-511) was associated with higher aggression, it has to be consid-
ered that also humans are not an isogenic population. One might
Table 2. Phenotype comparison of GRAS patients by MECP2 SNP rs2734647 genotypes
Males (GRAS sample)a C T P-value (F/Z/v2 value)b
Target variablesc N = 491 to 608 N = 73 to 109
Poor impulse control, mean  s.d. [range] 1.72  1.12 [1 to 6] 1.39  0.76 [1 to 4] 0.0001 (F = 14.65)
Excitement, mean  s.d. [range] 2.05  1.30 [1 to 7] 1.82  1.13 [1 to 6] 0.034 (F = 4.52)
Control variables
Sociodemographic variables
Age (at examination), years, mean  s.d. [range] 37.40  12.09 [17 to 78] 37.02  11.99 [21 to 71] 0.736 (Z = 0.34)
Education, years, mean  s.d. [range]d 12.11  3.10 [0 to 24] 11.32  2.48 [8 to 18] 0.020 (Z = 2.33)
Unemployment, No. (%) 107 (17.8) 22 (21.0) 0.446 (v2 = 0.58)
Clinical variables
PANSS general score, mean  s.d. [range]e 30.57  10.82 [15 to 81] 31.88  9.73 [16 to 55] 0.542 (Z = 0.61)
PANSS negative score, mean  s.d. [range] 18.04  7.67 [7 to 46] 19.23  7.31 [7 to 40] 0.070 (Z = 1.81)
PANSS positive score, mean  s.d. [range]f 11.61  5.25 [6 to 34] 11.39  5.15 [6 to 30] 0.667 (Z = 0.43)
Cognition composite score, mean  s.d. [range]g 0.09  0.84 [2.4 to 2.2] 0.00  0.84 [2.1 to 1.7] 0.543 (F = 0.37)
Chlorpromazine equivalents, mean  s.d. [range] 688  644 [0 to 4511] 725  734 [0 to 6324] 0.394 (Z = 0.85)
GAF score, mean  s.d. [range] 45.48  16.35 [5 to 90] 46.94  15.45 [15 to 85] 0.375 (Z = 0.89)
Females (GRAS sample)a CC CT TT
P-value
(F/Z/v2 value)b
Target variablesc N = 194 to 234 N = 73 to 91 N = 8 to 10
Poor impulse control, mean  s.d. [range] 1.73  1.15 [1 to 7] 1.57  0.94 [1 to 5] 1.60  1.07 [1 to 4] 0.729 (F = 0.31)
Excitement, mean  s.d. [range] 2.11  1.30 [1 to 7] 1.93  1.31 [1 to 7] 1.50  0.53 [1 to 2] 0.277 (F = 1.29)
Control variables
Sociodemographic variables
Age (at examination), years, mean  s.d.
[range]
43.41  12.90 [18 to 76] 41.82  12.47 [19 to 72] 43.52  12.10 [20 to 58] 0.657 (v2 = 0.84)
Education, years, mean  s.d. [range]d 12.61  3.36 [8 to 27] 12.14  2.83 [8 to 21] 12.15  3.76 [8 to 19] 0.750 (v2 = 0.58)
Unemployment, No. (%) 25 (10.9) 12 (13.6) 4 (40.0) 0.176 (v2 = 1.83)
Clinical variables
PANSS general score, mean  s.d. [range]e 33.04  12.10 [15 to 69] 32.38  12.25 [15 to 72] 31.30  10.64 [19 to 54] 0.872 (v2 = 0.28)
PANSS negative score, mean  s.d. [range] 18.13  8.50 [7 to 44] 17.82  8.11 [7 to 36] 19.30  9.36 [7 to 39] 0.904 (v2 = 0.20)
PANSS positive score, mean  s.d. [range]f 12.25  6.03 [6 to 32] 11.41  5.25 [6 to 30] 11.40  4.40 [6 to 18] 0.650 (v2 = 0.86)
Cognition composite score, mean  s.d.
[range]g
0.02  0.83 [2.0 to 1.9] 0.19  0.90 [2.0 to 2.0] 0.08  0.83 [1.5 to 1.1] 0.090 (F = 2.43)
Chlorpromazine equivalents, Mean  s.d.
[range]
677  839 [0 to 7375] 608  685 [0 to 4375] 640  512 [150 to 1680] 0.614 (v2 = 0.98)
GAF score, mean  s.d. [range] 45.44  19.07 [12 to 90] 47.07  18.60 [8 to 90] 48.80  14.73 [25 to 70] 0.472 (v2 = 1.50)
All P ≤ 0.05 are set in boldface.
GAF, global assessment of functioning
aDue to missing data, sample sizes vary.
bFor statistical methods, Mann–Whitney U/Kruskal–Wallis test (women) or Chi-square tests and for models including covariates ANCOVAs (target variables and
cognition composite score) were used.
cANCOVA with education, age at examination, negative symptoms (PANSS) and medication status (chlorpromazine equivalent) as covariates.
dYears spent in education system; patients currently in school or educational training included (score 0).
eItem 14 (target variable) excluded from sum score.
fItem 4 (target variable) excluded from sum score.
gANCOVA with age, negative symptoms (PANSS) and medication status (chlorpromazine equivalent) as covariates.
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thus, in analogy to our observation in different mouse strains, pre-
dict a human population with reduced aggression as suggested by
the C57BL/6N data (i.e., a bimodal aggression distribution when
combining different genetic backgrounds).
Although the results for women show a similar tendency for poor
impulse control and excitement as aggression readouts, they are far
from reaching significance, likely due to the smaller number of
individuals, but certainly also to the fact that MECP2 is X chromo-
somal. Homozygous T carriers in the female sample are therefore
expectedly very rare.
In our translational PGAS approach, we had the chance to explore
the aggression association of MECP2 genotypes in a phenotypically
very well-characterized large sample of schizophrenic individuals
(Ribbe et al, 2010), and we replicated the association findings in a
Table 3. Phenotype comparison of GRAS patients by MECP2 SNP rs2239464 genotypes
Males (GRAS sample)a G A P-value (F/Z/v2 value)b
Target variablesc N = 469 to 582 N = 94 to 134
Poor impulse control, mean  s.d. [range] 1.72  1.12 [1 to 6] 1.44  0.81 [1 to 4] 0.001 (F = 10.84)
Excitement, mean  s.d. [range] 2.05  1.31 [1 to 7] 1.83  1.11 [1 to 6] 0.056 (F = 3.67)
Control variables
Sociodemographic variables
Age (at examination), years, mean  s.d. [range] 37.31  12.07 [17 to 78] 37.27  12.12 [21 to 71] 0.918 (Z = 0.10)
Education, years, mean  s.d. [range]d 12.10  3.10 [0 to 24] 11.50  2.52 [8 to 20] 0.063 (Z = 1.86)
Unemployment, No. (%) 101 (17.6) 28 (21.5) 0.294 (v2 = 1.10)
Clinical variables
PANSS general score, mean  s.d. [range]e 31.71  10.84 [15 to 81] 31.36  9.83 [16 to 55] 0.966 (Z = 0.04)
PANSS negative score, mean  s.d. [range] 18.13  7.66 [7 to 46] 18.61  7.48 [7 to 40] 0.420 (Z = 0.81)
PANSS positive score, mean  s.d. [range]f 11.67  5.29 [6 to 34] 11.20  4.99 [6 to 30] 0.358 (Z = 0.92)
Cognition composite score, mean  s.d. [range]g 0.09  0.83 [2.4 to 2.2] 0.05  0.88 [2.1 to 1.9] 0.842 (F = 0.40)
Chlorpromazine equivalents, mean  s.d. [range] 691  635 [0 to 4511] 688  700 [0 to 6324] 0.936 (Z = 0.08)
GAF score, mean  s.d. [range] 45.11  16.26 [5 to 90] 45.27  15.7 [15 to 85] 0.045 (Z = 2.00)
Females (GRAS sample)a GG GA AA
P-value
(F/Z/v2 value)b
Target variablesc N = 173 to 206 N = 94 to 117 N = 10 to 13
Poor impulse control, mean  s.d. [range] 1.74  1.18 [1 to 7] 1.62  0.99 [1 to 5] 1.23  0.60 [1 to 3] 0.243 (F = 1.42)
Excitement, mean  s.d. [range] 2.12  1.29 [1 to 7] 1.98  1.31 [1 to 7] 1.62  1.12 [1 to 5] 0.416 (F = 0.88)
Control variables
Sociodemographic variables
Age (at examination), years, mean  s.d. [range] 43.65  13.11 [18 to 76] 42.01  12.15 [19 to 72] 42.66  12.37 [20 to 58] 0.665 (v2 = 0.82)
Education, years, mean  s.d. [range]d 12.66  3.32 [8 to 27] 12.22  3.05 [8 to 21] 11.96  3.28 [8 to 19] 0.538 (v2 = 1.24)
Unemployment, No. (%) 20 (10.0) 17 (14.5) 4 (30.8) 0.056 (v2 = 5.77)
Clinical variables
PANSS general score, mean  s.d. [range]e 32.92  12.42[15 to 69] 33.11  11.79 [15 to 72] 30.23  11.42 [19 to 54] 0.690 (v2 = 0.74)
PANSS negative score, mean  s.d. [range] 18.07  8.49 [7 to 44] 18.20  8.37 [7 to 39] 17.62  8.48 [7 to 39] 0.961 (v2 = 0.08)
PANSS positive score, mean  s.d. [range]f 12.28  5.99 [6 to 32] 11.74  5.55 [6 to 32] 10.00  4.26 [6 to 18] 0.440 (v2 = 1.64)
Cognition composite score, mean  s.d. [range]g 0.01  0.84 [2.0 to 1.9] 0.20  0.87 [2.0 to 2.0] 0.03  0.75 [1.5 to 1.4] 0.049 (F = 3.06)
Chlorpromazine equivalents, mean  s.d.
[range]
671  852[0 to 7375] 638  702 [0 to 4370] 650  504 [150 to 1680] 0.811 (v2 = 0.41)
GAF score, mean  s.d. [range] 46.07  19.12 [15 to 90] 45.13  18.87 [8 to 90] 51.38  12.35 [25 to 70] 0.323 (v2 = 2.26)
All P ≤ 0.05 are set in boldface.
aDue to missing data, sample sizes vary.
bFor statistical methods, Mann–Whitney U/Kruskal–Wallis test (women) or Chi-square tests and for models including covariates ANCOVAs (target variables and
cognition composite score) were used.
cANCOVA with education, age at examination, negative symptoms (PANSS) and medication status (chlorpromazine equivalent) as covariates.
dYears spent in education system; patients currently in school or educational training included (score 0).
eItem 14 (target variable) excluded from sum score.
fItem 4 (target variable) excluded from sum score.
gANCOVA with age, negative symptoms (PANSS) and medication status (chlorpromazine equivalent) as covariates.
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second, independent cohort of schizophrenic men. Therefore, we
cannot state with certainty at this point that the phenotype associa-
tion holds true in the same way for healthy individuals. Neverthe-
less, apart from the supporting data obtained for healthy mice, it has
to be emphasized that aggression is not a specific or unique symp-
tom in schizophrenia. Also, the range of aggressive features in the
whole GRAS patient sample follows a normal distribution, extending
from very low to very high aggression scores.
Along the same lines, the case–control study presented here,
including 1052 cases and 1248 controls, fails to attribute to MECP2
any schizophrenia risk gene role. In some contrast, a recent study
reported in a Han Chinese population an association of rs2734647 C
with the disease (498 cases versus 2025 controls, replicated in 1027
cases versus 1005 controls) (Wong et al, 2013). Although we did
not even find a respective trend (Fig 5C), we cannot entirely exclude
limited power of our case–control approach. On the other hand, the
association might well be population-specific. In any case, a poten-
tial risk gene status, even if confirmed by future GWAS including
X-chromosomal genotypes, will not be dramatic considering the large
number of individuals needed for its demonstration. Instead, MECP2
is most likely disease-independently involved in the regulation of a
basic mammalian behavioral phenotype, that is, aggression. Inter-
estingly, carriers of the minor allele of MECP2 SNP rs2239464 were
previously shown to have decreased cortical surface area in brain
regions such as the cuneus (Joyner et al, 2009), which is associated
with inhibitory control in patients with bipolar disorder (Haldane
et al, 2008).
In further support of an association between MECP2 and aggres-
sion, impulse control alterations in individuals with MECP2/Mecp2
gene duplication syndrome have been reported (Ramocki et al,
2009), even though the findings of the present study are more rele-
vant for the understanding of physiological gene-dose effects on
social behavior. Importantly, Mecp2/MECP2 functions as transcrip-
tional regulator targeting hundreds of other genes (Chen et al, 2003;
Sun & Wu, 2006; Bird, 2008; Chahrour et al, 2008; Ben-Shachar
et al, 2009; Wu et al, 2010). Thus, it is most likely a whole pattern
of genes—directly or indirectly influenced by this regulator—that
primes nuances of aggressive social behavior. As an example,
changes in the expression of a Mecp2 regulated gene, Prom1, are
associated with domestication and aggressive behavior in animals
(Albert et al, 2012; Gopisetty et al, 2012). Furthermore, Mecp2 is
known to control expression of brain-derived neurotrophic factor
(Bdnf) (Martinowich et al, 2003), which in turn is involved in the
regulation of aggression (Ito et al, 2011).
Aggression seems to be a strong target phenotype of mild Mecp2
overexpression independent of the genetic background, since these
expression changes did not lead to alterations in basic behavior,
including motor, sensory and cognitive functions. Male and female
TG mice of both the FVB/N and C57BL/6N genetic backgrounds dis-
played basic behavior comparable to their WT littermates. Apart
from aggression, only home cage activity, seizure propensity and
startle response were influenced by mild Mecp2 overexpression in a
fashion widely independent of the genetic background.
There have been reports on sexual dimorphism with respect to
Mecp2 expression and function in the brain. For instance, in amy-
gdalae and ventromedial hypothalamus, male rats express less
Mecp2 as compared to females (Kurian et al, 2007, 2008). Further-
more, conditional knockout of Mecp2 during amygdala development
caused subtle modifications of juvenile play behavior in male but
not female rats (Kurian et al, 2008). These findings may indicate a
role of Mecp2 in gender-specific modulation of behavior. In the pres-
ent work, however, sexual dimorphism was consistently observed
Table 4. Phenotype comparison of replication sample patients by MECP2 SNPs rs2734647 and rs2239464
rs2734647 genotypes
P-value (Z/v2 value)aMales (replication sample) C T
Target variablesb N = 322 N = 63
Poor impulse control, mean  s.d. [range] 3.16  1.91 [1 to 7] 2.86  1.93 [1 to 6] 0.05 (Z = 1.64)
Excitement, mean  s.d. [range] 3.79  1.60 [1 to 7] 3.52  1.56 [1 to 7] 0.09 (Z = 1.33)
Control variables
Age (at examination), years, mean  s.d. [range] 35.34  10.91 [19 to 65] 36.63  10.80 [18 to 67] 0.16 (Z = 1.01)
Education rating,% low, intermediate, high education level 47.8%, 22.4%, 29.8% 42.9%, 30.2%, 27.0% 0.21 (v2 = 1.78)
rs2239464 genotypes
P-value (Z/v2 value)aMales (replication sample) G A
Target variablesb N = 308 N = 77
Poor impulse control, mean  s.d. [range] 3.19  1.92 [1 to 7] 2.82  1.89 [1 to 6] 0.03 (Z = 1.91)
Excitement, mean  s.d. [range] 3.83  1.60 [1 to 7] 3.42  1.58 [1 to 7] 0.02 (Z = 2.07)
Control variables
Age (at examination), years, mean  s.d. [range] 35.28  11.01 [19 to 65] 36.66  10.40 [18 to 67] 0.12 (Z = 1.23)
Education rating,% low, intermediate, high education level 48.7%, 22.1%, 29.2% 40.3%, 29.9%, 29.9% 0.14 (v2 = 2.53)
All P ≤ 0.05 are set in boldface.
aFor statistical methods, Mann–Whitney U or Chi-square tests were used (all P-values one-sided).
bMann–Whitney U-tests with standardized residuals from linear regression with target variables as dependent variables and age at examination and negative
symptoms as independent variables.
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only with the startle response in a genotype and genetic background
independent manner.
Even though the explicit situations are still unknown in which
miR-511 regulated MECP2/Mecp2 expression might be of particular
physiological relevance, any kind of inflammation in the brain for
instance could play a pivotal role, considering the relatively high
expression found here in mouse microglia. The distinct suppression
of MECP2 expression by miR-511 in SNP rs2734647-T carriers
reported here may even be considered as a future treatment target
in MECP2 gene duplication syndrome. In any case, the high conser-
vation of the interaction between miR-511 and MECP2 in both
mouse and man makes a specific significance of their interplay very
likely. This significance is further supported by the here demon-
strated co-expression of MECP2 and miR-511 in human brain areas
pivotal for aggression and impulsivity regulation (Brower & Price,
2001; Horn et al, 2003; Berlin et al, 2004; Bauman et al, 2006; Zetz-
sche et al, 2007; Siever, 2008; Whelan et al, 2012). Interestingly,
miR-511 expression was found here also in different mouse brain
areas, with levels comparable across both genetic backgrounds.
To conclude, MECP2/Mecp2 has been shown here to be a regula-
tor of social aggressive behavior in mouse and man, with the genetic
background playing an important modifier role.
Materials and Methods
Mice
All mouse experiments have been approved by the Animal Care and
Use Committee of Lower Saxony, Oldenburg, Germany. The genera-
tion of Mecp2WT_EGFP TG mice with a 1.4–1.5-fold Mecp2 overexpres-
sion on FVB/N background has been described in detail previously
(Bodda et al, 2013). Briefly, a bacterial artificial chromosome (BAC)
clone, pBAC_B22804, containing 120 Kb of murine genomic frag-
ment with the intact Mecp2 gene and the flanking Opsin1 and Irak1
genes was used for generating the transgenic construct (Kifayathul-
lah et al, 2010). To generate the pBAC_Mecp2WT_EGFP construct,
the enhanced green fluorescent protein/kanamycin-resistant gene
(EGFP/kan) cassette was PCR amplified using pEGFP1 vector as
template with primers containing 50-bp flanking sequence from
either side of the Mecp2 stop codon. The endogenous stop codon
was replaced by two glycine residues inframe between the Mecp2
protein and the EGFP protein to facilitate the two proteins to fold
and function independently. The amplified EGFP/Kan cassette was
electroporated into E.coli harboring the BAC clone and pGET
recombination system, to facilitate the homologous recombination
of EGFP/Kan cassette at the site of stop codon of Mecp2. The correct
insertion of EGFP/Kan cassette after the recombination event into
the BAC clone was confirmed by sequencing. The Mecp2 flanking
genes, Opsin1 and Irak1 were deleted from the modified BAC clone
using additional BAC recombineering with zeocin selection cassette
(containing the BAC homology arms and zeocin antibiotic marker
gene driven by EM7 promoter from pSELECT vector) (InvivoGen,
Toulouse, France), to avoid any additional phenotype arising from
the overexpression of these genes. During the process of Opsin1
deletion, a MluI restriction site was introduced into BAC clone. The
final BAC construct pBAC_Mecp2WT_EGFP was linearized with
MluI restriction enzyme and micro-injected into the male pronuclei
of the fertilized mouse oocytes derived from the FVB/N strain. Next,
the injected oocytes were transplanted into the uteri of the foster
mothers. Genomic DNA isolated from tail biopsies was analyzed for
the presence of the transgene by PCR. Because the transgene was
not confirmed to be localized to the X chromosome, translational
relevance with respect to modeling mosaicism resulting from X
chromosome loss is limited.
To create a comparator congenic strain for behavioral analyses,
Mecp2 TG FVB/N mice were backcrossed for 10 generations to the
C57BL/6N background. For experiments reported here, male and
female Mecp2WT_EGFP TG (hemizygous) and their WT littermates on
either FVB/N or C57BL/6N backgrounds were used. Tail biopsies
were taken before weaning to obtain genomic DNA for genotyping
(Kifayathullah et al, 2010; Bodda et al, 2013). Western blot and
qPCR analyses for TG expression estimation were performed as
described previously (Bodda et al, 2013).
Behavioral analyses
After weaning and during the whole period of behavioral testing,
mice were housed individually in standard plastic cages
(26.5 × 20 × 14 cm) and kept under temperature-controlled envi-
ronment (21  2°C) on 12 h light/dark cycle with food and water
ad libitum, unless stated otherwise. Single housing was necessary
since male FVB/N mice exhibited extremely aggressive behavior in
a group-housed setting. In order to avoid housing differences as con-
founding variables, we decided to single-house all mice, indepen-
dent of gender and strain. All experiments were conducted by
investigators unaware of the genotype (“blinded”), during the light
phase of the day (between 8:00 am and 6 pm, except for automated
home cage behavioral assessment. Several independent cohorts of
mice (genders and strains tested separately, starting at 5 weeks of
Figure 6. SNP rs2734647 in the 30UTR of MECP2: Search for mechanistic insight.
A Human miRNAs predicted to bind to the MECP2 30UTR in an rs2734647 allele-specific manner. The bases corresponding to the SNP position are black-shadowed.
Numbers left and right of the nucleotide sequence refer to its base-pair position within the miRNA sequence.
B, C Luciferase assay results showing relative luciferase activity in HEK293 and N2a cells after co-transfection of candidate miRNAs with phRL-TK rs2734647C, or
rs2734647T, respectively; mean  s.e.m.; N = 7 (refers to biological replicates) for all conditions. Statistical significance was calculated relative to the non-
transfection control (100%).
D, E Relative expression of hsa-miR-511 and of MECP2 isoform 2 (MECP2 e2) or both isoforms (MECP2 e1&2) in aggression/impulsivity – relevant brain areas: FC=frontal
cortex, PFC, prefrontal cortex; TC, temporal cortex; OC, occipital cortex; HC, hippocampus; AM, amygdala; as well as in placenta (N = 1) as control tissue. Numbers
of individual brains included in the analysis are given in brackets; mean  s.e.m.
F Relative expression of MECP2 e2 or MECP2 e1&2 in peripheral blood mononuclear cells (PBMC) of male patients dependent on rs2734647 genotype; N numbers of
individuals in brackets; mean  s.e.m.
G Alignment of human and mouse MECP2 30UTRs around rs2734647 SNP position (black-shadowed) and human and mouse miR-511, illustrating a perfect species-
specific seed match; hsa-miR-511 perfectly matches the human MECP2 30UTR in case of rs2734647 T. Additional mismatches are gray-shadowed.
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age) were run through a battery of tests covering altogether basic
behavioral, sensory, motor, cognitive and social functions (for over-
view see Table 1a,b). The order of tests was always oriented toward
increasing invasiveness and performed as published in detail earlier
(Jamain et al, 2008; El-Kordi et al, 2012; Bodda et al, 2013): Elevated
plus maze (anxiety), open field (spontaneous activity), hole board
(exploratory behavior), grip strength and rotarod (motor force, bal-
ance and coordination), marble burying (stereotypies and obsessive–
compulsive behaviors), prepulse inhibition of the startle response
(sensorimotor gating), hearing test (startle curve upon random pre-
sentation of stimulus intensities from 65 dB to 120 dB), Y-maze
(working memory), novel object recognition, visual cliff (vision),
sociability (social preference, i.e., other mouse over object), buried
food finding (olfaction), sucrose preference (anhedonia), hot plate test
(pain sensation), and hole board (working and reference memory).
Moreover, automated home cage behavior analysis (LABORASTM),
ultrasound vocalization recording, nest building (social competence),
social tube (dominance), resident–intruder paradigm (aggression) and
seizure propensity (seizure induction by pentylenetetrazole) were per-
formed as indicated (Table 1a,b). In the following, the here relevant
tests (with significant results) will be described in detail, while for the
other tests the reader is politely referred to previous publications of
ourselves and others (Kuc et al, 2006; Jamain et al, 2008; Mandillo
et al, 2008; El-Kordi et al, 2012; Bodda et al, 2013).
Automated home cage behavior analysis
Automated home cage behavior analysis was performed using
LABORASTM system (Metris b.v., Hoofddorp, the Netherlands),
which consists of a triangular shaped sensor platform (Carbon Fiber
Plate 1000 mm × 700 mm × 30 mm), positioned on 2 orthogonally
placed force transducers (Single Point Load Cells) and a third fixed
point attached to a heavy bottom plate (Corian Plate
980 mm × 695 mm × 48 mm). The whole structure stands on 3
spikes, which are adjustable in height and absorb external vibra-
tions. Mice are housed in clear polycarbonate cages (Makrolon type
II cage, 22 cm × 16 cm × 14 cm) with wood-chip bedding covered
floors. The cage is placed directly onto the sensing platform, with
the upper part of the cage (including top, food hopper and drinking
bottle) suspended in a height-adjustable frame separate from the
sensing platform. Resultant electrical signals caused by mechanical
vibrations as induced by movement of the mouse are transformed
by each force transducer, amplified to a fixed signal range, filtered
to eliminate noise, digitized and stored on a computer. Stored sig-
nals are classified into separate behavioral categories like locomotor
activity, immobility and climbing, and quantified by the LABO-
RASTM software. Prior to each session, LABORASTM was calibrated.
Spontaneous mouse behavior was assessed from 6:00 pm until
9:00am, with 1-h cage habituation prior to initiation of recording.
Male (FVB/N: 10TG, 10WT; C57BL/6N: 12TG, 24WT) and female
mice (FVB/N: 10TG, 10WT; C57BL/6N: 13TG, 28WT) were tested.
Ultrasound vocalizations (USVs)
Ultrasound vocalizations (USVs) were recorded using a microphone
(UltraSoundGateCM16) connected to a preamplifier (UltraSound-
Gate116), which was linked to a computer. At the day of recording,
mice in their home cage (single-housed) were placed in the
recording room for 60s. Subsequently, the intruder mouse was put
into the resident’s cage, and vocalization behavior recorded for
3 min. The intruder mouse was an anesthetized unfamiliar female
(anesthetic: intraperitoneal injection of 0.25% tribromoethanol,
0.1 ml/10 g body weight). Number of calls per recording session
was counted, and USVs were separated from other sounds using the
whistles detection algorithm of Avisoft-SASLab 5.2 with following
selection criteria: Possible changes per step = 4 (4687 Hz), minimal
continuity = 8 ms, possible frequency range = 35–150 kHz. These
criteria had been tested in former studies of mouse USVs (El-Kordi
et al, 2012; Hammerschmidt et al, 2012). Avisoft Bioacoustics, Ber-
lin, Germany, delivered all sound recording hardware and software.
Male C57BL/6N mice (12TG and 23WT) were tested.
The resident–intruder test
The resident–intruder test was used to study inter-male aggression
in various independent cohorts of TG and WT mice of both genetic
backgrounds (FVB/N and C57BL/6N) and different age groups,
ranging from 8 to 32 weeks (Jamain et al, 2008; Bodda et al, 2013).
As standard opponents (intruders), group-housed males (4 weeks
younger than resident test males) of C57BL/6N background were
employed (Charles River, Sulzfeld, Germany). An intruder was
introduced into the home cage of the test resident. Observation
started when the resident first sniffed the opponent and stopped
(stop watch) at first attack (defined as bite) to prevent wounding,
but lasted for 300s (FVB/N) or 600s (C57BL/6N) if no attack
occurred (cut-off) (Mineur & Crusio, 2002; Pugh et al, 2004). Male
mice (FVB/N: 12TG, 22WT; C57BL/6N: 10TG, 13WT) were tested.
Over the first 180s (unless mice attacked before), frequency and
duration of following behaviors was additionally quantified in
C57BL/6N (10TG, 11WT): nose/snout and anogenital sniff, follow-
ing/chasing.
The social tube test
The social tube test measures social dominance (Messeri et al,
1975; Moretti et al, 2005; Garfield et al, 2011). The test apparatus
comprises a 30-cm-long transparent acrylic tube with an internal
diameter of 3 cm. Two mice are placed from opposite ends in the
tube and gently pushed to the middle, where they face each other
closely. Single-housed TG and WT C57BL/6N mice were challenged
with unrelated group-housed mice of C57BL/6N background. A
subject was declared “winner” when its opponent completely
retreated from the tube (“out”) within 300s (cut-off). To account for
both, winning/losing and time to win/lose, dominance values are
calculated using the following formulas: winner dominance
value = 100/time to out and loser dominance value = 1/
(300  time to out). Male C57BL/6N mice (10TG, 16WT) were
tested in this paradigm.
Nest building
Nest building is an important behavior in rodents, reflecting social
competence in reproduction (Deacon, 2006; Satoh et al, 2011; El-
Kordi et al, 2012). Two hours before dark phase, the nesting towel
was removed from home cages of single-housed mice and replaced
by a nestlet (pressed 2.7 g cotton square). Nest building quality was
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scored in the morning (Deacon, 2006; El-Kordi et al, 2012). Male
C57BL/6N mice (10TG, 16WT) were tested.
The pentylenetetrazole-induced seizure protocol
The pentylenetetrazole-induced seizure protocol has been described
in detail previously (Ferraro et al, 1999; Bodda et al, 2013; Wojcik
et al, 2013). Seizure activity was induced in wakeful mice by a sin-
gle intraperitoneal (i.p.) injection of pentylenetetrazole (PTZ)
(50 mg/kg body weight) followed by close observation for 30 min
in a small, clear homecage. Latencies to focal (partial clonic), gener-
alized clonic and maximal tonic-clonic behavioral seizures were
recorded. Furthermore, 4 phases in the continuum of behavioral
response to PTZ injection were defined as follows: (1) Hypoactivity
(progressive decrease in motor activity until resting in a crouched or
prone position with abdomen in full contact with cage bottom); (2)
Partial clonus (clonus seizure activity affecting face, head, and/or
forelimb or forelimbs); (3) Generalized clonus (sudden loss of
upright posture, whole body clonus involving all 4 limbs and tail,
rearing and autonomic signs); and (4) Tonic-clonic (maximal) sei-
zure (generalized seizure characterized by tonic hindlimb extension
—also associated with death). Finally, latencies to partial clonus
(PC), generalized clonus (GC), and tonic-clonic (TC) seizures were
summed to assign each mouse a seizure score that was used as a
quantitative trait measure for mapping according to the following
equation: Seizure score = (0.2)(1/PC latency) + (0.3)(1/GC
latency) + (0.5)(1/TC latency)] × 1000. The weighting factors (0.2,
0.3 and 0.5) in the equation were included as means of incorporat-
ing a measure of the progressive nature of the PTZ-induced seizure
phenotype into the severity rating because generalized clonus is
regarded as a more significant event than partial clonus, and tonic
hind limb extension is regarded as the most severe component of
the phenotype. Therefore, the seizure score reflects the degree of
progression of the seizure phenotype in each mouse.(Ferraro et al,
1999) The test was performed on adult Mecp2 TG of FVB/N and
C57BL/6N background (30–40 weeks old). Male (FVB/N: 6 TG, 10
WT; C57BL/6N: 12 TG, 10 WT) and female mice (FVB/N: 14 TG, 14
WT; C57BL/6N: 10 TG, 11 WT) were tested.
Human sample
Schizophrenic patients (discovery sample)
The GRAS (Go¨ttingen Research Association for Schizophrenia) data
collection(Ribbe et al, 2010) was approved by the ethics committee
of the Georg-August-University Go¨ttingen (master committee) and
respective review boards of collaborating centers. The project com-
plies with the Helsinki Declaration. Patients fulfilling DSM-IV crite-
ria for schizophrenia or schizoaffective disorder were included
regardless of disease stage (acute, chronic, residual, or remitted).
All study participants (European Caucasian 95.3%; other 2.0%;
unknown 2.7%) and, if applicable, their legal representatives gave
written informed consent. Of the included 1052 patients, 68.2%
were male (N = 717) and 31.8% female (N = 335). Average age was
39.14  12.56 years (range 17–78).
Healthy controls
Healthy voluntary blood donors were recruited by the Department
of Transfusion Medicine at the Georg-August-University of Go¨ttingen
according to national guidelines for blood donation. As such, they
widely fulfill health criteria, ensured by a broad predonation
screening process including standardized health questionnaires,
interviews, and assessment of hemoglobin concentration, blood
pressure, pulse, and body temperature. Of the N = 1248 success-
fully genotyped control subjects (European Caucasian 97.8%; other
2%; unknown 0.2%), 61.5% were male (N = 768) and 38.5%
female (N = 480). Average age was 37.44  13.23 years (range
18–69).
Independent schizophrenia sample (replicate sample)
To replicate in an independent sample the phenotype–genotype
associations found in male schizophrenic GRAS patients, data from
male schizophrenic subjects (N = 385) of the Munich/Halle collec-
tion of Dan Rujescu could be analyzed (Van den Oord et al, 2006).
Also in this replicate sample, written informed consent had been
obtained from all subjects after detailed and extensive description of
the study, which was approved by the local ethics committee and
carried out in accordance with the ethical standards laid down in
the Declarations of Helsinki.
Phenotyping—target variables
All schizophrenic patients of the GRAS data collection were compre-
hensively phenotyped (Ribbe et al, 2010). To prove our hypothesis
that MECP2 genotypes modulate aggressive behavior in human sub-
jects, we selected target variables closely related to (poor impulse
control) or predicting (excitement) aggressive behavior in schizo-
phrenic individuals (Arango et al, 1999; Soyka et al, 2007; Colasanti
et al, 2010). To assess the severity of poor impulse control, item 14
of the positive and negative syndrome scale (PANSS) (Kay et al,
1987) was used (“disordered regulation and control of action on
inner urges, resulting in sudden, unmodulated, arbitrary or misdi-
rected discharge of tension and emotions without concern about
consequences”). From the subscale covering positive symptomatol-
ogy, item 4 assessing excitement (“hyperactivity as reflected in
accelerated motor behavior, heightened responsivity to stimuli, hyper-
vigilance or excessive mood lability”) was employed (Tables 2
and 3). Both PANSS readouts were also available in the independent
sample of schizophrenic individuals (replicate sample). The choice
of items is supported by the literature: Cheung and colleagues com-
pared aggressive and non-aggressive schizophrenia patients (aggres-
sion assessed by the Staff Observation Aggression Scale) with
respect to single items of the PANSS (Cheung et al, 1997). The larg-
est group difference was found for the PANSS item “poor impulse
control”. Strikingly, the aggressive group had an average score of 4
(range: 1–7) on this item. Even after controlling for the total level of
psychopathology, the associations of “poor impulse control” and
aggressive behavior remained significant. Additionally, in a more
recent prospective study, “poor impulse control” as measured by
PANSS was highly predictive of aggressive behavior (assessed by
the Overt Aggression Scale)(Nolan et al, 2005).
Phenotyping—control variables
Control variables (and potential confounders) are also presented in
Tables 2 and 3. Sociodemographic data (age, years of education,
unemployment rate), a cognition composite score and clinical vari-
ables describing disease severity were used to characterize the
GRAS sample and exclude potential confounding effects explaining
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the target phenotype–genotype associations. The cognition compos-
ite score(Begemann et al, 2011) represents the mean of 3 z-stan-
dardized neuropsychological measures of higher cognitive
functioning: reasoning ability (Leistungspru¨fsystem subtest 3; Horn,
1983), executive functioning (Trail-Making Test B; Reitan, 1958)
and verbal learning and memory (Verbal Learning and Memory
Test; Helmstaedter et al, 2001). As further clinical variables, the
general, positive and negative scores of the PANSS (target variables
excluded from respective scores), chlorpromazine equivalents (stan-
dardized dosage of antipsychotic medication) (Rijcken et al, 2003;
Woods, 2003) and Global assessment of functioning (GAF; Wittchen
et al, 1997) as measure of impaired psychological, social and occu-
pational performance were used.
DNA extraction, normalization, and genotyping
Genomic DNA was purified from whole blood using JETQUICK
Blood & Cell Culture DNA Spin Kit (Genomed GmbH, Lo¨hne, Ger-
many) according to the manufacturer’s protocol. Resulting DNA
samples were aliquoted and stored at 80°C. For further analysis,
DNA was normalized to 50 ng/ll with an automated robotic plat-
form (Microlab Star, Hamilton, Bonaduz, Switzerland). For quality
control, each sample was analyzed with a 0.8% agarose gel. Geno-
typing was performed using SimpleProbes (TIB Molbiol, Berlin, Ger-
many) on LightCycler 480 (Roche Diagnostics, Basel, Switzerland),
according to the manufacturer’s instructions.
Transfection studies
Cell lines
Human embryonic kidney 293 (HEK293) and mouse neuroblastoma
(N2a) cells were maintained in DMEM supplemented with 1 g/l glu-
cose, L-glutamine (Glutamax), 5% fetal calf serum, 100U/ml penicil-
linG sodium and 100 lg/ml streptomycin sulfate. For luciferase
assays, cells were seeded into 12-well plates (220,000 cells/well/
2 ml medium), cultured for 24 h and co-transfected using Lipofecta-
mine 2000 (Invitrogen, Karlsruhe, Germany), following the manu-
facturer’s instructions.
Luciferase reporter constructs and detection assay
The reporter plasmids phRL-TK rs2734647C, or rs2734647T, respec-
tively, were constructed by cloning a 30UTR fragment of 346 bp and
including the SNP downstream of the Renilla luciferase open
reading frame, making use of the XbaI restriction site of phRL-TK
(forward primer: 50-ATTATCTAGACCAGGTCTACCCCTCCCGGC-30,
reverse primer: 50-ATTATCTAGAGGCTGCTCCCTGTCCCAGGT-30).
Sequence integrity was verified using Sanger sequencing. Of the
Renilla luciferase reporter construct (phRL-TK rs2734647C, or
rs2734647T, respectively), 1 lg (per well), plus 1 lg (per well) of
the reference construct pCMV-LacZ (Clontech, Mountain View, CA,
USA) were co-transfected in the presence of 10 pg of mirVana miR-
NA mimic hsa-miR-4711-3p, hsa-miR-511, hsa-miR-515-3p, hsa-
miR-519e-3p, negative control #2 (all Life Technologies, Darmstadt,
Germany), or no miRNA, respectively. After 24 h, cells were split in
96-well plates, creating four technical replicates for each condition,
and separately for luciferase and beta-galactosidase measurement.
Enzyme activity was determined using a Mithras LB 940 Plate
Reader (Berthold, Bad Wildbad, Germany). Renilla luciferase activ-
ity was normalized to beta-galactosidase activity.
RNA isolation and quantitative PCR
Peripheral blood mononuclear cells (PBMC) were isolated from
citrate blood of men with rs2734647C or rs2734647T genotype
(X-chromosomal gene), applying a standard isolation procedure (Fi-
coll-Paque Plus, GEHealthcare, Mu¨nchen, Germany). Human RNA
was extracted from deep-frozen human brain samples of adult male
subjects who had been free of neuropsychiatric diseases, from pla-
centa or PBMC, respectively, using a miRNeasy Mini kit (Qiagen, Hil-
den, Germany). The same kit was employed for isolation of mouse
RNA from whole E17 embryo (divided into body and head), hippo-
campus, amygdala, placenta, and cultured microglia. Synthesis of
cDNA was done by the SuperScriptIII system (Invitrogen, Karlsruhe,
Germany). Detection of MECP2 cDNA was performed using SYBR
green (Roche, Diagnostics GmbH, Mannheim, Germany) and specific
primer pairs amplifying the MECP2_e2 isoform (NCBI reference
sequence NM_004992), spanning exons 2–3 (forward primer: 50- CA
GCTCCAACAGGATTCCAT-30, reverse primer: 50- TGGAGGTCCTGG
TCTTCTGA-30), or both isoforms (NM_004992 and NM_001110792),
spanning exons 3–4 (forward primer: 50- AGCTTAAGCAAAGGAAAT
CTGG-30, reverse primer: 50-GCTTTTCCCTGGGGATTG-30). Specific
Taqman microRNA assays were used to detect hsa-miR-511, hsa-
miR-4711-3p, or mmu-miR-511 (Applied Biosystems, Foster City,
CA, USA), following the manufacturer’s instructions. MECP2
expression levels were normalized to GAPDH, human miRNA
expression levels to RNU43, and mouse miRNA expression levels to
sno-142.
Statistics
All experimental data acquisition was done by experimenters
unaware of group assignment (“‘blinded”). Mouse behavioral data
were analyzed by Mann–Whitney U-test or 2-way analysis of vari-
ance including post hoc Bonferroni testing, where applicable, using
Prism4 (GraphPad Software, San Diego, CA, USA). All data are pre-
sented as mean  s.e.m., unless stated otherwise. Luciferase assay
results from each experiment were normalized to the relative lucif-
erase activity without miRNA co-transfection and analyzed using
one-tailed unpaired t-tests. qPCR results were normalized to the
respective control genes and analyzed using one-tailed unpaired
t-tests. PLINK (v1.07) (Purcell et al, 2007) was used for the analysis
of statistical association between single SNPs and case or control
status (allelic test), and to test for deviations from Hardy–Weinberg
equilibrium. Statistical analyses of phenotype–genotype associations
in the human samples (both GRAS and replicate sample) were per-
formed using SPSS for Windows version 17.0 (SPSS Inc., Chicago,
IL, USA; http://www.spss.com). As MECP2 is X-linked, analyses
were performed separately for men and women. Genotype differ-
ences with respect to the target variables were assessed by analysis
of covariance. Covariates age at examination, years of education,
chlorpromazine equivalents and severity of negative symptoms
(PANSS) were used, as these parameters are likely to influence the
extent to which impulsive aggressive behavior becomes obvious in
a social situation. For the cognition composite score, analysis of
covariance with covariates age, chlorpromazine equivalents and
severity of negative symptoms was applied as these variables have
been widely reported to confound performance on neuropsychologi-
cal tests(Bilder et al, 1992; Hori et al, 2006). Genotype differences
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with respect to sociodemographic and clinical measures were tested
non-parametrically using chi-square (nominal variables) or Mann–
Whitney U/Kruskal–Wallis tests (continuous variables). All P-values
derived from statistical models for the GRAS sample are two-sided
(Tables 2 and 3). For the replicate sample one-sided P-values are
displayed (Table 4). Nominal significance level for all analyses was
set to P < 0.05.
Supplementary information for this article is available online:
http://embomolmed.embopress.org
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